1. Patent Search
  2. Details

CAR T cells that target B-cell antigens

12036242 ยท 2024-07-16

Assignee

Inventors

Cpc classification

International classification

Abstract

Disclosed are compositions and methods for targeted treatment of myeloid and B cell malignancies. In particular, chimeric antigen receptor (CAR) T cells are disclosed that can be used with adoptive cell transfer to target and kill myeloid and B cell malignancies with reduced antigen escape. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a myeloid and B cell malignancies that involves adoptive transfer of the disclosed CAR T cells.

Claims

1. A chimeric antigen receptor (CAR) polypeptide, comprising a CD19 antigen binding domain; an intracellular signaling domain; and a co-stimulatory signaling region, wherein the CD19 antigen binding domain is a single-chain variable fragment (scFv) of an antibody that specifically binds CD19 comprising a variable heavy (V.sub.H) domain having CDR1, CDR2 and CDR3 sequences and a variable light (V.sub.L) domain having CDR1, CDR2 and CDR3 sequences, and wherein the CDR1 sequence of the V.sub.H domain comprises the amino acid sequence SEQ ID NO:1; the CDR2 sequence of the V.sub.H domain comprises the amino acid sequence SEQ ID NO:9; the CDR3 sequence of the V.sub.H domain comprises the amino acid sequence SEQ ID NO:19; the CDR1 sequence of the V.sub.L comprises the amino acid sequence SEQ ID NO:29; the CDR2 sequence of the V.sub.L domain comprises the amino acid sequence SEQ ID NO:38; and the CDR3 sequence of the V.sub.L domain comprises the amino acid sequence SEQ ID NO:43; wherein the CDR1 sequence of the V.sub.H domain comprises the amino acid sequence SEQ ID NO:1; the CDR2 sequence of the V.sub.H domain comprises the amino acid sequence SEQ ID NO:10; the CDR3 sequence of the V.sub.H domain comprises the amino acid sequence SEQ ID NO:20; the CDR1 sequence of the V.sub.L comprises the amino acid sequence SEQ ID NO:30; the CDR2 sequence of the V.sub.L domain comprises the amino acid sequence SEQ ID NO:39; and the CDR3 sequence of the V.sub.L domain comprises the amino acid sequence SEQ ID NO:44; wherein the CDR1 sequence of the V.sub.H domain comprises the amino acid sequence SEQ ID NO:2; the CDR2 sequence of the V.sub.H domain comprises the amino acid sequence SEQ ID NO:11; the CDR3 sequence of the V.sub.H domain comprises the amino acid sequence SEQ ID NO:21; the CDR1 sequence of the V.sub.L comprises the amino acid sequence SEQ ID NO:31; the CDR2 sequence of the V.sub.L domain comprises the amino acid sequence SEQ ID NO:38; and the CDR3 sequence of the V.sub.L domain comprises the amino acid sequence SEQ ID NO:45; wherein the CDR1 sequence of the V.sub.H domain comprises the amino acid sequence SEQ ID NO:3; the CDR2 sequence of the V.sub.H domain comprises the amino acid sequence SEQ ID NO:12; the CDR3 sequence of the V.sub.H domain comprises the amino acid sequence SEQ ID NO:22; the CDR1 sequence of the V.sub.L comprises the amino acid sequence SEQ ID NO:32; the CDR2 sequence of the V.sub.L domain comprises the amino acid sequence SEQ ID NO:40; and the CDR3 sequence of the V.sub.L domain comprises the amino acid sequence SEQ ID NO:46; wherein the CDR1 sequence of the V.sub.H domain comprises the amino acid sequence SEQ ID NO:4; the CDR2 sequence of the V.sub.H domain comprises the amino acid sequence SEQ ID NO:13; the CDR3 sequence of the V.sub.H domain comprises the amino acid sequence SEQ ID NO:23; the CDR1 sequence of the V.sub.L comprises the amino acid sequence SEQ ID NO:33; the CDR2 sequence of the V.sub.L domain comprises the amino acid sequence SEQ ID NO:38; and the CDR3 sequence of the V.sub.L domain comprises the amino acid SEQ ID NO:47; wherein the CDR1 sequence of the V.sub.H domain comprises the amino acid sequence SEQ ID NO:5; the CDR2 sequence of the V.sub.H domain comprises the amino acid sequence SEQ ID NO:14; the CDR3 sequence of the V.sub.H domain comprises the amino acid sequence SEQ ID NO:24; the CDR1 sequence of the V.sub.L comprises the amino acid sequence SEQ ID NO:34; the CDR2 sequence of the V.sub.L domain comprises the amino acid sequence SEQ ID NO:41; and the CDR3 sequence of the V.sub.L domain comprises the amino acid sequence SEQ ID NO:48; wherein the CDR1 sequence of the V.sub.H domain comprises the amino acid sequence SEQ ID NO:6; the CDR2 sequence of the V.sub.H domain comprises the amino acid sequence SEQ ID NO:15; the CDR3 sequence of the V.sub.H domain comprises the amino acid sequence SEQ ID NO:25; the CDR1 sequence of the V.sub.L comprises the amino acid sequence SEQ ID NO:35; the CDR2 sequence of the V.sub.L domain comprises the amino acid sequence SEQ ID NO:40; and the CDR3 sequence of the V.sub.L domain comprises the amino acid sequence SEQ ID NO:49; wherein the CDR1 sequence of the V.sub.H domain comprises the amino acid sequence SEQ ID NO:8; the CDR2 sequence of the V.sub.H domain comprises the amino acid sequence SEQ ID NO:17; the CDR3 sequence of the V.sub.H domain comprises the amino acid sequence SEQ ID NO:27 the CDR1 sequence of the V.sub.L comprises the amino acid sequence SEQ ID NO:36; the CDR2 sequence of the V.sub.L domain comprises the amino acid sequence SEQ ID NO:41; and the CDR3 sequence of the V.sub.L domain comprises the amino acid sequence SEQ ID NO:50; or wherein the CDR1 sequence of the V.sub.H domain comprises the amino acid sequence SEQ ID NO:3; the CDR2 sequence of the V.sub.H domain comprises the amino acid sequence SEQ ID NO:18; the CDR3 sequence of the V.sub.H domain comprises the amino acid sequence SEQ ID NO:28; the CDR1 sequence of the V.sub.L comprises the amino acid sequence SEQ ID NO:37; the CDR2 sequence of the V.sub.L domain comprises the amino acid sequence SEQ ID NO:42; and the CDR3 sequence of the V.sub.L domain comprises the amino acid sequence SEQ ID NO:51.

2. The polypeptide of claim 1, wherein the anti-CD19 scFv V.sub.H domain comprises the amino acid sequence SEQ ID NO:53 and the anti-CD19 scFv V.sub.L domain comprises the amino acid sequence SEQ ID NO:63, or the anti-CD19 scFv V.sub.H domain comprises the amino acid sequence SEQ ID NO:54 and the anti-CD19 scFv V.sub.L domain comprises the amino acid sequence SEQ ID NO:64, or the anti-CD19 scFv V.sub.H domain comprises the amino acid sequence SEQ ID NO:55 and the anti-CD19 scFv V.sub.L domain comprises the amino acid sequence SEQ ID NO:65, or the anti-CD19 scFv V.sub.H domain comprises the amino acid sequence SEQ ID NO:56 and the anti-CD19 scFv V.sub.L domain comprises the amino acid sequence SEQ ID NO:66, or the anti-CD19 scFv V.sub.H domain comprises the amino acid sequence SEQ ID NO:57 and the anti-CD19 scFv V.sub.L domain comprises the amino acid sequence SEQ ID NO:67, or the anti-CD19 scFv V.sub.H domain comprises the amino acid sequence SEQ ID NO:58 and the anti-CD19 scFv V.sub.L domain comprises the amino acid sequence SEQ ID NO:68, or the anti-CD19 scFv V.sub.H domain comprises the amino acid sequence SEQ ID NO:59 and the anti-CD19 scFv V.sub.L domain comprises the amino acid sequence SEQ ID NO:69, or the anti-CD19 scFv V.sub.H domain comprises the amino acid sequence SEQ ID NO:60 and the anti-CD19 scFv V.sub.L domain comprises the amino acid sequence SEQ ID NO:70, or the anti-CD19 scFv V.sub.H domain comprises the amino acid sequence SEQ ID NO:62 and the anti-CD19 scFv V.sub.L domain comprises the amino acid sequence SEQ ID NO:72.

3. The polypeptide of claim 1, wherein the intracellular signaling domain comprises a CD3 zeta (CD3) signaling domain.

4. The polypeptide of claim 1, wherein the costimulatory signaling region comprises the cytoplasmic domain of a costimulatory molecule selected from the group consisting of CD27, CD28, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, and B7-H3.

5. A CAR T cell comprising at least one of the chimeric antigen receptor polypeptide(s) of claim 1.

6. The CAR T cell of claim 5, wherein the cell is selected from the group consisting of an ??T cell, ??T cell, a Natural Killer (NK) cell, a Natural Killer T (NKT) cell, a B cell, an innate lymphoid cell (ILC), a cytokine induced killer (CIK) cell, a cytotoxic T lymphocyte (CTL), a lymphokine activated killer (LAK) cell, a regulatory T cell, or any combination thereof.

Description

DESCRIPTION OF DRAWINGS

(1) FIGS. 1A and 1B contain bar graphs showing CAR candidates activate NFKB. NFKB reporter cells were transduced with ?-retrovirus containing CD19 (FIG. 1A) or CD22 (FIG. 1B) CARs. Cell lysates from transduced or untransduced cells were used for luciferase assay. Bioluminescence indicates the level of NFKB activation. h19BBzGFP, positive control; 1A10 etc., hybridoma cell IDs from which CAR scFvs were derived.

(2) FIG. 2 is a bar graph showing HL CAR expression. CD19-, CD20- or CD22-targeted CAR T cells were produced and CAR expression was analyzed by flow cytometry. GFP % reflects CAR expression. HL, heavy chain in front of light chain orientation for scFv design.

(3) FIG. 3 contains graphs showing CTL with HL CARs. CD19-, CD20- or CD22-targeted CAR T cells were produced and co-cultured with CD19-, CD20- or CD22-expressing target cells at a 10:1 ET ratio. Target cell killing was monitored on an xCELLigence RTCA system. 0:1. Normalized cell index reflects cell growth. UT, untransduced T cell.

(4) FIG. 4 contains bar graphs showing 24 hour cytokine expression with CD19 HL CAR.

(5) FIG. 5 contains bar graphs showing 24 hour cytokine expression with CD20 HL CAR.

(6) FIG. 6 contains bar graphs showing 24 hour cytokine expression with CD22 HL CAR.

DETAILED DESCRIPTION

(7) Disclosed herein are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express CAR polypeptides that selectively bind B cell antigens (BCAs). Therefore, also disclosed are methods for providing an anti-tumor immunity in a subject with myeloid or B cell malignancies that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CAR polypeptides.

(8) Chimeric Antigen Receptors (CAR)

(9) Disclosed herein is a chimeric antigen receptor (CAR) polypeptide that can be that can be expressed in immune effector cells to enhance antitumor activity against myeloid or B cell malignancies.

(10) The disclosed CAR is generally made up of three domains: an ectodomain, a transmembrane domain, and an endodomain. The ectodomain comprises a CD19-binding region, a CD20-binding region, or a CD22-binding region and is responsible for antigen recognition. It also optionally contains a signal peptide (SP) so that the CAR can be glycosylated and anchored in the cell membrane of the immune effector cell. The transmembrane domain (TD), is as its name suggests, connects the ectodomain to the endodomain and resides within the cell membrane when expressed by a cell. The endodomain is the business end of the CAR that transmits an activation signal to the immune effector cell after antigen recognition. For example, the endodomain can contain an intracellular signaling domain (ISD) and optionally a co-stimulatory signaling region (CSR).

(11) A signaling domain (SD) generally contains immunoreceptor tyrosine-based activation motifs (ITAMs) that activate a signaling cascade when the ITAM is phosphorylated. The term co-stimulatory signaling region (CSR) refers to intracellular signaling domains from costimulatory protein receptors, such as CD28, 41BB, and ICOS, that are able to enhance T-cell activation by T-cell receptors.

(12) In some embodiments, the endodomain contains an SD or a CSR, but not both. In these embodiments, an immune effector cell containing the disclosed CAR is only activated if another CAR (or a T-cell receptor) containing the missing domain also binds its respective antigen.

(13) In some embodiments, the disclosed CAR is defined by the formula:
SP-BCA-HG-TM-CSR-SD; or
SP-BCA-HG-TM-SD-CSR; wherein SP represents an optional signal peptide, wherein BCA represents a B cell antigen binding region, wherein HG represents an optional hinge domain, wherein TM represents a transmembrane domain, wherein CSR represents one or more co-stimulatory signaling regions, wherein SD represents a signaling domain, and wherein - represents a peptide bond or linker.

(14) Additional CAR constructs are described, for example, in Fresnak A D, et al. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016 Aug. 23; 16(9):566-81, which is incorporated by reference in its entirety for the teaching of these CAR models.

(15) For example, the CAR can be a TRUCK, Universal CAR, Self-driving CAR, Armored CAR, Self-destruct CAR, Conditional CAR, Marked CAR, TenCAR, Dual CAR, or sCAR.

(16) TRUCKs (T cells redirected for universal cytokine killing) co-express a chimeric antigen receptor (CAR) and an antitumor cytokine. Cytokine expression may be constitutive or induced by T cell activation. Targeted by CAR specificity, localized production of pro-inflammatory cytokines recruits endogenous immune cells to tumor sites and may potentiate an antitumor response.

(17) Universal, allogeneic CAR T cells are engineered to no longer express endogenous T cell receptor (TCR) and/or major histocompatibility complex (MHC) molecules, thereby preventing graft-versus-host disease (GVHD) or rejection, respectively.

(18) Self-driving CARs co-express a CAR and a chemokine receptor, which binds to a tumor ligand, thereby enhancing tumor homing.

(19) CAR T cells engineered to be resistant to immunosuppression (Armored CARs) may be genetically modified to no longer express various immune checkpoint molecules (for example, cytotoxic T lymphocyte-associated antigen 4 (CTLA4) or programmed cell death protein 1 (PD1)), with an immune checkpoint switch receptor, or may be administered with a monoclonal antibody that blocks immune checkpoint signaling.

(20) A self-destruct CAR may be designed using RNA delivered by electroporation to encode the CAR. Alternatively, inducible apoptosis of the T cell may be achieved based on ganciclovir binding to thymidine kinase in gene-modified lymphocytes or the more recently described system of activation of human caspase 9 by a small-molecule dimerizer.

(21) A conditional CAR T cell is by default unresponsive, or switched off, until the addition of a small molecule to complete the circuit, enabling full transduction of both signal 1 and signal 2, thereby activating the CAR T cell. Alternatively, T cells may be engineered to express an adaptor-specific receptor with affinity for subsequently administered secondary antibodies directed at target antigen.

(22) Marked CAR T cells express a CAR plus a tumor epitope to which an existing monoclonal antibody agent binds. In the setting of intolerable adverse effects, administration of the monoclonal antibody clears the CAR T cells and alleviates symptoms with no additional off-tumor effects.

(23) A tandem CAR (TanCAR) T cell expresses a single CAR consisting of two linked single-chain variable fragments (scFvs) that have different affinities fused to intracellular co-stimulatory domain(s) and a CD3 domain. TanCAR T cell activation is achieved only when target cells co-express both targets.

(24) A dual CAR T cell expresses two separate CARs with different ligand binding targets; one CAR includes only the CD3 domain and the other CAR includes only the co-stimulatory domain(s). Dual CAR T cell activation requires co-expression of both targets on the tumor.

(25) A safety CAR (sCAR) consists of an extracellular scFv fused to an intracellular inhibitory domain. sCAR T cells co-expressing a standard CAR become activated only when encountering target cells that possess the standard CAR target but lack the sCAR target.

(26) The antigen recognition domain of the disclosed CAR is usually an scFv. There are however many alternatives. An antigen recognition domain from native T-cell receptor (TCR) alpha and beta single chains have been described, as have simple ectodomains (e.g. CD4 ectodomain to recognize HIV infected cells) and more exotic recognition components such as a linked cytokine (which leads to recognition of cells bearing the cytokine receptor). In fact almost anything that binds a given target with high affinity can be used as an antigen recognition region.

(27) The endodomain is the business end of the CAR that after antigen recognition transmits a signal to the immune effector cell, activating at least one of the normal effector functions of the immune effector cell. Effector function of a T cell, for example, may be cytolytic activity or helper activity including the secretion of cytokines. Therefore, the endodomain may comprise the intracellular signaling domain of a T cell receptor (TCR) and optional co-receptors. While usually the entire intracellular signaling domain can be employed, in many cases it is not necessary to use the entire chain. To the extent that a truncated portion of the intracellular signaling domain is used, such truncated portion may be used in place of the intact chain as long as it transduces the effector function signal.

(28) Cytoplasmic signaling sequences that regulate primary activation of the TCR complex that act in a stimulatory manner may contain signaling motifs which are known as immunoreceptor tyrosine-based activation motifs (ITAMs). Examples of ITAM containing cytoplasmic signaling sequences include those derived from CD8, CD3?, CD3?, CD3?, CD3?, CD32 (Fc gamma RIIa), DAP10, DAP12, CD79a, CD79b, Fc?RI?, Fc?RIII?, Fc?RI? (FCERIB), and Fc?RI? (FCERIG). Variant CD3? signaling domains lacking one or more ITAM domains may also find use in the herein described CARs. Such variant CD3? signaling domains include those described by Bridgeman et al., Clin. Exp. Immunol. 175:258-267 (2013), which is herein incorporated by reference.

(29) In particular embodiments, the intracellular signaling domain is derived from CD3 zeta (CD3?) (TCR zeta, GenBank accno. BAG36664.1). T-cell surface glycoprotein CD3 zeta (CD3) chain, also known as T-cell receptor T3 zeta chain or CD247 (Cluster of Differentiation 247), is a protein that in humans is encoded by the CD247 gene.

(30) First-generation CARs typically had the intracellular domain from the CD3? chain, which is the primary transmitter of signals from endogenous TCRs. Second-generation CARs add intracellular signaling domains from various costimulatory protein receptors (e.g., CD28, 41BB, ICOS) to the endodomain of the CAR to provide additional signals to the T cell. Preclinical studies have indicated that the second generation of CAR designs improves the antitumor activity of T cells. More recent, third-generation CARs combine multiple signaling domains to further augment potency. T cells grafted with these CARs have demonstrated improved expansion, activation, persistence, and tumor-eradicating efficiency independent of costimulatory receptor/ligand interaction (Imai C, et al. Leukemia 2004 18:676-84; Maher J, et al. Nat Biotechnol 2002 20:70-5).

(31) For example, the endodomain of the CAR can be designed to comprise the CD3? signaling domain by itself or combined with any other desired cytoplasmic domain(s) useful in the context of the CAR of the invention. For example, the cytoplasmic domain of the CAR can comprise a CD3? chain portion and a costimulatory signaling region. The costimulatory signaling region refers to a portion of the CAR comprising the intracellular domain of a costimulatory molecule. A costimulatory molecule is a cell surface molecule other than an antigen receptor or their ligands that is required for an efficient response of lymphocytes to an antigen. Examples of such molecules include CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and a ligand that specifically binds with CD83, CD8, CD4, b2c, CD80, CD86, DAP10, DAP12, MyD88, BTNL3, and NKG2D. Thus, while the CAR is exemplified primarily with CD28 as the co-stimulatory signaling element, other costimulatory elements can be used alone or in combination with other co-stimulatory signaling elements.

(32) In some embodiments, the CAR comprises a hinge sequence. A hinge sequence is a short sequence of amino acids that facilitates antibody flexibility (see, e.g., Woof et al., Nat. Rev. Immunol., 4(2): 89-99 (2004)). The hinge sequence may be positioned between the antigen recognition moiety (e.g., anti-CD19, -CD20, or -CD22 scFv) and the transmembrane domain. The hinge sequence can be any suitable sequence derived or obtained from any suitable molecule. In some embodiments, for example, the hinge sequence is derived from a CD8a molecule or a CD28 molecule.

(33) The transmembrane domain may be derived either from a natural or from a synthetic source. Where the source is natural, the domain may be derived from any membrane-bound or transmembrane protein. For example, the transmembrane region may be derived from (i.e. comprise at least the transmembrane region(s) of) the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8 (e.g., CD8 alpha, CD8 beta), CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, or CD154, KIRDS2, OX40, CD2, CD27, LFA-1 (CD11a, CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), CD160, CD19, IL2R beta, IL2R gamma, IL7R ?, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, and PAG/Cbp. Alternatively the transmembrane domain may be synthetic, in which case it will comprise predominantly hydrophobic residues such as leucine and valine. In some cases, a triplet of phenylalanine, tryptophan and valine will be found at each end of a synthetic transmembrane domain. A short oligo- or polypeptide linker, such as between 2 and 10 amino acids in length, may form the linkage between the transmembrane domain and the endoplasmic domain of the CAR.

(34) In some embodiments, the CAR has more than one transmembrane domain, which can be a repeat of the same transmembrane domain, or can be different transmembrane domains.

(35) In some embodiments, the CAR is a multi-chain CAR, as described in WO2015/039523, which is incorporated by reference for this teaching. A multi-chain CAR can comprise separate extracellular ligand binding and signaling domains in different transmembrane polypeptides. The signaling domains can be designed to assemble in juxtamembrane position, which forms flexible architecture closer to natural receptors, that confers optimal signal transduction. For example, the multi-chain CAR can comprise a part of an FCERI alpha chain and a part of an FCERI beta chain such that the FCERI chains spontaneously dimerize together to form a CAR.

(36) Tables 1, 2, and 3 below provide some example combinations of BCA-binding region, co-stimulatory signaling regions, and intracellular signaling domain that can occur in the disclosed CARs.

(37) TABLE-US-00001 TABLE 1 First Generation CARs ScFv Signal Domain BCA CD8 BCA CD3? BCA CD3? BCA CD3? BCA CD3? BCA Fc?RI-? BCA Fc?RIII-? BCA Fc?RI? BCA Fc?RI? BCA DAP10 BCA DAP12 BCA CD32 BCA CD79a

(38) TABLE-US-00002 TABLE 2 Second Generation CARs Co-stimulatory Signal Co-stimulatory Signal ScFv Signal Domain ScFv Signal Domain BCA CD28 CD8 BCA CD80 Fc?RI? BCA CD28 CD3? BCA CD80 Fc?RI? BCA CD28 CD3? BCA CD80 DAP10 BCA CD28 CD3? BCA CD80 DAP12 BCA CD28 CD3? BCA CD80 CD32 BCA CD28 Fc?RI-? BCA CD80 CD79a BCA CD28 Fc?RIII-? BCA CD80 CD79b BCA CD28 Fc?RI? BCA CD86 CD8 BCA CD28 Fc?RI? BCA CD86 CD3? BCA CD28 DAP10 BCA CD86 CD3? BCA CD28 DAP12 BCA CD86 CD3? BCA CD28 CD32 BCA CD86 CD3? BCA CD28 CD79a BCA CD86 Fc?RI-? BCA CD28 CD79b BCA CD86 Fc?RIII-? BCA CD8 CD8 BCA CD86 Fc?RI? BCA CD8 CD3? BCA CD86 Fc?RI? BCA CD8 CD3? BCA CD86 DAP10 BCA CD8 CD3? BCA CD86 DAP12 BCA CD8 CD3? BCA CD86 CD32 BCA CD8 Fc?RI-? BCA CD86 CD79a BCA CD8 Fc?RIII-? BCA CD86 CD79b BCA CD8 Fc?RI? BCA OX40 CD8 BCA CD8 Fc?RI? BCA OX40 CD3? BCA CD8 DAP10 BCA OX40 CD3? BCA CD8 DAP12 BCA OX40 CD3? BCA CD8 CD32 BCA OX40 CD3? BCA CD8 CD79a BCA OX40 Fc?RI-? BCA CD8 CD79b BCA OX40 Fc?RIII-? BCA CD4 CD8 BCA OX40 Fc?RI? BCA CD4 CD3? BCA OX40 Fc?RI? BCA CD4 CD3? BCA OX40 DAP10 BCA CD4 CD3? BCA OX40 DAP12 BCA CD4 CD3? BCA OX40 CD32 BCA CD4 Fc?RI-? BCA OX40 CD79a BCA CD4 Fc?RIII-? BCA OX40 CD79b BCA CD4 Fc?RI? BCA DAP10 CD8 BCA CD4 Fc?RI? BCA DAP10 CD3? BCA CD4 DAP10 BCA DAP10 CD3? BCA CD4 DAP12 BCA DAP10 CD3? BCA CD4 CD32 BCA DAP10 CD3? BCA CD4 CD79a BCA DAP10 Fc?RI-? BCA CD4 CD79b BCA DAP10 Fc?RIII-? BCA b2c CD8 BCA DAP10 Fc?RI? BCA b2c CD3? BCA DAP10 Fc?RI? BCA b2c CD3? BCA DAP10 DAP10 BCA b2c CD3? BCA DAP10 DAP12 BCA b2c CD3? BCA DAP10 CD32 BCA b2c Fc?RI-? BCA DAP10 CD79a BCA b2c Fc?RIII-? BCA DAP10 CD79b BCA b2c Fc?RI? BCA DAP12 CD8 BCA b2c Fc?RI? BCA DAP12 CD3? BCA b2c DAP10 BCA DAP12 CD3? BCA b2c DAP12 BCA DAP12 CD3? BCA b2c CD32 BCA DAP12 CD3? BCA b2c CD79a BCA DAP12 Fc?RI-? BCA b2c CD79b BCA DAP12 Fc?RIII-? BCA CD137/41BB CD8 BCA DAP12 Fc?RI? BCA CD137/41BB CD3? BCA DAP12 Fc?RI? BCA CD137/41BB CD3? BCA DAP12 DAP10 BCA CD137/41BB CD3? BCA DAP12 DAP12 BCA CD137/41BB CD3? BCA DAP12 CD32 BCA CD137/41BB Fc?RI-? BCA DAP12 CD79a BCA CD137/41BB Fc?RIII-? BCA DAP12 CD79b BCA CD137/41BB Fc?RI? BCA MyD88 CD8 BCA CD137/41BB Fc?RI? BCA MyD88 CD3? BCA CD137/41BB DAP10 BCA MyD88 CD3? BCA CD137/41BB DAP12 BCA MyD88 CD3? BCA CD137/41BB CD32 BCA MyD88 CD3? BCA CD137/41BB CD79a BCA MyD88 Fc?RI-? BCA CD137/41BB CD79b BCA MyD88 Fc?RIII-? BCA ICOS CD8 BCA MyD88 Fc?RI? BCA ICOS CD3? BCA MyD88 Fc?RI? BCA ICOS CD3? BCA MyD88 DAP10 BCA ICOS CD3? BCA MyD88 DAP12 BCA ICOS CD3? BCA MyD88 CD32 BCA ICOS Fc?RI-? BCA MyD88 CD79a BCA ICOS Fc?RIII-? BCA MyD88 CD79b BCA ICOS Fc?RI? BCA CD7 CD8 BCA ICOS Fc?RI? BCA CD7 CD3? BCA ICOS DAP10 BCA CD7 CD3? BCA ICOS DAP12 BCA CD7 CD3? BCA ICOS CD32 BCA CD7 CD3? BCA ICOS CD79a BCA CD7 Fc?RI-? BCA ICOS CD79b BCA CD7 Fc?RIII-? BCA CD27 CD8 BCA CD7 Fc?RI? BCA CD27 CD3? BCA CD7 Fc?RI? BCA CD27 CD3? BCA CD7 DAP10 BCA CD27 CD3? BCA CD7 DAP12 BCA CD27 CD3? BCA CD7 CD32 BCA CD27 Fc?RI-? BCA CD7 CD79a BCA CD27 Fc?RIII-? BCA CD7 CD79b BCA CD27 Fc?RI? BCA BTNL3 CD8 BCA CD27 Fc?RI? BCA BTNL3 CD3? BCA CD27 DAP10 BCA BTNL3 CD3? BCA CD27 DAP12 BCA BTNL3 CD3? BCA CD27 CD32 BCA BTNL3 CD3? BCA CD27 CD79a BCA BTNL3 Fc?RI-? BCA CD27 CD79b BCA BTNL3 Fc?RIII-? BCA CD28? CD8 BCA BTNL3 Fc?RI? BCA CD28? CD3? BCA BTNL3 Fc?RI? BCA CD28? CD3? BCA BTNL3 DAP10 BCA CD28? CD3? BCA BTNL3 DAP12 BCA CD28? CD3? BCA BTNL3 CD32 BCA CD28? Fc?RI-? BCA BTNL3 CD79a BCA CD28? Fc?RIII-? BCA BTNL3 CD79b BCA CD28? Fc?RI? BCA NKG2D CD8 BCA CD28? Fc?RI? BCA NKG2D CD3? BCA CD28? DAP10 BCA NKG2D CD3? BCA CD28? DAP12 BCA NKG2D CD3? BCA CD28? CD32 BCA NKG2D CD3? BCA CD28? CD79a BCA NKG2D Fc?RI-? BCA CD28? CD79b BCA NKG2D Fc?RIII-? BCA CD80 CD8 BCA NKG2D Fc?RI? BCA CD80 CD3? BCA NKG2D Fc?RI? BCA CD80 CD3? BCA NKG2D DAP10 BCA CD80 CD3? BCA NKG2D DAP12 BCA CD80 CD3? BCA NKG2D CD32 BCA CD80 Fc?RI-? BCA NKG2D CD79a BCA CD80 Fc?RIII-? BCA NKG2D CD79b

(39) TABLE-US-00003 TABLE 3 Third Generation CARs Co-stimulatory Co-stimulatory Signal ScFv Signal Signal Domain BCA CD28 CD28 CD8 BCA CD28 CD28 CD3? BCA CD28 CD28 CD3? BCA CD28 CD28 CD3? BCA CD28 CD28 CD3? BCA CD28 CD28 Fc?RI-? BCA CD28 CD28 Fc?RIII-? BCA CD28 CD28 Fc?RI? BCA CD28 CD28 Fc?RI? BCA CD28 CD28 DAP10 BCA CD28 CD28 DAP12 BCA CD28 CD28 CD32 BCA CD28 CD28 CD79a BCA CD28 CD28 CD79b BCA CD28 CD8 CD8 BCA CD28 CD8 CD3? BCA CD28 CD8 CD3? BCA CD28 CD8 CD3? BCA CD28 CD8 CD3? BCA CD28 CD8 Fc?RI-? BCA CD28 CD8 Fc?RIII-? BCA CD28 CD8 Fc?RI? BCA CD28 CD8 Fc?RI? BCA CD28 CD8 DAP10 BCA CD28 CD8 DAP12 BCA CD28 CD8 CD32 BCA CD28 CD8 CD79a BCA CD28 CD8 CD79b BCA CD28 CD4 CD8 BCA CD28 CD4 CD3? BCA CD28 CD4 CD3? BCA CD28 CD4 CD3? BCA CD28 CD4 CD3? BCA CD28 CD4 Fc?RI-? BCA CD28 CD4 Fc?RIII-? BCA CD28 CD4 Fc?RI? BCA CD28 CD4 Fc?RI? BCA CD28 CD4 DAP10 BCA CD28 CD4 DAP12 BCA CD28 CD4 CD32 BCA CD28 CD4 CD79a BCA CD28 CD4 CD79b BCA CD28 b2c CD8 BCA CD28 b2c CD3? BCA CD28 b2c CD3? BCA CD28 b2c CD3? BCA CD28 b2c CD3? BCA CD28 b2c Fc?RI-? BCA CD28 b2c Fc?RIII-? BCA CD28 b2c Fc?RI? BCA CD28 b2c Fc?RI? BCA CD28 b2c DAP10 BCA CD28 b2c DAP12 BCA CD28 b2c CD32 BCA CD28 b2c CD79a BCA CD28 b2c CD79b BCA CD28 CD137/41BB CD8 BCA CD28 CD137/41BB CD3? BCA CD28 CD137/41BB CD3? BCA CD28 CD137/41BB CD3? BCA CD28 CD137/41BB CD3? BCA CD28 CD137/41BB Fc?RI-? BCA CD28 CD137/41BB Fc?RIII-? BCA CD28 CD137/41BB Fc?RI? BCA CD28 CD137/41BB Fc?RI? BCA CD28 CD137/41BB DAP10 BCA CD28 CD137/41BB DAP12 BCA CD28 CD137/41BB CD32 BCA CD28 CD137/41BB CD79a BCA CD28 CD137/41BB CD79b BCA CD28 ICOS CD8 BCA CD28 ICOS CD3? BCA CD28 ICOS CD3? BCA CD28 ICOS CD3? BCA CD28 ICOS CD3? BCA CD28 ICOS Fc?RI-? BCA CD28 ICOS Fc?RIII-? BCA CD28 ICOS Fc?RI? BCA CD28 ICOS Fc?RI? BCA CD28 ICOS DAP10 BCA CD28 ICOS DAP12 BCA CD28 ICOS CD32 BCA CD28 ICOS CD79a BCA CD28 ICOS CD79b BCA CD28 CD27 CD8 BCA CD28 CD27 CD3? BCA CD28 CD27 CD3? BCA CD28 CD27 CD3? BCA CD28 CD27 CD3? BCA CD28 CD27 Fc?RI-? BCA CD28 CD27 Fc?RIII-? BCA CD28 CD27 Fc?RI? BCA CD28 CD27 Fc?RI? BCA CD28 CD27 DAP10 BCA CD28 CD27 DAP12 BCA CD28 CD27 CD32 BCA CD28 CD27 CD79a BCA CD28 CD27 CD79b BCA CD28 CD28? CD8 BCA CD28 CD28? CD3? BCA CD28 CD28? CD3? BCA CD28 CD28? CD3? BCA CD28 CD28? CD3? BCA CD28 CD28? Fc?RI-? BCA CD28 CD28? Fc?RIII-? BCA CD28 CD28? Fc?RI? BCA CD28 CD28? Fc?RI? BCA CD28 CD28? DAP10 BCA CD28 CD28? DAP12 BCA CD28 CD28? CD32 BCA CD28 CD28? CD79a BCA CD28 CD28? CD79b BCA CD28 CD80 CD8 BCA CD28 CD80 CD3? BCA CD28 CD80 CD3? BCA CD28 CD80 CD3? BCA CD28 CD80 CD3? BCA CD28 CD80 Fc?RI-? BCA CD28 CD80 Fc?RIII-? BCA CD28 CD80 Fc?RI? BCA CD28 CD80 Fc?RI? BCA CD28 CD80 DAP10 BCA CD28 CD80 DAP12 BCA CD28 CD80 CD32 BCA CD28 CD80 CD79a BCA CD28 CD80 CD79b BCA CD28 CD86 CD8 BCA CD28 CD86 CD3? BCA CD28 CD86 CD3? BCA CD28 CD86 CD3? BCA CD28 CD86 CD3? BCA CD28 CD86 Fc?RI-? BCA CD28 CD86 Fc?RIII-? BCA CD28 CD86 Fc?RI? BCA CD28 CD86 Fc?RI? BCA CD28 CD86 DAP10 BCA CD28 CD86 DAP12 BCA CD28 CD86 CD32 BCA CD28 CD86 CD79a BCA CD28 CD86 CD79b BCA CD28 OX40 CD8 BCA CD28 OX40 CD3? BCA CD28 OX40 CD3? BCA CD28 OX40 CD3? BCA CD28 OX40 CD3? BCA CD28 OX40 Fc?RI-? BCA CD28 OX40 Fc?RIII-? BCA CD28 OX40 Fc?RI? BCA CD28 OX40 Fc?RI? BCA CD28 OX40 DAP10 BCA CD28 OX40 DAP12 BCA CD28 OX40 CD32 BCA CD28 OX40 CD79a BCA CD28 OX40 CD79b BCA CD28 DAP10 CD8 BCA CD28 DAP10 CD3? BCA CD28 DAP10 CD3? BCA CD28 DAP10 CD3? BCA CD28 DAP10 CD3? BCA CD28 DAP10 Fc?RI-? BCA CD28 DAP10 Fc?RIII-? BCA CD28 DAP10 Fc?RI? BCA CD28 DAP10 Fc?RI? BCA CD28 DAP10 DAP10 BCA CD28 DAP10 DAP12 BCA CD28 DAP10 CD32 BCA CD28 DAP10 CD79a BCA CD28 DAP10 CD79b BCA CD28 DAP12 CD8 BCA CD28 DAP12 CD3? BCA CD28 DAP12 CD3? BCA CD28 DAP12 CD3? BCA CD28 DAP12 CD3? BCA CD28 DAP12 Fc?RI-? BCA CD28 DAP12 Fc?RIII-? BCA CD28 DAP12 Fc?RI? BCA CD28 DAP12 Fc?RI? BCA CD28 DAP12 DAP10 BCA CD28 DAP12 DAP12 BCA CD28 DAP12 CD32 BCA CD28 DAP12 CD79a BCA CD28 DAP12 CD79b BCA CD28 MyD88 CD8 BCA CD28 MyD88 CD3? BCA CD28 MyD88 CD3? BCA CD28 MyD88 CD3? BCA CD28 MyD88 CD3? BCA CD28 MyD88 Fc?RI-? BCA CD28 MyD88 Fc?RIII-? BCA CD28 MyD88 Fc?RI? BCA CD28 MyD88 Fc?RI? BCA CD28 MyD88 DAP10 BCA CD28 MyD88 DAP12 BCA CD28 MyD88 CD32 BCA CD28 MyD88 CD79a BCA CD28 MyD88 CD79b BCA CD28 CD7 CD8 BCA CD28 CD7 CD3? BCA CD28 CD7 CD3? BCA CD28 CD7 CD3? BCA CD28 CD7 CD3? BCA CD28 CD7 Fc?RI-? BCA CD28 CD7 Fc?RIII-? BCA CD28 CD7 Fc?RI? BCA CD28 CD7 Fc?RI? BCA CD28 CD7 DAP10 BCA CD28 CD7 DAP12 BCA CD28 CD7 CD32 BCA CD28 CD7 CD79a BCA CD28 CD7 CD79b BCA CD28 BTNL3 CD8 BCA CD28 BTNL3 CD3? BCA CD28 BTNL3 CD3? BCA CD28 BTNL3 CD3? BCA CD28 BTNL3 CD3? BCA CD28 BTNL3 Fc?RI-? BCA CD28 BTNL3 Fc?RIII-? BCA CD28 BTNL3 Fc?RI? BCA CD28 BTNL3 Fc?RI? BCA CD28 BTNL3 DAP10 BCA CD28 BTNL3 DAP12 BCA CD28 BTNL3 CD32 BCA CD28 BTNL3 CD79a BCA CD28 BTNL3 CD79b BCA CD28 NKG2D CD8 BCA CD28 NKG2D CD3? BCA CD28 NKG2D CD3? BCA CD28 NKG2D CD3? BCA CD28 NKG2D CD3? BCA CD28 NKG2D Fc?RI-? BCA CD28 NKG2D Fc?RIII-? BCA CD28 NKG2D Fc?RI? BCA CD28 NKG2D Fc?RI? BCA CD28 NKG2D DAP10 BCA CD28 NKG2D DAP12 BCA CD28 NKG2D CD32 BCA CD28 NKG2D CD79a BCA CD28 NKG2D CD79b BCA CD8 CD28 CD8 BCA CD8 CD28 CD3? BCA CD8 CD28 CD3? BCA CD8 CD28 CD3? BCA CD8 CD28 CD3? BCA CD8 CD28 Fc?RI-? BCA CD8 CD28 Fc?RIII-? BCA CD8 CD28 Fc?RI? BCA CD8 CD28 Fc?RI? BCA CD8 CD28 DAP10 BCA CD8 CD28 DAP12 BCA CD8 CD28 CD32 BCA CD8 CD28 CD79a BCA CD8 CD28 CD79b BCA CD8 CD8 CD8 BCA CD8 CD8 CD3? BCA CD8 CD8 CD3? BCA CD8 CD8 CD3? BCA CD8 CD8 CD3? BCA CD8 CD8 Fc?RI-? BCA CD8 CD8 Fc?RIII-? BCA CD8 CD8 Fc?RI? BCA CD8 CD8 Fc?RI? BCA CD8 CD8 DAP10 BCA CD8 CD8 DAP12 BCA CD8 CD8 CD32 BCA CD8 CD8 CD79a BCA CD8 CD8 CD79b BCA CD8 CD4 CD8 BCA CD8 CD4 CD3? BCA CD8 CD4 CD3? BCA CD8 CD4 CD3? BCA CD8 CD4 CD3? BCA CD8 CD4 Fc?RI-? BCA CD8 CD4 Fc?RIII-? BCA CD8 CD4 Fc?RI? BCA CD8 CD4 Fc?RI? BCA CD8 CD4 DAP10 BCA CD8 CD4 DAP12 BCA CD8 CD4 CD32 BCA CD8 CD4 CD79a BCA CD8 CD4 CD79b BCA CD8 b2c CD8 BCA CD8 b2c CD3? BCA CD8 b2c CD3? BCA CD8 b2c CD3? BCA CD8 b2c CD3? BCA CD8 b2c Fc?RI-? BCA CD8 b2c Fc?RIII-? BCA CD8 b2c Fc?RI? BCA CD8 b2c Fc?RI? BCA CD8 b2c DAP10 BCA CD8 b2c DAP12 BCA CD8 b2c CD32 BCA CD8 b2c CD79a BCA CD8 b2c CD79b BCA CD8 CD137/41BB CD8 BCA CD8 CD137/41BB CD3? BCA CD8 CD137/41BB CD3? BCA CD8 CD137/41BB CD3? BCA CD8 CD137/41BB CD3? BCA CD8 CD137/41BB Fc?RI-? BCA CD8 CD137/41BB Fc?RIII-? BCA CD8 CD137/41BB Fc?RI? BCA CD8 CD137/41BB Fc?RI? BCA CD8 CD137/41BB DAP10 BCA CD8 CD137/41BB DAP12 BCA CD8 CD137/41BB CD32 BCA CD8 CD137/41BB CD79a BCA CD8 CD137/41BB CD79b BCA CD8 ICOS CD8 BCA CD8 ICOS CD3? BCA CD8 ICOS CD3? BCA CD8 ICOS CD3? BCA CD8 ICOS CD3? BCA CD8 ICOS Fc?RI-? BCA CD8 ICOS Fc?RIII-? BCA CD8 ICOS Fc?RI? BCA CD8 ICOS Fc?RI? BCA CD8 ICOS DAP10 BCA CD8 ICOS DAP12 BCA CD8 ICOS CD32 BCA CD8 ICOS CD79a BCA CD8 ICOS CD79b BCA CD8 CD27 CD8 BCA CD8 CD27 CD3? BCA CD8 CD27 CD3? BCA CD8 CD27 CD3? BCA CD8 CD27 CD3? BCA CD8 CD27 Fc?RI-? BCA CD8 CD27 Fc?RIII-? BCA CD8 CD27 Fc?RI? BCA CD8 CD27 Fc?RI? BCA CD8 CD27 DAP10 BCA CD8 CD27 DAP12 BCA CD8 CD27 CD32 BCA CD8 CD27 CD79a BCA CD8 CD27 CD79b BCA CD8 CD280 CD8 BCA CD8 CD28? CD3? BCA CD8 CD28? CD3? BCA CD8 CD28? CD3? BCA CD8 CD28? CD3? BCA CD8 CD28? Fc?RI-? BCA CD8 CD28? Fc?RIII-? BCA CD8 CD28? Fc?RI? BCA CD8 CD28? Fc?RI? BCA CD8 CD28? DAP10 BCA CD8 CD28? DAP12 BCA CD8 CD28? CD32 BCA CD8 CD28? CD79a BCA CD8 CD28? CD79b BCA CD8 CD80 CD8 BCA CD8 CD80 CD3? BCA CD8 CD80 CD3? BCA CD8 CD80 CD3? BCA CD8 CD80 CD3? BCA CD8 CD80 Fc?RI-? BCA CD8 CD80 Fc?RIII-? BCA CD8 CD80 Fc?RI? BCA CD8 CD80 Fc?RI? BCA CD8 CD80 DAP10 BCA CD8 CD80 DAP12 BCA CD8 CD80 CD32 BCA CD8 CD80 CD79a BCA CD8 CD80 CD79b BCA CD8 CD86 CD8 BCA CD8 CD86 CD3? BCA CD8 CD86 CD3? BCA CD8 CD86 CD3? BCA CD8 CD86 CD3? BCA CD8 CD86 Fc?RI-? BCA CD8 CD86 Fc?RIII-? BCA CD8 CD86 Fc?RI? BCA CD8 CD86 Fc?RI? BCA CD8 CD86 DAP10 BCA CD8 CD86 DAP12 BCA CD8 CD86 CD32 BCA CD8 CD86 CD79a BCA CD8 CD86 CD79b BCA CD8 OX40 CD8 BCA CD8 OX40 CD3? BCA CD8 OX40 CD3? BCA CD8 OX40 CD3? BCA CD8 OX40 CD3? BCA CD8 OX40 Fc?RI-? BCA CD8 OX40 Fc?RIII-? BCA CD8 OX40 Fc?RI? BCA CD8 OX40 Fc?RI? BCA CD8 OX40 DAP10 BCA CD8 OX40 DAP12 BCA CD8 OX40 CD32 BCA CD8 OX40 CD79a BCA CD8 OX40 CD79b BCA CD8 DAP10 CD8 BCA CD8 DAP10 CD3? BCA CD8 DAP10 CD3? BCA CD8 DAP10 CD3? BCA CD8 DAP10 CD3? BCA CD8 DAP10 Fc?RI-? BCA CD8 DAP10 Fc?RIII-? BCA CD8 DAP10 Fc?RI? BCA CD8 DAP10 Fc?RI? BCA CD8 DAP10 DAP10 BCA CD8 DAP10 DAP12 BCA CD8 DAP10 CD32 BCA CD8 DAP10 CD79a BCA CD8 DAP10 CD79b BCA CD8 DAP12 CD8 BCA CD8 DAP12 CD3? BCA CD8 DAP12 CD3? BCA CD8 DAP12 CD3? BCA CD8 DAP12 CD3? BCA CD8 DAP12 Fc?RI-? BCA CD8 DAP12 Fc?RIII-? BCA CD8 DAP12 Fc?RI? BCA CD8 DAP12 Fc?RI? BCA CD8 DAP12 DAP10 BCA CD8 DAP12 DAP12 BCA CD8 DAP12 CD32 BCA CD8 DAP12 CD79a BCA CD8 DAP12 CD79b BCA CD8 MyD88 CD8 BCA CD8 MyD88 CD3? BCA CD8 MyD88 CD3? BCA CD8 MyD88 CD3? BCA CD8 MyD88 CD3? BCA CD8 MyD88 Fc?RI-? BCA CD8 MyD88 Fc?RIII-? BCA CD8 MyD88 Fc?RI? BCA CD8 MyD88 Fc?RI? BCA CD8 MyD88 DAP10 BCA CD8 MyD88 DAP12 BCA CD8 MyD88 CD32 BCA CD8 MyD88 CD79a BCA CD8 MyD88 CD79b BCA CD8 CD7 CD8 BCA CD8 CD7 CD3? BCA CD8 CD7 CD3? BCA CD8 CD7 CD3? BCA CD8 CD7 CD3? BCA CD8 CD7 Fc?RI-? BCA CD8 CD7 Fc?RIII-? BCA CD8 CD7 Fc?RI? BCA CD8 CD7 Fc?RI? BCA CD8 CD7 DAP10 BCA CD8 CD7 DAP12 BCA CD8 CD7 CD32 BCA CD8 CD7 CD79a BCA CD8 CD7 CD79b BCA CD8 BTNL3 CD8 BCA CD8 BTNL3 CD3? BCA CD8 BTNL3 CD3? BCA CD8 BTNL3 CD3? BCA CD8 BTNL3 CD3? BCA CD8 BTNL3 Fc?RI-? BCA CD8 BTNL3 Fc?RIII-? BCA CD8 BTNL3 Fc?RI? BCA CD8 BTNL3 Fc?RI? BCA CD8 BTNL3 DAP10 BCA CD8 BTNL3 DAP12 BCA CD8 BTNL3 CD32 BCA CD8 BTNL3 CD79a BCA CD8 BTNL3 CD79b BCA CD8 NKG2D CD8 BCA CD8 NKG2D CD3? BCA CD8 NKG2D CD3? BCA CD8 NKG2D CD3? BCA CD8 NKG2D CD3? BCA CD8 NKG2D Fc?RI-? BCA CD8 NKG2D Fc?RIII-? BCA CD8 NKG2D Fc?RI? BCA CD8 NKG2D Fc?RI? BCA CD8 NKG2D DAP10 BCA CD8 NKG2D DAP12 BCA CD8 NKG2D CD32 BCA CD8 NKG2D CD79a BCA CD8 NKG2D CD79b BCA CD4 CD28 CD8 BCA CD4 CD28 CD3? BCA CD4 CD28 CD3? BCA CD4 CD28 CD3? BCA CD4 CD28 CD3? BCA CD4 CD28 Fc?RI-? BCA CD4 CD28 Fc?RIII-? BCA CD4 CD28 Fc?RI? BCA CD4 CD28 Fc?RI? BCA CD4 CD28 DAP10 BCA CD4 CD28 DAP12 BCA CD4 CD28 CD32 BCA CD4 CD28 CD79a BCA CD4 CD28 CD79b BCA CD4 CD8 CD8 BCA CD4 CD8 CD3? BCA CD4 CD8 CD3? BCA CD4 CD8 CD3? BCA CD4 CD8 CD3? BCA CD4 CD8 Fc?RI-? BCA CD4 CD8 Fc?RIII-? BCA CD4 CD8 Fc?RI? BCA CD4 CD8 Fc?RI? BCA CD4 CD8 DAP10 BCA CD4 CD8 DAP12 BCA CD4 CD8 CD32 BCA CD4 CD8 CD79a BCA CD4 CD8 CD79b BCA CD4 CD4 CD8 BCA CD4 CD4 CD3? BCA CD4 CD4 CD3? BCA CD4 CD4 CD3? BCA CD4 CD4 CD3? BCA CD4 CD4 Fc?RI-? BCA CD4 CD4 Fc?RIII-? BCA CD4 CD4 Fc?RI? BCA CD4 CD4 Fc?RI? BCA CD4 CD4 DAP10 BCA CD4 CD4 DAP12 BCA CD4 CD4 CD32 BCA CD4 CD4 CD79a BCA CD4 CD4 CD79b BCA CD4 b2c CD8 BCA CD4 b2c CD3? BCA CD4 b2c CD3? BCA CD4 b2c CD3? BCA CD4 b2c CD3? BCA CD4 b2c Fc?RI-? BCA CD4 b2c Fc?RIII-? BCA CD4 b2c Fc?RI? BCA CD4 b2c Fc?RI? BCA CD4 b2c DAP10 BCA CD4 b2c DAP12 BCA CD4 b2c CD32 BCA CD4 b2c CD79a BCA CD4 b2c CD79b BCA CD4 CD137/41BB CD8 BCA CD4 CD137/41BB CD3? BCA CD4 CD137/41BB CD3? BCA CD4 CD137/41BB CD3? BCA CD4 CD137/41BB CD3? BCA CD4 CD137/41BB Fc?RI-? BCA CD4 CD137/41BB Fc?RIII-? BCA CD4 CD137/41BB Fc?RI? BCA CD4 CD137/41BB Fc?RI? BCA CD4 CD137/41BB DAP10 BCA CD4 CD137/41BB DAP12 BCA CD4 CD137/41BB CD32 BCA CD4 CD137/41BB CD79a BCA CD4 CD137/41BB CD79b BCA CD4 ICOS CD8 BCA CD4 ICOS CD3? BCA CD4 ICOS CD3? BCA CD4 ICOS CD3? BCA CD4 ICOS CD3? BCA CD4 ICOS Fc?RI-? BCA CD4 ICOS Fc?RIII-? BCA CD4 ICOS Fc?RI? BCA CD4 ICOS Fc?RI? BCA CD4 ICOS DAP10 BCA CD4 ICOS DAP12 BCA CD4 ICOS CD32 BCA CD4 ICOS CD79a BCA CD4 ICOS CD79b BCA CD4 CD27 CD8 BCA CD4 CD27 CD3? BCA CD4 CD27 CD3? BCA CD4 CD27 CD3? BCA CD4 CD27 CD3? BCA CD4 CD27 Fc?RI-? BCA CD4 CD27 Fc?RIII-? BCA CD4 CD27 Fc?RI? BCA CD4 CD27 Fc?RI? BCA CD4 CD27 DAP10 BCA CD4 CD27 DAP12 BCA CD4 CD27 CD32 BCA CD4 CD27 CD79a BCA CD4 CD27 CD79b BCA CD4 CD280 CD8 BCA CD4 CD28? CD3? BCA CD4 CD28? CD3? BCA CD4 CD28? CD3? BCA CD4 CD28? CD3? BCA CD4 CD28? Fc?RI-? BCA CD4 CD28? Fc?RIII-? BCA CD4 CD28? Fc?RI? BCA CD4 CD28? Fc?RI? BCA CD4 CD28? DAP10 BCA CD4 CD28? DAP12 BCA CD4 CD28? CD32 BCA CD4 CD28? CD79a BCA CD4 CD28? CD79b BCA CD4 CD80 CD8 BCA CD4 CD80 CD3? BCA CD4 CD80 CD3? BCA CD4 CD80 CD3? BCA CD4 CD80 CD3? BCA CD4 CD80 Fc?RI-? BCA CD4 CD80 Fc?RIII-? BCA CD4 CD80 Fc?RI? BCA CD4 CD80 Fc?RI? BCA CD4 CD80 DAP10 BCA CD4 CD80 DAP12 BCA CD4 CD80 CD32 BCA CD4 CD80 CD79a BCA CD4 CD80 CD79b BCA CD4 CD86 CD8 BCA CD4 CD86 CD3? BCA CD4 CD86 CD3? BCA CD4 CD86 CD3? BCA CD4 CD86 CD3? BCA CD4 CD86 Fc?RI-? BCA CD4 CD86 Fc?RIII-? BCA CD4 CD86 Fc?RI? BCA CD4 CD86 Fc?RI? BCA CD4 CD86 DAP10 BCA CD4 CD86 DAP12 BCA CD4 CD86 CD32 BCA CD4 CD86 CD79a BCA CD4 CD86 CD79b BCA CD4 OX40 CD8 BCA CD4 OX40 CD3? BCA CD4 OX40 CD3? BCA CD4 OX40 CD3? BCA CD4 OX40 CD3? BCA CD4 OX40 Fc?RI-? BCA CD4 OX40 Fc?RIII-? BCA CD4 OX40 Fc?RI? BCA CD4 OX40 Fc?RI? BCA CD4 OX40 DAP10 BCA CD4 OX40 DAP12 BCA CD4 OX40 CD32 BCA CD4 OX40 CD79a BCA CD4 OX40 CD79b BCA CD4 DAP10 CD8 BCA CD4 DAP10 CD3? BCA CD4 DAP10 CD3? BCA CD4 DAP10 CD3? BCA CD4 DAP10 CD3? BCA CD4 DAP10 Fc?RI-? BCA CD4 DAP10 Fc?RIII-? BCA CD4 DAP10 Fc?RI? BCA CD4 DAP10 Fc?RI? BCA CD4 DAP10 DAP10 BCA CD4 DAP10 DAP12 BCA CD4 DAP10 CD32 BCA CD4 DAP10 CD79a BCA CD4 DAP10 CD79b BCA CD4 DAP12 CD8 BCA CD4 DAP12 CD3? BCA CD4 DAP12 CD3? BCA CD4 DAP12 CD3? BCA CD4 DAP12 CD3? BCA CD4 DAP12 Fc?RI-? BCA CD4 DAP12 Fc?RIII-? BCA CD4 DAP12 Fc?RI? BCA CD4 DAP12 Fc?RI? BCA CD4 DAP12 DAP10 BCA CD4 DAP12 DAP12 BCA CD4 DAP12 CD32 BCA CD4 DAP12 CD79a BCA CD4 DAP12 CD79b BCA CD4 MyD88 CD8 BCA CD4 MyD88 CD3? BCA CD4 MyD88 CD3? BCA CD4 MyD88 CD3? BCA CD4 MyD88 CD3? BCA CD4 MyD88 Fc?RI-? BCA CD4 MyD88 Fc?RIII-? BCA CD4 MyD88 Fc?RI? BCA CD4 MyD88 Fc?RI? BCA CD4 MyD88 DAP10 BCA CD4 MyD88 DAP12 BCA CD4 MyD88 CD32 BCA CD4 MyD88 CD79a BCA CD4 MyD88 CD79b BCA CD4 CD7 CD8 BCA CD4 CD7 CD3? BCA CD4 CD7 CD3? BCA CD4 CD7 CD3? BCA CD4 CD7 CD3? BCA CD4 CD7 Fc?RI-? BCA CD4 CD7 Fc?RIII-? BCA CD4 CD7 Fc?RI? BCA CD4 CD7 Fc?RI? BCA CD4 CD7 DAP10 BCA CD4 CD7 DAP12 BCA CD4 CD7 CD32 BCA CD4 CD7 CD79a BCA CD4 CD7 CD79b BCA CD4 BTNL3 CD8 BCA CD4 BTNL3 CD3? BCA CD4 BTNL3 CD3? BCA CD4 BTNL3 CD3? BCA CD4 BTNL3 CD3? BCA CD4 BTNL3 Fc?RI-? BCA CD4 BTNL3 Fc?RIII-? BCA CD4 BTNL3 Fc?RI? BCA CD4 BTNL3 Fc?RI? BCA CD4 BTNL3 DAP10 BCA CD4 BTNL3 DAP12 BCA CD4 BTNL3 CD32 BCA CD4 BTNL3 CD79a BCA CD4 BTNL3 CD79b BCA CD4 NKG2D CD8 BCA CD4 NKG2D CD3? BCA CD4 NKG2D CD3? BCA CD4 NKG2D CD3? BCA CD4 NKG2D CD3? BCA CD4 NKG2D Fc?RI-? BCA CD4 NKG2D Fc?RIII-? BCA CD4 NKG2D Fc?RI? BCA CD4 NKG2D Fc?RI? BCA CD4 NKG2D DAP10 BCA CD4 NKG2D DAP12 BCA CD4 NKG2D CD32 BCA CD4 NKG2D CD79a BCA CD4 NKG2D CD79b BCA b2c CD28 CD8 BCA b2c CD28 CD3? BCA b2c CD28 CD3? BCA b2c CD28 CD3? BCA b2c CD28 CD3? BCA b2c CD28 Fc?RI-? BCA b2c CD28 Fc?RIII-? BCA b2c CD28 Fc?RI? BCA b2c CD28 Fc?RI? BCA b2c CD28 DAP10 BCA b2c CD28 DAP12 BCA b2c CD28 CD32 BCA b2c CD28 CD79a BCA b2c CD28 CD79b BCA b2c CD8 CD8 BCA b2c CD8 CD3? BCA b2c CD8 CD3? BCA b2c CD8 CD3? BCA b2c CD8 CD3? BCA b2c CD8 Fc?RI-? BCA b2c CD8 Fc?RIII-? BCA b2c CD8 Fc?RI? BCA b2c CD8 Fc?RI? BCA b2c CD8 DAP10 BCA b2c CD8 DAP12 BCA b2c CD8 CD32 BCA b2c CD8 CD79a BCA b2c CD8 CD79b BCA b2c CD4 CD8 BCA b2c CD4 CD3? BCA b2c CD4 CD3? BCA b2c CD4 CD3? BCA b2c CD4 CD3? BCA b2c CD4 Fc?RI-? BCA b2c CD4 Fc?RIII-? BCA b2c CD4 Fc?RI? BCA b2c CD4 Fc?RI? BCA b2c CD4 DAP10 BCA b2c CD4 DAP12 BCA b2c CD4 CD32 BCA b2c CD4 CD79a BCA b2c CD4 CD79b BCA b2c b2c CD8 BCA b2c b2c CD3? BCA b2c b2c CD3? BCA b2c b2c CD3? BCA b2c b2c CD3? BCA b2c b2c Fc?RI-? BCA b2c b2c Fc?RIII-? BCA b2c b2c Fc?RI? BCA b2c b2c Fc?RI? BCA b2c b2c DAP10 BCA b2c b2c DAP12 BCA b2c b2c CD32 BCA b2c b2c CD79a BCA b2c b2c CD79b BCA b2c CD137/41BB CD8 BCA b2c CD137/41BB CD3? BCA b2c CD137/41BB CD3? BCA b2c CD137/41BB CD3? BCA b2c CD137/41BB CD3? BCA b2c CD137/41BB Fc?RI-? BCA b2c CD137/41BB Fc?RIII-? BCA b2c CD137/41BB Fc?RI? BCA b2c CD137/41BB Fc?RI? BCA b2c CD137/41BB DAP10 BCA b2c CD137/41BB DAP12 BCA b2c CD137/41BB CD32 BCA b2c CD137/41BB CD79a BCA b2c CD137/41BB CD79b BCA b2c ICOS CD8 BCA b2c ICOS CD3? BCA b2c ICOS CD3? BCA b2c ICOS CD3? BCA b2c ICOS CD3? BCA b2c ICOS Fc?RI-? BCA b2c ICOS Fc?RIII-? BCA b2c ICOS Fc?RI? BCA b2c ICOS Fc?RI? BCA b2c ICOS DAP10 BCA b2c ICOS DAP12 BCA b2c ICOS CD32 BCA b2c ICOS CD79a BCA b2c ICOS CD79b BCA b2c CD27 CD8 BCA b2c CD27 CD3? BCA b2c CD27 CD3? BCA b2c CD27 CD3? BCA b2c CD27 CD3? BCA b2c CD27 Fc?RI-? BCA b2c CD27 Fc?RIII-? BCA b2c CD27 Fc?RI? BCA b2c CD27 Fc?RI? BCA b2c CD27 DAP10 BCA b2c CD27 DAP12 BCA b2c CD27 CD32 BCA b2c CD27 CD79a BCA b2c CD27 CD79b BCA b2c CD280 CD8 BCA b2c CD28? CD3? BCA b2c CD28? CD3? BCA b2c CD28? CD3? BCA b2c CD28? CD3? BCA b2c CD28? Fc?RI-? BCA b2c CD28? Fc?RIII-? BCA b2c CD28? Fc?RI? BCA b2c CD28? Fc?RI? BCA b2c CD28? DAP10 BCA b2c CD28? DAP12 BCA b2c CD28? CD32 BCA b2c CD28? CD79a BCA b2c CD28? CD79b BCA b2c CD80 CD8 BCA b2c CD80 CD3? BCA b2c CD80 CD3? BCA b2c CD80 CD3? BCA b2c CD80 CD3? BCA b2c CD80 Fc?RI-? BCA b2c CD80 Fc?RIII-? BCA b2c CD80 Fc?RI? BCA b2c CD80 Fc?RI? BCA b2c CD80 DAP10 BCA b2c CD80 DAP12 BCA b2c CD80 CD32 BCA b2c CD80 CD79a BCA b2c CD80 CD79b BCA b2c CD86 CD8 BCA b2c CD86 CD3? BCA b2c CD86 CD3? BCA b2c CD86 CD3? BCA b2c CD86 CD3? BCA b2c CD86 Fc?RI-? BCA b2c CD86 Fc?RIII-? BCA b2c CD86 Fc?RI? BCA b2c CD86 Fc?RI? BCA b2c CD86 DAP10 BCA b2c CD86 DAP12 BCA b2c CD86 CD32 BCA b2c CD86 CD79a BCA b2c CD86 CD79b BCA b2c OX40 CD8 BCA b2c OX40 CD3? BCA b2c OX40 CD3? BCA b2c OX40 CD3? BCA b2c OX40 CD3? BCA b2c OX40 Fc?RI-? BCA b2c OX40 Fc?RIII-? BCA b2c OX40 Fc?RI? BCA b2c OX40 Fc?RI? BCA b2c OX40 DAP10 BCA b2c OX40 DAP12 BCA b2c OX40 CD32 BCA b2c OX40 CD79a BCA b2c OX40 CD79b BCA b2c DAP10 CD8 BCA b2c DAP10 CD3? BCA b2c DAP10 CD3? BCA b2c DAP10 CD3? BCA b2c DAP10 CD3? BCA b2c DAP10 Fc?RI-? BCA b2c DAP10 Fc?RIII-? BCA b2c DAP10 Fc?RI? BCA b2c DAP10 Fc?RI? BCA b2c DAP10 DAP10 BCA b2c DAP10 DAP12 BCA b2c DAP10 CD32 BCA b2c DAP10 CD79a BCA b2c DAP10 CD79b BCA b2c DAP12 CD8 BCA b2c DAP12 CD3? BCA b2c DAP12 CD3? BCA b2c DAP12 CD3? BCA b2c DAP12 CD3? BCA b2c DAP12 Fc?RI-? BCA b2c DAP12 Fc?RIII-? BCA b2c DAP12 Fc?RI? BCA b2c DAP12 Fc?RI? BCA b2c DAP12 DAP10 BCA b2c DAP12 DAP12 BCA b2c DAP12 CD32 BCA b2c DAP12 CD79a BCA b2c DAP12 CD79b BCA b2c MyD88 CD8 BCA b2c MyD88 CD3? BCA b2c MyD88 CD3? BCA b2c MyD88 CD3? BCA b2c MyD88 CD3? BCA b2c MyD88 Fc?RI-? BCA b2c MyD88 Fc?RIII-? BCA b2c MyD88 Fc?RI? BCA b2c MyD88 Fc?RI? BCA b2c MyD88 DAP10 BCA b2c MyD88 DAP12 BCA b2c MyD88 CD32 BCA b2c MyD88 CD79a BCA b2c MyD88 CD79b BCA b2c CD7 CD8 BCA b2c CD7 CD3? BCA b2c CD7 CD3? BCA b2c CD7 CD3? BCA b2c CD7 CD3? BCA b2c CD7 Fc?RI-? BCA b2c CD7 Fc?RIII-? BCA b2c CD7 Fc?RI? BCA b2c CD7 Fc?RI? BCA b2c CD7 DAP10 BCA b2c CD7 DAP12 BCA b2c CD7 CD32 BCA b2c CD7 CD79a BCA b2c CD7 CD79b BCA b2c BTNL3 CD8 BCA b2c BTNL3 CD3? BCA b2c BTNL3 CD3? BCA b2c BTNL3 CD3? BCA b2c BTNL3 CD3? BCA b2c BTNL3 Fc?RI-? BCA b2c BTNL3 Fc?RIII-? BCA b2c BTNL3 Fc?RI? BCA b2c BTNL3 Fc?RI? BCA b2c BTNL3 DAP10 BCA b2c BTNL3 DAP12 BCA b2c BTNL3 CD32 BCA b2c BTNL3 CD79a BCA b2c BTNL3 CD79b BCA b2c NKG2D CD8 BCA b2c NKG2D CD3? BCA b2c NKG2D CD3? BCA b2c NKG2D CD3? BCA b2c NKG2D CD3? BCA b2c NKG2D Fc?RI-? BCA b2c NKG2D Fc?RIII-? BCA b2c NKG2D Fc?RI? BCA b2c NKG2D Fc?RI? BCA b2c NKG2D DAP10 BCA b2c NKG2D DAP12 BCA b2c NKG2D CD32 BCA b2c NKG2D CD79a BCA b2c NKG2D CD79b BCA CD137/41BB CD28 CD8 BCA CD137/41BB CD28 CD3? BCA CD137/41BB CD28 CD3? BCA CD137/41BB CD28 CD3? BCA CD137/41BB CD28 CD3? BCA CD137/41BB CD28 Fc?RI-? BCA CD137/41BB CD28 Fc?RIII-? BCA CD137/41BB CD28 Fc?RI? BCA CD137/41BB CD28 Fc?RI? BCA CD137/41BB CD28 DAP10 BCA CD137/41BB CD28 DAP12 BCA CD137/41BB CD28 CD32 BCA CD137/41BB CD28 CD79a BCA CD137/41BB CD28 CD79b BCA CD137/41BB CD8 CD8 BCA CD137/41BB CD8 CD3? BCA CD137/41BB CD8 CD3? BCA CD137/41BB CD8 CD3? BCA CD137/41BB CD8 CD3? BCA CD137/41BB CD8 Fc?RI-? BCA CD137/41BB CD8 Fc?RIII-? BCA CD137/41BB CD8 Fc?RI? BCA CD137/41BB CD8 Fc?RI? BCA CD137/41BB CD8 DAP10 BCA CD137/41BB CD8 DAP12 BCA CD137/41BB CD8 CD32 BCA CD137/41BB CD8 CD79a BCA CD137/41BB CD8 CD79b BCA CD137/41BB CD4 CD8 BCA CD137/41BB CD4 CD3? BCA CD137/41BB CD4 CD3? BCA CD137/41BB CD4 CD3? BCA CD137/41BB CD4 CD3? BCA CD137/41BB CD4 Fc?RI-? BCA CD137/41BB CD4 Fc?RIII-? BCA CD137/41BB CD4 Fc?RI? BCA CD137/41BB CD4 Fc?RI? BCA CD137/41BB CD4 DAP10 BCA CD137/41BB CD4 DAP12 BCA CD137/41BB CD4 CD32 BCA CD137/41BB CD4 CD79a BCA CD137/41BB CD4 CD79b BCA CD137/41BB b2c CD8 BCA CD137/41BB b2c CD3? BCA CD137/41BB b2c CD3? BCA CD137/41BB b2c CD3? BCA CD137/41BB b2c CD3? BCA CD137/41BB b2c Fc?RI-? BCA CD137/41BB b2c Fc?RIII-? BCA CD137/41BB b2c Fc?RI? BCA CD137/41BB b2c Fc?RI? BCA CD137/41BB b2c DAP10 BCA CD137/41BB b2c DAP12 BCA CD137/41BB b2c CD32 BCA CD137/41BB b2c CD79a BCA CD137/41BB b2c CD79b BCA CD137/41BB CD137/41BB CD8 BCA CD137/41BB CD137/41BB CD3? BCA CD137/41BB CD137/41BB CD3? BCA CD137/41BB CD137/41BB CD3? BCA CD137/41BB CD137/41BB CD3? BCA CD137/41BB CD137/41BB Fc?RI-? BCA CD137/41BB CD137/41BB Fc?RIII-? BCA CD137/41BB CD137/41BB Fc?RI? BCA CD137/41BB CD137/41BB Fc?RI? BCA CD137/41BB CD137/41BB DAP10 BCA CD137/41BB CD137/41BB DAP12 BCA CD137/41BB CD137/41BB CD32 BCA CD137/41BB CD137/41BB CD79a BCA CD137/41BB CD137/41BB CD79b BCA CD137/41BB ICOS CD8 BCA CD137/41BB ICOS CD3? BCA CD137/41BB ICOS CD3? BCA CD137/41BB ICOS CD3? BCA CD137/41BB ICOS CD3? BCA CD137/41BB ICOS Fc?RI-? BCA CD137/41BB ICOS Fc?RIII-? BCA CD137/41BB ICOS Fc?RI? BCA CD137/41BB ICOS Fc?RI? BCA CD137/41BB ICOS DAP10 BCA CD137/41BB ICOS DAP12 BCA CD137/41BB ICOS CD32 BCA CD137/41BB ICOS CD79a BCA CD137/41BB ICOS CD79b BCA CD137/41BB CD27 CD8 BCA CD137/41BB CD27 CD3? BCA CD137/41BB CD27 CD3? BCA CD137/41BB CD27 CD3? BCA CD137/41BB CD27 CD3? BCA CD137/41BB CD27 Fc?RI-? BCA CD137/41BB CD27 Fc?RIII-? BCA CD137/41BB CD27 Fc?RI? BCA CD137/41BB CD27 Fc?RI? BCA CD137/41BB CD27 DAP10 BCA CD137/41BB CD27 DAP12 BCA CD137/41BB CD27 CD32 BCA CD137/41BB CD27 CD79a BCA CD137/41BB CD27 CD79b BCA CD137/41BB CD28? CD8 BCA CD137/41BB CD280 CD3? BCA CD137/41BB CD28? CD3? BCA CD137/41BB CD28? CD3? BCA CD137/41BB CD28? CD3? BCA CD137/41BB CD28? Fc?RI-? BCA CD137/41BB CD28? Fc?RIII-? BCA CD137/41BB CD28? Fc?RI? BCA CD137/41BB CD28? Fc?RI? BCA CD137/41BB CD28? DAP10 BCA CD137/41BB CD28? DAP12 BCA CD137/41BB CD28? CD32 BCA CD137/41BB CD28? CD79a BCA CD137/41BB CD28? CD79b BCA CD137/41BB CD80 CD8 BCA CD137/41BB CD80 CD3? BCA CD137/41BB CD80 CD3? BCA CD137/41BB CD80 CD3? BCA CD137/41BB CD80 CD3? BCA CD137/41BB CD80 Fc?RI-? BCA CD137/41BB CD80 Fc?RIII-? BCA CD137/41BB CD80 Fc?RI? BCA CD137/41BB CD80 Fc?RI? BCA CD137/41BB CD80 DAP10 BCA CD137/41BB CD80 DAP12 BCA CD137/41BB CD80 CD32 BCA CD137/41BB CD80 CD79a BCA CD137/41BB CD80 CD79b BCA CD137/41BB CD86 CD8 BCA CD137/41BB CD86 CD3? BCA CD137/41BB CD86 CD3? BCA CD137/41BB CD86 CD3? BCA CD137/41BB CD86 CD3? BCA CD137/41BB CD86 Fc?RI-? BCA CD137/41BB CD86 Fc?RIII-? BCA CD137/41BB CD86 Fc?RI? BCA CD137/41BB CD86 Fc?RI? BCA CD137/41BB CD86 DAP10 BCA CD137/41BB CD86 DAP12 BCA CD137/41BB CD86 CD32 BCA CD137/41BB CD86 CD79a BCA CD137/41BB CD86 CD79b BCA CD137/41BB OX40 CD8 BCA CD137/41BB OX40 CD3? BCA CD137/41BB OX40 CD3? BCA CD137/41BB OX40 CD3? BCA CD137/41BB OX40 CD3? BCA CD137/41BB OX40 Fc?RI-? BCA CD137/41BB OX40 Fc?RIII-? BCA CD137/41BB OX40 Fc?RI? BCA CD137/41BB OX40 Fc?RI? BCA CD137/41BB OX40 DAP10 BCA CD137/41BB OX40 DAP12 BCA CD137/41BB OX40 CD32 BCA CD137/41BB OX40 CD79a BCA CD137/41BB OX40 CD79b BCA CD137/41BB DAP10 CD8 BCA CD137/41BB DAP10 CD3? BCA CD137/41BB DAP10 CD3? BCA CD137/41BB DAP10 CD3? BCA CD137/41BB DAP10 CD3? BCA CD137/41BB DAP10 Fc?RI-? BCA CD137/41BB DAP10 Fc?RIII-? BCA CD137/41BB DAP10 Fc?RI? BCA CD137/41BB DAP10 Fc?RI? BCA CD137/41BB DAP10 DAP10 BCA CD137/41BB DAP10 DAP12 BCA CD137/41BB DAP10 CD32 BCA CD137/41BB DAP10 CD79a BCA CD137/41BB DAP10 CD79b BCA CD137/41BB DAP12 CD8 BCA CD137/41BB DAP12 CD3? BCA CD137/41BB DAP12 CD3? BCA CD137/41BB DAP12 CD3? BCA CD137/41BB DAP12 CD3? BCA CD137/41BB DAP12 Fc?RI-? BCA CD137/41BB DAP12 Fc?RIII-? BCA CD137/41BB DAP12 Fc?RI? BCA CD137/41BB DAP12 Fc?RI? BCA CD137/41BB DAP12 DAP10 BCA CD137/41BB DAP12 DAP12 BCA CD137/41BB DAP12 CD32 BCA CD137/41BB DAP12 CD79a BCA CD137/41BB DAP12 CD79b BCA CD137/41BB MyD88 CD8 BCA CD137/41BB MyD88 CD3? BCA CD137/41BB MyD88 CD3? BCA CD137/41BB MyD88 CD3? BCA CD137/41BB MyD88 CD3? BCA CD137/41BB MyD88 Fc?RI-? BCA CD137/41BB MyD88 Fc?RIII-? BCA CD137/41BB MyD88 Fc?RI? BCA CD137/41BB MyD88 Fc?RI? BCA CD137/41BB MyD88 DAP10 BCA CD137/41BB MyD88 DAP12 BCA CD137/41BB MyD88 CD32 BCA CD137/41BB MyD88 CD79a BCA CD137/41BB MyD88 CD79b BCA CD137/41BB CD7 CD8 BCA CD137/41BB CD7 CD3? BCA CD137/41BB CD7 CD3? BCA CD137/41BB CD7 CD3? BCA CD137/41BB CD7 CD3? BCA CD137/41BB CD7 Fc?RI-? BCA CD137/41BB CD7 Fc?RIII-? BCA CD137/41BB CD7 Fc?RI? BCA CD137/41BB CD7 Fc?RI? BCA CD137/41BB CD7 DAP10 BCA CD137/41BB CD7 DAP12 BCA CD137/41BB CD7 CD32 BCA CD137/41BB CD7 CD79a BCA CD137/41BB CD7 CD79b BCA CD137/41BB BTNL3 CD8 BCA CD137/41BB BTNL3 CD3? BCA CD137/41BB BTNL3 CD3? BCA CD137/41BB BTNL3 CD3? BCA CD137/41BB BTNL3 CD3? BCA CD137/41BB BTNL3 Fc?RI-? BCA CD137/41BB BTNL3 Fc?RIII-? BCA CD137/41BB BTNL3 Fc?RI? BCA CD137/41BB BTNL3 Fc?RI? BCA CD137/41BB BTNL3 DAP10 BCA CD137/41BB BTNL3 DAP12 BCA CD137/41BB BTNL3 CD32 BCA CD137/41BB BTNL3 CD79a BCA CD137/41BB BTNL3 CD79b BCA CD137/41BB NKG2D CD8 BCA CD137/41BB NKG2D CD3? BCA CD137/41BB NKG2D CD3? BCA CD137/41BB NKG2D CD3? BCA CD137/41BB NKG2D CD3? BCA CD137/41BB NKG2D Fc?RI-? BCA CD137/41BB NKG2D Fc?RIII-? BCA CD137/41BB NKG2D Fc?RI? BCA CD137/41BB NKG2D Fc?RI? BCA CD137/41BB NKG2D DAP10 BCA CD137/41BB NKG2D DAP12 BCA CD137/41BB NKG2D CD32 BCA CD137/41BB NKG2D CD79a BCA CD137/41BB NKG2D CD79b BCA ICOS CD28 CD8 BCA ICOS CD28 CD3? BCA ICOS CD28 CD3? BCA ICOS CD28 CD3? BCA ICOS CD28 CD3? BCA ICOS CD28 Fc?RI-? BCA ICOS CD28 Fc?RIII-? BCA ICOS CD28 Fc?RI? BCA ICOS CD28 Fc?RI? BCA ICOS CD28 DAP10 BCA ICOS CD28 DAP12 BCA ICOS CD28 CD32 BCA ICOS CD28 CD79a BCA ICOS CD28 CD79b BCA ICOS CD8 CD8 BCA ICOS CD8 CD3? BCA ICOS CD8 CD3? BCA ICOS CD8 CD3? BCA ICOS CD8 CD3? BCA ICOS CD8 Fc?RI-? BCA ICOS CD8 Fc?RIII-? BCA ICOS CD8 Fc?RI? BCA ICOS CD8 Fc?RI? BCA ICOS CD8 DAP10 BCA ICOS CD8 DAP12 BCA ICOS CD8 CD32 BCA ICOS CD8 CD79a BCA ICOS CD8 CD79b BCA ICOS CD4 CD8 BCA ICOS CD4 CD3? BCA ICOS CD4 CD3? BCA ICOS CD4 CD3? BCA ICOS CD4 CD3? BCA ICOS CD4 Fc?RI-? BCA ICOS CD4 Fc?RIII-? BCA ICOS CD4 Fc?RI? BCA ICOS CD4 Fc?RI? BCA ICOS CD4 DAP10 BCA ICOS CD4 DAP12 BCA ICOS CD4 CD32 BCA ICOS CD4 CD79a BCA ICOS CD4 CD79b BCA ICOS b2c CD8 BCA ICOS b2c CD3? BCA ICOS b2c CD3? BCA ICOS b2c CD3? BCA ICOS b2c CD3? BCA ICOS b2c Fc?RI-? BCA ICOS b2c Fc?RIII-? BCA ICOS b2c Fc?RI? BCA ICOS b2c Fc?RI? BCA ICOS b2c DAP10 BCA ICOS b2c DAP12 BCA ICOS b2c CD32 BCA ICOS b2c CD79a BCA ICOS b2c CD79b BCA ICOS CD137/41BB CD8 BCA ICOS CD137/41BB CD3? BCA ICOS CD137/41BB CD3? BCA ICOS CD137/41BB CD3? BCA ICOS CD137/41BB CD3? BCA ICOS CD137/41BB Fc?RI-? BCA ICOS CD137/41BB Fc?RIII-? BCA ICOS CD137/41BB Fc?RI? BCA ICOS CD137/41BB Fc?RI? BCA ICOS CD137/41BB DAP10 BCA ICOS CD137/41BB DAP12 BCA ICOS CD137/41BB CD32 BCA ICOS CD137/41BB CD79a BCA ICOS CD137/41BB CD79b BCA ICOS ICOS CD8 BCA ICOS ICOS CD3? BCA ICOS ICOS CD3? BCA ICOS ICOS CD3? BCA ICOS ICOS CD3? BCA ICOS ICOS Fc?RI-? BCA ICOS ICOS Fc?RIII-? BCA ICOS ICOS Fc?RI? BCA ICOS ICOS Fc?RI? BCA ICOS ICOS DAP10 BCA ICOS ICOS DAP12 BCA ICOS ICOS CD32 BCA ICOS ICOS CD79a BCA ICOS ICOS CD79b BCA ICOS CD27 CD8 BCA ICOS CD27 CD3? BCA ICOS CD27 CD3? BCA ICOS CD27 CD3? BCA ICOS CD27 CD3? BCA ICOS CD27 Fc?RI-? BCA ICOS CD27 Fc?RIII-? BCA ICOS CD27 Fc?RI? BCA ICOS CD27 Fc?RI? BCA ICOS CD27 DAP10 BCA ICOS CD27 DAP12 BCA ICOS CD27 CD32 BCA ICOS CD27 CD79a BCA ICOS CD27 CD79b BCA ICOS CD280 CD8 BCA ICOS CD28? CD3? BCA ICOS CD28? CD3? BCA ICOS CD28? CD3? BCA ICOS CD28? CD3? BCA ICOS CD28? Fc?RI-? BCA ICOS CD28? Fc?RIII-? BCA ICOS CD28? Fc?RI? BCA ICOS CD28? Fc?RI? BCA ICOS CD28? DAP10 BCA ICOS CD28? DAP12 BCA ICOS CD28? CD32 BCA ICOS CD28? CD79a BCA ICOS CD28? CD79b BCA ICOS CD80 CD8 BCA ICOS CD80 CD3? BCA ICOS CD80 CD3? BCA ICOS CD80 CD3? BCA ICOS CD80 CD3? BCA ICOS CD80 Fc?RI-? BCA ICOS CD80 Fc?RIII-? BCA ICOS CD80 Fc?RI? BCA ICOS CD80 Fc?RI? BCA ICOS CD80 DAP10 BCA ICOS CD80 DAP12 BCA ICOS CD80 CD32 BCA ICOS CD80 CD79a BCA ICOS CD80 CD79b BCA ICOS CD86 CD8 BCA ICOS CD86 CD3? BCA ICOS CD86 CD3? BCA ICOS CD86 CD3? BCA ICOS CD86 CD3? BCA ICOS CD86 Fc?RI-? BCA ICOS CD86 Fc?RIII-? BCA ICOS CD86 Fc?RI? BCA ICOS CD86 Fc?RI? BCA ICOS CD86 DAP10 BCA ICOS CD86 DAP12 BCA ICOS CD86 CD32 BCA ICOS CD86 CD79a BCA ICOS CD86 CD79b BCA ICOS OX40 CD8 BCA ICOS OX40 CD3? BCA ICOS OX40 CD3? BCA ICOS OX40 CD3? BCA ICOS OX40 CD3? BCA ICOS OX40 Fc?RI-? BCA ICOS OX40 Fc?RIII-? BCA ICOS OX40 Fc?RI? BCA ICOS OX40 Fc?RI? BCA ICOS OX40 DAP10 BCA ICOS OX40 DAP12 BCA ICOS OX40 CD32 BCA ICOS OX40 CD79a BCA ICOS OX40 CD79b BCA ICOS DAP10 CD8 BCA ICOS DAP10 CD3? BCA ICOS DAP10 CD3? BCA ICOS DAP10 CD3? BCA ICOS DAP10 CD3? BCA ICOS DAP10 Fc?RI-? BCA ICOS DAP10 Fc?RIII-? BCA ICOS DAP10 Fc?RI? BCA ICOS DAP10 Fc?RI? BCA ICOS DAP10 DAP10 BCA ICOS DAP10 DAP12 BCA ICOS DAP10 CD32 BCA ICOS DAP10 CD79a BCA ICOS DAP10 CD79b BCA ICOS DAP12 CD8 BCA ICOS DAP12 CD3? BCA ICOS DAP12 CD3? BCA ICOS DAP12 CD3? BCA ICOS DAP12 CD3? BCA ICOS DAP12 Fc?RI-? BCA ICOS DAP12 Fc?RIII-? BCA ICOS DAP12 Fc?RI? BCA ICOS DAP12 Fc?RI? BCA ICOS DAP12 DAP10 BCA ICOS DAP12 DAP12 BCA ICOS DAP12 CD32 BCA ICOS DAP12 CD79a BCA ICOS DAP12 CD79b BCA ICOS MyD88 CD8 BCA ICOS MyD88 CD3? BCA ICOS MyD88 CD3? BCA ICOS MyD88 CD3? BCA ICOS MyD88 CD3? BCA ICOS MyD88 Fc?RI-? BCA ICOS MyD88 Fc?RIII-? BCA ICOS MyD88 Fc?RI? BCA ICOS MyD88 Fc?RI? BCA ICOS MyD88 DAP10 BCA ICOS MyD88 DAP12 BCA ICOS MyD88 CD32 BCA ICOS MyD88 CD79a BCA ICOS MyD88 CD79b BCA ICOS CD7 CD8 BCA ICOS CD7 CD3? BCA ICOS CD7 CD3? BCA ICOS CD7 CD3? BCA ICOS CD7 CD3? BCA ICOS CD7 Fc?RI-? BCA ICOS CD7 Fc?RIII-? BCA ICOS CD7 Fc?RI? BCA ICOS CD7 Fc?RI? BCA ICOS CD7 DAP10 BCA ICOS CD7 DAP12 BCA ICOS CD7 CD32 BCA ICOS CD7 CD79a BCA ICOS CD7 CD79b BCA ICOS BTNL3 CD8 BCA ICOS BTNL3 CD3? BCA ICOS BTNL3 CD3? BCA ICOS BTNL3 CD3? BCA ICOS BTNL3 CD3? BCA ICOS BTNL3 Fc?RI-? BCA ICOS BTNL3 Fc?RIII-? BCA ICOS BTNL3 Fc?RI? BCA ICOS BTNL3 Fc?RI? BCA ICOS BTNL3 DAP10 BCA ICOS BTNL3 DAP12 BCA ICOS BTNL3 CD32 BCA ICOS BTNL3 CD79a BCA ICOS BTNL3 CD79b BCA ICOS NKG2D CD8 BCA ICOS NKG2D CD3? BCA ICOS NKG2D CD3? BCA ICOS NKG2D CD3? BCA ICOS NKG2D CD3? BCA ICOS NKG2D Fc?RI-? BCA ICOS NKG2D Fc?RIII-? BCA ICOS NKG2D Fc?RI? BCA ICOS NKG2D Fc?RI? BCA ICOS NKG2D DAP10 BCA ICOS NKG2D DAP12 BCA ICOS NKG2D CD32 BCA ICOS NKG2D CD79a BCA ICOS NKG2D CD79b BCA CD27 CD28 CD8 BCA CD27 CD28 CD3? BCA CD27 CD28 CD3? BCA CD27 CD28 CD3? BCA CD27 CD28 CD3? BCA CD27 CD28 Fc?RI-? BCA CD27 CD28 Fc?RIII-? BCA CD27 CD28 Fc?RI? BCA CD27 CD28 Fc?RI? BCA CD27 CD28 DAP10 BCA CD27 CD28 DAP12 BCA CD27 CD28 CD32 BCA CD27 CD28 CD79a BCA CD27 CD28 CD79b BCA CD27 CD8 CD8 BCA CD27 CD8 CD3? BCA CD27 CD8 CD3? BCA CD27 CD8 CD3? BCA CD27 CD8 CD3? BCA CD27 CD8 Fc?RI-? BCA CD27 CD8 Fc?RIII-? BCA CD27 CD8 Fc?RI? BCA CD27 CD8 Fc?RI? BCA CD27 CD8 DAP10 BCA CD27 CD8 DAP12 BCA CD27 CD8 CD32 BCA CD27 CD8 CD79a BCA CD27 CD8 CD79b BCA CD27 CD4 CD8 BCA CD27 CD4 CD3? BCA CD27 CD4 CD3? BCA CD27 CD4 CD3? BCA CD27 CD4 CD3? BCA CD27 CD4 Fc?RI-? BCA CD27 CD4 Fc?RIII-? BCA CD27 CD4 Fc?RI? BCA CD27 CD4 Fc?RI? BCA CD27 CD4 DAP10 BCA CD27 CD4 DAP12 BCA CD27 CD4 CD32 BCA CD27 CD4 CD79a BCA CD27 CD4 CD79b BCA CD27 b2c CD8 BCA CD27 b2c CD3? BCA CD27 b2c CD3? BCA CD27 b2c CD3? BCA CD27 b2c CD3? BCA CD27 b2c Fc?RI-? BCA CD27 b2c Fc?RIII-? BCA CD27 b2c Fc?RI? BCA CD27 b2c Fc?RI? BCA CD27 b2c DAP10 BCA CD27 b2c DAP12 BCA CD27 b2c CD32 BCA CD27 b2c CD79a BCA CD27 b2c CD79b BCA CD27 CD137/41BB CD8 BCA CD27 CD137/41BB CD3? BCA CD27 CD137/41BB CD3? BCA CD27 CD137/41BB CD3? BCA CD27 CD137/41BB CD3? BCA CD27 CD137/41BB Fc?RI-? BCA CD27 CD137/41BB Fc?RIII-? BCA CD27 CD137/41BB Fc?RI? BCA CD27 CD137/41BB Fc?RI? BCA CD27 CD137/41BB DAP10 BCA CD27 CD137/41BB DAP12 BCA CD27 CD137/41BB CD32 BCA CD27 CD137/41BB CD79a BCA CD27 CD137/41BB CD79b BCA CD27 ICOS CD8 BCA CD27 ICOS CD3? BCA CD27 ICOS CD3? BCA CD27 ICOS CD3? BCA CD27 ICOS CD3? BCA CD27 ICOS Fc?RI-? BCA CD27 ICOS Fc?RIII-? BCA CD27 ICOS Fc?RI? BCA CD27 ICOS Fc?RI? BCA CD27 ICOS DAP10 BCA CD27 ICOS DAP12 BCA CD27 ICOS CD32 BCA CD27 ICOS CD79a BCA CD27 ICOS CD79b BCA CD27 CD27 CD8 BCA CD27 CD27 CD3? BCA CD27 CD27 CD3? BCA CD27 CD27 CD3? BCA CD27 CD27 CD3? BCA CD27 CD27 Fc?RI-? BCA CD27 CD27 Fc?RIII-? BCA CD27 CD27 Fc?RI? BCA CD27 CD27 Fc?RI? BCA CD27 CD27 DAP10 BCA CD27 CD27 DAP12 BCA CD27 CD27 CD32 BCA CD27 CD27 CD79a BCA CD27 CD27 CD79b BCA CD27 CD28? CD8 BCA CD27 CD28? CD3? BCA CD27 CD28? CD3? BCA CD27 CD28? CD3? BCA CD27 CD28? CD3? BCA CD27 CD28? Fc?RI-? BCA CD27 CD28? Fc?RIII-? BCA CD27 CD28? Fc?RI? BCA CD27 CD28? Fc?RI? BCA CD27 CD28? DAP10 BCA CD27 CD28? DAP12 BCA CD27 CD28? CD32 BCA CD27 CD28? CD79a BCA CD27 CD28? CD79b BCA CD27 CD80 CD8 BCA CD27 CD80 CD3? BCA CD27 CD80 CD3? BCA CD27 CD80 CD3? BCA CD27 CD80 CD3? BCA CD27 CD80 Fc?RI-? BCA CD27 CD80 Fc?RIII-? BCA CD27 CD80 Fc?RI? BCA CD27 CD80 Fc?RI? BCA CD27 CD80 DAP10 BCA CD27 CD80 DAP12 BCA CD27 CD80 CD32 BCA CD27 CD80 CD79a BCA CD27 CD80 CD79b BCA CD27 CD86 CD8 BCA CD27 CD86 CD3? BCA CD27 CD86 CD3? BCA CD27 CD86 CD3? BCA CD27 CD86 CD3? BCA CD27 CD86 Fc?RI-? BCA CD27 CD86 Fc?RIII-? BCA CD27 CD86 Fc?RI? BCA CD27 CD86 Fc?RI? BCA CD27 CD86 DAP10 BCA CD27 CD86 DAP12 BCA CD27 CD86 CD32 BCA CD27 CD86 CD79a BCA CD27 CD86 CD79b BCA CD27 OX40 CD8 BCA CD27 OX40 CD3? BCA CD27 OX40 CD3? BCA CD27 OX40 CD3? BCA CD27 OX40 CD3? BCA CD27 OX40 Fc?RI-? BCA CD27 OX40 Fc?RIII-? BCA CD27 OX40 Fc?RI? BCA CD27 OX40 Fc?RI? BCA CD27 OX40 DAP10 BCA CD27 OX40 DAP12 BCA CD27 OX40 CD32 BCA CD27 OX40 CD79a BCA CD27 OX40 CD79b BCA CD27 DAP10 CD8 BCA CD27 DAP10 CD3? BCA CD27 DAP10 CD3? BCA CD27 DAP10 CD3? BCA CD27 DAP10 CD3? BCA CD27 DAP10 Fc?RI-? BCA CD27 DAP10 Fc?RIII-? BCA CD27 DAP10 Fc?RI? BCA CD27 DAP10 Fc?RI? BCA CD27 DAP10 DAP10 BCA CD27 DAP10 DAP12 BCA CD27 DAP10 CD32 BCA CD27 DAP10 CD79a BCA CD27 DAP10 CD79b BCA CD27 DAP12 CD8 BCA CD27 DAP12 CD3? BCA CD27 DAP12 CD3? BCA CD27 DAP12 CD3? BCA CD27 DAP12 CD3? BCA CD27 DAP12 Fc?RI-? BCA CD27 DAP12 Fc?RIII-? BCA CD27 DAP12 Fc?RI? BCA CD27 DAP12 Fc?RI? BCA CD27 DAP12 DAP10 BCA CD27 DAP12 DAP12 BCA CD27 DAP12 CD32 BCA CD27 DAP12 CD79a BCA CD27 DAP12 CD79b BCA CD27 MyD88 CD8 BCA CD27 MyD88 CD3? BCA CD27 MyD88 CD3? BCA CD27 MyD88 CD3? BCA CD27 MyD88 CD3? BCA CD27 MyD88 Fc?RI-? BCA CD27 MyD88 Fc?RIII-? BCA CD27 MyD88 Fc?RI? BCA CD27 MyD88 Fc?RI? BCA CD27 MyD88 DAP10 BCA CD27 MyD88 DAP12 BCA CD27 MyD88 CD32 BCA CD27 MyD88 CD79a BCA CD27 MyD88 CD79b BCA CD27 CD7 CD8 BCA CD27 CD7 CD3? BCA CD27 CD7 CD3? BCA CD27 CD7 CD3? BCA CD27 CD7 CD3? BCA CD27 CD7 Fc?RI-? BCA CD27 CD7 Fc?RIII-? BCA CD27 CD7 Fc?RI? BCA CD27 CD7 Fc?RI? BCA CD27 CD7 DAP10 BCA CD27 CD7 DAP12 BCA CD27 CD7 CD32 BCA CD27 CD7 CD79a BCA CD27 CD7 CD79b BCA CD27 BTNL3 CD8 BCA CD27 BTNL3 CD3? BCA CD27 BTNL3 CD3? BCA CD27 BTNL3 CD3? BCA CD27 BTNL3 CD3? BCA CD27 BTNL3 Fc?RI-? BCA CD27 BTNL3 Fc?RIII-? BCA CD27 BTNL3 Fc?RI? BCA CD27 BTNL3 Fc?RI? BCA CD27 BTNL3 DAP10 BCA CD27 BTNL3 DAP12 BCA CD27 BTNL3 CD32 BCA CD27 BTNL3 CD79a BCA CD27 BTNL3 CD79b BCA CD27 NKG2D CD8 BCA CD27 NKG2D CD3? BCA CD27 NKG2D CD3? BCA CD27 NKG2D CD3? BCA CD27 NKG2D CD3? BCA CD27 NKG2D Fc?RI-? BCA CD27 NKG2D Fc?RIII-? BCA CD27 NKG2D Fc?RI? BCA CD27 NKG2D Fc?RI? BCA CD27 NKG2D DAP10 BCA CD27 NKG2D DAP12 BCA CD27 NKG2D CD32 BCA CD27 NKG2D CD79a BCA CD27 NKG2D CD79b BCA CD28? CD28 CD8 BCA CD28? CD28 CD3? BCA CD28? CD28 CD3? BCA CD28? CD28 CD3? BCA CD28? CD28 CD3? BCA CD28? CD28 Fc?RI-? BCA CD28? CD28 Fc?RIII-? BCA CD28? CD28 Fc?RI? BCA CD28? CD28 Fc?RI? BCA CD28? CD28 DAP10 BCA CD28? CD28 DAP12 BCA CD28? CD28 CD32 BCA CD28? CD28 CD79a BCA CD28? CD28 CD79b BCA CD28? CD8 CD8 BCA CD28? CD8 CD3? BCA CD28? CD8 CD3? BCA CD28? CD8 CD3? BCA CD28? CD8 CD3? BCA CD28? CD8 Fc?RI-? BCA CD28? CD8 Fc?RIII-? BCA CD28? CD8 Fc?RI? BCA CD28? CD8 Fc?RI? BCA CD28? CD8 DAP10 BCA CD28? CD8 DAP12 BCA CD28? CD8 CD32 BCA CD28? CD8 CD79a BCA CD28? CD8 CD79b BCA CD28? CD4 CD8 BCA CD28? CD4 CD3? BCA CD28? CD4 CD3? BCA CD28? CD4 CD3? BCA CD28? CD4 CD3? BCA CD28? CD4 Fc?RI-? BCA CD28? CD4 Fc?RIII-? BCA CD28? CD4 Fc?RI? BCA CD28? CD4 Fc?RI? BCA CD28? CD4 DAP10 BCA CD28? CD4 DAP12 BCA CD28? CD4 CD32 BCA CD28? CD4 CD79a BCA CD28? CD4 CD79b BCA CD28? b2c CD8 BCA CD28? b2c CD3? BCA CD28? b2c CD3? BCA CD28? b2c CD3? BCA CD28? b2c CD3? BCA CD28? b2c Fc?RI-? BCA CD28? b2c Fc?RIII-? BCA CD28? b2c Fc?RI? BCA CD28? b2c Fc?RI? BCA CD28? b2c DAP10 BCA CD28? b2c DAP12 BCA CD28? b2c CD32 BCA CD28? b2c CD79a BCA CD28? b2c CD79b BCA CD28? CD137/41BB CD8 BCA CD28? CD137/41BB CD3? BCA CD28? CD137/41BB CD3? BCA CD28? CD137/41BB CD3? BCA CD28? CD137/41BB CD3? BCA CD28? CD137/41BB Fc?RI-? BCA CD28? CD137/41BB Fc?RIII-? BCA CD28? CD137/41BB Fc?RI? BCA CD28? CD137/41BB Fc?RI? BCA CD28? CD137/41BB DAP10 BCA CD28? CD137/41BB DAP12 BCA CD28? CD137/41BB CD32 BCA CD28? CD137/41BB CD79a BCA CD28? CD137/41BB CD79b BCA CD28? ICOS CD8 BCA CD28? ICOS CD3? BCA CD28? ICOS CD3? BCA CD28? ICOS CD3? BCA CD28? ICOS CD3? BCA CD28? ICOS Fc?RI-? BCA CD28? ICOS Fc?RIII-? BCA CD28? ICOS Fc?RI? BCA CD28? ICOS Fc?RI? BCA CD28? ICOS DAP10 BCA CD28? ICOS DAP12 BCA CD28? ICOS CD32 BCA CD28? ICOS CD79a BCA CD28? ICOS CD79b BCA CD28? CD27 CD8 BCA CD28? CD27 CD3? BCA CD28? CD27 CD3? BCA CD28? CD27 CD3? BCA CD28? CD27 CD3? BCA CD28? CD27 Fc?RI-? BCA CD28? CD27 Fc?RIII-? BCA CD28? CD27 Fc?RI? BCA CD28? CD27 Fc?RI? BCA CD28? CD27 DAP10 BCA CD28? CD27 DAP12 BCA CD28? CD27 CD32 BCA CD28? CD27 CD79a BCA CD28? CD27 CD79b BCA CD28? CD28? CD8 BCA CD28? CD28? CD3? BCA CD28? CD28? CD3? BCA CD28? CD28? CD3? BCA CD28? CD28? CD3? BCA CD28? CD28? Fc?RI-? BCA CD28? CD28? Fc?RIII-? BCA CD28? CD28? Fc?RI? BCA CD28? CD28? Fc?RI? BCA CD28? CD28? DAP10 BCA CD28? CD28? DAP12 BCA CD28? CD28? CD32 BCA CD28? CD28? CD79a BCA CD28? CD28? CD79b BCA CD28? CD80 CD8 BCA CD28? CD80 CD3? BCA CD28? CD80 CD3? BCA CD28? CD80 CD3? BCA CD28? CD80 CD3? BCA CD28? CD80 Fc?RI-? BCA CD28? CD80 Fc?RIII-? BCA CD28? CD80 Fc?RI? BCA CD28? CD80 Fc?RI? BCA CD28? CD80 DAP10 BCA CD28? CD80 DAP12 BCA CD28? CD80 CD32 BCA CD28? CD80 CD79a BCA CD28? CD80 CD79b BCA CD28? CD86 CD8 BCA CD28? CD86 CD3? BCA CD28? CD86 CD3? BCA CD28? CD86 CD3? BCA CD28? CD86 CD3? BCA CD28? CD86 Fc?RI-? BCA CD28? CD86 Fc?RIII-? BCA CD28? CD86 Fc?RI? BCA CD28? CD86 Fc?RI? BCA CD28? CD86 DAP10 BCA CD28? CD86 DAP12 BCA CD28? CD86 CD32 BCA CD28? CD86 CD79a BCA CD28? CD86 CD79b BCA CD28? OX40 CD8 BCA CD28? OX40 CD3? BCA CD28? OX40 CD3? BCA CD28? OX40 CD3? BCA CD28? OX40 CD3? BCA CD28? OX40 Fc?RI-? BCA CD28? OX40 Fc?RIII-? BCA CD28? OX40 Fc?RI? BCA CD28? OX40 Fc?RI? BCA CD28? OX40 DAP10 BCA CD28? OX40 DAP12 BCA CD28? OX40 CD32 BCA CD28? OX40 CD79a BCA CD28? OX40 CD79b BCA CD28? DAP10 CD8 BCA CD28? DAP10 CD3? BCA CD28? DAP10 CD3? BCA CD28? DAP10 CD3? BCA CD28? DAP10 CD3? BCA CD28? DAP10 Fc?RI-? BCA CD28? DAP10 Fc?RIII-? BCA CD28? DAP10 Fc?RI? BCA CD28? DAP10 Fc?RI? BCA CD28? DAP10 DAP10 BCA CD28? DAP10 DAP12 BCA CD28? DAP10 CD32 BCA CD28? DAP10 CD79a BCA CD28? DAP10 CD79b BCA CD28? DAP12 CD8 BCA CD28? DAP12 CD3? BCA CD28? DAP12 CD3? BCA CD28? DAP12 CD3? BCA CD28? DAP12 CD3? BCA CD28? DAP12 Fc?RI-? BCA CD28? DAP12 Fc?RIII-? BCA CD28? DAP12 Fc?RI? BCA CD28? DAP12 Fc?RI? BCA CD28? DAP12 DAP10 BCA CD28? DAP12 DAP12 BCA CD28? DAP12 CD32 BCA CD28? DAP12 CD79a BCA CD28? DAP12 CD79b BCA CD28? MyD88 CD8 BCA CD28? MyD88 CD3? BCA CD28? MyD88 CD3? BCA CD28? MyD88 CD3? BCA CD28? MyD88 CD3? BCA CD28? MyD88 Fc?RI-? BCA CD28? MyD88 Fc?RIII-? BCA CD28? MyD88 Fc?RI? BCA CD28? MyD88 Fc?RI? BCA CD28? MyD88 DAP10 BCA CD28? MyD88 DAP12 BCA CD28? MyD88 CD32 BCA CD28? MyD88 CD79a BCA CD28? MyD88 CD79b BCA CD28? CD7 CD8 BCA CD28? CD7 CD3? BCA CD28? CD7 CD3? BCA CD28? CD7 CD3? BCA CD28? CD7 CD3? BCA CD28? CD7 Fc?RI-? BCA CD28? CD7 Fc?RIII-? BCA CD28? CD7 Fc?RI? BCA CD28? CD7 Fc?RI? BCA CD28? CD7 DAP10 BCA CD28? CD7 DAP12 BCA CD28? CD7 CD32 BCA CD28? CD7 CD79a BCA CD28? CD7 CD79b BCA CD28? BTNL3 CD8 BCA CD28? BTNL3 CD3? BCA CD28? BTNL3 CD3? BCA CD28? BTNL3 CD3? BCA CD28? BTNL3 CD3? BCA CD28? BTNL3 Fc?RI-? BCA CD28? BTNL3 Fc?RIII-? BCA CD28? BTNL3 Fc?RI? BCA CD28? BTNL3 Fc?RI? BCA CD28? BTNL3 DAP10 BCA CD28? BTNL3 DAP12 BCA CD28? BTNL3 CD32 BCA CD28? BTNL3 CD79a BCA CD28? BTNL3 CD79b BCA CD28? NKG2D CD8 BCA CD28? NKG2D CD3? BCA CD28? NKG2D CD3? BCA CD28? NKG2D CD3? BCA CD28? NKG2D CD3? BCA CD28? NKG2D Fc?RI-? BCA CD28? NKG2D Fc?RIII-? BCA CD28? NKG2D Fc?RI? BCA CD28? NKG2D Fc?RI? BCA CD28? NKG2D DAP10 BCA CD28? NKG2D DAP12 BCA CD28? NKG2D CD32 BCA CD28? NKG2D CD79a BCA CD28? NKG2D CD79b BCA CD80 CD28 CD8 BCA CD80 CD28 CD3? BCA CD80 CD28 CD3? BCA CD80 CD28 CD3? BCA CD80 CD28 CD3? BCA CD80 CD28 Fc?RI-? BCA CD80 CD28 Fc?RIII-? BCA CD80 CD28 Fc?RI? BCA CD80 CD28 Fc?RI? BCA CD80 CD28 DAP10 BCA CD80 CD28 DAP12 BCA CD80 CD28 CD32 BCA CD80 CD28 CD79a BCA CD80 CD28 CD79b BCA CD80 CD8 CD8 BCA CD80 CD8 CD3? BCA CD80 CD8 CD3? BCA CD80 CD8 CD3? BCA CD80 CD8 CD3? BCA CD80 CD8 Fc?RI-? BCA CD80 CD8 Fc?RIII-? BCA CD80 CD8 Fc?RI? BCA CD80 CD8 Fc?RI? BCA CD80 CD8 DAP10 BCA CD80 CD8 DAP12 BCA CD80 CD8 CD32 BCA CD80 CD8 CD79a BCA CD80 CD8 CD79b BCA CD80 CD4 CD8 BCA CD80 CD4 CD3? BCA CD80 CD4 CD3? BCA CD80 CD4 CD3? BCA CD80 CD4 CD3? BCA CD80 CD4 Fc?RI-? BCA CD80 CD4 Fc?RIII-? BCA CD80 CD4 Fc?RI? BCA CD80 CD4 Fc?RI? BCA CD80 CD4 DAP10 BCA CD80 CD4 DAP12 BCA CD80 CD4 CD32 BCA CD80 CD4 CD79a BCA CD80 CD4 CD79b BCA CD80 b2c CD8 BCA CD80 b2c CD3? BCA CD80 b2c CD3? BCA CD80 b2c CD3? BCA CD80 b2c CD3? BCA CD80 b2c Fc?RI-? BCA CD80 b2c Fc?RIII-? BCA CD80 b2c Fc?RI? BCA CD80 b2c Fc?RI? BCA CD80 b2c DAP10 BCA CD80 b2c DAP12 BCA CD80 b2c CD32 BCA CD80 b2c CD79a BCA CD80 b2c CD79b BCA CD80 CD137/41BB CD8 BCA CD80 CD137/41BB CD3? BCA CD80 CD137/41BB CD3? BCA CD80 CD137/41BB CD3? BCA CD80 CD137/41BB CD3? BCA CD80 CD137/41BB Fc?RI-? BCA CD80 CD137/41BB Fc?RIII-? BCA CD80 CD137/41BB Fc?RI? BCA CD80 CD137/41BB Fc?RI? BCA CD80 CD137/41BB DAP10 BCA CD80 CD137/41BB DAP12 BCA CD80 CD137/41BB CD32 BCA CD80 CD137/41BB CD79a BCA CD80 CD137/41BB CD79b BCA CD80 ICOS CD8 BCA CD80 ICOS CD3? BCA CD80 ICOS CD3? BCA CD80 ICOS CD3? BCA CD80 ICOS CD3? BCA CD80 ICOS Fc?RI-? BCA CD80 ICOS Fc?RIII-? BCA CD80 ICOS Fc?RI? BCA CD80 ICOS Fc?RI? BCA CD80 ICOS DAP10 BCA CD80 ICOS DAP12 BCA CD80 ICOS CD32 BCA CD80 ICOS CD79a BCA CD80 ICOS CD79b BCA CD80 CD27 CD8 BCA CD80 CD27 CD3? BCA CD80 CD27 CD3? BCA CD80 CD27 CD3? BCA CD80 CD27 CD3? BCA CD80 CD27 Fc?RI-? BCA CD80 CD27 Fc?RIII-? BCA CD80 CD27 Fc?RI? BCA CD80 CD27 Fc?RI? BCA CD80 CD27 DAP10 BCA CD80 CD27 DAP12 BCA CD80 CD27 CD32 BCA CD80 CD27 CD79a BCA CD80 CD27 CD79b BCA CD80 CD28? CD8 BCA CD80 CD28? CD3? BCA CD80 CD28? CD3? BCA CD80 CD28? CD3? BCA CD80 CD28? CD3? BCA CD80 CD28? Fc?RI-? BCA CD80 CD28? Fc?RIII-? BCA CD80 CD28? Fc?RI? BCA CD80 CD28? Fc?RI? BCA CD80 CD28? DAP10 BCA CD80 CD28? DAP12 BCA CD80 CD28? CD32 BCA CD80 CD28? CD79a BCA CD80 CD28? CD79b BCA CD80 CD80 CD8 BCA CD80 CD80 CD3? BCA CD80 CD80 CD3? BCA CD80 CD80 CD3? BCA CD80 CD80 CD3? BCA CD80 CD80 Fc?RI-? BCA CD80 CD80 Fc?RIII-? BCA CD80 CD80 Fc?RI? BCA CD80 CD80 Fc?RI? BCA CD80 CD80 DAP10 BCA CD80 CD80 DAP12 BCA CD80 CD80 CD32 BCA CD80 CD80 CD79a BCA CD80 CD80 CD79b BCA CD80 CD86 CD8 BCA CD80 CD86 CD3? BCA CD80 CD86 CD3? BCA CD80 CD86 CD3? BCA CD80 CD86 CD3? BCA CD80 CD86 Fc?RI-? BCA CD80 CD86 Fc?RIII-? BCA CD80 CD86 Fc?RI? BCA CD80 CD86 Fc?RI? BCA CD80 CD86 DAP10 BCA CD80 CD86 DAP12 BCA CD80 CD86 CD32 BCA CD80 CD86 CD79a BCA CD80 CD86 CD79b BCA CD80 OX40 CD8 BCA CD80 OX40 CD3? BCA CD80 OX40 CD3? BCA CD80 OX40 CD3? BCA CD80 OX40 CD3? BCA CD80 OX40 Fc?RI-? BCA CD80 OX40 Fc?RIII-? BCA CD80 OX40 Fc?RI? BCA CD80 OX40 Fc?RI? BCA CD80 OX40 DAP10 BCA CD80 OX40 DAP12 BCA CD80 OX40 CD32 BCA CD80 OX40 CD79a BCA CD80 OX40 CD79b BCA CD80 DAP10 CD8 BCA CD80 DAP10 CD3? BCA CD80 DAP10 CD3? BCA CD80 DAP10 CD3? BCA CD80 DAP10 CD3? BCA CD80 DAP10 Fc?RI-? BCA CD80 DAP10 Fc?RIII-? BCA CD80 DAP10 Fc?RI? BCA CD80 DAP10 Fc?RI? BCA CD80 DAP10 DAP10 BCA CD80 DAP10 DAP12 BCA CD80 DAP10 CD32 BCA CD80 DAP10 CD79a BCA CD80 DAP10 CD79b BCA CD80 DAP12 CD8 BCA CD80 DAP12 CD3? BCA CD80 DAP12 CD3? BCA CD80 DAP12 CD3? BCA CD80 DAP12 CD3? BCA CD80 DAP12 Fc?RI-? BCA CD80 DAP12 Fc?RIII-? BCA CD80 DAP12 Fc?RI? BCA CD80 DAP12 Fc?RI? BCA CD80 DAP12 DAP10 BCA CD80 DAP12 DAP12 BCA CD80 DAP12 CD32 BCA CD80 DAP12 CD79a BCA CD80 DAP12 CD79b BCA CD80 MyD88 CD8 BCA CD80 MyD88 CD3? BCA CD80 MyD88 CD3? BCA CD80 MyD88 CD3? BCA CD80 MyD88 CD3? BCA CD80 MyD88 Fc?RI-? BCA CD80 MyD88 Fc?RIII-? BCA CD80 MyD88 Fc?RI? BCA CD80 MyD88 Fc?RI? BCA CD80 MyD88 DAP10 BCA CD80 MyD88 DAP12 BCA CD80 MyD88 CD32 BCA CD80 MyD88 CD79a BCA CD80 MyD88 CD79b BCA CD80 CD7 CD8 BCA CD80 CD7 CD3? BCA CD80 CD7 CD3? BCA CD80 CD7 CD3? BCA CD80 CD7 CD3? BCA CD80 CD7 Fc?RI-? BCA CD80 CD7 Fc?RIII-? BCA CD80 CD7 Fc?RI? BCA CD80 CD7 Fc?RI? BCA CD80 CD7 DAP10 BCA CD80 CD7 DAP12 BCA CD80 CD7 CD32 BCA CD80 CD7 CD79a BCA CD80 CD7 CD79b BCA CD80 BTNL3 CD8 BCA CD80 BTNL3 CD3? BCA CD80 BTNL3 CD3? BCA CD80 BTNL3 CD3? BCA CD80 BTNL3 CD3? BCA CD80 BTNL3 Fc?RI-? BCA CD80 BTNL3 Fc?RIII-? BCA CD80 BTNL3 Fc?RI? BCA CD80 BTNL3 Fc?RI? BCA CD80 BTNL3 DAP10 BCA CD80 BTNL3 DAP12 BCA CD80 BTNL3 CD32 BCA CD80 BTNL3 CD79a BCA CD80 BTNL3 CD79b BCA CD80 NKG2D CD8 BCA CD80 NKG2D CD3? BCA CD80 NKG2D CD3? BCA CD80 NKG2D CD3? BCA CD80 NKG2D CD3? BCA CD80 NKG2D Fc?RI-? BCA CD80 NKG2D Fc?RIII-? BCA CD80 NKG2D Fc?RI? BCA CD80 NKG2D Fc?RI? BCA CD80 NKG2D DAP10 BCA CD80 NKG2D DAP12 BCA CD80 NKG2D CD32 BCA CD80 NKG2D CD79a BCA CD80 NKG2D CD79b BCA CD86 CD28 CD8 BCA CD86 CD28 CD3? BCA CD86 CD28 CD3? BCA CD86 CD28 CD3? BCA CD86 CD28 CD3? BCA CD86 CD28 Fc?RI-? BCA CD86 CD28 Fc?RIII-? BCA CD86 CD28 Fc?RI? BCA CD86 CD28 Fc?RI? BCA CD86 CD28 DAP10 BCA CD86 CD28 DAP12 BCA CD86 CD28 CD32 BCA CD86 CD28 CD79a BCA CD86 CD28 CD79b BCA CD86 CD8 CD8 BCA CD86 CD8 CD3? BCA CD86 CD8 CD3? BCA CD86 CD8 CD3? BCA CD86 CD8 CD3? BCA CD86 CD8 Fc?RI-? BCA CD86 CD8 Fc?RIII-? BCA CD86 CD8 Fc?RI? BCA CD86 CD8 Fc?RI? BCA CD86 CD8 DAP10 BCA CD86 CD8 DAP12 BCA CD86 CD8 CD32 BCA CD86 CD8 CD79a BCA CD86 CD8 CD79b BCA CD86 CD4 CD8 BCA CD86 CD4 CD3? BCA CD86 CD4 CD3? BCA CD86 CD4 CD3? BCA CD86 CD4 CD3? BCA CD86 CD4 Fc?RI-? BCA CD86 CD4 Fc?RIII-? BCA CD86 CD4 Fc?RI? BCA CD86 CD4 Fc?RI? BCA CD86 CD4 DAP10 BCA CD86 CD4 DAP12 BCA CD86 CD4 CD32 BCA CD86 CD4 CD79a BCA CD86 CD4 CD79b BCA CD86 b2c CD8 BCA CD86 b2c CD3? BCA CD86 b2c CD3? BCA CD86 b2c CD3? BCA CD86 b2c CD3? BCA CD86 b2c Fc?RI-? BCA CD86 b2c Fc?RIII-? BCA CD86 b2c Fc?RI? BCA CD86 b2c Fc?RI? BCA CD86 b2c DAP10 BCA CD86 b2c DAP12 BCA CD86 b2c CD32 BCA CD86 b2c CD79a BCA CD86 b2c CD79b BCA CD86 CD137/41BB CD8 BCA CD86 CD137/41BB CD3? BCA CD86 CD137/41BB CD3? BCA CD86 CD137/41BB CD3? BCA CD86 CD137/41BB CD3? BCA CD86 CD137/41BB Fc?RI-? BCA CD86 CD137/41BB Fc?RIII-? BCA CD86 CD137/41BB Fc?RI? BCA CD86 CD137/41BB Fc?RI? BCA CD86 CD137/41BB DAP10 BCA CD86 CD137/41BB DAP12 BCA CD86 CD137/41BB CD32 BCA CD86 CD137/41BB CD79a BCA CD86 CD137/41BB CD79b BCA CD86 ICOS CD8 BCA CD86 ICOS CD3? BCA CD86 ICOS CD3? BCA CD86 ICOS CD3? BCA CD86 ICOS CD3? BCA CD86 ICOS Fc?RI-? BCA CD86 ICOS Fc?RIII-? BCA CD86 ICOS Fc?RI? BCA CD86 ICOS Fc?RI? BCA CD86 ICOS DAP10 BCA CD86 ICOS DAP12 BCA CD86 ICOS CD32 BCA CD86 ICOS CD79a BCA CD86 ICOS CD79b BCA CD86 CD27 CD8 BCA CD86 CD27 CD3? BCA CD86 CD27 CD3? BCA CD86 CD27 CD3? BCA CD86 CD27 CD3? BCA CD86 CD27 Fc?RI-? BCA CD86 CD27 Fc?RIII-? BCA CD86 CD27 Fc?RI? BCA CD86 CD27 Fc?RI? BCA CD86 CD27 DAP10 BCA CD86 CD27 DAP12 BCA CD86 CD27 CD32 BCA CD86 CD27 CD79a BCA CD86 CD27 CD79b BCA CD86 CD28? CD8 BCA CD86 CD28? CD3? BCA CD86 CD28? CD3? BCA CD86 CD28? CD3? BCA CD86 CD28? CD3? BCA CD86 CD28? Fc?RI-? BCA CD86 CD28? Fc?RIII-? BCA CD86 CD28? Fc?RI? BCA CD86 CD28? Fc?RI? BCA CD86 CD28? DAP10 BCA CD86 CD28? DAP12 BCA CD86 CD28? CD32 BCA CD86 CD28? CD79a BCA CD86 CD28? CD79b BCA CD86 CD80 CD8 BCA CD86 CD80 CD3? BCA CD86 CD80 CD3? BCA CD86 CD80 CD3? BCA CD86 CD80 CD3? BCA CD86 CD80 Fc?RI-? BCA CD86 CD80 Fc?RIII-? BCA CD86 CD80 Fc?RI? BCA CD86 CD80 Fc?RI? BCA CD86 CD80 DAP10 BCA CD86 CD80 DAP12 BCA CD86 CD80 CD32 BCA CD86 CD80 CD79a BCA CD86 CD80 CD79b BCA CD86 CD86 CD8 BCA CD86 CD86 CD3? BCA CD86 CD86 CD3? BCA CD86 CD86 CD3? BCA CD86 CD86 CD3? BCA CD86 CD86 Fc?RI-? BCA CD86 CD86 Fc?RIII-? BCA CD86 CD86 Fc?RI? BCA CD86 CD86 Fc?RI? BCA CD86 CD86 DAP10 BCA CD86 CD86 DAP12 BCA CD86 CD86 CD32 BCA CD86 CD86 CD79a BCA CD86 CD86 CD79b BCA CD86 OX40 CD8 BCA CD86 OX40 CD3? BCA CD86 OX40 CD3? BCA CD86 OX40 CD3? BCA CD86 OX40 CD3? BCA CD86 OX40 Fc?RI-? BCA CD86 OX40 Fc?RIII-? BCA CD86 OX40 Fc?RI? BCA CD86 OX40 Fc?RI? BCA CD86 OX40 DAP10 BCA CD86 OX40 DAP12 BCA CD86 OX40 CD32 BCA CD86 OX40 CD79a BCA CD86 OX40 CD79b BCA CD86 DAP10 CD8 BCA CD86 DAP10 CD3? BCA CD86 DAP10 CD3? BCA CD86 DAP10 CD3? BCA CD86 DAP10 CD3? BCA CD86 DAP10 Fc?RI-? BCA CD86 DAP10 Fc?RIII-? BCA CD86 DAP10 Fc?RI? BCA CD86 DAP10 Fc?RI? BCA CD86 DAP10 DAP10 BCA CD86 DAP10 DAP12 BCA CD86 DAP10 CD32 BCA CD86 DAP10 CD79a BCA CD86 DAP10 CD79b BCA CD86 DAP12 CD8 BCA CD86 DAP12 CD3? BCA CD86 DAP12 CD3? BCA CD86 DAP12 CD3? BCA CD86 DAP12 CD3? BCA CD86 DAP12 Fc?RI-? BCA CD86 DAP12 Fc?RIII-? BCA CD86 DAP12 Fc?RI? BCA CD86 DAP12 Fc?RI? BCA CD86 DAP12 DAP10 BCA CD86 DAP12 DAP12 BCA CD86 DAP12 CD32 BCA CD86 DAP12 CD79a BCA CD86 DAP12 CD79b BCA CD86 MyD88 CD8 BCA CD86 MyD88 CD3? BCA CD86 MyD88 CD3? BCA CD86 MyD88 CD3? BCA CD86 MyD88 CD3? BCA CD86 MyD88 Fc?RI-? BCA CD86 MyD88 Fc?RIII-? BCA CD86 MyD88 Fc?RI? BCA CD86 MyD88 Fc?RI? BCA CD86 MyD88 DAP10 BCA CD86 MyD88 DAP12 BCA CD86 MyD88 CD32 BCA CD86 MyD88 CD79a BCA CD86 MyD88 CD79b BCA CD86 CD7 CD8 BCA CD86 CD7 CD3? BCA CD86 CD7 CD3? BCA CD86 CD7 CD3? BCA CD86 CD7 CD3? BCA CD86 CD7 Fc?RI-? BCA CD86 CD7 Fc?RIII-? BCA CD86 CD7 Fc?RI? BCA CD86 CD7 Fc?RI? BCA CD86 CD7 DAP10 BCA CD86 CD7 DAP12 BCA CD86 CD7 CD32 BCA CD86 CD7 CD79a BCA CD86 CD7 CD79b BCA CD86 BTNL3 CD8 BCA CD86 BTNL3 CD3? BCA CD86 BTNL3 CD3? BCA CD86 BTNL3 CD3? BCA CD86 BTNL3 CD3? BCA CD86 BTNL3 Fc?RI-? BCA CD86 BTNL3 Fc?RIII-? BCA CD86 BTNL3 Fc?RI? BCA CD86 BTNL3 Fc?RI? BCA CD86 BTNL3 DAP10 BCA CD86 BTNL3 DAP12 BCA CD86 BTNL3 CD32 BCA CD86 BTNL3 CD79a BCA CD86 BTNL3 CD79b BCA CD86 NKG2D CD8 BCA CD86 NKG2D CD3? BCA CD86 NKG2D CD3? BCA CD86 NKG2D CD3? BCA CD86 NKG2D CD3? BCA CD86 NKG2D Fc?RI-? BCA CD86 NKG2D Fc?RIII-? BCA CD86 NKG2D Fc?RI? BCA CD86 NKG2D Fc?RI? BCA CD86 NKG2D DAP10 BCA CD86 NKG2D DAP12 BCA CD86 NKG2D CD32 BCA CD86 NKG2D CD79a BCA CD86 NKG2D CD79b BCA OX40 CD28 CD8 BCA OX40 CD28 CD3? BCA OX40 CD28 CD3? BCA OX40 CD28 CD3? BCA OX40 CD28 CD3? BCA OX40 CD28 Fc?RI-? BCA OX40 CD28 Fc?RIII-? BCA OX40 CD28 Fc?RI? BCA OX40 CD28 Fc?RI? BCA OX40 CD28 DAP10 BCA OX40 CD28 DAP12 BCA OX40 CD28 CD32 BCA OX40 CD28 CD79a BCA OX40 CD28 CD79b BCA OX40 CD8 CD8 BCA OX40 CD8 CD3? BCA OX40 CD8 CD3? BCA OX40 CD8 CD3? BCA OX40 CD8 CD3? BCA OX40 CD8 Fc?RI-? BCA OX40 CD8 Fc?RIII-? BCA OX40 CD8 Fc?RI? BCA OX40 CD8 Fc?RI? BCA OX40 CD8 DAP10 BCA OX40 CD8 DAP12 BCA OX40 CD8 CD32 BCA OX40 CD8 CD79a BCA OX40 CD8 CD79b BCA OX40 CD4 CD8 BCA OX40 CD4 CD3? BCA OX40 CD4 CD3? BCA OX40 CD4 CD3? BCA OX40 CD4 CD3? BCA OX40 CD4 Fc?RI-? BCA OX40 CD4 Fc?RIII-? BCA OX40 CD4 Fc?RI? BCA OX40 CD4 Fc?RI? BCA OX40 CD4 DAP10 BCA OX40 CD4 DAP12 BCA OX40 CD4 CD32 BCA OX40 CD4 CD79a BCA OX40 CD4 CD79b BCA OX40 b2c CD8 BCA OX40 b2c CD3? BCA OX40 b2c CD3? BCA OX40 b2c CD3? BCA OX40 b2c CD3? BCA OX40 b2c Fc?RI-? BCA OX40 b2c Fc?RIII-? BCA OX40 b2c Fc?RI? BCA OX40 b2c Fc?RI? BCA OX40 b2c DAP10 BCA OX40 b2c DAP12 BCA OX40 b2c CD32 BCA OX40 b2c CD79a BCA OX40 b2c CD79b BCA OX40 CD137/41BB CD8 BCA OX40 CD137/41BB CD3? BCA OX40 CD137/41BB CD3? BCA OX40 CD137/41BB CD3? BCA OX40 CD137/41BB CD3? BCA OX40 CD137/41BB Fc?RI-? BCA OX40 CD137/41BB Fc?RIII-? BCA OX40 CD137/41BB Fc?RI? BCA OX40 CD137/41BB Fc?RI? BCA OX40 CD137/41BB DAP10 BCA OX40 CD137/41BB DAP12 BCA OX40 CD137/41BB CD32 BCA OX40 CD137/41BB CD79a BCA OX40 CD137/41BB CD79b BCA OX40 ICOS CD8 BCA OX40 ICOS CD3? BCA OX40 ICOS CD3? BCA OX40 ICOS CD3? BCA OX40 ICOS CD3? BCA OX40 ICOS Fc?RI-? BCA OX40 ICOS Fc?RIII-? BCA OX40 ICOS Fc?RI? BCA OX40 ICOS Fc?RI? BCA OX40 ICOS DAP10 BCA OX40 ICOS DAP12 BCA OX40 ICOS CD32 BCA OX40 ICOS CD79a BCA OX40 ICOS CD79b BCA OX40 CD27 CD8 BCA OX40 CD27 CD3? BCA OX40 CD27 CD3? BCA OX40 CD27 CD3? BCA OX40 CD27 CD3? BCA OX40 CD27 Fc?RI-? BCA OX40 CD27 Fc?RIII-? BCA OX40 CD27 Fc?RI? BCA OX40 CD27 Fc?RI? BCA OX40 CD27 DAP10 BCA OX40 CD27 DAP12 BCA OX40 CD27 CD32 BCA OX40 CD27 CD79a BCA OX40 CD27 CD79b BCA OX40 CD28? CD8 BCA OX40 CD28? CD3? BCA OX40 CD28? CD3? BCA OX40 CD28? CD3? BCA OX40 CD28? CD3? BCA OX40 CD28? Fc?RI-? BCA OX40 CD28? Fc?RIII-? BCA OX40 CD28? Fc?RI? BCA OX40 CD28? Fc?RI? BCA OX40 CD28? DAP10 BCA OX40 CD28? DAP12 BCA OX40 CD28? CD32 BCA OX40 CD28? CD79a BCA OX40 CD28? CD79b BCA OX40 CD80 CD8 BCA OX40 CD80 CD3? BCA OX40 CD80 CD3? BCA OX40 CD80 CD3? BCA OX40 CD80 CD3? BCA OX40 CD80 Fc?RI-? BCA OX40 CD80 Fc?RIII-? BCA OX40 CD80 Fc?RI? BCA OX40 CD80 Fc?RI? BCA OX40 CD80 DAP10 BCA OX40 CD80 DAP12 BCA OX40 CD80 CD32 BCA OX40 CD80 CD79a BCA OX40 CD80 CD79b BCA OX40 CD86 CD8 BCA OX40 CD86 CD3? BCA OX40 CD86 CD3? BCA OX40 CD86 CD3? BCA OX40 CD86 CD3? BCA OX40 CD86 Fc?RI-? BCA OX40 CD86 Fc?RIII-? BCA OX40 CD86 Fc?RI? BCA OX40 CD86 Fc?RI? BCA OX40 CD86 DAP10 BCA OX40 CD86 DAP12 BCA OX40 CD86 CD32 BCA OX40 CD86 CD79a BCA OX40 CD86 CD79b BCA OX40 OX40 CD8 BCA OX40 OX40 CD3? BCA OX40 OX40 CD3? BCA OX40 OX40 CD3? BCA OX40 OX40 CD3? BCA OX40 OX40 Fc?RI-? BCA OX40 OX40 Fc?RIII-? BCA OX40 OX40 Fc?RI? BCA OX40 OX40 Fc?RI? BCA OX40 OX40 DAP10 BCA OX40 OX40 DAP12 BCA OX40 OX40 CD32 BCA OX40 OX40 CD79a BCA OX40 OX40 CD79b BCA OX40 DAP10 CD8 BCA OX40 DAP10 CD3? BCA OX40 DAP10 CD3? BCA OX40 DAP10 CD3? BCA OX40 DAP10 CD3? BCA OX40 DAP10 Fc?RI-? BCA OX40 DAP10 Fc?RIII-? BCA OX40 DAP10 Fc?RI? BCA OX40 DAP10 Fc?RI? BCA OX40 DAP10 DAP10 BCA OX40 DAP10 DAP12 BCA OX40 DAP10 CD32 BCA OX40 DAP10 CD79a BCA OX40 DAP10 CD79b BCA OX40 DAP12 CD8 BCA OX40 DAP12 CD3? BCA OX40 DAP12 CD3? BCA OX40 DAP12 CD3? BCA OX40 DAP12 CD3? BCA OX40 DAP12 Fc?RI-? BCA OX40 DAP12 Fc?RIII-? BCA OX40 DAP12 Fc?RI? BCA OX40 DAP12 Fc?RI? BCA OX40 DAP12 DAP10 BCA OX40 DAP12 DAP12 BCA OX40 DAP12 CD32 BCA OX40 DAP12 CD79a BCA OX40 DAP12 CD79b BCA OX40 MyD88 CD8 BCA OX40 MyD88 CD3? BCA OX40 MyD88 CD3? BCA OX40 MyD88 CD3? BCA OX40 MyD88 CD3? BCA OX40 MyD88 Fc?RI-? BCA OX40 MyD88 Fc?RIII-? BCA OX40 MyD88 Fc?RI? BCA OX40 MyD88 Fc?RI? BCA OX40 MyD88 DAP10 BCA OX40 MyD88 DAP12 BCA OX40 MyD88 CD32 BCA OX40 MyD88 CD79a BCA OX40 MyD88 CD79b BCA OX40 CD7 CD8 BCA OX40 CD7 CD3? BCA OX40 CD7 CD3? BCA OX40 CD7 CD3? BCA OX40 CD7 CD3? BCA OX40 CD7 Fc?RI-? BCA OX40 CD7 Fc?RIII-? BCA OX40 CD7 Fc?RI? BCA OX40 CD7 Fc?RI? BCA OX40 CD7 DAP10 BCA OX40 CD7 DAP12 BCA OX40 CD7 CD32 BCA OX40 CD7 CD79a BCA OX40 CD7 CD79b BCA OX40 BTNL3 CD8 BCA OX40 BTNL3 CD3? BCA OX40 BTNL3 CD3? BCA OX40 BTNL3 CD3? BCA OX40 BTNL3 CD3? BCA OX40 BTNL3 Fc?RI-? BCA OX40 BTNL3 Fc?RIII-? BCA OX40 BTNL3 Fc?RI? BCA OX40 BTNL3 Fc?RI? BCA OX40 BTNL3 DAP10 BCA OX40 BTNL3 DAP12 BCA OX40 BTNL3 CD32 BCA OX40 BTNL3 CD79a BCA OX40 BTNL3 CD79b BCA OX40 NKG2D CD8 BCA OX40 NKG2D CD3? BCA OX40 NKG2D CD3? BCA OX40 NKG2D CD3? BCA OX40 NKG2D CD3? BCA OX40 NKG2D Fc?RI-? BCA OX40 NKG2D Fc?RIII-? BCA OX40 NKG2D Fc?RI? BCA OX40 NKG2D Fc?RI? BCA OX40 NKG2D DAP10 BCA OX40 NKG2D DAP12 BCA OX40 NKG2D CD32 BCA OX40 NKG2D CD79a BCA OX40 NKG2D CD79b BCA DAP10 CD28 CD8 BCA DAP10 CD28 CD3? BCA DAP10 CD28 CD3? BCA DAP10 CD28 CD3? BCA DAP10 CD28 CD3? BCA DAP10 CD28 Fc?RI-? BCA DAP10 CD28 Fc?RIII-? BCA DAP10 CD28 Fc?RI? BCA DAP10 CD28 Fc?RI? BCA DAP10 CD28 DAP10 BCA DAP10 CD28 DAP12 BCA DAP10 CD28 CD32 BCA DAP10 CD28 CD79a BCA DAP10 CD28 CD79b BCA DAP10 CD8 CD8 BCA DAP10 CD8 CD3? BCA DAP10 CD8 CD3? BCA DAP10 CD8 CD3? BCA DAP10 CD8 CD3? BCA DAP10 CD8 Fc?RI-? BCA DAP10 CD8 Fc?RIII-? BCA DAP10 CD8 Fc?RI? BCA DAP10 CD8 Fc?RI? BCA DAP10 CD8 DAP10 BCA DAP10 CD8 DAP12 BCA DAP10 CD8 CD32 BCA DAP10 CD8 CD79a BCA DAP10 CD8 CD79b BCA DAP10 CD4 CD8 BCA DAP10 CD4 CD3? BCA DAP10 CD4 CD3? BCA DAP10 CD4 CD3? BCA DAP10 CD4 CD3? BCA DAP10 CD4 Fc?RI-? BCA DAP10 CD4 Fc?RIII-? BCA DAP10 CD4 Fc?RI? BCA DAP10 CD4 Fc?RI? BCA DAP10 CD4 DAP10 BCA DAP10 CD4 DAP12 BCA DAP10 CD4 CD32 BCA DAP10 CD4 CD79a BCA DAP10 CD4 CD79b BCA DAP10 b2c CD8 BCA DAP10 b2c CD3? BCA DAP10 b2c CD3? BCA DAP10 b2c CD3? BCA DAP10 b2c CD3? BCA DAP10 b2c Fc?RI-? BCA DAP10 b2c Fc?RIII-? BCA DAP10 b2c Fc?RI? BCA DAP10 b2c Fc?RI? BCA DAP10 b2c DAP10 BCA DAP10 b2c DAP12 BCA DAP10 b2c CD32 BCA DAP10 b2c CD79a BCA DAP10 b2c CD79b BCA DAP10 CD137/41BB CD8 BCA DAP10 CD137/41BB CD3? BCA DAP10 CD137/41BB CD3? BCA DAP10 CD137/41BB CD3? BCA DAP10 CD137/41BB CD3? BCA DAP10 CD137/41BB Fc?RI-? BCA DAP10 CD137/41BB Fc?RIII-? BCA DAP10 CD137/41BB Fc?RI? BCA DAP10 CD137/41BB Fc?RI? BCA DAP10 CD137/41BB DAP10 BCA DAP10 CD137/41BB DAP12 BCA DAP10 CD137/41BB CD32 BCA DAP10 CD137/41BB CD79a BCA DAP10 CD137/41BB CD79b BCA DAP10 ICOS CD8 BCA DAP10 ICOS CD3? BCA DAP10 ICOS CD3? BCA DAP10 ICOS CD3? BCA DAP10 ICOS CD3? BCA DAP10 ICOS Fc?RI-? BCA DAP10 ICOS Fc?RIII-? BCA DAP10 ICOS Fc?RI? BCA DAP10 ICOS Fc?RI? BCA DAP10 ICOS DAP10 BCA DAP10 ICOS DAP12 BCA DAP10 ICOS CD32 BCA DAP10 ICOS CD79a BCA DAP10 ICOS CD79b BCA DAP10 CD27 CD8 BCA DAP10 CD27 CD3? BCA DAP10 CD27 CD3? BCA DAP10 CD27 CD3? BCA DAP10 CD27 CD3? BCA DAP10 CD27 Fc?RI-? BCA DAP10 CD27 Fc?RIII-? BCA DAP10 CD27 Fc?RI? BCA DAP10 CD27 Fc?RI? BCA DAP10 CD27 DAP10 BCA DAP10 CD27 DAP12 BCA DAP10 CD27 CD32 BCA DAP10 CD27 CD79a BCA DAP10 CD27 CD79b BCA DAP10 CD28? CD8 BCA DAP10 CD28? CD3? BCA DAP10 CD28? CD3? BCA DAP10 CD28? CD3? BCA DAP10 CD28? CD3? BCA DAP10 CD28? Fc?RI-? BCA DAP10 CD28? Fc?RIII-? BCA DAP10 CD28? Fc?RI? BCA DAP10 CD28? Fc?RI? BCA DAP10 CD28? DAP10 BCA DAP10 CD28? DAP12 BCA DAP10 CD28? CD32 BCA DAP10 CD28? CD79a BCA DAP10 CD28? CD79b BCA DAP10 CD80 CD8 BCA DAP10 CD80 CD3? BCA DAP10 CD80 CD3? BCA DAP10 CD80 CD3? BCA DAP10 CD80 CD3? BCA DAP10 CD80 Fc?RI-? BCA DAP10 CD80 Fc?RIII-? BCA DAP10 CD80 Fc?RI? BCA DAP10 CD80 Fc?RI? BCA DAP10 CD80 DAP10 BCA DAP10 CD80 DAP12 BCA DAP10 CD80 CD32 BCA DAP10 CD80 CD79a BCA DAP10 CD80 CD79b BCA DAP10 CD86 CD8 BCA DAP10 CD86 CD3? BCA DAP10 CD86 CD3? BCA DAP10 CD86 CD3? BCA DAP10 CD86 CD3? BCA DAP10 CD86 Fc?RI-? BCA DAP10 CD86 Fc?RIII-? BCA DAP10 CD86 Fc?RI? BCA DAP10 CD86 Fc?RI? BCA DAP10 CD86 DAP10 BCA DAP10 CD86 DAP12 BCA DAP10 CD86 CD32 BCA DAP10 CD86 CD79a BCA DAP10 CD86 CD79b BCA DAP10 OX40 CD8 BCA DAP10 OX40 CD3? BCA DAP10 OX40 CD3? BCA DAP10 OX40 CD3? BCA DAP10 OX40 CD3? BCA DAP10 OX40 Fc?RI-? BCA DAP10 OX40 Fc?RIII-? BCA DAP10 OX40 Fc?RI? BCA DAP10 OX40 Fc?RI? BCA DAP10 OX40 DAP10 BCA DAP10 OX40 DAP12 BCA DAP10 OX40 CD32 BCA DAP10 OX40 CD79a BCA DAP10 OX40 CD79b BCA DAP10 DAP10 CD8 BCA DAP10 DAP10 CD3? BCA DAP10 DAP10 CD3? BCA DAP10 DAP10 CD3? BCA DAP10 DAP10 CD3? BCA DAP10 DAP10 Fc?RI-? BCA DAP10 DAP10 Fc?RIII-? BCA DAP10 DAP10 Fc?RI? BCA DAP10 DAP10 Fc?RI? BCA DAP10 DAP10 DAP10 BCA DAP10 DAP10 DAP12 BCA DAP10 DAP10 CD32 BCA DAP10 DAP10 CD79a BCA DAP10 DAP10 CD79b BCA DAP10 DAP12 CD8 BCA DAP10 DAP12 CD3? BCA DAP10 DAP12 CD3? BCA DAP10 DAP12 CD3? BCA DAP10 DAP12 CD3? BCA DAP10 DAP12 Fc?RI-? BCA DAP10 DAP12 Fc?RIII-? BCA DAP10 DAP12 Fc?RI? BCA DAP10 DAP12 Fc?RI? BCA DAP10 DAP12 DAP10 BCA DAP10 DAP12 DAP12 BCA DAP10 DAP12 CD32 BCA DAP10 DAP12 CD79a BCA DAP10 DAP12 CD79b BCA DAP10 MyD88 CD8 BCA DAP10 MyD88 CD3? BCA DAP10 MyD88 CD3? BCA DAP10 MyD88 CD3? BCA DAP10 MyD88 CD3? BCA DAP10 MyD88 Fc?RI-? BCA DAP10 MyD88 Fc?RIII-? BCA DAP10 MyD88 Fc?RI? BCA DAP10 MyD88 Fc?RI? BCA DAP10 MyD88 DAP10 BCA DAP10 MyD88 DAP12 BCA DAP10 MyD88 CD32 BCA DAP10 MyD88 CD79a BCA DAP10 MyD88 CD79b BCA DAP10 CD7 CD8 BCA DAP10 CD7 CD3? BCA DAP10 CD7 CD3? BCA DAP10 CD7 CD3? BCA DAP10 CD7 CD3? BCA DAP10 CD7 Fc?RI-? BCA DAP10 CD7 Fc?RIII-? BCA DAP10 CD7 Fc?RI? BCA DAP10 CD7 Fc?RI? BCA DAP10 CD7 DAP10 BCA DAP10 CD7 DAP12 BCA DAP10 CD7 CD32 BCA DAP10 CD7 CD79a BCA DAP10 CD7 CD79b BCA DAP10 BTNL3 CD8 BCA DAP10 BTNL3 CD3? BCA DAP10 BTNL3 CD3? BCA DAP10 BTNL3 CD3? BCA DAP10 BTNL3 CD3? BCA DAP10 BTNL3 Fc?RI-? BCA DAP10 BTNL3 Fc?RIII-? BCA DAP10 BTNL3 Fc?RI? BCA DAP10 BTNL3 Fc?RI? BCA DAP10 BTNL3 DAP10 BCA DAP10 BTNL3 DAP12 BCA DAP10 BTNL3 CD32 BCA DAP10 BTNL3 CD79a BCA DAP10 BTNL3 CD79b BCA DAP10 NKG2D CD8 BCA DAP10 NKG2D CD3? BCA DAP10 NKG2D CD3? BCA DAP10 NKG2D CD3? BCA DAP10 NKG2D CD3? BCA DAP10 NKG2D Fc?RI-? BCA DAP10 NKG2D Fc?RIII-? BCA DAP10 NKG2D Fc?RI? BCA DAP10 NKG2D Fc?RI? BCA DAP10 NKG2D DAP10 BCA DAP10 NKG2D DAP12 BCA DAP10 NKG2D CD32 BCA DAP10 NKG2D CD79a BCA DAP10 NKG2D CD79b BCA DAP12 CD28 CD8 BCA DAP12 CD28 CD3? BCA DAP12 CD28 CD3? BCA DAP12 CD28 CD3? BCA DAP12 CD28 CD3? BCA DAP12 CD28 Fc?RI-? BCA DAP12 CD28 Fc?RIII-? BCA DAP12 CD28 Fc?RI? BCA DAP12 CD28 Fc?RI? BCA DAP12 CD28 DAP10 BCA DAP12 CD28 DAP12 BCA DAP12 CD28 CD32 BCA DAP12 CD28 CD79a BCA DAP12 CD28 CD79b BCA DAP12 CD8 CD8 BCA DAP12 CD8 CD3? BCA DAP12 CD8 CD3? BCA DAP12 CD8 CD3? BCA DAP12 CD8 CD3? BCA DAP12 CD8 Fc?RI-? BCA DAP12 CD8 Fc?RIII-? BCA DAP12 CD8 Fc?RI? BCA DAP12 CD8 Fc?RI? BCA DAP12 CD8 DAP10 BCA DAP12 CD8 DAP12 BCA DAP12 CD8 CD32 BCA DAP12 CD8 CD79a BCA DAP12 CD8 CD79b BCA DAP12 CD4 CD8 BCA DAP12 CD4 CD3? BCA DAP12 CD4 CD3? BCA DAP12 CD4 CD3? BCA DAP12 CD4 CD3? BCA DAP12 CD4 Fc?RI-? BCA DAP12 CD4 Fc?RIII-? BCA DAP12 CD4 Fc?RI? BCA DAP12 CD4 Fc?RI? BCA DAP12 CD4 DAP10 BCA DAP12 CD4 DAP12 BCA DAP12 CD4 CD32 BCA DAP12 CD4 CD79a BCA DAP12 CD4 CD79b BCA DAP12 b2c CD8 BCA DAP12 b2c CD3? BCA DAP12 b2c CD3? BCA DAP12 b2c CD3? BCA DAP12 b2c CD3? BCA DAP12 b2c Fc?RI-? BCA DAP12 b2c Fc?RIII-? BCA DAP12 b2c Fc?RI? BCA DAP12 b2c Fc?RI? BCA DAP12 b2c DAP10 BCA DAP12 b2c DAP12 BCA DAP12 b2c CD32 BCA DAP12 b2c CD79a BCA DAP12 b2c CD79b BCA DAP12 CD137/41BB CD8 BCA DAP12 CD137/41BB CD3? BCA DAP12 CD137/41BB CD3? BCA DAP12 CD137/41BB CD3? BCA DAP12 CD137/41BB CD3? BCA DAP12 CD137/41BB Fc?RI-? BCA DAP12 CD137/41BB Fc?RIII-? BCA DAP12 CD137/41BB Fc?RI? BCA DAP12 CD137/41BB Fc?RI? BCA DAP12 CD137/41BB DAP10 BCA DAP12 CD137/41BB DAP12 BCA DAP12 CD137/41BB CD32 BCA DAP12 CD137/41BB CD79a BCA DAP12 CD137/41BB CD79b BCA DAP12 ICOS CD8 BCA DAP12 ICOS CD3? BCA DAP12 ICOS CD3? BCA DAP12 ICOS CD3? BCA DAP12 ICOS CD3? BCA DAP12 ICOS Fc?RI-? BCA DAP12 ICOS Fc?RIII-? BCA DAP12 ICOS Fc?RI? BCA DAP12 ICOS Fc?RI? BCA DAP12 ICOS DAP10 BCA DAP12 ICOS DAP12 BCA DAP12 ICOS CD32 BCA DAP12 ICOS CD79a BCA DAP12 ICOS CD79b BCA DAP12 CD27 CD8 BCA DAP12 CD27 CD3? BCA DAP12 CD27 CD3? BCA DAP12 CD27 CD3? BCA DAP12 CD27 CD3? BCA DAP12 CD27 Fc?RI-? BCA DAP12 CD27 Fc?RIII-? BCA DAP12 CD27 Fc?RI? BCA DAP12 CD27 Fc?RI? BCA DAP12 CD27 DAP10 BCA DAP12 CD27 DAP12 BCA DAP12 CD27 CD32 BCA DAP12 CD27 CD79a BCA DAP12 CD27 CD79b BCA DAP12 CD28? CD8 BCA DAP12 CD28? CD3? BCA DAP12 CD28? CD3? BCA DAP12 CD28? CD3? BCA DAP12 CD28? CD3? BCA DAP12 CD28? Fc?RI-? BCA DAP12 CD28? Fc?RIII-? BCA DAP12 CD28? Fc?RI? BCA DAP12 CD28? Fc?RI? BCA DAP12 CD28? DAP10 BCA DAP12 CD28? DAP12 BCA DAP12 CD28? CD32 BCA DAP12 CD28? CD79a BCA DAP12 CD28? CD79b BCA DAP12 CD80 CD8 BCA DAP12 CD80 CD3? BCA DAP12 CD80 CD3? BCA DAP12 CD80 CD3? BCA DAP12 CD80 CD3? BCA DAP12 CD80 Fc?RI-? BCA DAP12 CD80 Fc?RIII-? BCA DAP12 CD80 Fc?RI? BCA DAP12 CD80 Fc?RI? BCA DAP12 CD80 DAP10 BCA DAP12 CD80 DAP12 BCA DAP12 CD80 CD32 BCA DAP12 CD80 CD79a BCA DAP12 CD80 CD79b BCA DAP12 CD86 CD8 BCA DAP12 CD86 CD3? BCA DAP12 CD86 CD3? BCA DAP12 CD86 CD3? BCA DAP12 CD86 CD3? BCA DAP12 CD86 Fc?RI-? BCA DAP12 CD86 Fc?RIII-? BCA DAP12 CD86 Fc?RI? BCA DAP12 CD86 Fc?RI? BCA DAP12 CD86 DAP10 BCA DAP12 CD86 DAP12 BCA DAP12 CD86 CD32 BCA DAP12 CD86 CD79a BCA DAP12 CD86 CD79b BCA DAP12 OX40 CD8 BCA DAP12 OX40 CD3? BCA DAP12 OX40 CD3? BCA DAP12 OX40 CD3? BCA DAP12 OX40 CD3? BCA DAP12 OX40 Fc?RI-? BCA DAP12 OX40 Fc?RIII-? BCA DAP12 OX40 Fc?RI? BCA DAP12 OX40 Fc?RI? BCA DAP12 OX40 DAP10 BCA DAP12 OX40 DAP12 BCA DAP12 OX40 CD32 BCA DAP12 OX40 CD79a BCA DAP12 OX40 CD79b BCA DAP12 DAP10 CD8 BCA DAP12 DAP10 CD3? BCA DAP12 DAP10 CD3? BCA DAP12 DAP10 CD3? BCA DAP12 DAP10 CD3? BCA DAP12 DAP10 Fc?RI-? BCA DAP12 DAP10 Fc?RIII-? BCA DAP12 DAP10 Fc?RI? BCA DAP12 DAP10 Fc?RI? BCA DAP12 DAP10 DAP10 BCA DAP12 DAP10 DAP12 BCA DAP12 DAP10 CD32 BCA DAP12 DAP10 CD79a BCA DAP12 DAP10 CD79b BCA DAP12 DAP12 CD8 BCA DAP12 DAP12 CD3? BCA DAP12 DAP12 CD3? BCA DAP12 DAP12 CD3? BCA DAP12 DAP12 CD3? BCA DAP12 DAP12 Fc?RI-? BCA DAP12 DAP12 Fc?RIII-? BCA DAP12 DAP12 Fc?RI? BCA DAP12 DAP12 Fc?RI? BCA DAP12 DAP12 DAP10 BCA DAP12 DAP12 DAP12 BCA DAP12 DAP12 CD32 BCA DAP12 DAP12 CD79a BCA DAP12 DAP12 CD79b BCA DAP12 MyD88 CD8 BCA DAP12 MyD88 CD3? BCA DAP12 MyD88 CD3? BCA DAP12 MyD88 CD3? BCA DAP12 MyD88 CD3? BCA DAP12 MyD88 Fc?RI-? BCA DAP12 MyD88 Fc?RIII-? BCA DAP12 MyD88 Fc?RI? BCA DAP12 MyD88 Fc?RI? BCA DAP12 MyD88 DAP10 BCA DAP12 MyD88 DAP12 BCA DAP12 MyD88 CD32 BCA DAP12 MyD88 CD79a BCA DAP12 MyD88 CD79b BCA DAP12 CD7 CD8 BCA DAP12 CD7 CD3? BCA DAP12 CD7 CD3? BCA DAP12 CD7 CD3? BCA DAP12 CD7 CD3? BCA DAP12 CD7 Fc?RI-? BCA DAP12 CD7 Fc?RIII-? BCA DAP12 CD7 Fc?RI? BCA DAP12 CD7 Fc?RI? BCA DAP12 CD7 DAP10 BCA DAP12 CD7 DAP12 BCA DAP12 CD7 CD32 BCA DAP12 CD7 CD79a BCA DAP12 CD7 CD79b BCA DAP12 BTNL3 CD8 BCA DAP12 BTNL3 CD3? BCA DAP12 BTNL3 CD3? BCA DAP12 BTNL3 CD3? BCA DAP12 BTNL3 CD3? BCA DAP12 BTNL3 Fc?RI-? BCA DAP12 BTNL3 Fc?RIII-? BCA DAP12 BTNL3 Fc?RI? BCA DAP12 BTNL3 Fc?RI? BCA DAP12 BTNL3 DAP10 BCA DAP12 BTNL3 DAP12 BCA DAP12 BTNL3 CD32 BCA DAP12 BTNL3 CD79a BCA DAP12 BTNL3 CD79b BCA DAP12 NKG2D CD8 BCA DAP12 NKG2D CD3? BCA DAP12 NKG2D CD3? BCA DAP12 NKG2D CD3? BCA DAP12 NKG2D CD3? BCA DAP12 NKG2D Fc?RI-? BCA DAP12 NKG2D Fc?RIII-? BCA DAP12 NKG2D Fc?RI? BCA DAP12 NKG2D Fc?RI? BCA DAP12 NKG2D DAP10 BCA DAP12 NKG2D DAP12 BCA DAP12 NKG2D CD32 BCA DAP12 NKG2D CD79a BCA DAP12 NKG2D CD79b BCA MyD88 CD28 CD8 BCA MyD88 CD28 CD3? BCA MyD88 CD28 CD3? BCA MyD88 CD28 CD3? BCA MyD88 CD28 CD3? BCA MyD88 CD28 Fc?RI-? BCA MyD88 CD28 Fc?RIII-? BCA MyD88 CD28 Fc?RI? BCA MyD88 CD28 Fc?RI? BCA MyD88 CD28 DAP10 BCA MyD88 CD28 DAP12 BCA MyD88 CD28 CD32 BCA MyD88 CD28 CD79a BCA MyD88 CD28 CD79b BCA MyD88 CD8 CD8 BCA MyD88 CD8 CD3? BCA MyD88 CD8 CD3? BCA MyD88 CD8 CD3? BCA MyD88 CD8 CD3? BCA MyD88 CD8 Fc?RI-? BCA MyD88 CD8 Fc?RIII-? BCA MyD88 CD8 Fc?RI? BCA MyD88 CD8 Fc?RI? BCA MyD88 CD8 DAP10 BCA MyD88 CD8 DAP12 BCA MyD88 CD8 CD32 BCA MyD88 CD8 CD79a BCA MyD88 CD8 CD79b BCA MyD88 CD4 CD8 BCA MyD88 CD4 CD3? BCA MyD88 CD4 CD3? BCA MyD88 CD4 CD3? BCA MyD88 CD4 CD3? BCA MyD88 CD4 Fc?RI-? BCA MyD88 CD4 Fc?RIII-? BCA MyD88 CD4 Fc?RI? BCA MyD88 CD4 Fc?RI? BCA MyD88 CD4 DAP10 BCA MyD88 CD4 DAP12 BCA MyD88 CD4 CD32 BCA MyD88 CD4 CD79a BCA MyD88 CD4 CD79b BCA MyD88 b2c CD8 BCA MyD88 b2c CD3? BCA MyD88 b2c CD3? BCA MyD88 b2c CD3? BCA MyD88 b2c CD3? BCA MyD88 b2c Fc?RI-? BCA MyD88 b2c Fc?RIII-? BCA MyD88 b2c Fc?RI? BCA MyD88 b2c Fc?RI? BCA MyD88 b2c DAP10 BCA MyD88 b2c DAP12 BCA MyD88 b2c CD32 BCA MyD88 b2c CD79a BCA MyD88 b2c CD79b BCA MyD88 CD137/41BB CD8 BCA MyD88 CD137/41BB CD3? BCA MyD88 CD137/41BB CD3? BCA MyD88 CD137/41BB CD3? BCA MyD88 CD137/41BB CD3? BCA MyD88 CD137/41BB Fc?RI-? BCA MyD88 CD137/41BB Fc?RIII-? BCA MyD88 CD137/41BB Fc?RI? BCA MyD88 CD137/41BB Fc?RI? BCA MyD88 CD137/41BB DAP10 BCA MyD88 CD137/41BB DAP12 BCA MyD88 CD137/41BB CD32 BCA MyD88 CD137/41BB CD79a BCA MyD88 CD137/41BB CD79b BCA MyD88 ICOS CD8 BCA MyD88 ICOS CD3? BCA MyD88 ICOS CD3? BCA MyD88 ICOS CD3? BCA MyD88 ICOS CD3? BCA MyD88 ICOS Fc?RI-? BCA MyD88 ICOS Fc?RIII-? BCA MyD88 ICOS Fc?RI? BCA MyD88 ICOS Fc?RI? BCA MyD88 ICOS DAP10 BCA MyD88 ICOS DAP12 BCA MyD88 ICOS CD32 BCA MyD88 ICOS CD79a BCA MyD88 ICOS CD79b BCA MyD88 CD27 CD8 BCA MyD88 CD27 CD3? BCA MyD88 CD27 CD3? BCA MyD88 CD27 CD3? BCA MyD88 CD27 CD3? BCA MyD88 CD27 Fc?RI-? BCA MyD88 CD27 Fc?RIII-? BCA MyD88 CD27 Fc?RI? BCA MyD88 CD27 Fc?RI? BCA MyD88 CD27 DAP10 BCA MyD88 CD27 DAP12 BCA MyD88 CD27 CD32 BCA MyD88 CD27 CD79a BCA MyD88 CD27 CD79b BCA MyD88 CD28? CD8 BCA MyD88 CD28? CD3? BCA MyD88 CD28? CD3? BCA MyD88 CD28? CD3? BCA MyD88 CD28? CD3? BCA MyD88 CD28? Fc?RI-? BCA MyD88 CD28? Fc?RIII-? BCA MyD88 CD28? Fc?RI? BCA MyD88 CD28? Fc?RI? BCA MyD88 CD28? DAP10 BCA MyD88 CD28? DAP12 BCA MyD88 CD28? CD32 BCA MyD88 CD28? CD79a BCA MyD88 CD28? CD79b BCA MyD88 CD80 CD8 BCA MyD88 CD80 CD3? BCA MyD88 CD80 CD3? BCA MyD88 CD80 CD3? BCA MyD88 CD80 CD3? BCA MyD88 CD80 Fc?RI-? BCA MyD88 CD80 Fc?RIII-? BCA MyD88 CD80 Fc?RI? BCA MyD88 CD80 Fc?RI? BCA MyD88 CD80 DAP10 BCA MyD88 CD80 DAP12 BCA MyD88 CD80 CD32 BCA MyD88 CD80 CD79a BCA MyD88 CD80 CD79b BCA MyD88 CD86 CD8 BCA MyD88 CD86 CD3? BCA MyD88 CD86 CD3? BCA MyD88 CD86 CD3? BCA MyD88 CD86 CD3? BCA MyD88 CD86 Fc?RI-? BCA MyD88 CD86 Fc?RIII-? BCA MyD88 CD86 Fc?RI? BCA MyD88 CD86 Fc?RI? BCA MyD88 CD86 DAP10 BCA MyD88 CD86 DAP12 BCA MyD88 CD86 CD32 BCA MyD88 CD86 CD79a BCA MyD88 CD86 CD79b BCA MyD88 OX40 CD8 BCA MyD88 OX40 CD3? BCA MyD88 OX40 CD3? BCA MyD88 OX40 CD3? BCA MyD88 OX40 CD3? BCA MyD88 OX40 Fc?RI-? BCA MyD88 OX40 Fc?RIII-? BCA MyD88 OX40 Fc?RI? BCA MyD88 OX40 Fc?RI? BCA MyD88 OX40 DAP10 BCA MyD88 OX40 DAP12 BCA MyD88 OX40 CD32 BCA MyD88 OX40 CD79a BCA MyD88 OX40 CD79b BCA MyD88 DAP10 CD8 BCA MyD88 DAP10 CD3? BCA MyD88 DAP10 CD3? BCA MyD88 DAP10 CD3? BCA MyD88 DAP10 CD3? BCA MyD88 DAP10 Fc?RI-? BCA MyD88 DAP10 Fc?RIII-? BCA MyD88 DAP10 Fc?RI? BCA MyD88 DAP10 Fc?RI? BCA MyD88 DAP10 DAP10 BCA MyD88 DAP10 DAP12 BCA MyD88 DAP10 CD32 BCA MyD88 DAP10 CD79a BCA MyD88 DAP10 CD79b BCA MyD88 DAP12 CD8 BCA MyD88 DAP12 CD3? BCA MyD88 DAP12 CD3? BCA MyD88 DAP12 CD3? BCA MyD88 DAP12 CD3? BCA MyD88 DAP12 Fc?RI-? BCA MyD88 DAP12 Fc?RIII-? BCA MyD88 DAP12 Fc?RI? BCA MyD88 DAP12 Fc?RI? BCA MyD88 DAP12 DAP10 BCA MyD88 DAP12 DAP12 BCA MyD88 DAP12 CD32 BCA MyD88 DAP12 CD79a BCA MyD88 DAP12 CD79b BCA MyD88 MyD88 CD8 BCA MyD88 MyD88 CD3? BCA MyD88 MyD88 CD3? BCA MyD88 MyD88 CD3? BCA MyD88 MyD88 CD3? BCA MyD88 MyD88 Fc?RI-? BCA MyD88 MyD88 Fc?RIII-? BCA MyD88 MyD88 Fc?RI? BCA MyD88 MyD88 Fc?RI? BCA MyD88 MyD88 DAP10 BCA MyD88 MyD88 DAP12 BCA MyD88 MyD88 CD32 BCA MyD88 MyD88 CD79a BCA MyD88 MyD88 CD79b BCA MyD88 CD7 CD8 BCA MyD88 CD7 CD3? BCA MyD88 CD7 CD3? BCA MyD88 CD7 CD3? BCA MyD88 CD7 CD3? BCA MyD88 CD7 Fc?RI-? BCA MyD88 CD7 Fc?RIII-? BCA MyD88 CD7 Fc?RI? BCA MyD88 CD7 Fc?RI? BCA MyD88 CD7 DAP10 BCA MyD88 CD7 DAP12 BCA MyD88 CD7 CD32 BCA MyD88 CD7 CD79a BCA MyD88 CD7 CD79b BCA MyD88 BTNL3 CD8 BCA MyD88 BTNL3 CD3? BCA MyD88 BTNL3 CD3? BCA MyD88 BTNL3 CD3? BCA MyD88 BTNL3 CD3? BCA MyD88 BTNL3 Fc?RI-? BCA MyD88 BTNL3 Fc?RIII-? BCA MyD88 BTNL3 Fc?RI? BCA MyD88 BTNL3 Fc?RI? BCA MyD88 BTNL3 DAP10 BCA MyD88 BTNL3 DAP12 BCA MyD88 BTNL3 CD32 BCA MyD88 BTNL3 CD79a BCA MyD88 BTNL3 CD79b BCA MyD88 NKG2D CD8 BCA MyD88 NKG2D CD3? BCA MyD88 NKG2D CD3? BCA MyD88 NKG2D CD3? BCA MyD88 NKG2D CD3? BCA MyD88 NKG2D Fc?RI-? BCA MyD88 NKG2D Fc?RIII-? BCA MyD88 NKG2D Fc?RI? BCA MyD88 NKG2D Fc?RI? BCA MyD88 NKG2D DAP10 BCA MyD88 NKG2D DAP12 BCA MyD88 NKG2D CD32 BCA MyD88 NKG2D CD79a BCA MyD88 NKG2D CD79b BCA CD7 CD28 CD8 BCA CD7 CD28 CD3? BCA CD7 CD28 CD3? BCA CD7 CD28 CD3? BCA CD7 CD28 CD3? BCA CD7 CD28 Fc?RI-? BCA CD7 CD28 Fc?RIII-? BCA CD7 CD28 Fc?RI? BCA CD7 CD28 Fc?RI? BCA CD7 CD28 DAP10 BCA CD7 CD28 DAP12 BCA CD7 CD28 CD32 BCA CD7 CD28 CD79a BCA CD7 CD28 CD79b BCA CD7 CD8 CD8 BCA CD7 CD8 CD3? BCA CD7 CD8 CD3? BCA CD7 CD8 CD3? BCA CD7 CD8 CD3? BCA CD7 CD8 Fc?RI-? BCA CD7 CD8 Fc?RIII-? BCA CD7 CD8 Fc?RI? BCA CD7 CD8 Fc?RI? BCA CD7 CD8 DAP10 BCA CD7 CD8 DAP12 BCA CD7 CD8 CD32 BCA CD7 CD8 CD79a BCA CD7 CD8 CD79b BCA CD7 CD4 CD8 BCA CD7 CD4 CD3? BCA CD7 CD4 CD3? BCA CD7 CD4 CD3? BCA CD7 CD4 CD3? BCA CD7 CD4 Fc?RI-? BCA CD7 CD4 Fc?RIII-? BCA CD7 CD4 Fc?RI? BCA CD7 CD4 Fc?RI? BCA CD7 CD4 DAP10 BCA CD7 CD4 DAP12 BCA CD7 CD4 CD32 BCA CD7 CD4 CD79a BCA CD7 CD4 CD79b BCA CD7 b2c CD8 BCA CD7 b2c CD3? BCA CD7 b2c CD3? BCA CD7 b2c CD3? BCA CD7 b2c CD3? BCA CD7 b2c Fc?RI-? BCA CD7 b2c Fc?RIII-? BCA CD7 b2c Fc?RI? BCA CD7 b2c Fc?RI? BCA CD7 b2c DAP10 BCA CD7 b2c DAP12 BCA CD7 b2c CD32 BCA CD7 b2c CD79a BCA CD7 b2c CD79b BCA CD7 CD137/41BB CD8 BCA CD7 CD137/41BB CD3? BCA CD7 CD137/41BB CD3? BCA CD7 CD137/41BB CD3? BCA CD7 CD137/41BB CD3? BCA CD7 CD137/41BB Fc?RI-? BCA CD7 CD137/41BB Fc?RIII-? BCA CD7 CD137/41BB Fc?RI? BCA CD7 CD137/41BB Fc?RI? BCA CD7 CD137/41BB DAP10 BCA CD7 CD137/41BB DAP12 BCA CD7 CD137/41BB CD32 BCA CD7 CD137/41BB CD79a BCA CD7 CD137/41BB CD79b BCA CD7 ICOS CD8 BCA CD7 ICOS CD3? BCA CD7 ICOS CD3? BCA CD7 ICOS CD3? BCA CD7 ICOS CD3? BCA CD7 ICOS Fc?RI-? BCA CD7 ICOS Fc?RIII-? BCA CD7 ICOS Fc?RI? BCA CD7 ICOS Fc?RI? BCA CD7 ICOS DAP10 BCA CD7 ICOS DAP12 BCA CD7 ICOS CD32 BCA CD7 ICOS CD79a BCA CD7 ICOS CD79b BCA CD7 CD27 CD8 BCA CD7 CD27 CD3? BCA CD7 CD27 CD3? BCA CD7 CD27 CD3? BCA CD7 CD27 CD3? BCA CD7 CD27 Fc?RI-? BCA CD7 CD27 Fc?RIII-? BCA CD7 CD27 Fc?RI? BCA CD7 CD27 Fc?RI? BCA CD7 CD27 DAP10 BCA CD7 CD27 DAP12 BCA CD7 CD27 CD32 BCA CD7 CD27 CD79a BCA CD7 CD27 CD79b BCA CD7 CD28? CD8 BCA CD7 CD28? CD3? BCA CD7 CD28? CD3? BCA CD7 CD28? CD3? BCA CD7 CD28? CD3? BCA CD7 CD28? Fc?RI-? BCA CD7 CD28? Fc?RIII-? BCA CD7 CD28? Fc?RI? BCA CD7 CD28? Fc?RI? BCA CD7 CD28? DAP10 BCA CD7 CD28? DAP12 BCA CD7 CD28? CD32 BCA CD7 CD28? CD79a BCA CD7 CD28? CD79b BCA CD7 CD80 CD8 BCA CD7 CD80 CD3? BCA CD7 CD80 CD3? BCA CD7 CD80 CD3? BCA CD7 CD80 CD3? BCA CD7 CD80 Fc?RI-? BCA CD7 CD80 Fc?RIII-? BCA CD7 CD80 Fc?RI? BCA CD7 CD80 Fc?RI? BCA CD7 CD80 DAP10 BCA CD7 CD80 DAP12 BCA CD7 CD80 CD32 BCA CD7 CD80 CD79a BCA CD7 CD80 CD79b BCA CD7 CD86 CD8 BCA CD7 CD86 CD3? BCA CD7 CD86 CD3? BCA CD7 CD86 CD3? BCA CD7 CD86 CD3? BCA CD7 CD86 Fc?RI-? BCA CD7 CD86 Fc?RIII-? BCA CD7 CD86 Fc?RI? BCA CD7 CD86 Fc?RI? BCA CD7 CD86 DAP10 BCA CD7 CD86 DAP12 BCA CD7 CD86 CD32 BCA CD7 CD86 CD79a BCA CD7 CD86 CD79b BCA CD7 OX40 CD8 BCA CD7 OX40 CD3? BCA CD7 OX40 CD3? BCA CD7 OX40 CD3? BCA CD7 OX40 CD3? BCA CD7 OX40 Fc?RI-? BCA CD7 OX40 Fc?RIII-? BCA CD7 OX40 Fc?RI? BCA CD7 OX40 Fc?RI? BCA CD7 OX40 DAP10 BCA CD7 OX40 DAP12 BCA CD7 OX40 CD32 BCA CD7 OX40 CD79a BCA CD7 OX40 CD79b BCA CD7 DAP10 CD8 BCA CD7 DAP10 CD3? BCA CD7 DAP10 CD3? BCA CD7 DAP10 CD3? BCA CD7 DAP10 CD3? BCA CD7 DAP10 Fc?RI-? BCA CD7 DAP10 Fc?RIII-? BCA CD7 DAP10 Fc?RI? BCA CD7 DAP10 Fc?RI? BCA CD7 DAP10 DAP10 BCA CD7 DAP10 DAP12 BCA CD7 DAP10 CD32 BCA CD7 DAP10 CD79a BCA CD7 DAP10 CD79b BCA CD7 DAP12 CD8 BCA CD7 DAP12 CD3? BCA CD7 DAP12 CD3? BCA CD7 DAP12 CD3? BCA CD7 DAP12 CD3? BCA CD7 DAP12 Fc?RI-? BCA CD7 DAP12 Fc?RIII-? BCA CD7 DAP12 Fc?RI? BCA CD7 DAP12 Fc?RI? BCA CD7 DAP12 DAP10 BCA CD7 DAP12 DAP12 BCA CD7 DAP12 CD32 BCA CD7 DAP12 CD79a BCA CD7 DAP12 CD79b BCA CD7 MyD88 CD8 BCA CD7 MyD88 CD3? BCA CD7 MyD88 CD3? BCA CD7 MyD88 CD3? BCA CD7 MyD88 CD3? BCA CD7 MyD88 Fc?RI-? BCA CD7 MyD88 Fc?RIII-? BCA CD7 MyD88 Fc?RI? BCA CD7 MyD88 Fc?RI? BCA CD7 MyD88 DAP10 BCA CD7 MyD88 DAP12 BCA CD7 MyD88 CD32 BCA CD7 MyD88 CD79a BCA CD7 MyD88 CD79b BCA CD7 CD7 CD8 BCA CD7 CD7 CD3? BCA CD7 CD7 CD3? BCA CD7 CD7 CD3? BCA CD7 CD7 CD3? BCA CD7 CD7 Fc?RI-? BCA CD7 CD7 Fc?RIII-? BCA CD7 CD7 Fc?RI? BCA CD7 CD7 Fc?RI? BCA CD7 CD7 DAP10 BCA CD7 CD7 DAP12 BCA CD7 CD7 CD32 BCA CD7 CD7 CD79a BCA CD7 CD7 CD79b BCA CD7 BTNL3 CD8 BCA CD7 BTNL3 CD3? BCA CD7 BTNL3 CD3? BCA CD7 BTNL3 CD3? BCA CD7 BTNL3 CD3? BCA CD7 BTNL3 Fc?RI-? BCA CD7 BTNL3 Fc?RIII-? BCA CD7 BTNL3 Fc?RI? BCA CD7 BTNL3 Fc?RI? BCA CD7 BTNL3 DAP10 BCA CD7 BTNL3 DAP12 BCA CD7 BTNL3 CD32 BCA CD7 BTNL3 CD79a BCA CD7 BTNL3 CD79b BCA CD7 NKG2D CD8 BCA CD7 NKG2D CD3? BCA CD7 NKG2D CD3? BCA CD7 NKG2D CD3? BCA CD7 NKG2D CD3? BCA CD7 NKG2D Fc?RI-? BCA CD7 NKG2D Fc?RIII-? BCA CD7 NKG2D Fc?RI? BCA CD7 NKG2D Fc?RI? BCA CD7 NKG2D DAP10 BCA CD7 NKG2D DAP12 BCA CD7 NKG2D CD32 BCA CD7 NKG2D CD79a BCA CD7 NKG2D CD79b BCA BTNL3 CD28 CD8 BCA BTNL3 CD28 CD3? BCA BTNL3 CD28 CD3? BCA BTNL3 CD28 CD3? BCA BTNL3 CD28 CD3? BCA BTNL3 CD28 Fc?RI-? BCA BTNL3 CD28 Fc?RIII-? BCA BTNL3 CD28 Fc?RI? BCA BTNL3 CD28 Fc?RI? BCA BTNL3 CD28 DAP10 BCA BTNL3 CD28 DAP12 BCA BTNL3 CD28 CD32 BCA BTNL3 CD28 CD79a BCA BTNL3 CD28 CD79b BCA BTNL3 CD8 CD8 BCA BTNL3 CD8 CD3? BCA BTNL3 CD8 CD3? BCA BTNL3 CD8 CD3? BCA BTNL3 CD8 CD3? BCA BTNL3 CD8 Fc?RI-? BCA BTNL3 CD8 Fc?RIII-? BCA BTNL3 CD8 Fc?RI? BCA BTNL3 CD8 Fc?RI? BCA BTNL3 CD8 DAP10 BCA BTNL3 CD8 DAP12 BCA BTNL3 CD8 CD32 BCA BTNL3 CD8 CD79a BCA BTNL3 CD8 CD79b BCA BTNL3 CD4 CD8 BCA BTNL3 CD4 CD3? BCA BTNL3 CD4 CD3? BCA BTNL3 CD4 CD3? BCA BTNL3 CD4 CD3? BCA BTNL3 CD4 Fc?RI-? BCA BTNL3 CD4 Fc?RIII-? BCA BTNL3 CD4 Fc?RI? BCA BTNL3 CD4 Fc?RI? BCA BTNL3 CD4 DAP10 BCA BTNL3 CD4 DAP12 BCA BTNL3 CD4 CD32 BCA BTNL3 CD4 CD79a BCA BTNL3 CD4 CD79b BCA BTNL3 b2c CD8 BCA BTNL3 b2c CD3? BCA BTNL3 b2c CD3? BCA BTNL3 b2c CD3? BCA BTNL3 b2c CD3? BCA BTNL3 b2c Fc?RI-? BCA BTNL3 b2c Fc?RIII-? BCA BTNL3 b2c Fc?RI? BCA BTNL3 b2c Fc?RI? BCA BTNL3 b2c DAP10 BCA BTNL3 b2c DAP12 BCA BTNL3 b2c CD32 BCA BTNL3 b2c CD79a BCA BTNL3 b2c CD79b BCA BTNL3 CD137/41BB CD8 BCA BTNL3 CD137/41BB CD3? BCA BTNL3 CD137/41BB CD3? BCA BTNL3 CD137/41BB CD3? BCA BTNL3 CD137/41BB CD3? BCA BTNL3 CD137/41BB Fc?RI-? BCA BTNL3 CD137/41BB Fc?RIII-? BCA BTNL3 CD137/41BB Fc?RI? BCA BTNL3 CD137/41BB Fc?RI? BCA BTNL3 CD137/41BB DAP10 BCA BTNL3 CD137/41BB DAP12 BCA BTNL3 CD137/41BB CD32 BCA BTNL3 CD137/41BB CD79a BCA BTNL3 CD137/41BB CD79b BCA BTNL3 ICOS CD8 BCA BTNL3 ICOS CD3? BCA BTNL3 ICOS CD3? BCA BTNL3 ICOS CD3? BCA BTNL3 ICOS CD3? BCA BTNL3 ICOS Fc?RI-? BCA BTNL3 ICOS Fc?RIII-? BCA BTNL3 ICOS Fc?RI? BCA BTNL3 ICOS Fc?RI? BCA BTNL3 ICOS DAP10 BCA BTNL3 ICOS DAP12 BCA BTNL3 ICOS CD32 BCA BTNL3 ICOS CD79a BCA BTNL3 ICOS CD79b BCA BTNL3 CD27 CD8 BCA BTNL3 CD27 CD3? BCA BTNL3 CD27 CD3? BCA BTNL3 CD27 CD3? BCA BTNL3 CD27 CD3? BCA BTNL3 CD27 Fc?RI-? BCA BTNL3 CD27 Fc?RIII-? BCA BTNL3 CD27 Fc?RI? BCA BTNL3 CD27 Fc?RI? BCA BTNL3 CD27 DAP10 BCA BTNL3 CD27 DAP12 BCA BTNL3 CD27 CD32 BCA BTNL3 CD27 CD79a BCA BTNL3 CD27 CD79b BCA BTNL3 CD28? CD8 BCA BTNL3 CD28? CD3? BCA BTNL3 CD28? CD3? BCA BTNL3 CD28? CD3? BCA BTNL3 CD28? CD3? BCA BTNL3 CD28? Fc?RI-? BCA BTNL3 CD28? Fc?RIII-? BCA BTNL3 CD28? Fc?RI? BCA BTNL3 CD28? Fc?RI? BCA BTNL3 CD28? DAP10 BCA BTNL3 CD28? DAP12 BCA BTNL3 CD28? CD32 BCA BTNL3 CD28? CD79a BCA BTNL3 CD28? CD79b BCA BTNL3 CD80 CD8 BCA BTNL3 CD80 CD3? BCA BTNL3 CD80 CD3? BCA BTNL3 CD80 CD3? BCA BTNL3 CD80 CD3? BCA BTNL3 CD80 Fc?RI-? BCA BTNL3 CD80 Fc?RIII-? BCA BTNL3 CD80 Fc?RI? BCA BTNL3 CD80 Fc?RI? BCA BTNL3 CD80 DAP10 BCA BTNL3 CD80 DAP12 BCA BTNL3 CD80 CD32 BCA BTNL3 CD80 CD79a BCA BTNL3 CD80 CD79b BCA BTNL3 CD86 CD8 BCA BTNL3 CD86 CD3? BCA BTNL3 CD86 CD3? BCA BTNL3 CD86 CD3? BCA BTNL3 CD86 CD3? BCA BTNL3 CD86 Fc?RI-? BCA BTNL3 CD86 Fc?RIII-? BCA BTNL3 CD86 Fc?RI? BCA BTNL3 CD86 Fc?RI? BCA BTNL3 CD86 DAP10 BCA BTNL3 CD86 DAP12 BCA BTNL3 CD86 CD32 BCA BTNL3 CD86 CD79a BCA BTNL3 CD86 CD79b BCA BTNL3 OX40 CD8 BCA BTNL3 OX40 CD3? BCA BTNL3 OX40 CD3? BCA BTNL3 OX40 CD3? BCA BTNL3 OX40 CD3? BCA BTNL3 OX40 Fc?RI-? BCA BTNL3 OX40 Fc?RIII-? BCA BTNL3 OX40 Fc?RI? BCA BTNL3 OX40 Fc?RI? BCA BTNL3 OX40 DAP10 BCA BTNL3 OX40 DAP12 BCA BTNL3 OX40 CD32 BCA BTNL3 OX40 CD79a BCA BTNL3 OX40 CD79b BCA BTNL3 DAP10 CD8 BCA BTNL3 DAP10 CD3? BCA BTNL3 DAP10 CD3? BCA BTNL3 DAP10 CD3? BCA BTNL3 DAP10 CD3? BCA BTNL3 DAP10 Fc?RI-? BCA BTNL3 DAP10 Fc?RIII-? BCA BTNL3 DAP10 Fc?RI? BCA BTNL3 DAP10 Fc?RI? BCA BTNL3 DAP10 DAP10 BCA BTNL3 DAP10 DAP12 BCA BTNL3 DAP10 CD32 BCA BTNL3 DAP10 CD79a BCA BTNL3 DAP10 CD79b BCA BTNL3 DAP12 CD8 BCA BTNL3 DAP12 CD3? BCA BTNL3 DAP12 CD3? BCA BTNL3 DAP12 CD3? BCA BTNL3 DAP12 CD3? BCA BTNL3 DAP12 Fc?RI-? BCA BTNL3 DAP12 Fc?RIII-? BCA BTNL3 DAP12 Fc?RI? BCA BTNL3 DAP12 Fc?RI? BCA BTNL3 DAP12 DAP10 BCA BTNL3 DAP12 DAP12 BCA BTNL3 DAP12 CD32 BCA BTNL3 DAP12 CD79a BCA BTNL3 DAP12 CD79b BCA BTNL3 MyD88 CD8 BCA BTNL3 MyD88 CD3? BCA BTNL3 MyD88 CD3? BCA BTNL3 MyD88 CD3? BCA BTNL3 MyD88 CD3? BCA BTNL3 MyD88 Fc?RI-? BCA BTNL3 MyD88 Fc?RIII-? BCA BTNL3 MyD88 Fc?RI? BCA BTNL3 MyD88 Fc?RI? BCA BTNL3 MyD88 DAP10 BCA BTNL3 MyD88 DAP12 BCA BTNL3 MyD88 CD32 BCA BTNL3 MyD88 CD79a BCA BTNL3 MyD88 CD79b BCA BTNL3 CD7 CD8 BCA BTNL3 CD7 CD3? BCA BTNL3 CD7 CD3? BCA BTNL3 CD7 CD3? BCA BTNL3 CD7 CD3? BCA BTNL3 CD7 Fc?RI-? BCA BTNL3 CD7 Fc?RIII-? BCA BTNL3 CD7 Fc?RI? BCA BTNL3 CD7 Fc?RI? BCA BTNL3 CD7 DAP10 BCA BTNL3 CD7 DAP12 BCA BTNL3 CD7 CD32 BCA BTNL3 CD7 CD79a BCA BTNL3 CD7 CD79b BCA BTNL3 BTNL3 CD8 BCA BTNL3 BTNL3 CD3? BCA BTNL3 BTNL3 CD3? BCA BTNL3 BTNL3 CD3? BCA BTNL3 BTNL3 CD3? BCA BTNL3 BTNL3 Fc?RI-? BCA BTNL3 BTNL3 Fc?RIII-? BCA BTNL3 BTNL3 Fc?RI? BCA BTNL3 BTNL3 Fc?RI? BCA BTNL3 BTNL3 DAP10 BCA BTNL3 BTNL3 DAP12 BCA BTNL3 BTNL3 CD32 BCA BTNL3 BTNL3 CD79a BCA BTNL3 BTNL3 CD79b BCA BTNL3 NKG2D CD8 BCA BTNL3 NKG2D CD3? BCA BTNL3 NKG2D CD3? BCA BTNL3 NKG2D CD3? BCA BTNL3 NKG2D CD3? BCA BTNL3 NKG2D Fc?RI-? BCA BTNL3 NKG2D Fc?RIII-? BCA BTNL3 NKG2D Fc?RI? BCA BTNL3 NKG2D Fc?RI? BCA BTNL3 NKG2D DAP10 BCA BTNL3 NKG2D DAP12 BCA BTNL3 NKG2D CD32 BCA BTNL3 NKG2D CD79a BCA BTNL3 NKG2D CD79b BCA NKG2D CD28 CD8 BCA NKG2D CD28 CD3? BCA NKG2D CD28 CD3? BCA NKG2D CD28 CD3? BCA NKG2D CD28 CD3? BCA NKG2D CD28 Fc?RI-? BCA NKG2D CD28 Fc?RIII-? BCA NKG2D CD28 Fc?RI? BCA NKG2D CD28 Fc?RI? BCA NKG2D CD28 DAP10 BCA NKG2D CD28 DAP12 BCA NKG2D CD28 CD32 BCA NKG2D CD28 CD79a BCA NKG2D CD28 CD79b BCA NKG2D CD8 CD8 BCA NKG2D CD8 CD3? BCA NKG2D CD8 CD3? BCA NKG2D CD8 CD3? BCA NKG2D CD8 CD3? BCA NKG2D CD8 Fc?RI-? BCA NKG2D CD8 Fc?RIII-? BCA NKG2D CD8 Fc?RI? BCA NKG2D CD8 Fc?RI? BCA NKG2D CD8 DAP10 BCA NKG2D CD8 DAP12 BCA NKG2D CD8 CD32 BCA NKG2D CD8 CD79a BCA NKG2D CD8 CD79b BCA NKG2D CD4 CD8 BCA NKG2D CD4 CD3? BCA NKG2D CD4 CD3? BCA NKG2D CD4 CD3? BCA NKG2D CD4 CD3? BCA NKG2D CD4 Fc?RI-? BCA NKG2D CD4 Fc?RIII-? BCA NKG2D CD4 Fc?RI? BCA NKG2D CD4 Fc?RI? BCA NKG2D CD4 DAP10 BCA NKG2D CD4 DAP12 BCA NKG2D CD4 CD32 BCA NKG2D CD4 CD79a BCA NKG2D CD4 CD79b BCA NKG2D b2c CD8 BCA NKG2D b2c CD3? BCA NKG2D b2c CD3? BCA NKG2D b2c CD3? BCA NKG2D b2c CD3? BCA NKG2D b2c Fc?RI-? BCA NKG2D b2c Fc?RIII-? BCA NKG2D b2c Fc?RI? BCA NKG2D b2c Fc?RI? BCA NKG2D b2c DAP10 BCA NKG2D b2c DAP12 BCA NKG2D b2c CD32 BCA NKG2D b2c CD79a BCA NKG2D b2c CD79b BCA NKG2D CD137/41BB CD8 BCA NKG2D CD137/41BB CD3? BCA NKG2D CD137/41BB CD3? BCA NKG2D CD137/41BB CD3? BCA NKG2D CD137/41BB CD3? BCA NKG2D CD137/41BB Fc?RI-? BCA NKG2D CD137/41BB Fc?RIII-? BCA NKG2D CD137/41BB Fc?RI? BCA NKG2D CD137/41BB Fc?RI? BCA NKG2D CD137/41BB DAP10 BCA NKG2D CD137/41BB DAP12 BCA NKG2D CD137/41BB CD32 BCA NKG2D CD137/41BB CD79a BCA NKG2D CD137/41BB CD79b BCA NKG2D ICOS CD8 BCA NKG2D ICOS CD3? BCA NKG2D ICOS CD3? BCA NKG2D ICOS CD3? BCA NKG2D ICOS CD3? BCA NKG2D ICOS Fc?RI-? BCA NKG2D ICOS Fc?RIII-? BCA NKG2D ICOS Fc?RI? BCA NKG2D ICOS Fc?RI? BCA NKG2D ICOS DAP10 BCA NKG2D ICOS DAP12 BCA NKG2D ICOS CD32 BCA NKG2D ICOS CD79a BCA NKG2D ICOS CD79b BCA NKG2D CD27 CD8 BCA NKG2D CD27 CD3? BCA NKG2D CD27 CD3? BCA NKG2D CD27 CD3? BCA NKG2D CD27 CD3? BCA NKG2D CD27 Fc?RI-? BCA NKG2D CD27 Fc?RIII-? BCA NKG2D CD27 Fc?RI? BCA NKG2D CD27 Fc?RI? BCA NKG2D CD27 DAP10 BCA NKG2D CD27 DAP12 BCA NKG2D CD27 CD32 BCA NKG2D CD27 CD79a BCA NKG2D CD27 CD79b BCA NKG2D CD28? CD8 BCA NKG2D CD28? CD3? BCA NKG2D CD28? CD3? BCA NKG2D CD28? CD3? BCA NKG2D CD28? CD3? BCA NKG2D CD28? Fc?RI-? BCA NKG2D CD28? Fc?RIII-? BCA NKG2D CD28? Fc?RI? BCA NKG2D CD28? Fc?RI? BCA NKG2D CD28? DAP10 BCA NKG2D CD28? DAP12 BCA NKG2D CD28? CD32 BCA NKG2D CD28? CD79a BCA NKG2D CD28? CD79b BCA NKG2D CD80 CD8 BCA NKG2D CD80 CD3? BCA NKG2D CD80 CD3? BCA NKG2D CD80 CD3? BCA NKG2D CD80 CD3? BCA NKG2D CD80 Fc?RI-? BCA NKG2D CD80 Fc?RIII-? BCA NKG2D CD80 Fc?RI? BCA NKG2D CD80 Fc?RI? BCA NKG2D CD80 DAP10 BCA NKG2D CD80 DAP12 BCA NKG2D CD80 CD32 BCA NKG2D CD80 CD79a BCA NKG2D CD80 CD79b BCA NKG2D CD86 CD8 BCA NKG2D CD86 CD3? BCA NKG2D CD86 CD3? BCA NKG2D CD86 CD3? BCA NKG2D CD86 CD3? BCA NKG2D CD86 Fc?RI-? BCA NKG2D CD86 Fc?RIII-? BCA NKG2D CD86 Fc?RI? BCA NKG2D CD86 Fc?RI? BCA NKG2D CD86 DAP10 BCA NKG2D CD86 DAP12 BCA NKG2D CD86 CD32 BCA NKG2D CD86 CD79a BCA NKG2D CD86 CD79b BCA NKG2D OX40 CD8 BCA NKG2D OX40 CD3? BCA NKG2D OX40 CD3? BCA NKG2D OX40 CD3? BCA NKG2D OX40 CD3? BCA NKG2D OX40 Fc?RI-? BCA NKG2D OX40 Fc?RIII-? BCA NKG2D OX40 Fc?RI? BCA NKG2D OX40 Fc?RI? BCA NKG2D OX40 DAP10 BCA NKG2D OX40 DAP12 BCA NKG2D OX40 CD32 BCA NKG2D OX40 CD79a BCA NKG2D OX40 CD79b BCA NKG2D DAP10 CD8 BCA NKG2D DAP10 CD3? BCA NKG2D DAP10 CD3? BCA NKG2D DAP10 CD3? BCA NKG2D DAP10 CD3? BCA NKG2D DAP10 Fc?RI-? BCA NKG2D DAP10 Fc?RIII-? BCA NKG2D DAP10 Fc?RI? BCA NKG2D DAP10 Fc?RI? BCA NKG2D DAP10 DAP10 BCA NKG2D DAP10 DAP12 BCA NKG2D DAP10 CD32 BCA NKG2D DAP10 CD79a BCA NKG2D DAP10 CD79b BCA NKG2D DAP12 CD8 BCA NKG2D DAP12 CD3? BCA NKG2D DAP12 CD3? BCA NKG2D DAP12 CD3? BCA NKG2D DAP12 CD3? BCA NKG2D DAP12 Fc?RI-? BCA NKG2D DAP12 Fc?RIII-? BCA NKG2D DAP12 Fc?RI? BCA NKG2D DAP12 Fc?RI? BCA NKG2D DAP12 DAP10 BCA NKG2D DAP12 DAP12 BCA NKG2D DAP12 CD32 BCA NKG2D DAP12 CD79a BCA NKG2D DAP12 CD79b BCA NKG2D MyD88 CD8 BCA NKG2D MyD88 CD3? BCA NKG2D MyD88 CD3? BCA NKG2D MyD88 CD3? BCA NKG2D MyD88 CD3? BCA NKG2D MyD88 Fc?RI-? BCA NKG2D MyD88 Fc?RIII-? BCA NKG2D MyD88 Fc?RI? BCA NKG2D MyD88 Fc?RI? BCA NKG2D MyD88 DAP10 BCA NKG2D MyD88 DAP12 BCA NKG2D MyD88 CD32 BCA NKG2D MyD88 CD79a BCA NKG2D MyD88 CD79b BCA NKG2D CD7 CD8 BCA NKG2D CD7 CD3? BCA NKG2D CD7 CD3? BCA NKG2D CD7 CD3? BCA NKG2D CD7 CD3? BCA NKG2D CD7 Fc?RI-? BCA NKG2D CD7 Fc?RIII-? BCA NKG2D CD7 Fc?RI? BCA NKG2D CD7 Fc?RI? BCA NKG2D CD7 DAP10 BCA NKG2D CD7 DAP12 BCA NKG2D CD7 CD32 BCA NKG2D CD7 CD79a BCA NKG2D CD7 CD79b BCA NKG2D BTNL3 CD8 BCA NKG2D BTNL3 CD3? BCA NKG2D BTNL3 CD3? BCA NKG2D BTNL3 CD3? BCA NKG2D BTNL3 CD3? BCA NKG2D BTNL3 Fc?RI-? BCA NKG2D BTNL3 Fc?RIII-? BCA NKG2D BTNL3 Fc?RI? BCA NKG2D BTNL3 Fc?RI? BCA NKG2D BTNL3 DAP10 BCA NKG2D BTNL3 DAP12 BCA NKG2D BTNL3 CD32 BCA NKG2D BTNL3 CD79a BCA NKG2D BTNL3 CD79b BCA NKG2D NKG2D CD8 BCA NKG2D NKG2D CD3? BCA NKG2D NKG2D CD3? BCA NKG2D NKG2D CD3? BCA NKG2D NKG2D CD3? BCA NKG2D NKG2D Fc?RI-? BCA NKG2D NKG2D Fc?RIII-? BCA NKG2D NKG2D Fc?RI? BCA NKG2D NKG2D Fc?RI? BCA NKG2D NKG2D DAP10 BCA NKG2D NKG2D DAP12 BCA NKG2D NKG2D CD32 BCA NKG2D NKG2D CD79a BCA NKG2D NKG2D CD79b

(40) TABLE-US-00004 TABLE 4 CARs lacking Co-Simulatory Signal (for dual CAR approach) ScFv Co-stimulatory Signal Signal Domain BCA none CD8 BCA none CD3? BCA none CD3? BCA none CD3? BCA none CD3? BCA none Fc?RI-? BCA none Fc?RIII-? BCA none Fc?RI? BCA none Fc?RI? BCA none DAP10 BCA none DAP12 BCA none CD32 BCA none CD79a BCA none CD8 BCA none CD3? BCA none CD3? BCA none CD3? BCA none CD3? BCA none Fc?RI-?

(41) TABLE-US-00005 TABLE 5 CARs lacking Signal Domain (for dual CAR approach) ScFv Co-stimulatory Signal Signal Domain BCA CD28 none BCA CD8 none BCA CD4 none BCA b2c none BCA CD137/41BB none BCA ICOS none BCA CD27 none BCA CD28? none BCA CD80 none BCA CD86 none BCA OX40 none BCA DAP10 none BCA MyD88 none BCA CD7 none BCA DAP12 none BCA MyD88 none BCA CD7 none BCA BTNL3 none BCA NKG2D none

(42) TABLE-US-00006 TABLE 6 Third Generation CARs lacking Signal Domain (for dual CAR approach) Co-stimulatory Co-stimulatory Signal ScFv Signal Signal Domain BCA CD28 CD28 none BCA CD28 CD8 none BCA CD28 CD4 none BCA CD28 b2c none BCA CD28 CD137/41BB none BCA CD28 ICOS none BCA CD28 CD27 none BCA CD28 CD28? none BCA CD28 CD80 none BCA CD28 CD86 none BCA CD28 OX40 none BCA CD28 DAP10 none BCA CD28 MyD88 none BCA CD28 CD7 none BCA CD28 DAP12 none BCA CD28 MyD88 none BCA CD28 CD7 none BCA CD8 CD28 none BCA CD8 CD8 none BCA CD8 CD4 none BCA CD8 b2c none BCA CD8 CD137/41BB none BCA CD8 ICOS none BCA CD8 CD27 none BCA CD8 CD28? none BCA CD8 CD80 none BCA CD8 CD86 none BCA CD8 OX40 none BCA CD8 DAP10 none BCA CD8 MyD88 none BCA CD8 CD7 none BCA CD8 DAP12 none BCA CD8 MyD88 none BCA CD8 CD7 none BCA CD4 CD28 none BCA CD4 CD8 none BCA CD4 CD4 none BCA CD4 b2c none BCA CD4 CD137/41BB none BCA CD4 ICOS none BCA CD4 CD27 none BCA CD4 CD28? none BCA CD4 CD80 none BCA CD4 CD86 none BCA CD4 OX40 none BCA CD4 DAP10 none BCA CD4 MyD88 none BCA CD4 CD7 none BCA CD4 DAP12 none BCA CD4 MyD88 none BCA CD4 CD7 none BCA b2c CD28 none BCA b2c CD8 none BCA b2c CD4 none BCA b2c b2c none BCA b2c CD137/41BB none BCA b2c ICOS none BCA b2c CD27 none BCA b2c CD28? none BCA b2c CD80 none BCA b2c CD86 none BCA b2c OX40 none BCA b2c DAP10 none BCA b2c MyD88 none BCA b2c CD7 none BCA b2c DAP12 none BCA b2c MyD88 none BCA b2c CD7 none BCA CD137/41BB CD28 none BCA CD137/41BB CD8 none BCA CD137/41BB CD4 none BCA CD137/41BB b2c none BCA CD137/41BB CD137/41BB none BCA CD137/41BB ICOS none BCA CD137/41BB CD27 none BCA CD137/41BB CD28? none BCA CD137/41BB CD80 none BCA CD137/41BB CD86 none BCA CD137/41BB OX40 none BCA CD137/41BB DAP10 none BCA CD137/41BB MyD88 none BCA CD137/41BB CD7 none BCA CD137/41BB DAP12 none BCA CD137/41BB MyD88 none BCA CD137/41BB CD7 none BCA ICOS CD28 none BCA ICOS CD8 none BCA ICOS CD4 none BCA ICOS b2c none BCA ICOS CD137/41BB none BCA ICOS ICOS none BCA ICOS CD27 none BCA ICOS CD28? none BCA ICOS CD80 none BCA ICOS CD86 none BCA ICOS OX40 none BCA ICOS DAP10 none BCA ICOS MyD88 none BCA ICOS CD7 none BCA ICOS DAP12 none BCA ICOS MyD88 none BCA ICOS CD7 none BCA ICOS CD28 none BCA ICOS CD8 none BCA ICOS CD4 none BCA ICOS b2c none BCA ICOS CD137/41BB none BCA ICOS ICOS none BCA ICOS CD27 none BCA ICOS CD28? none BCA ICOS CD80 none BCA ICOS CD86 none BCA ICOS OX40 none BCA ICOS DAP10 none BCA ICOS MyD88 none BCA ICOS CD7 none BCA ICOS DAP12 none BCA ICOS MyD88 none BCA ICOS CD7 none BCA CD27 CD28 none BCA CD27 CD8 none BCA CD27 CD4 none BCA CD27 b2c none BCA CD27 CD137/41BB none BCA CD27 ICOS none BCA CD27 CD27 none BCA CD27 CD28? none BCA CD27 CD80 none BCA CD27 CD86 none BCA CD27 OX40 none BCA CD27 DAP10 none BCA CD27 MyD88 none BCA CD27 CD7 none BCA CD27 DAP12 none BCA CD27 MyD88 none BCA CD27 CD7 none BCA CD28? CD28 none BCA CD28? CD8 none BCA CD28? CD4 none BCA CD28? b2c none BCA CD28? CD137/41BB none BCA CD28? ICOS none BCA CD28? CD27 none BCA CD28? CD28? none BCA CD28? CD80 none BCA CD28? CD86 none BCA CD28? OX40 none BCA CD28? DAP10 none BCA CD28? MyD88 none BCA CD28? CD7 none BCA CD28? DAP12 none BCA CD28? MyD88 none BCA CD28? CD7 none BCA CD80 CD28 none BCA CD80 CD8 none BCA CD80 CD4 none BCA CD80 b2c none BCA CD80 CD137/41BB none BCA CD80 ICOS none BCA CD80 CD27 none BCA CD80 CD28? none BCA CD80 CD80 none BCA CD80 CD86 none BCA CD80 OX40 none BCA CD80 DAP10 none BCA CD80 MyD88 none BCA CD80 CD7 none BCA CD80 DAP12 none BCA CD80 MyD88 none BCA CD80 CD7 none BCA CD86 CD28 none BCA CD86 CD8 none BCA CD86 CD4 none BCA CD86 b2c none BCA CD86 CD137/41BB none BCA CD86 ICOS none BCA CD86 CD27 none BCA CD86 CD28? none BCA CD86 CD80 none BCA CD86 CD86 none BCA CD86 OX40 none BCA CD86 DAP10 none BCA CD86 MyD88 none BCA CD86 CD7 none BCA CD86 DAP12 none BCA CD86 MyD88 none BCA CD86 CD7 none BCA OX40 CD28 none BCA OX40 CD8 none BCA OX40 CD4 none BCA OX40 b2c none BCA OX40 CD137/41BB none BCA OX40 ICOS none BCA OX40 CD27 none BCA OX40 CD28? none BCA OX40 CD80 none BCA OX40 CD86 none BCA OX40 OX40 none BCA OX40 DAP10 none BCA OX40 MyD88 none BCA OX40 CD7 none BCA OX40 DAP12 none BCA OX40 MyD88 none BCA OX40 CD7 none BCA DAP10 CD28 none BCA DAP10 CD8 none BCA DAP10 CD4 none BCA DAP10 b2c none BCA DAP10 CD137/41BB none BCA DAP10 ICOS none BCA DAP10 CD27 none BCA DAP10 CD28? none BCA DAP10 CD80 none BCA DAP10 CD86 none BCA DAP10 OX40 none BCA DAP10 DAP10 none BCA DAP10 MyD88 none BCA DAP10 CD7 none BCA DAP10 DAP12 none BCA DAP10 MyD88 none BCA DAP10 CD7 none BCA DAP12 CD28 none BCA DAP12 CD8 none BCA DAP12 CD4 none BCA DAP12 b2c none BCA DAP12 CD137/41BB none BCA DAP12 ICOS none BCA DAP12 CD27 none BCA DAP12 CD28? none BCA DAP12 CD80 none BCA DAP12 CD86 none BCA DAP12 OX40 none BCA DAP12 DAP10 none BCA DAP12 MyD88 none BCA DAP12 CD7 none BCA DAP12 DAP12 none BCA DAP12 MyD88 none BCA DAP12 CD7 none BCA MyD88 CD28 none BCA MyD88 CD8 none BCA MyD88 CD4 none BCA MyD88 b2c none BCA MyD88 CD137/41BB none BCA MyD88 ICOS none BCA MyD88 CD27 none BCA MyD88 CD28? none BCA MyD88 CD80 none BCA MyD88 CD86 none BCA MyD88 OX40 none BCA MyD88 DAP10 none BCA MyD88 MyD88 none BCA MyD88 CD7 none BCA MyD88 DAP12 none BCA MyD88 MyD88 none BCA MyD88 CD7 none BCA CD7 CD28 none BCA CD7 CD8 none BCA CD7 CD4 none BCA CD7 b2c none BCA CD7 CD137/41BB none BCA CD7 ICOS none BCA CD7 CD27 none BCA CD7 CD28? none BCA CD7 CD80 none BCA CD7 CD86 none BCA CD7 OX40 none BCA CD7 DAP10 none BCA CD7 MyD88 none BCA CD7 CD7 none BCA CD7 DAP12 none BCA CD7 MyD88 none BCA CD7 CD7 none BCA BTNL3 CD28 none BCA BTNL3 CD8 none BCA BTNL3 CD4 none BCA BTNL3 b2c none BCA BTNL3 CD137/41BB none BCA BTNL3 ICOS none BCA BTNL3 CD27 none BCA BTNL3 CD28? none BCA BTNL3 CD80 none BCA BTNL3 CD86 none BCA BTNL3 OX40 none BCA BTNL3 DAP10 none BCA BTNL3 MyD88 none BCA BTNL3 CD7 none BCA BTNL3 DAP12 none BCA BTNL3 MyD88 none BCA BTNL3 CD7 none BCA NKG2D CD28 none BCA NKG2D CD8 none BCA NKG2D CD4 none BCA NKG2D b2c none BCA NKG2D CD137/41BB none BCA NKG2D ICOS none BCA NKG2D CD27 none BCA NKG2D CD28? none BCA NKG2D CD80 none BCA NKG2D CD86 none BCA NKG2D OX40 none BCA NKG2D DAP10 none BCA NKG2D MyD88 none BCA NKG2D CD7 none BCA NKG2D DAP12 none BCA NKG2D MyD88 none BCA NKG2D CD7 none

(43) In some embodiments, the anti-BCA binding agent is single chain variable fragment (scFv) antibody. The affinity/specificity of an anti-BCA scFv is driven in large part by specific sequences within complementarity determining regions (CDRs) in the heavy (V.sub.H) and light (V.sub.L) chain. Each V.sub.H and V.sub.L sequence will have three CDRs (CDR1, CDR2, CDR3).

(44) In some embodiments, the anti-BCA binding agent is derived from natural antibodies, such as monoclonal antibodies. In some cases, the antibody is human. In some cases, the antibody has undergone an alteration to render it less immunogenic when administered to humans. For example, the alteration comprises one or more techniques selected from the group consisting of chimerization, humanization, CDR-grafting, deimmunization, and mutation of framework amino acids to correspond to the closest human germline sequence.

(45) Also disclosed are bi-specific CARs that target a BCA and at least one additional tumor antigen. Also disclosed are CARs designed to work only in conjunction with another CAR that binds a different antigen, such as a tumor antigen. For example, in these embodiments, the endodomain of the disclosed CAR can contain only an signaling domain (SD) or a co-stimulatory signaling region (CSR), but not both. The second CAR (or endogenous T-cell) provides the missing signal if it is activated. For example, if the disclosed CAR contains an SD but not a CSR, then the immune effector cell containing this CAR is only activated if another CAR (or T-cell) containing a CSR binds its respective antigen. Likewise, if the disclosed CAR contains a CSR but not a SD, then the immune effector cell containing this CAR is only activated if another CAR (or T-cell) containing an SD binds its respective antigen.

(46) Tumor antigens are proteins that are produced by tumor cells that elicit an immune response, particularly T-cell mediated immune responses. The additional antigen binding domain can be an antibody or a natural ligand of the tumor antigen. The selection of the additional antigen binding domain will depend on the particular type of cancer to be treated. Tumor antigens are well known in the art and include, for example, a glioma-associated antigen, carcinoembryonic antigen (CEA), EGFRvIII, IL-IIRa, IL-13Ra, EGFR, FAP, B7H3, Kit, CA LX, CS-1, MUC1, BCMA, bcr-abl, HER2, ?-human chorionic gonadotropin, alphafetoprotein (AFP), ALK, CD19, TIM3, cyclin BI, lectin-reactive AFP, Fos-related antigen 1, ADRB3, thyroglobulin, EphA2, RAGE-1, RUI, RU2, SSX2, AKAP-4, LCK, OY-TESI, PAX5, SART3, CLL-1, fucosyl GM1, GloboH, MN-CA IX, EPCAM, EVT6-AML, TGS5, human telomerase reverse transcriptase, plysialic acid, PLAC1, RUI, RU2 (AS), intestinal carboxyl esterase, lewisY, sLe, LY6K, mut hsp70-2, M-CSF, MYCN, RhoC, TRP-2, CYPIBI, BORIS, prostase, prostate-specific antigen (PSA), PAX3, PAP, NY-ESO-1, LAGE-Ia, LMP2, NCAM, p53, p53 mutant, Ras mutant, gplOO, prostein, OR51E2, PANX3, PSMA, PSCA, Her2/neu, hTERT, HMWMAA, HAVCR1, VEGFR2, PDGFR-beta, survivin and telomerase, legumain, HPV E6, E7, sperm protein 17, SSEA-4, tyrosinase, TARP, WT1, prostate-carcinoma tumor antigen-1 (PCTA-1), ML-IAP, MAGE, MAGE-A1,MAD-CT-1, MAD-CT-2, MelanA/MART 1, XAGE1, ELF2M, ERG (TMPRSS2 ETS fusion gene), NA17, neutrophil elastase, sarcoma translocation breakpoints, NY-BR-1, ephnnB2, CD20, CD22, CD24, CD30, TIM3, CD38, CD44v6, CD97, CD171, CD179a, androgen receptor, FAP, insulin growth factor (IGF)-I, IGFII, IGF-I receptor, GD2, o-acetyl-GD2, GD3, GM3, GPRC5D, GPR20, CXORF61, folate receptor (FRa), folate receptor beta, ROR1, FIt3, TAG72, TN Ag, Tie 2, TEM1, TEM7R, CLDN6, TSHR, UPK2, and mesothelin. In a preferred embodiment, the tumor antigen is selected from the group consisting of folate receptor (FRa), mesothelin, EGFRvIII, IL-13Ra, CD123, CD19, TIM3, BCMA, GD2, CLL-1, CA-IX, MUCI, HER2, and any combination thereof.

(47) Non-limiting examples of tumor antigens include the following: Differentiation antigens such as tyrosinase, TRP-1, TRP-2 and tumor-specific multilineage antigens such as MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-2, pi 5; overexpressed embryonic antigens such as CEA; overexpressed oncogenes and mutated tumor-suppressor genes such as p53, Ras, HER-2/neu; unique tumor antigens resulting from chromosomal translocations; such as BCR-ABL, E2A-PRL, H4-RET, IGH-IGK, MYL-RAR; and viral antigens, such as the Epstein Barr virus antigens EBVA and the human papillomavirus (HPV) antigens E6 and E7. Other large, protein-based antigens include TSP-180, MAGE-4, MAGE-5, MAGE-6, RAGE, NY-ESO, pl85erbB2, pl80erbB-3, c-met, nm-23H1, PSA, CA 19-9, CA 72-4, CAM 17.1, NuMa, K-ras, beta-Catenin, CDK4, Mum-1, p 15, p 16, 43-9F, 5T4, 791Tgp72, alpha-fetoprotein, beta-HCG, BCA225, BTAA, CA 125, CA 15-3\CA 27.29\BCAA, CA 195, CA 242, CA-50, CAM43, CD68\P1, CO-029, FGF-5, G250, Ga733\EpCAM, HTgp-175, M344, MA-50, MG7-Ag, MOV18, NB/70K, NY-CO-1, RCASI, SDCCAG1 6, TA-90\Mac-2 binding protein\cyclophilm C-associated protein, TAAL6, TAG72, TLP, TPS, GPC3, MUC16, LMP1, EBMA-1, BARF-1, CS1, CD319, HER1, B7H6, L1CAM, IL6, and MET.

(48) Single Chain Antibodies

(49) CARs generally incorporate an antigen recognition domain from the single-chain variable fragments (scFv) of a monoclonal antibody (mAb) with transmembrane signaling motifs involved in lymphocyte activation (Sadelain M, et al. Nat Rev Cancer 2003 3:35-45).

(50) Anti-CD19 scFv

(51) In some embodiments, the anti-CD19 scFv is derived from hybridoma from plate CD19 Plate 1, CD19 Plate 2, CD19 Plate 3, CD19 Plate 4, CD19 Plate 5, CD19 Plate 6, CD19 Plate 7, CD19 Plate 8, CD19 Plate 9, CD19 Plate 10, CD19 Plate 11, CD19 Plate 12, CD19 Plate 13, CD19 Plate 14, CD19 Plate 15, CD19 Plate 16, CD19 Plate 17, CD19 Plate 18, CD19 Plate 19, CD19 Plate 20, CD19 Plate 21, or CD19 Plate 22. Each plate has 96 wells consisting of 8 columns (A-H) and 12 rows (1-12), so each well contains 96 hybridomas identified by their plate and well, e.g. CD19 Plate1-A1. In some embodiments, the anti-CD19 scFv can comprise a variable heavy (V.sub.H) domain having CDR1, CDR2 and CDR3 sequences and a variable light (V.sub.L) domain having CDR1, CDR2 and CDR3 sequences.

(52) In some embodiments, the anti-CD19 scFv can comprise a variable heavy (V.sub.H) domain having CDR1, CDR2 and CDR3 sequences and a variable light (V.sub.L) domain having CDR1, CDR2 and CDR3 sequences.

(53) For example, in some embodiments, the CDR1 sequence of the V.sub.H domain comprises the amino acid sequence GFTFSSYA (SEQ ID NO:1), GFSLTNFG (SEQ ID NO:2), GYTFTSYW (SEQ ID NO:3), GISITTGNYR (SEQ ID NO:4), GFTFSRYA (SEQ ID NO:5), GYSITSDYA (SEQ ID NO:6), YTFTDYYY (SEQ ID NO:7), or GFSLSRYS (SEQ ID NO:8); CDR2 sequence of the V.sub.H domain comprises the amino acid sequence ISSGGST (SEQ ID NO:9), ISSGGSFT (SEQ ID NO:10), IWRGGST (SEQ ID NO:11), IAPGTGST (SEQ ID NO:12), IYYSGTI (SEQ ID NO:13), ISPGGGYI (SEQ ID NO:14), ISYSGST (SEQ ID NO:15), IYPNNSGT (SEQ ID NO:16), IWVNGNT (SEQ ID NO:17), or IYPGNSDT (SEQ ID NO:18); CDR3 sequence of the V.sub.H domain comprises the amino acid sequence ARGRDGYSLYFDY (SEQ ID NO:19), AREGVYSDYRAWFAY (SEQ ID NO:20), AKMGITYYFDY (SEQ ID NO:21), AREGGRYYTLDC (SEQ ID NO:22), ARWLNNFDV (SEQ ID NO:23), AGDYVDY (SEQ ID NO:24), ARNWVYAMDY (SEQ ID NO:25), ARYYDGFNAGFAY (SEQ ID NO:26), ATYYGNYDSFTY (SEQ ID NO:27), or TTSLAY (SEQ ID NO:28); CDR1 sequence of the V.sub.L comprises the amino acid sequence QNVGTN (SEQ ID NO:29), ETIDNYGISF (SEQ ID NO:30), QNVDTN (SEQ ID NO:31), QDVGTA (SEQ ID NO:32), QDVSTA (SEQ ID NO:33), QSLLNSDGKTF (SEQ ID NO:34), QSLLYSSNQKNY (SEQ ID NO:35), QSLLDSDGKTY (SEQ ID NO:36), or SSVSSSY (SEQ ID NO:37); CDR2 sequence of the V.sub.L domain comprises the amino acid sequence SAS (SEQ ID NO:38), GAS (SEQ ID NO:39), WAS (SEQ ID NO:40), LVS (SEQ ID NO:41), or STS (SEQ ID NO:42); and CDR3 sequence of the V.sub.L domain comprises the amino acid sequence QQYNTYPYT (SEQ ID NO:43), QQNKEFPWT (SEQ ID NO:44), QQYNSYPLT (SEQ ID NO:45), QQYSSYPLT (SEQ ID NO:46), QQHYSTPYT (SEQ ID NO:47), WQGTHFPYT (SEQ ID NO:48), QQYYSYPRT (SEQ ID NO:49), WQGTHFPHT (SEQ ID NO:50), or QQYSGYPLT (SEQ ID NO:51).

(54) The heavy and light chains are preferably separated by a linker. Suitable linkers for scFv antibodies are known in the art. In some embodiments, the linker comprises the amino acid sequence GGGGSGGGGSGGGGS (SEQ ID NO:52).

(55) In some embodiments, the anti-CD19 scFv is derived from hybridoma 1A10, 1H1, 2B1, 2H8, 4A12, 3A10, 4F1, 4H9, 5H5, or 6F10.

(56) Therefore, in some embodiments, the anti-CD19 scFv V.sub.H domain comprises the amino acid sequence:

(57) TABLE-US-00007 (SEQIDNO:53,1A10) EVKLEESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVA SISSGGSTYYPDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCARG RDGYSLYFDYWGQGTTLTVSS.

(58) Therefore, in some embodiments, the anti-CD19 scFv V.sub.H domain is encoded by the nucleic acid sequence:

(59) TABLE-US-00008 (SEQIDNO:73,1A10) GAAGTGAAGCTGGAGGAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGGGT CCCTGAAACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTAGCTATGC CATGTCTTGGGTTCGCCAGACTCCAGAGAAGAGGCTGGAGTGGGTCGCA TCCATTAGTAGTGGTGGTAGCACCTACTATCCTGACAGTGTGAAGGGCC GATTCACCATCTCCAGAGATAATGCCAGGAACACCCTGTACCTGCAAAT GAGCAGTCTGAGGTCTGAGGACACGGCCATGTATTACTGTGCAAGAGGC CGGGATGGTTACTCCCTTTACTTTGACTACTGGGGCCAAGGCACCACTC TCACAGTCTCCTCA.

(60) Therefore, in some embodiments, the anti-CD19 scFv V.sub.H domain comprises the amino acid sequence:

(61) TABLE-US-00009 (SEQIDNO:54,1H1) QVKLQESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWV AGISSGGSFTYYPDTVKGRFTISRDNARNTLYLQMSSLRSEDTAMYSC AREGVYSDYRAWFAYWGQGTLVTVSG.

(62) Therefore, in some embodiments, the anti-CD19 scFv V.sub.H domain is encoded by the nucleic acid sequence:

(63) TABLE-US-00010 (SEQIDNO:74,1H1) CAAGTCAAGCTGCAGGAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGGG TCCCTGAAACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTAGTTAT GCCATGTCTTGGGTTCGCCAGACTCCGGAGAAGAGGCTGGAGTGGGTC GCAGGGATTAGTAGTGGTGGTAGTTTCACTTACTATCCAGACACTGTG AAGGGACGATTCACCATTTCCAGAGACAATGCCAGGAACACCCTTTAC CTGCAAATGAGCAGTCTGAGGTCTGAGGACACGGCCATGTATTCCTGT GCAAGAGAAGGGGTCTATAGTGACTACAGGGCCTGGTTTGCTTACTGG GGCCAAGGGACTCTGGTCACTGTCTCTGGA.

(64) Therefore, in some embodiments, the anti-CD19 scFv V.sub.H domain comprises the amino acid sequence:

(65) TABLE-US-00011 (SEQIDNO:55,2B1) EVKLEQSGPSLVQPSQSLSITCTVSGFSLTNFGVHWVRQSPGKGLEWL GLIWRGGSTDYNAAFMSRLSITKDNSKSQVFFKMNSLQADDTAIYYCA KMGITYYFDYWGQGTTLTVSS.

(66) Therefore, in some embodiments, the anti-CD19 scFv V.sub.H domain is encoded by the nucleic acid sequence:

(67) TABLE-US-00012 (SEQIDNO:75,2B1) GAGGTAAAGCTGGAGCAGTCAGGACCTAGCCTAGTGCAGCCCTCACAG AGCCTGTCCATAACCTGCACAGTCTCTGGTTTCTCATTAACTAACTTT GGTGTACACTGGGTTCGCCAGTCTCCAGGAAAGGGTCTGGAGTGGCTG GGACTGATATGGAGAGGTGGAAGCACAGACTACAATGCAGCTTTCATG TCCAGACTGAGCATCACCAAGGACAACTCCAAGAGCCAAGTTTTCTTT AAAATGAACAGTCTGCAAGCTGATGACACTGCCATATACTACTGTGCC AAAATGGGGATTACGTACTACTTTGACTACTGGGGCCAAGGCACCACT CTCACAGTCTCCTCA.

(68) Therefore, in some embodiments, the anti-CD19 scFv V.sub.H domain comprises the amino acid sequence:

(69) TABLE-US-00013 (SEQIDNO:56,2H8) QVKLQQSGDDLVKPGASVKLSCKASGYTFTSYWINWIKQRPGQGLEW IGHIAPGTGSTYYSEMFKDKATLTVDTPSSSAYIQLSSLSSEDSAVY FCAREGGRYYTLDCWGQGTSVTVSS.

(70) Therefore, in some embodiments, the anti-CD19 scFv V.sub.H domain is encoded by the nucleic acid sequence:

(71) TABLE-US-00014 (SEQIDNO:76,2H8) CAGGTAAAGCTGCAGCAGTCTGGAGATGATCTGGTAAAGCCTGGGGC CTCAGTGAAGCTGTCCTGCAAGGCTTCTGGCTACACCTTCACCAGCT ACTGGATTAACTGGATAAAACAGAGGCCTGGACAGGGCCTTGAGTGG ATAGGACATATTGCTCCTGGAACTGGTAGTACTTACTACAGTGAAAT GTTCAAGGACAAGGCAACACTGACTGTAGACACACCCTCCAGCTCAG CCTACATTCAGCTCAGCAGCCTGTCATCTGAGGACTCTGCTGTCTAT TTCTGTGCAAGAGAGGGGGGACGATACTATACTTTGGACTGCTGGGG TCAAGGAACCTCAGTCACCGTCTCCTCA.

(72) Therefore, in some embodiments, the anti-CD19 scFv V.sub.H domain comprises the amino acid sequence:

(73) TABLE-US-00015 (SEQIDNO:57,4A12) QVQLEESGPGLVKPSQTVSLTCTVTGISITTGNYRWSWIRQFPGNKL EWIGYIYYSGTITYNPSLTSRTTITRDTSKNQFFLEMNSLTAEDTAT YYCARWLNNFDVWGTGTTVTVS.

(74) Therefore, in some embodiments, the anti-CD19 scFv V.sub.H domain is encoded by the nucleic acid sequence:

(75) TABLE-US-00016 (SEQIDNO:77,4A12) CAGGTGCAGCTGGAGGAGTCAGGACCTGGTCTGGTGAAACCTTCTCAG ACAGTGTCCCTCACCTGCACTGTCACTGGCATCTCCATCACCACTGGA AATTACAGATGGAGCTGGATCCGGCAGTTTCCAGGAAACAAACTGGAG TGGATAGGGTACATATACTACAGTGGTACCATTACCTACAATCCATCT CTCACAAGTCGAACCACCATCACTAGAGACACTTCCAAGAACCAATTC TTCCTGGAAATGAACTCTTTGACTGCTGAAGACACAGCCACATACTAC TGTGCACGATGGTTAAACAACTTCGATGTCTGGGGCACAGGGACCACG GTCACCGTCTCCTCA.

(76) Therefore, in some embodiments, the anti-CD19 scFv V.sub.H domain comprises the amino acid sequence:

(77) TABLE-US-00017 (SEQIDNO:58,3A10) EVMLVESGGGLVKPGGSLKLSCAASGFTFSRYAMSWNRQTPEKRLEW VATISPGGGYIYYSDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMY YCAGDYVDYWGQGTTLTVSS.

(78) Therefore, in some embodiments, the anti-CD19 scFv V.sub.H domain is encoded by the nucleic acid sequence:

(79) TABLE-US-00018 (SEQIDNO:78,3A10) GAAGTGATGCTGGTGGAATCTGGGGGAGGCTTAGTGAAGCCTGGAGGG TCCCTGAAACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTAGGTAT GCCATGTCTTGGAATCGCCAGACTCCGGAGAAGAGGCTGGAGTGGGTC GCAACAATTAGTCCTGGTGGTGGTTACATATACTATTCAGACAGTGTG AAGGGGCGATTCACCATCTCCAGAGACAATGCCAGGAACACCCTGTAT CTGCAAATGAGCAGTCTGAGGTCTGAGGACACGGCCATGTATTACTGT GCAGGGGACTATGTTGACTATTGGGGCCAAGGCACCACTCTCACAGTC TCCTCA.

(80) Therefore, in some embodiments, the anti-CD19 scFv V.sub.H domain comprises the amino acid sequence:

(81) TABLE-US-00019 (SEQIDNO:59,4F1) QVQLQESGPGLVKPSQSLSLTCTVTGYSITSDYAWNWIRQFPGNKLE WMGYISYSGSTTYNPSLKGRISFTRDTSKNQFFLHLKSVTTEDSATY YCARNWVYAMDYWGQGTSVTVSS.

(82) Therefore, in some embodiments, the anti-CD19 scFv V.sub.H domain is encoded by the nucleic acid sequence:

(83) TABLE-US-00020 (SEQIDNO:79,4F1) CAAGTTCAGCTGCAGGAGTCGGGACCTGGCCTGGTAAAACCTTCTCA GTCTCTGTCCCTCACCTGCACTGTCACTGGCTACTCAATCACCAGTG ATTATGCCTGGAACTGGATCCGGCAGTTTCCAGGAAACAAACTGGAG TGGATGGGCTACATAAGCTACAGTGGTAGCACTACCTACAACCCATC TCTCAAAGGTCGAATCTCTTTCACTCGAGACACCTCCAAGAACCAGT TCTTCCTGCACTTGAAATCTGTGACTACTGAGGACTCAGCCACATAT TACTGTGCAAGAAACTGGGTCTATGCTATGGACTACTGGGGTCAAGG AACCTCAGTCACCGTCTCCTCA.

(84) Therefore, in some embodiments, the anti-CD19 scFv V.sub.H domain comprises the amino acid sequence:

(85) TABLE-US-00021 (SEQIDNO:60,4H9) EVKLQQSGPVLVKPGASVKISCKASGYTFTDYYYMNWVKQSHGKSL EWIGYIYPNNSGTSYNQKFRGKATLTVDKSSSTAYMEVRSLTSEDS AVYYCARYYDGFNAGFAYWGQGTLVTVSA.

(86) Therefore, in some embodiments, the anti-CD19 scFv V.sub.H domain is encoded by the nucleic acid sequence:

(87) TABLE-US-00022 (SEQIDNO:80,4H9) GAGGTAAAGCTGCAGCAGTCTGGACCTGTACTGGTGAAGCCTGGGGC TTCAGTGAAGATATCCTGCAAGGCTTCTGGATACACATTCACTGACT ACTACTACATGAATTGGGTGAAGCAGAGCCATGGAAAGAGCCTTGAG TGGATTGGATATATTTATCCTAACAATAGTGGTACTAGTTACAACCA GAAGTTCAGGGGCAAGGCCACATTGACTGTTGACAAGTCCTCCAGCA CAGCCTACATGGAGGTCCGCAGCCTGACATCTGAGGATTCTGCAGTC TATTACTGTGCGAGATACTATGATGGTTTCAACGCCGGGTTTGCTTA CTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA.

(88) Therefore, in some embodiments, the anti-CD19 scFv V.sub.H domain comprises the amino acid sequence:

(89) TABLE-US-00023 (SEQIDNO:61,5H5) QVQLEESGPGLVAPSQSLSITCTVSGFSLSRYSVHWVRQPPGKGLEWLG MIWVNGNTDYNSALKSRLNINKDNSKSQVFLKMNSLQTDDTAMYYCATY YGNYDSFTYWGQGTLVTVSA.

(90) Therefore, in some embodiments, the anti-CD19 scFv V.sub.H domain is encoded by the nucleic acid sequence:

(91) TABLE-US-00024 (SEQIDNO:81,5H5) CAAGTGCAGCTGGAGGAGTCAGGACCTGGCCTGGTGGCACCCTCACAGA GCCTGTCCATCACATGCACTGTCTCTGGGTTCTCATTATCCAGATATAG TGTACACTGGGTTCGCCAGCCTCCAGGAAAGGGTCTGGAATGGCTGGGA ATGATATGGGTTAATGGAAACACAGACTATAATTCAGCTCTCAAATCCA GACTTAACATCAACAAGGACAACTCCAAGAGCCAAGTTTTCTTAAAAAT GAACAGTCTGCAAACTGATGACACAGCCATGTACTATTGTGCCACCTAT TATGGAAACTACGATTCCTTTACTTACTGGGGCCAGGGGACTCTGGTCA CTGTCTCTGCA.

(92) Therefore, in some embodiments, the anti-CD19 scFv V.sub.H domain comprises the amino acid sequence:

(93) TABLE-US-00025 (SEQIDNO:62,6F10) EVQLQESGAELARPGASVKMSCKASGYTFTSYWMHWVKQRPGQGLEWIG AIYPGNSDTSYNQKFKGKAKLTAVTSASTAYMELSSLTNEDSAVYYCTT SLAYWGQGTLVTVSA.

(94) Therefore, in some embodiments, the anti-CD19 scFv V.sub.H domain is encoded by the nucleic acid sequence:

(95) TABLE-US-00026 (SEQIDNO:82,6F10) GAGGTGCAGCTGCAGGAGTCTGGGGCTGAGCTGGCAAGACCTGGGGCTT CAGTGAAGATGTCCTGCAAGGCTTCTGGCTACACCTTTACCAGCTACTG GATGCACTGGGTAAAACAGAGGCCTGGACAGGGTCTGGAATGGATTGGC GCTATTTATCCTGGAAATAGTGATACTAGCTACAATCAGAAGTTCAAGG GCAAGGCCAAACTGACTGCAGTCACATCCGCCAGCACTGCCTACATGGA GCTCAGCAGCCTAACAAATGAGGACTCTGCGGTCTATTACTGTACAACC TCCCTTGCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA.

(96) In some embodiments, the anti-CD19 scFv V.sub.L domain comprises the amino acid sequence:

(97) TABLE-US-00027 (SEQIDNO:63,1A10) DIVLTQSHKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIF SASYRNSGVPDRFTGSGSGTDFTLTITNVQSEDLLEYFCQQYNTYPYTF GGGTKLEIKR.

(98) In some embodiments, the anti-CD19 scFv V.sub.L domain encoded by the nucleic acid sequence:

(99) TABLE-US-00028 (SEQIDNO:83,1A10) GATATTGTGCTGACCCAATCTCACAAATTCATGTCCACATCAGTTGGAG ACAGGGTCAGCGTCACCTGCAAGGCCAGTCAGAATGTGGGTACTAATGT AGCCTGGTATCAACAGAAACCAGGGCAATCTCCTAAAGCACTGATTTTC TCGGCATCCTACCGGAACAGTGGAGTCCCTGATCGCTTCACAGGCAGTG GATCTGGGACAGATTTCACTCTCACCATCACCAATGTGCAGTCTGAAGA CTTGTTAGAGTATTTCTGTCAGCAATATAACACCTATCCGTACACGTTC GGAGGGGGGACCAAGCTGGAAATAAAACGG.

(100) In some embodiments, the anti-CD19 scFv V.sub.L domain comprises the amino acid sequence:

(101) TABLE-US-00029 (SEQIDNO:64,1H1) DIVMTQSPASLAVSLGQRATISCRASETIDNYGISFMNWFQQKPGQPPK LLIYGASNQGSGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQNKEF PWTFGGGTKLEIKR.

(102) In some embodiments, the anti-CD19 scFv V.sub.L domain encoded by the nucleic acid sequence:

(103) TABLE-US-00030 (SEQIDNO:84,1H1) GATATTGTGATGACCCAATCTCCAGCTTCTTTGGCTGTGTCTCTAGGAC AGAGGGCCACCATCTCCTGCAGAGCCAGCGAAACTATTGATAATTATGG CATTAGTTTTATGAACTGGTTCCAACAGAAACCAGGACAGCCACCCAAG CTCCTCATCTATGGTGCATCCAACCAAGGATCCGGGGTCCCTGCCAGGT TTAGTGGCAGTGGGTCTGGGACAGACTTCAGCCTCAACATCCATCCTAT GGAGGAGGATGATACTGCAATGTATTTCTGTCAGCAAAATAAGGAATTT CCGTGGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAACGG.

(104) In some embodiments, the anti-CD19 scFv V.sub.L domain comprises the amino acid sequence:

(105) TABLE-US-00031 (SEQIDNO:65,2B1) DIVMTQSHKFMSTSVGGRVSVTCKASQNVDTNVAWYQQKPGQSPKALIY SASYRYSGVPDRFTGSGSGTDFTLTITNVQSEDLAEYFCQQYNSYPLTF GAGTKLELKR.

(106) In some embodiments, the anti-CD19 scFv V.sub.L domain encoded by the nucleic acid sequence:

(107) TABLE-US-00032 (SEQIDNO:85,2B1) GACATTGTGATGACCCAATCTCACAAATTCATGTCCACATCAGTAGGAG GCAGGGTCAGTGTCACCTGCAAGGCCAGTCAGAATGTGGATACTAATGT AGCCTGGTATCAACAGAAACCAGGGCAATCTCCTAAAGCACTGATTTAC TCGGCATCGTACCGGTACAGTGGAGTCCCTGATCGCTTCACAGGCAGTG GATCTGGGACAGATTTCACTCTCACCATCACTAATGTGCAGTCTGAAGA CTTGGCAGAGTATTTCTGTCAGCAATATAACAGCTATCCGCTCACGTTC GGTGCTGGGACCAAGCTGGAGCTGAAACGG.

(108) In some embodiments, the anti-CD19 scFv V.sub.L domain comprises the amino acid sequence:

(109) TABLE-US-00033 (SEQIDNO:66,2H8) DIVLTQTHKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLLIY WASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYSSYPLTF GGGTKLEIKR.

(110) In some embodiments, the anti-CD19 scFv V.sub.L domain encoded by the nucleic acid sequence:

(111) TABLE-US-00034 (SEQIDNO:86,2H8) GACATTGTGCTCACACAGACTCACAAATTCATGTCCACATCAGTAGGAG ACAGGGTCAGCATCACCTGCAAGGCCAGTCAGGATGTGGGTACTGCTGT AGCCTGGTATCAACAGAAACCAGGGCAATCTCCTAAACTACTGATTTAC TGGGCATCCACCCGGCACACTGGAGTCCCTGATCGCTTCACAGGCAGTG GATCTGGGACAGATTTCACTCTCACCATTAGCAATGTGCAGTCTGAAGA CTTGGCAGATTATTTCTGTCAGCAATATAGCAGCTATCCTCTCACGTTC GGAGGGGGGACCAAGCTGGAAATAAAACGG.

(112) In some embodiments, the anti-CD19 scFv V.sub.L domain comprises the amino acid sequence:

(113) TABLE-US-00035 (SEQIDNO:67,4A12) DIVITQSHKFMPTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIY SASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSTPYTF GGGTKLEIKR.

(114) In some embodiments, the anti-CD19 scFv V.sub.L domain encoded by the nucleic acid sequence:

(115) TABLE-US-00036 (SEQIDNO:87,4A12) GACATTGTGATCACACAATCTCACAAATTCATGCCCACATCAGTAGGAG ACAGGGTCAGCATCACCTGCAAGGCCAGTCAGGATGTGAGTACTGCTGT AGCCTGGTATCAACAGAAACCAGGACAATCTCCTAAACTACTGATTTAC TCGGCATCCTACCGGTACACTGGAGTCCCTGATCGCTTCACTGGCAGTG GATCTGGGACGGATTTCACTTTCACCATCAGCAGTGTGCAGGCTGAAGA CCTGGCAGTTTATTACTGTCAGCAACATTATAGTACTCCGTACACGTTC GGAGGGGGGACCAAGCTGGAAATAAAACGG.

(116) In some embodiments, the anti-CD19 scFv V.sub.L domain comprises the amino acid sequence:

(117) TABLE-US-00037 (SEQIDNO:68,3A10) DWMTQTPLTLSVTTGQPASISCKSSQSLLNSDGKTFLNWLLQRPGQSPK RLIYLVSKLDSGVPDRFTGSGSGTDFTLKICRVEAEDLGVYYCWQGTHF PYTFGGGTKLEIKR.

(118) In some embodiments, the anti-CD19 scFv V.sub.L domain encoded by the nucleic acid sequence:

(119) TABLE-US-00038 (SEQIDNO:88,3A10) GATGTTGTGATGACCCAGACTCCACTCACTTTGTCGGTTACCACTGGACA ACCAGCCTCCATCTCTTGCAAGTCAAGTCAGAGCCTCTTAAATAGTGATG GAAAGACATTTTTGAATTGGTTGTTACAGAGGCCAGGGCAGTCTCCAAAG CGCCTAATCTATCTGGTGTCTAAACTGGACTCTGGAGTCCCTGACAGGTT CACTGGCAGTGGATCAGGGACAGATTTCACACTGAAAATCTGCAGAGTGG AGGCTGAGGATTTGGGAGTTTATTATTGCTGGCAAGGTACACATTTTCCA TACACGTTCGGAGGGGGGACCAAGCTGGAAATAAAACGG.

(120) In some embodiments, the anti-CD19 scFv V.sub.L domain comprises the amino acid sequence:

(121) TABLE-US-00039 (SEQIDNO:69,4F1) DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQSP KLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSY PRTFGGGTKLEIKR.

(122) In some embodiments, the anti-CD19 scFv V.sub.L domain encoded by the nucleic acid sequence:

(123) TABLE-US-00040 (SEQIDNO:89,4F1) GACATTGTGATGTCACAGTCTCCATCCTCCCTAGCTGTGTCAGTTGGAGA GAAGGTTACTATGAGCTGCAAGTCCAGTCAGAGCCTTTTATATAGTAGCA ATCAAAAGAACTACTTGGCCTGGTACCAGCAGAAACCAGGGCAGTCTCCT AAACTGCTGATTTACTGGGCATCCACTAGGGAATCTGGGGTCCCTGATCG CTTCACAGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTG TGAAGGCTGAAGACCTGGCAGTTTATTACTGTCAGCAATATTATAGCTAT CCTCGGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAACGG.

(124) In some embodiments, the anti-CD19 scFv V.sub.L domain comprises the amino acid sequence:

(125) TABLE-US-00041 (SEQIDNO:70,4H9) DIVLTQSTSSLAVSVGEKVTMSCKSSQSLLFGSNQKNYLAWYQQKLGQSP KLLIFWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSY PFTFGSGTKLEIKR.

(126) In some embodiments, the anti-CD19 scFv V.sub.L domain encoded by the nucleic acid sequence:

(127) TABLE-US-00042 (SEQIDNO:90,4H9) GACATTGTGCTGACCCAATCTACATCCTCCCTAGCTGTGTCAGTTGGAGA GAAGGTTACTATGAGCTGCAAGTCCAGTCAGAGCCTTTTATTTGGTAGCA ATCAAAAGAACTACTTGGCCTGGTACCAGCAGAAATTAGGGCAGTCTCCT AAACTACTAATTTTCTGGGCATCCACTAGGGAATCTGGGGTCCCTGATCG CTTCACAGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTG TGAAGGCTGAAGACCTGGCAGTTTATTACTGTCAGCAATATTATAGCTAT CCATTCACGTTCGGCTCGGGGACAAAGTTGGAAATAAAACGG.

(128) In some embodiments, the anti-CD19 scFv V.sub.L domain comprises the amino acid sequence:

(129) TABLE-US-00043 (SEQIDNO:71,5H5) DIVLTQTNLTLSITIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPK RLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVGAEDLGIYYCWQGTHFP HTFGGGTKLEIKR.

(130) In some embodiments, the anti-CD19 scFv V.sub.L domain encoded by the nucleic acid sequence:

(131) TABLE-US-00044 (SEQIDNO:91,5H5) GATATTGTGCTCACCCAGACTAACCTCACTTTGTCGATTACCATTGGACA ACCAGCCTCCATCTCTTGCAAGTCAAGTCAGAGCCTCTTAGATAGTGATG GAAAGACATATTTGAATTGGTTGTTACAGAGGCCAGGCCAGTCTCCAAAG CGCCTAATCTATCTGGTGTCTAAACTGGACTCTGGAGTCCCTGACAGGTT CACTGGCAGTGGATCAGGGACAGATTTCACACTGAAAATCAGCAGAGTGG GGGCTGAGGATTTGGGAATTTATTATTGCTGGCAAGGTACACATTTTCCT CACACGTTCGGAGGGGGGACCAAGCTGGAAATAAAACGG.

(132) In some embodiments, the anti-CD19 scFv V.sub.L domain comprises the amino acid sequence:

(133) TABLE-US-00045 (SEQIDNO:72,6F10) DIVLTQSPAIMSASPGEKVTMTCRASSSVSSSYLHWYQQKSGASPKLWIY STSNLASGVPARFSGSGSGTSYSLTISSVEAEDAATYYCQQYSGYPLTFG AGTKLELKR.

(134) In some embodiments, the anti-CD19 scFv V.sub.L domain encoded by the nucleic acid sequence:

(135) TABLE-US-00046 (SEQIDNO:92,6F10) GATATTGTGCTGACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGA AAAGGTCACCATGACCTGCAGGGCCAGCTCAAGTGTAAGTTCCAGTTACT TGCACTGGTACCAGCAGAAGTCAGGTGCCTCCCCCAAACTCTGGATTTAT AGCACATCCAACTTGGCTTCTGGAGTCCCTGCTCGCTTCAGTGGCAGTGG GTCTGGGACCTCTTACTCTCTCACAATCAGCAGTGTGGAGGCTGAAGATG CTGCCACTTATTACTGCCAGCAGTACAGTGGTTACCCACTCACGTTCGGT GCTGGGACCAAGCTGGAGCTGAAACGG.

(136) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(137) TABLE-US-00047 (SEQIDNO:93) EVKLEESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVAS ISSGGSTYYPDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCARGRD GYSLYFDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVLTQSHKFMSTSVG DRVSVTCKASQNVGTNVAWYQQKPGQSPKALIFSASYRNSGVPDRFTGSG SGTDFTLTITNVQSEDLLEYFCQQYNTYPYTFGGGTKLEIKR.

(138) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(139) TABLE-US-00048 (SEQIDNO:94) EVKLEESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVAS ISSGGSTYYPDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCARGRD GYSLYFDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVMTQSPASLAVSLG QRATISCRASETIDNYGISFMNWFQQKPGQPPKLLIYGASNQGSGVPARF SGSGSGTDFSLNIHPMEEDDTAMYFCQQNKEFPWTFGGGTKLEIK.

(140) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(141) TABLE-US-00049 (SEQIDNO:95) EVKLEESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVAS ISSGGSTYYPDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCARGRD GYSLYFDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVMTQSHKFMSTSVG GRVSVTCKASQNVDTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSG SGTDFTLTITNVQSEDLAEYFCQQYNSYPLTFGAGTKLELKR.

(142) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(143) TABLE-US-00050 (SEQIDNO:96) EVKLEESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVAS ISSGGSTYYPDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCARGRD GYSLYFDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVLTQTHKFMSTSVG DRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSG SGTDFTLTISNVQSEDLADYFCQQYSSYPLTFGGGTKLEIKR.

(144) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(145) TABLE-US-00051 (SEQIDNO:97) EVKLEESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVAS ISSGGSTYYPDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCARGRD GYSLYFDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVITQSHKFMPTSVG DRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSG SGTDFTFTISSVQAEDLAVYYCQQHYSTPYTFGGGTKLEIKR.

(146) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(147) TABLE-US-00052 (SEQIDNO:98) EVKLEESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVAS ISSGGSTYYPDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCARGRD GYSLYFDYWGQGTTLTVSSGGGGGGGGSGGGGSDVVMTQTPLTLSVTTGQ PASISCKSSQSLLNSDGKTFLNWLLQRPGQSPKRLIYLVSKLDSGVPDRF TGSGSGTDFTLKICRVEAEDLGVYYCWQGTHFPYTFGGGTKLEIKR.

(148) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(149) TABLE-US-00053 (SEQIDNO:99) EVKLEESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVA SISSGGSTYYPDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCARG RDGYSLYFDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVMSQSPSSLAV SVGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRES GVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPRTFGGGTKLE IKR.

(150) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(151) TABLE-US-00054 (SEQIDNO:100) EVKLEESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVA SISSGGSTYYPDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCARG RDGYSLYFDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVLTQSTSSLAV SVGEKVTMSCKSSQSLLFGSNQKNYLAWYQQKLGQSPKLLIFWASTRES GVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPFTFGSGTKLE IKR.

(152) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(153) TABLE-US-00055 (SEQIDNO:101) EVKLEESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVA SISSGGSTYYPDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCARG RDGYSLYFDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVLTQTNLTLSI TIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSG VPDRFTGSGSGTDFTLKISRVGAEDLGIYYCWQGTHFPHTFGGGTKLEI KR.

(154) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(155) TABLE-US-00056 (SEQIDNO:102) EVKLEESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVA SISSGGSTYYPDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCARG RDGYSLYFDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVLTQSPAIMSA SPGEKVTMTCRASSSVSSSYLHWYQQKSGASPKLWIYSTSNLASGVPAR FSGSGSGTSYSLTISSVEAEDAATYYCQQYSGYPLTFGAGTKLELKR.

(156) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(157) TABLE-US-00057 (SEQIDNO:103) QVKLQESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVA GISSGGSFTYYPDTVKGRFTISRDNARNTLYLQMSSLRSEDTAMYSCAR EGVYSDYRAWFAYWGQGTLVTVSGGGGGSGGGGSGGGGSDIVLTQSHKF MSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIFSASYRNSGVP DRFTGSGSGTDFTLTITNVQSEDLLEYFCQQYNTYPYTFGGGTKLEIKR.

(158) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(159) TABLE-US-00058 (SEQIDNO:104) QVKLQESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVA GISSGGSFTYYPDTVKGRFTISRDNARNTLYLQMSSLRSEDTAMYSCAR EGVYSDYRAWFAYWGQGTLVTVSGGGGGSGGGGSGGGGSDIVMTQSPAS LAVSLGQRATISCRASETIDNYGISFMNWFQQKPGQPPKLLIYGASNQG SGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQNKEFPWTFGGGTKL EIK.
In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(160) TABLE-US-00059 (SEQIDNO:105) QVKLQESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVA GISSGGSFTYYPDTVKGRFTISRDNARNTLYLQMSSLRSEDTAMYSCAR EGVYSDYRAWFAYWGQGTLVTVSGGGGGSGGGGSGGGGSDIVMTQSHKF MSTSVGGRVSVTCKASQNVDTNVAWYQQKPGQSPKALIYSASYRYSGVP DRFTGSGSGTDFTLTITNVQSEDLAEYFCQQYNSYPLTFGAGTKLELKR.

(161) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(162) TABLE-US-00060 (SEQIDNO:106) QVKLQESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVA GISSGGSFTYYPDTVKGRFTISRDNARNTLYLQMSSLRSEDTAMYSCAR EGVYSDYRAWFAYWGQGTLVTVSGGGGGSGGGGSGGGGSDIVLTQTHKF MSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYWASTRHTGVP DRFTGSGSGTDFTLTISNVQSEDLADYFCQQYSSYPLTFGGGTKLEIKR.

(163) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(164) TABLE-US-00061 (SEQIDNO:107) QVKLQESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVA GISSGGSFTYYPDTVKGRFTISRDNARNTLYLQMSSLRSEDTAMYSCAR EGVYSDYRAWFAYWGQGTLVTVSGGGGGSGGGGSGGGGSDIVITQSHKF MPTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVP DRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSTPYTFGGGTKLEIKR.

(165) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(166) TABLE-US-00062 (SEQIDNO:108) QVKLQESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVA GISSGGSFTYYPDTVKGRFTISRDNARNTLYLQMSSLRSEDTAMYSCAR EGVYSDYRAWFAYWGQGTLVTVSGGGGGSGGGGSGGGGSDVVMTQTPLT LSVTTGQPASISCKSSQSLLNSDGKTFLNWLLQRPGQSPKRLIYLVSKL DSGVPDRFTGSGSGTDFTLKICRVEAEDLGVYYCWQGTHFPYTFGGGTK LEIKR.

(167) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(168) TABLE-US-00063 (SEQIDNO:109) QVKLQESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVA GISSGGSFTYYPDTVKGRFTISRDNARNTLYLQMSSLRSEDTAMYSCAR EGVYSDYRAWFAYWGQGTLVTVSGGGGGSGGGGSGGGGSDIVMSQSPSS LAVSVGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQSPKLLIYWAST RESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPRTFGGGT KLEIKR.

(169) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(170) TABLE-US-00064 (SEQIDNO:110) QVKLQESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVA GISSGGSFTYYPDTVKGRFTISRDNARNTLYLQMSSLRSEDTAMYSCAR EGVYSDYRAWFAYWGQGTLVTVSGGGGGSGGGGSGGGGSDIVLTQSTSS LAVSVGEKVTMSCKSSQSLLFGSNQKNYLAWYQQKLGQSPKLLIFWAST RESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPFTFGSGT KLEIKR.

(171) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(172) TABLE-US-00065 (SEQIDNO:111) QVKLQESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVA GISSGGSFTYYPDTVKGRFTISRDNARNTLYLQMSSLRSEDTAMYSCAR EGVYSDYRAWFAYWGQGTLVTVSGGGGGSGGGGSGGGGSDIVLTQTNLT LSITIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKL DSGVPDRFTGSGSGTDFTLKISRVGAEDLGIYYCWQGTHFPHTFGGGTK LEIKR.

(173) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(174) TABLE-US-00066 (SEQIDNO:112) QVKLQESGGGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVA GISSGGSFTYYPDTVKGRFTISRDNARNTLYLQMSSLRSEDTAMYSCAR EGVYSDYRAWFAYWGQGTLVTVSGGGGGSGGGGSGGGGSDIVLTQSPAI MSASPGEKVTMTCRASSSVSSSYLHWYQQKSGASPKLWIYSTSNLASGV PARFSGSGSGTSYSLTISSVEAEDAATYYCQQYSGYPLTFGAGTKLELK R.

(175) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(176) TABLE-US-00067 (SEQIDNO:113) EVKLEQSGPSLVQPSQSLSITCTVSGFSLTNFGVHWVRQSPGKGLEWLG LIWRGGSTDYNAAFMSRLSITKDNSKSQVFFKMNSLQADDTAIYYCAKM GITYYFDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVLTQSHKFMSTSV GDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIFSASYRNSGVPDRFTG SGSGTDFTLTITNVQSEDLLEYFCQQYNTYPYTFGGGTKLEIKR.

(177) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(178) TABLE-US-00068 (SEQIDNO:114) EVKLEQSGPSLVQPSQSLSITCTVSGFSLTNFGVHWVRQSPGKGLEWLGL IWRGGSTDYNAAFMSRLSITKDNSKSQVFFKMNSLQADDTAIYYCAKMGI TYYFDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVMTQSPASLAVSLGQR ATISCRASETIDNYGISFMNWFQQKPGQPPKLLIYGASNQGSGVPARFSG SGSGTDFSLNIHPMEEDDTAMYFCQQNKEFPWTFGGGTKLEIK.

(179) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(180) TABLE-US-00069 (SEQIDNO:115) EVKLEQSGPSLVQPSQSLSITCTVSGFSLTNFGVHWVRQSPGKGLEWLGL IWRGGSTDYNAAFMSRLSITKDNSKSQVFFKMNSLQADDTAIYYCAKMGI TYYFDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVMTQSHKFMSTSVGGR VSVTCKASQNVDTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSG TDFTLTITNVQSEDLAEYFCQQYNSYPLTFGAGTKLELKR.

(181) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(182) TABLE-US-00070 (SEQIDNO:116) EVKLEQSGPSLVQPSQSLSITCTVSGFSLTNFGVHWVRQSPGKGLEWLGL IWRGGSTDYNAAFMSRLSITKDNSKSQVFFKMNSLQADDTAIYYCAKMGI TYYFDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVLTQTHKFMSTSVGDR VSITCKASQDVGTAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSG TDFTLTISNVQSEDLADYFCQQYSSYPLTFGGGTKLEIKR.

(183) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(184) TABLE-US-00071 (SEQIDNO:117) EVKLEQSGPSLVQPSQSLSITCTVSGFSLTNFGVHWVRQSPGKGLEWLGL IWRGGSTDYNAAFMSRLSITKDNSKSQVFFKMNSLQADDTAIYYCAKMGI TYYFDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVITQSHKFMPTSVGDR VSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSG TDFTFTISSVQAEDLAVYYCQQHYSTPYTFGGGTKLEIKR.

(185) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(186) TABLE-US-00072 (SEQIDNO:118) EVKLEQSGPSLVQPSQSLSITCTVSGFSLTNFGVHWVRQSPGKGLEWLGL IWRGGSTDYNAAFMSRLSITKDNSKSQVFFKMNSLQADDTAIYYCAKMGI TYYFDYWGQGTTLTVSSGGGGSGGGGSGGGGSDWMTQTPLTLSVTTGQPA SISCKSSQSLLNSDGKTFLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTG SGSGTDFTLKICRVEAEDLGVYYCWQGTHFPYTFGGGTKLEIKR.

(187) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(188) TABLE-US-00073 (SEQIDNO:119) EVKLEQSGPSLVQPSQSLSITCTVSGFSLTNFGVHWVRQSPGKGLEWLGL IWRGGSTDYNAAFMSRLSITKDNSKSQVFFKMNSLQADDTAIYYCAKMGI TYYFDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVMSQSPSSLAVSVGEK VTMSCKSSQSLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRF TGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPRTFGGGTKLEIKR.

(189) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(190) TABLE-US-00074 (SEQIDNO:120) EVKLEQSGPSLVQPSQSLSITCTVSGFSLTNFGVHWVRQSPGKGLEWLGL IWRGGSTDYNAAFMSRLSITKDNSKSQVFFKMNSLQADDTAIYYCAKMGI TYYFDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVLTQSTSSLAVSVGEK VTMSCKSSQSLLFGSNQKNYLAWYQQKLGQSPKLLIFWASTRESGVPDRF TGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPFTFGSGTKLEIKR.

(191) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(192) TABLE-US-00075 (SEQIDNO:121) EVKLEQSGPSLVQPSQSLSITCTVSGFSLTNFGVHWVRQSPGKGLEWLGL IWRGGSTDYNAAFMSRLSITKDNSKSQVFFKMNSLQADDTAIYYCAKMGI TYYFDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVLTQTNLTLSITIGQP ASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFT GSGSGTDFTLKISRVGAEDLGIYYCWQGTHFPHTFGGGTKLEIKR.

(193) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(194) TABLE-US-00076 (SEQIDNO:122) EVKLEQSGPSLVQPSQSLSITCTVSGFSLTNFGVHWVRQSPGKGLEWLGL IWRGGSTDYNAAFMSRLSITKDNSKSQVFFKMNSLQADDTAIYYCAKMGI TYYFDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVLTQSPAIMSASPGEK VTMTCRASSSVSSSYLHWYQQKSGASPKLWIYSTSNLASGVPARFSGSGS GTSYSLTISSVEAEDAATYYCQQYSGYPLTFGAGTKLELKR.

(195) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(196) TABLE-US-00077 (SEQIDNO:123) QVKLQQSGDDLVKPGASVKLSCKASGYTFTSYWINWIKQRPGQGLEWIGH IAPGTGSTYYSEMFKDKATLTVDTPSSSAYIQLSSLSSEDSAVYFCAREG GRYYTLDCWGQGTSVTVSSGGGGSGGGGSGGGGSDIVLTQSHKFMSTSVG DRVSVTCKASQNVGTNVAWYQQKPGQSPKALIFSASYRNSGVPDRFTGSG SGTDFTLTITNVQSEDLLEYFCQQYNTYPYTFGGGTKLEIKR.

(197) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(198) TABLE-US-00078 (SEQIDNO:124) QVKLQQSGDDLVKPGASVKLSCKASGYTFTSYWINWIKQRPGQGLEWIGH IAPGTGSTYYSEMFKDKATLTVDTPSSSAYIQLSSLSSEDSAVYFCAREG GRYYTLDCWGQGTSVTVSSGGGGSGGGGSGGGGSDIVMTQSPASLAVSLG QRATISCRASETIDNYGISFMNWFQQKPGQPPKLLIYGASNQGSGVPARF SGSGSGTDFSLNIHPMEEDDTAMYFCQQNKEFPWTFGGGTKLEIK.

(199) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(200) TABLE-US-00079 (SEQIDNO:125) QVKLQQSGDDLVKPGASVKLSCKASGYTFTSYWINWIKQRPGQGLEWIGH IAPGTGSTYYSEMFKDKATLTVDTPSSSAYIQLSSLSSEDSAVYFCAREG GRYYTLDCWGQGTSVTVSSGGGGGGGGSGGGGSDIVMTQSHKFMSTSVGG RVSVTCKASQNVDTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGS GTDFTLTITNVQSEDLAEYFCQQYNSYPLTFGAGTKLELKR.

(201) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(202) TABLE-US-00080 (SEQIDNO:126) QVKLQQSGDDLVKPGASVKLSCKASGYTFTSYWINWIKQRPGQGLEWIGH IAPGTGSTYYSEMFKDKATLTVDTPSSSAYIQLSSLSSEDSAVYFCAREG GRYYTLDCWGQGTSVTVSSGGGGSGGGGSGGGGSDIVLTQTHKFMSTSVG DRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSG SGTDFTLTISNVQSEDLADYFCQQYSSYPLTFGGGTKLEIKR.

(203) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(204) TABLE-US-00081 (SEQIDNO:127) QVKLQQSGDDLVKPGASVKLSCKASGYTFTSYWINWIKQRPGQGLEWIGH IAPGTGSTYYSEMFKDKATLTVDTPSSSAYIQLSSLSSEDSAVYFCAREG GRYYTLDCWGQGTSVTVSSGGGGSGGGGSGGGGSDIVITQSHKFMPTSVG DRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSG SGTDFTFTISSVQAEDLAVYYCQQHYSTPYTFGGGTKLEIKR.

(205) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(206) TABLE-US-00082 (SEQIDNO:128) QVKLQQSGDDLVKPGASVKLSCKASGYTFTSYWINWIKQRPGQGLEWIGH IAPGTGSTYYSEMFKDKATLTVDTPSSSAYIQLSSLSSEDSAVYFCAREG GRYYTLDCWGQGTSVTVSSGGGGSGGGGSGGGGSDVVMTQTPLTLSVTTG QPASISCKSSQSLLNSDGKTFLNWLLQRPGQSPKRLIYLVSKLDSGVPDR FTGSGSGTDFTLKICRVEAEDLGVYYCWQGTHFPYTFGGGTKLEIKR.

(207) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(208) TABLE-US-00083 (SEQIDNO:129) QVKLQQSGDDLVKPGASVKLSCKASGYTFTSYWINWIKQRPGQGLEWIG HIAPGTGSTYYSEMFKDKATLTVDTPSSSAYIQLSSLSSEDSAVYFCAR EGGRYYTLDCWGQGTSVTVSSGGGGSGGGGSGGGGSDIVMSQSPSSLAV SVGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRES GVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPRTFGGGTKLE IKR.

(209) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(210) TABLE-US-00084 (SEQIDNO:130) QVKLQQSGDDLVKPGASVKLSCKASGYTFTSYWINWIKQRPGQGLEWIG HIAPGTGSTYYSEMFKDKATLTVDTPSSSAYIQLSSLSSEDSAVYFCAR EGGRYYTLDCWGQGTSVTVSSGGGGSGGGGSGGGGSDIVLTQSTSSLAV SVGEKVTMSCKSSQSLLFGSNQKNYLAWYQQKLGQSPKLLIFWASTRES GVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPFTFGSGTKLE IKR.

(211) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(212) TABLE-US-00085 (SEQIDNO:131) QVKLQQSGDDLVKPGASVKLSCKASGYTFTSYWINWIKQRPGQGLEWIG HIAPGTGSTYYSEMFKDKATLTVDTPSSSAYIQLSSLSSEDSAVYFCAR EGGRYYTLDCWGQGTSVTVSSGGGGSGGGGSGGGGSDIVLTQTNLTLSI TIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSG VPDRFTGSGSGTDFTLKISRVGAEDLGIYYCWQGTHFPHTFGGGTKLEI KR.

(213) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(214) TABLE-US-00086 (SEQIDNO:132) QVKLQQSGDDLVKPGASVKLSCKASGYTFTSYWINWIKQRPGQGLEWIG HIAPGTGSTYYSEMFKDKATLTVDTPSSSAYIQLSSLSSEDSAVYFCAR EGGRYYTLDCWGQGTSVTVSSGGGGSGGGGSGGGGSDIVLTQSPAIMSA SPGEKVTMTCRASSSVSSSYLHWYQQKSGASPKLWIYSTSNLASGVPAR FSGSGSGTSYSLTISSVEAEDAATYYCQQYSGYPLTFGAGTKLELKR.

(215) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(216) TABLE-US-00087 (SEQIDNO:133) QVQLEESGPGLVKPSQTVSLTCTVTGISITTGNYRWSWIRQFPGNKLEW IGYIYYSGTITYNPSLTSRTTITRDTSKNQFFLEMNSLTAEDTATYYCA RWLNNFDVWGTGTTVTVSGGGGSGGGGSGGGGSDIVLTQSHKFMSTSVG DRVSVTCKASQNVGTNVAWYQQKPGQSPKALIFSASYRNSGVPDRFTGS GSGTDFTLTITNVQSEDLLEYFCQQYNTYPYTFGGGTKLEIKR.

(217) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(218) TABLE-US-00088 (SEQIDNO:134) QVQLEESGPGLVKPSQTVSLTCTVTGISITTGNYRWSWIRQFPGNKLEW IGYIYYSGTITYNPSLTSRTTITRDTSKNQFFLEMNSLTAEDTATYYCA RWLNNFDVWGTGTTVTVSGGGGSGGGGSGGGGSDIVMTQSPASLAVSLG QRATISCRASETIDNYGISFMNWFQQKPGQPPKLLIYGASNQGSGVPAR FSGSGSGTDFSLNIHPMEEDDTAMYFCQQNKEFPWTFGGGTKLEIK.

(219) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(220) TABLE-US-00089 (SEQIDNO:135) QVQLEESGPGLVKPSQTVSLTCTVTGISITTGNYRWSWIRQFPGNKLEW IGYIYYSGTITYNPSLTSRTTITRDTSKNQFFLEMNSLTAEDTATYYCA RWLNNFDVWGTGTTVTVSGGGGSGGGGSGGGGSDIVMTQSHKFMSTSVG GRVSVTCKASQNVDTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGS GSGTDFTLTITNVQSEDLAEYFCQQYNSYPLTFGAGTKLELKR.

(221) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(222) TABLE-US-00090 (SEQIDNO:136) QVQLEESGPGLVKPSQTVSLTCTVTGISITTGNYRWSWIRQFPGNKLEW IGYIYYSGTITYNPSLTSRTTITRDTSKNQFFLEMNSLTAEDTATYYCA RWLNNFDVWGTGTTVTVSGGGGSGGGGSGGGGSDIVLTQTHKFMSTSVG DRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGS GSGTDFTLTISNVQSEDLADYFCQQYSSYPLTFGGGTKLEIKR.

(223) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(224) TABLE-US-00091 (SEQIDNO:137) QVQLEESGPGLVKPSQTVSLTCTVTGISITTGNYRWSWIRQFPGNKLEW IGYIYYSGTITYNPSLTSRTTITRDTSKNQFFLEMNSLTAEDTATYYCA RWLNNFDVWGTGTTVTVSGGGGSGGGGSGGGGSDIVITQSHKFMPTSVG DRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGS GSGTDFTFTISSVQAEDLAVYYCQQHYSTPYTFGGGTKLEIKR.

(225) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(226) TABLE-US-00092 (SEQIDNO:138) QVQLEESGPGLVKPSQTVSLTCTVTGISITTGNYRWSWIRQFPGNKLEW IGYIYYSGTITYNPSLTSRTTITRDTSKNQFFLEMNSLTAEDTATYYCA RWLNNFDVWGTGTTVTVSGGGGSGGGGSGGGGSDVVMTQTPLTLSVTTG QPASISCKSSQSLLNSDGKTFLNWLLQRPGQSPKRLIYLVSKLDSGVPD RFTGSGSGTDFTLKICRVEAEDLGVYYCWQGTHFPYTFGGGTKLEIKR.

(227) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(228) TABLE-US-00093 (SEQIDNO:139) QVQLEESGPGLVKPSQTVSLTCTVTGISITTGNYRWSWIRQFPGNKLEW IGYIYYSGTITYNPSLTSRTTITRDTSKNQFFLEMNSLTAEDTATYYCA RWLNNFDVWGTGTTVTVSGGGGSGGGGSGGGGSDIVMSQSPSSLAVSVG EKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVP DRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPRTFGGGTKLEIKR.

(229) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(230) TABLE-US-00094 (SEQIDNO:140) QVQLEESGPGLVKPSQTVSLTCTVTGISITTGNYRWSWIRQFPGNKLEW IGYIYYSGTITYNPSLTSRTTITRDTSKNQFFLEMNSLTAEDTATYYCA RWLNNFDVWGTGTTVTVSGGGGSGGGGSGGGGSDIVLTQSTSSLAVSVG EKVTMSCKSSQSLLFGSNQKNYLAWYQQKLGQSPKLLIFWASTRESGVP DRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPFTFGSGTKLEIKR.

(231) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(232) TABLE-US-00095 (SEQIDNO:141) QVQLEESGPGLVKPSQTVSLTCTVTGISITTGNYRWSWIRQFPGNKLEW IGYIYYSGTITYNPSLTSRTTITRDTSKNQFFLEMNSLTAEDTATYYCA RWLNNFDVWGTGTTVTVSGGGGGGGGSGGGGSDIVLTQTNLTLSITIGQ PASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDR FTGSGSGTDFTLKISRVGAEDLGIYYCWQGTHFPHTFGGGTKLEIKR.

(233) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(234) TABLE-US-00096 (SEQIDNO:142) QVQLEESGPGLVKPSQTVSLTCTVTGISITTGNYRWSWIRQFPGNKLEW IGYIYYSGTITYNPSLTSRTTITRDTSKNQFFLEMNSLTAEDTATYYCA RWLNNFDVWGTGTTVTVSGGGGSGGGGSGGGGSDIVLTQSPAIMSASPG EKVTMTCRASSSVSSSYLHWYQQKSGASPKLWIYSTSNLASGVPARFSG SGSGTSYSLTISSVEAEDAATYYCQQYSGYPLTFGAGTKLELKR.

(235) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(236) TABLE-US-00097 (SEQIDNO:143) EVMLVESGGGLVKPGGSLKLSCAASGFTFSRYAMSWNRQTPEKRLEWVA TISPGGGYIYYSDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCAG DYVDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVLTQSHKFMSTSVGDR VSVTCKASQNVGTNVAWYQQKPGQSPKALIFSASYRNSGVPDRFTGSGS GTDFTLTITNVQSEDLLEYFCQQYNTYPYTFGGGTKLEIKR.

(237) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(238) TABLE-US-00098 (SEQIDNO:144) EVMLVESGGGLVKPGGSLKLSCAASGFTFSRYAMSWNRQTPEKRLEWVA TISPGGGYIYYSDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCAG DYVDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVMTQSPASLAVSLGQR ATISCRASETIDNYGISFMNWFQQKPGQPPKLLIYGASNQGSGVPARFS GSGSGTDFSLNIHPMEEDDTAMYFCQQNKEFPWTFGGGTKLEIKR.

(239) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(240) TABLE-US-00099 (SEQIDNO:145) EVMLVESGGGLVKPGGSLKLSCAASGFTFSRYAMSWNRQTPEKRLEWVA TISPGGGYIYYSDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCAG DYVDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVMTQSHKFMSTSVGGR VSVTCKASQNVDTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGS GTDFTLTITNVQSEDLAEYFCQQYNSYPLTFGAGTKLELKR.

(241) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(242) TABLE-US-00100 (SEQIDNO:146) EVMLVESGGGLVKPGGSLKLSCAASGFTFSRYAMSWNRQTPEKRLEWVA TISPGGGYIYYSDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCAG DYVDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVLTQTHKFMSTSVGDR VSITCKASQDVGTAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGS GTDFTLTISNVQSEDLADYFCQQYSSYPLTFGGGTKLEIKR.

(243) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(244) TABLE-US-00101 (SEQIDNO:147) EVMLVESGGGLVKPGGSLKLSCAASGFTFSRYAMSWNRQTPEKRLEWVA TISPGGGYIYYSDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCAG DYVDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVITQSHKFMPTSVGDR VSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGS GTDFTFTISSVQAEDLAVYYCQQHYSTPYTFGGGTKLEIKR.

(245) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(246) TABLE-US-00102 (SEQIDNO:148) EVMLVESGGGLVKPGGSLKLSCAASGFTFSRYAMSWNRQTPEKRLEWVA TISPGGGYIYYSDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCAG DYVDYWGQGTTLTVSSGGGGSGGGGSGGGGSDVVMTQTPLTLSVTTGQP ASISCKSSQSLLNSDGKTFLNWLLQRPGQSPKRLIYLVSKLDSGVPDRF TGSGSGTDFTLKICRVEAEDLGVYYCWQGTHFPYTFGGGTKLEIKR.

(247) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(248) TABLE-US-00103 (SEQIDNO:149) EVMLVESGGGLVKPGGSLKLSCAASGFTFSRYAMSWNRQTPEKRLEWVA TISPGGGYIYYSDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCAG DYVDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVMSQSPSSLAVSVGEK VTMSCKSSQSLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDR FTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPRTFGGGTKLEIKR.

(249) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(250) TABLE-US-00104 (SEQIDNO:150) EVMLVESGGGLVKPGGSLKLSCAASGFTFSRYAMSWNRQTPEKRLEWVA TISPGGGYIYYSDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCAG DYVDYWGQGTTLTVSSGGGGGGGGSGGGGSDIVLTQSTSSLAVSVGEKV TMSCKSSQSLLFGSNQKNYLAWYQQKLGQSPKLLIFWASTRESGVPDRF TGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPFTFGSGTKLEIKR.

(251) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(252) TABLE-US-00105 (SEQIDNO:151) EVMLVESGGGLVKPGGSLKLSCAASGFTFSRYAMSWNRQTPEKRLEWVA TISPGGGYIYYSDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCAG DYVDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVLTQTNLTLSITIGQP ASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDRF TGSGSGTDFTLKISRVGAEDLGIYYCWQGTHFPHTFGGGTKLEIKR.

(253) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(254) TABLE-US-00106 (SEQIDNO:152) EVMLVESGGGLVKPGGSLKLSCAASGFTFSRYAMSWNRQTPEKRLEWVA TISPGGGYIYYSDSVKGRFTISRDNARNTLYLQMSSLRSEDTAMYYCAG DYVDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVLTQSPAIMSASPGEK VTMTCRASSSVSSSYLHWYQQKSGASPKLWIYSTSNLASGVPARFSGSG SGTSYSLTISSVEAEDAATYYCQQYSGYPLTFGAGTKLELKR.

(255) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(256) TABLE-US-00107 (SEQIDNO:153) QVQLQESGPGLVKPSQSLSLTCTVTGYSITSDYAWNWIRQFPGNKLEWM GYISYSGSTTYNPSLKGRISFTRDTSKNQFFLHLKSVTTEDSATYYCAR NWVYAMDYWGQGTSVTVSSGGGGSGGGGSGGGGSDIVLTQSHKFMSTSV GDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIFSASYRNSGVPDRFTG SGSGTDFTLTITNVQSEDLLEYFCQQYNTYPYTFGGGTKLEIKR.

(257) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(258) TABLE-US-00108 (SEQIDNO:154) QVQLQESGPGLVKPSQSLSLTCTVTGYSITSDYAWNWIRQFPGNKLEWM GYISYSGSTTYNPSLKGRISFTRDTSKNQFFLHLKSVTTEDSATYYCAR NWVYAMDYWGQGTSVTVSSGGGGSGGGGSGGGGSDIVMTQSPASLAVSL GQRATISCRASETIDNYGISFMNWFQQKPGQPPKLLIYGASNQGSGVPA RFSGSGSGTDFSLNIHPMEEDDTAMYFCQQNKEFPWTFGGGTKLEIKR.

(259) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(260) TABLE-US-00109 (SEQIDNO:155) QVQLQESGPGLVKPSQSLSLTCTVTGYSITSDYAWNWIRQFPGNKLEWM GYISYSGSTTYNPSLKGRISFTRDTSKNQFFLHLKSVTTEDSATYYCAR NWVYAMDYWGQGTSVTVSSGGGGSGGGGSGGGGSDIVMTQSHKFMSTSV GGRVSVTCKASQNVDTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTG SGSGTDFTLTITNVQSEDLAEYFCQQYNSYPLTFGAGTKLELKR.

(261) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(262) TABLE-US-00110 (SEQIDNO:156) QVQLQESGPGLVKPSQSLSLTCTVTGYSITSDYAWNWIRQFPGNKLEWM GYISYSGSTTYNPSLKGRISFTRDTSKNQFFLHLKSVTTEDSATYYCAR NWVYAMDYWGQGTSVTVSSGGGGSGGGGSGGGGSDIVLTQSHKFMSTSV GDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIFSASYRNSGVPDRFTG SGSGTDFTLTITNVQSEDLLEYFCQQYNTYPYTFGGGTKLEIKR.

(263) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(264) TABLE-US-00111 (SEQIDNO:157) QVQLQESGPGLVKPSQSLSLTCTVTGYSITSDYAWNWIRQFPGNKLEWM GYISYSGSTTYNPSLKGRISFTRDTSKNQFFLHLKSVTTEDSATYYCAR NWVYAMDYWGQGTSVTVSSGGGGSGGGGSGGGGSDIVITQSHKFMPTSV GDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTG SGSGTDFTFTISSVQAEDLAVYYCQQHYSTPYTFGGGTKLEIKR.

(265) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(266) TABLE-US-00112 (SEQIDNO:158) QVQLQESGPGLVKPSQSLSLTCTVTGYSITSDYAWNWIRQFPGNKLEWM GYISYSGSTTYNPSLKGRISFTRDTSKNQFFLHLKSVTTEDSATYYCAR NWVYAMDYWGQGTSVTVSSGGGGSGGGGSGGGGSDVVMTQTPLTLSVTT GQPASISCKSSQSLLNSDGKTFLNWLLQRPGQSPKRLIYLVSKLDSGVP DRFTGSGSGTDFTLKICRVEAEDLGVYYCWQGTHFPYTFGGGTKLEIKR.

(267) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(268) TABLE-US-00113 (SEQIDNO:159) QVQLQESGPGLVKPSQSLSLTCTVTGYSITSDYAWNWIRQFPGNKLEWMG YISYSGSTTYNPSLKGRISFTRDTSKNQFFLHLKSVTTEDSATYYCARNW VYAMDYWGQGTSVTVSSGGGGSGGGGSGGGGSDIVMSQSPSSLAVSVGEK VTMSCKSSQSLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRF TGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPRTFGGGTKLEIKR.

(269) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(270) TABLE-US-00114 (SEQIDNO:160) QVQLQESGPGLVKPSQSLSLTCTVTGYSITSDYAWNWIRQFPGNKLEWMG YISYSGSTTYNPSLKGRISFTRDTSKNQFFLHLKSVTTEDSATYYCARNW VYAMDYWGQGTSVTVSSGGGGSGGGGSGGGGSDIVLTQSTSSLAVSVGEK VTMSCKSSQSLLFGSNQKNYLAWYQQKLGQSPKLLIFWASTRESGVPDRF TGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPFTFGSGTKLEIKR.

(271) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(272) TABLE-US-00115 (SEQIDNO:161) QVQLQESGPGLVKPSQSLSLTCTVTGYSITSDYAWNWIRQFPGNKLEWMG YISYSGSTTYNPSLKGRISFTRDTSKNQFFLHLKSVTTEDSATYYCARNW VYAMDYWGQGTSVTVSSGGGGSGGGGSGGGGSDIVLTQTNLTLSITIGQP ASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFT GSGSGTDFTLKISRVGAEDLGIYYCWQGTHFPHTFGGGTKLEIKR.

(273) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(274) TABLE-US-00116 (SEQIDNO:162) QVQLQESGPGLVKPSQSLSLTCTVTGYSITSDYAWNWIRQFPGNKLEWMG YISYSGSTTYNPSLKGRISFTRDTSKNQFFLHLKSVTTEDSATYYCARNW VYAMDYWGQGTSVTVSSGGGGSGGGGSGGGGSDIVLTQSPAIMSASPGEK VTMTCRASSSVSSSYLHWYQQKSGASPKLWIYSTSNLASGVPARFSGSGS GTSYSLTISSVEAEDAATYYCQQYSGYPLTFGAGTKLELKR.

(275) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(276) TABLE-US-00117 (SEQIDNO:163) EVKLQQSGPVLVKPGASVKISCKASGYTFTDYYYMNWVKQSHGKSLEWIG YIYPNNSGTSYNQKFRGKATLTVDKSSSTAYMEVRSLTSEDSAVYYCARY YDGFNAGFAYWGQGTLVTVSAGGGGSGGGGSGGGGSDIVLTQSHKFMSTS VGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIFSASYRNSGVPDRFTG SGSGTDFTLTITNVQSEDLLEYFCQQYNTYPYTFGGGTKLEIKR.

(277) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(278) TABLE-US-00118 (SEQIDNO:164) EVKLQQSGPVLVKPGASVKISCKASGYTFTDYYYMNWVKQSHGKSLEWIG YIYPNNSGTSYNQKFRGKATLTVDKSSSTAYMEVRSLTSEDSAVYYCARY YDGFNAGFAYWGQGTLVTVSAGGGGSGGGGSGGGGSDIVMTQSPASLAVS LGQRATISCRASETIDNYGISFMNWFQQKPGQPPKLLIYGASNQGSGVPA RFSGSGSGTDFSLNIHPMEEDDTAMYFCQQNKEFPWTFGGGTKLEIKR.

(279) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(280) TABLE-US-00119 (SEQIDNO:165) EVKLQQSGPVLVKPGASVKISCKASGYTFTDYYYMNWVKQSHGKSLEWIG YIYPNNSGTSYNQKFRGKATLTVDKSSSTAYMEVRSLTSEDSAVYYCARY YDGFNAGFAYWGQGTLVTVSAGGGGSGGGGSGGGGSDIVMTQSHKFMSTS VGGRVSVTCKASQNVDTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTG SGSGTDFTLTITNVQSEDLAEYFCQQYNSYPLTFGAGTKLELKR.

(281) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(282) TABLE-US-00120 (SEQIDNO:166) EVKLQQSGPVLVKPGASVKISCKASGYTFTDYYYMNWVKQSHGKSLEWIG YIYPNNSGTSYNQKFRGKATLTVDKSSSTAYMEVRSLTSEDSAVYYCARY YDGFNAGFAYWGQGTLVTVSAGGGGSGGGGSGGGGSDIVLTQSHKFMSTS VGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIFSASYRNSGVPDRFTG SGSGTDFTLTITNVQSEDLLEYFCQQYNTYPYTFGGGTKLEIKR.

(283) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(284) TABLE-US-00121 (SEQIDNO:167) EVKLQQSGPVLVKPGASVKISCKASGYTFTDYYYMNWVKQSHGKSLEWIG YIYPNNSGTSYNQKFRGKATLTVDKSSSTAYMEVRSLTSEDSAVYYCARY YDGFNAGFAYWGQGTLVTVSAGGGGSGGGGSGGGGSDIVITQSHKFMPTS VGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTG SGSGTDFTFTISSVQAEDLAVYYCQQHYSTPYTFGGGTKLEIKR.

(285) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(286) TABLE-US-00122 (SEQIDNO:168) EVKLQQSGPVLVKPGASVKISCKASGYTFTDYYYMNWVKQSHGKSLEWIG YIYPNNSGTSYNQKFRGKATLTVDKSSSTAYMEVRSLTSEDSAVYYCARY YDGFNAGFAYWGQGTLVTVSAGGGGSGGGGSGGGGSDVVMTQTPLTLSVT TGQPASISCKSSQSLLNSDGKTFLNWLLQRPGQSPKRLIYLVSKLDSGVP DRFTGSGSGTDFTLKICRVEAEDLGVYYCWQGTHFPYTFGGGTKLEIKR.

(287) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(288) TABLE-US-00123 (SEQIDNO:169) EVKLQQSGPVLVKPGASVKISCKASGYTFTDYYYMNWVKQSHGKSLEWI GYIYPNNSGTSYNQKFRGKATLTVDKSSSTAYMEVRSLTSEDSAVYYCA RYYDGFNAGFAYWGQGTLVTVSAGGGGSGGGGSGGGGSDIVMSQSPSSL AVSVGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTR ESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPRTFGGGTK LEIKR.

(289) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(290) TABLE-US-00124 (SEQIDNO:170) EVKLQQSGPVLVKPGASVKISCKASGYTFTDYYYMNWVKQSHGKSLEWI GYIYPNNSGTSYNQKFRGKATLTVDKSSSTAYMEVRSLTSEDSAVYYCA RYYDGFNAGFAYWGQGTLVTVSAGGGGSGGGGSGGGGSDIVLTQSTSSL AVSVGEKVTMSCKSSQSLLFGSNQKNYLAWYQQKLGQSPKLLIFWASTR ESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPFTFGSGTK LEIKR.

(291) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(292) TABLE-US-00125 (SEQIDNO:171) EVKLQQSGPVLVKPGASVKISCKASGYTFTDYYYMNWVKQSHGKSLEWIG YIYPNNSGTSYNQKFRGKATLTVDKSSSTAYMEVRSLTSEDSAVYYCARY YDGFNAGFAYWGQGTLVTVSAGGGGSGGGGSGGGGSDIVLTQTNLTLSIT IGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVP DRFTGSGSGTDFTLKISRVGAEDLGIYYCWQGTHFPHTFGGGTKLEIKR.

(293) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(294) TABLE-US-00126 (SEQIDNO:172) EVKLQQSGPVLVKPGASVKISCKASGYTFTDYYYMNWVKQSHGKSLEWIG YIYPNNSGTSYNQKFRGKATLTVDKSSSTAYMEVRSLTSEDSAVYYCARY YDGFNAGFAYWGQGTLVTVSAGGGGSGGGGSGGGGSDIVLTQSPAIMSAS PGEKVTMTCRASSSVSSSYLHWYQQKSGASPKLWIYSTSNLASGVPARFS GSGSGTSYSLTISSVEAEDAATYYCQQYSGYPLTFGAGTKLELKR.

(295) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(296) TABLE-US-00127 (SEQIDNO:173) QVQLEESGPGLVAPSQSLSITCTVSGFSLSRYSVHWVRQPPGKGLEWLGM IWVNGNTDYNSALKSRLNINKDNSKSQVFLKMNSLQTDDTAMYYCATYYG NYDSFTYWGQGTLVTVSAGGGGSGGGGSGGGGSDIVLTQSHKFMSTSVGD RVSVTCKASQNVGTNVAWYQQKPGQSPKALIFSASYRNSGVPDRFTGSGS GTDFTLTITNVQSEDLLEYFCQQYNTYPYTFGGGTKLEIKR.

(297) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(298) TABLE-US-00128 (SEQIDNO:174) QVQLEESGPGLVAPSQSLSITCTVSGFSLSRYSVHWVRQPPGKGLEWLG MIWVNGNTDYNSALKSRLNINKDNSKSQVFLKMNSLQTDDTAMYYCATY YGNYDSFTYWGQGTLVTVSAGGGGSGGGGSGGGGSDIVMTQSPASLAVS LGQRATISCRASETIDNYGISFMNWFQQKPGQPPKLLIYGASNQGSGVP ARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQNKEFPWTFGGGTKLEIKR.

(299) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(300) TABLE-US-00129 (SEQIDNO:175) QVQLEESGPGLVAPSQSLSITCTVSGFSLSRYSVHWVRQPPGKGLEWLG MIWVNGNTDYNSALKSRLNINKDNSKSQVFLKMNSLQTDDTAMYYCATY YGNYDSFTYWGQGTLVTVSAGGGGSGGGGSGGGGSDIVMTQSHKFMSTS VGGRVSVTCKASQNVDTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFT GSGSGTDFTLTITNVQSEDLAEYFCQQYNSYPLTFGAGTKLELKR.

(301) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(302) TABLE-US-00130 (SEQIDNO:176) QVQLEESGPGLVAPSQSLSITCTVSGFSLSRYSVHWVRQPPGKGLEWLG MIWVNGNTDYNSALKSRLNINKDNSKSQVFLKMNSLQTDDTAMYYCATY YGNYDSFTYWGQGTLVTVSAGGGGSGGGGSGGGGSDIVLTQSHKFMSTS VGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIFSASYRNSGVPDRFT GSGSGTDFTLTITNVQSEDLLEYFCQQYNTYPYTFGGGTKLEIKR.

(303) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(304) TABLE-US-00131 (SEQIDNO:177) QVQLEESGPGLVAPSQSLSITCTVSGFSLSRYSVHWVRQPPGKGLEWLG MIWVNGNTDYNSALKSRLNINKDNSKSQVFLKMNSLQTDDTAMYYCATY YGNYDSFTYWGQGTLVTVSAGGGGSGGGGSGGGGSDIVITQSHKFMPTS VGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFT GSGSGTDFTFTISSVQAEDLAVYYCQQHYSTPYTFGGGTKLEIKR.

(305) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(306) TABLE-US-00132 (SEQIDNO:178) QVQLEESGPGLVAPSQSLSITCTVSGFSLSRYSVHWVRQPPGKGLEWLG MIWVNGNTDYNSALKSRLNINKDNSKSQVFLKMNSLQTDDTAMYYCATY YGNYDSFTYWGQGTLVTVSAGGGGSGGGGSGGGGSDVVMTQTPLTLSVT TGQPASISCKSSQSLLNSDGKTFLNWLLQRPGQSPKRLIYLVSKLDSGV PDRFTGSGSGTDFTLKICRVEAEDLGVYYCWQGTHFPYTFGGGTKLEIK R.

(307) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(308) TABLE-US-00133 (SEQIDNO:179) QVQLEESGPGLVAPSQSLSITCTVSGFSLSRYSVHWVRQPPGKGLEWLG MIWVNGNTDYNSALKSRLNINKDNSKSQVFLKMNSLQTDDTAMYYCATY YGNYDSFTYWGQGTLVTVSAGGGGSGGGGSGGGGSDIVMSQSPSSLAVS VGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESG VPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPRTFGGGTKLEI KR.

(309) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(310) TABLE-US-00134 (SEQIDNO:180) QVQLEESGPGLVAPSQSLSITCTVSGFSLSRYSVHWVRQPPGKGLEWLG MIWVNGNTDYNSALKSRLNINKDNSKSQVFLKMNSLQTDDTAMYYCATY YGNYDSFTYWGQGTLVTVSAGGGGSGGGGSGGGGSDIVLTQSTSSLAVS VGEKVTMSCKSSQSLLFGSNQKNYLAWYQQKLGQSPKLLIFWASTRESG VPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPFTFGSGTKLEI KR.

(311) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(312) TABLE-US-00135 (SEQIDNO:181) QVQLEESGPGLVAPSQSLSITCTVSGFSLSRYSVHWVRQPPGKGLEWLG MIWVNGNTDYNSALKSRLNINKDNSKSQVFLKMNSLQTDDTAMYYCATY YGNYDSFTYWGQGTLVTVSAGGGGSGGGGSGGGGSDIVLTQTNLTLSIT IGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSGV PDRFTGSGSGTDFTLKISRVGAEDLGIYYCWQGTHFPHTFGGGTKLEIK R.

(313) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(314) TABLE-US-00136 (SEQIDNO:182) QVQLEESGPGLVAPSQSLSITCTVSGFSLSRYSVHWVRQPPGKGLEWLG MIWVNGNTDYNSALKSRLNINKDNSKSQVFLKMNSLQTDDTAMYYCATY YGNYDSFTYWGQGTLVTVSAGGGGSGGGGSGGGGSDIVLTQSPAIMSAS PGEKVTMTCRASSSVSSSYLHWYQQKSGASPKLWIYSTSNLASGVPARF SGSGSGTSYSLTISSVEAEDAATYYCQQYSGYPLTFGAGTKLELKR.

(315) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(316) TABLE-US-00137 (SEQIDNO:183) EVQLQESGAELARPGASVKMSCKASGYTFTSYWMHWVKQRPGQGLEWIG AIYPGNSDTSYNQKFKGKAKLTAVTSASTAYMELSSLTNEDSAVYYCTT SLAYWGQGTLVTVSAGGGGSGGGGSGGGGSDIVLTQSHKFMSTSVGDRV SVTCKASQNVGTNVAWYQQKPGQSPKALIFSASYRNSGVPDRFTGSGSG TDFTLTITNVQSEDLLEYFCQQYNTYPYTFGGGTKLEIKR.

(317) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(318) TABLE-US-00138 (SEQIDNO:184) EVQLQESGAELARPGASVKMSCKASGYTFTSYWMHWVKQRPGQGLEWIG AIYPGNSDTSYNQKFKGKAKLTAVTSASTAYMELSSLTNEDSAVYYCTT SLAYWGQGTLVTVSAGGGGSGGGGSGGGGSDIVMTQSPASLAVSLGQRA TISCRASETIDNYGISFMNWFQQKPGQPPKLLIYGASNQGSGVPARFSG SGSGTDFSLNIHPMEEDDTAMYFCQQNKEFPWTFGGGTKLEIKR.

(319) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(320) TABLE-US-00139 (SEQIDNO:185) EVQLQESGAELARPGASVKMSCKASGYTFTSYWMHWVKQRPGQGLEWIG AIYPGNSDTSYNQKFKGKAKLTAVTSASTAYMELSSLTNEDSAVYYCTT SLAYWGQGTLVTVSAGGGGSGGGGSGGGGSDIVMTQSHKFMSTSVGGRV SVTCKASQNVDTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSG TDFTLTITNVQSEDLAEYFCQQYNSYPLTFGAGTKLELKR.

(321) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(322) TABLE-US-00140 (SEQIDNO:186) EVQLQESGAELARPGASVKMSCKASGYTFTSYWMHWVKQRPGQGLEWIG AIYPGNSDTSYNQKFKGKAKLTAVTSASTAYMELSSLTNEDSAVYYCTT SLAYWGQGTLVTVSAGGGGSGGGGSGGGGSDIVLTQSHKFMSTSVGDRV SVTCKASQNVGTNVAWYQQKPGQSPKALIFSASYRNSGVPDRFTGSGSG TDFTLTITNVQSEDLLEYFCQQYNTYPYTFGGGTKLEIKR.

(323) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(324) TABLE-US-00141 (SEQIDNO:187) EVQLQESGAELARPGASVKMSCKASGYTFTSYWMHWVKQRPGQGLEWIG AIYPGNSDTSYNQKFKGKAKLTAVTSASTAYMELSSLTNEDSAVYYCTT SLAYWGQGTLVTVSAGGGGSGGGGSGGGGSDIVITQSHKFMPTSVGDRV SITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSG TDFTFTISSVQAEDLAVYYCQQHYSTPYTFGGGTKLEIKR.

(325) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(326) TABLE-US-00142 (SEQIDNO:188) EVQLQESGAELARPGASVKMSCKASGYTFTSYWMHWVKQRPGQGLEWIG AIYPGNSDTSYNQKFKGKAKLTAVTSASTAYMELSSLTNEDSAVYYCTT SLAYWGQGTLVTVSAGGGGSGGGGSGGGGSDVVMTQTPLTLSVTTGQPA SISCKSSQSLLNSDGKTFLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFT GSGSGTDFTLKICRVEAEDLGVYYCWQGTHFPYTFGGGTKLEIKR.

(327) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(328) TABLE-US-00143 (SEQIDNO:189) EVQLQESGAELARPGASVKMSCKASGYTFTSYWMHWVKQRPGQGLEWIG AIYPGNSDTSYNQKFKGKAKLTAVTSASTAYMELSSLTNEDSAVYYCTT SLAYWGQGTLVTVSAGGGGSGGGGSGGGGSDIVMSQSPSSLAVSVGEKV TMSCKSSQSLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRF TGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPRTFGGGTKLEIKR.

(329) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(330) TABLE-US-00144 (SEQIDNO:190) EVQLQESGAELARPGASVKMSCKASGYTFTSYWMHWVKQRPGQGLEWIG AIYPGNSDTSYNQKFKGKAKLTAVTSASTAYMELSSLTNEDSAVYYCTT SLAYWGQGTLVTVSAGGGGSGGGGSGGGGSDIVLTQSTSSLAVSVGEKV TMSCKSSQSLLFGSNQKNYLAWYQQKLGQSPKLLIFWASTRESGVPDRF TGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPFTFGSGTKLEIKR.

(331) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(332) TABLE-US-00145 (SEQIDNO:191) EVQLQESGAELARPGASVKMSCKASGYTFTSYWMHWVKQRPGQGLEWIG AIYPGNSDTSYNQKFKGKAKLTAVTSASTAYMELSSLTNEDSAVYYCTT SLAYWGQGTLVTVSAGGGGGGGGSGGGGSDIVLTQTNLTLSITIGQPAS ISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTG SGSGTDFTLKISRVGAEDLGIYYCWQGTHFPHTFGGGTKLEIKR.

(333) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(334) TABLE-US-00146 (SEQIDNO:192) EVQLQESGAELARPGASVKMSCKASGYTFTSYWMHWVKQRPGQGLEWIG AIYPGNSDTSYNQKFKGKAKLTAVTSASTAYMELSSLTNEDSAVYYCTT SLAYWGQGTLVTVSAGGGGSGGGGSGGGGSDIVLTQSPAIMSASPGEKV TMTCRASSSVSSSYLHWYQQKSGASPKLWIYSTSNLASGVPARFSGSGS GTSYSLTISSVEAEDAATYYCQQYSGYPLTFGAGTKLELKR.

(335) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(336) TABLE-US-00147 (SEQIDNO:193) DIVLTQSHKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIF SASYRNSGVPDRFTGSGSGTDFTLTITNVQSEDLLEYFCQQYNTYPYTF GGGTKLEIKRGGGGSGGGGSGGGGSEVKLEESGGGLVKPGGSLKLSCAA SGFTFSSYAMSWVRQTPEKRLEWVASISSGGSTYYPDSVKGRFTISRDN ARNTLYLQMSSLRSEDTAMYYCARGRDGYSLYFDYWGQGTTLTVSS.

(337) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(338) TABLE-US-00148 (SEQIDNO:194) DIVLTQSHKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIF SASYRNSGVPDRFTGSGSGTDFTLTITNVQSEDLLEYFCQQYNTYPYTF GGGTKLEIKRGGGGSGGGGSGGGGSQVKLQESGGGLVKPGGSLKLSCAA SGFTFSSYAMSWVRQTPEKRLEWVAGISSGGSFTYYPDTVKGRFTISRD NARNTLYLQMSSLRSEDTAMYSCAREGVYSDYRAWFAYWGQGTLVT.

(339) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(340) TABLE-US-00149 (SEQIDNO:195) DIVLTQSHKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIF SASYRNSGVPDRFTGSGSGTDFTLTITNVQSEDLLEYFCQQYNTYPYTF GGGTKLEIKRGGGGSGGGGSGGGGSEVKLEQSGPSLVQPSQSLSITCTV SGFSLTNFGVHWVRQSPGKGLEWLGLIWRGGSTDYNAAFMSRLSITKDN SKSQVFFKMNSLQADDTAIYYCAKMGITYYFDYWGQGTTLTVSS.

(341) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(342) TABLE-US-00150 (SEQIDNO:196) DIVLTQSHKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIF SASYRNSGVPDRFTGSGSGTDFTLTITNVQSEDLLEYFCQQYNTYPYTF GGGTKLEIKRGGGGSGGGGSGGGGSQVKLQQSGDDLVKPGASVKLSCKA SGYTFTSYWINWIKQRPGQGLEWIGHIAPGTGSTYYSEMFKDKATLTVD TPSSSAYIQLSSLSSEDSAVYFCAREGGRYYTLDCWGQGTSVTVSS.

(343) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(344) TABLE-US-00151 (SEQIDNO:197) DIVLTQSHKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIF SASYRNSGVPDRFTGSGSGTDFTLTITNVQSEDLLEYFCQQYNTYPYTF GGGTKLEIKRGGGGSGGGGSGGGGSQVQLEESGPGLVKPSQTVSLTCTV TGISITTGNYRWSWIRQFPGNKLEWIGYIYYSGTITYNPSLTSRTTITR DTSKNQFFLEMNSLTAEDTATYYCARWLNNFDVWGTGTTVTVS.

(345) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(346) TABLE-US-00152 (SEQIDNO:198) DIVLTQSHKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIF SASYRNSGVPDRFTGSGSGTDFTLTITNVQSEDLLEYFCQQYNTYPYTF GGGTKLEIKRGGGGSGGGGSGGGGSDVVMTQTPLTLSVTTGQPASISCK SSQSLLNSDGKTFLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSG TDFTLKICRVEAEDLGVYYCWQGTHFPYTFGGGTKLEIKR.

(347) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(348) TABLE-US-00153 (SEQIDNO:199) DIVLTQSHKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIF SASYRNSGVPDRFTGSGSGTDFTLTITNVQSEDLLEYFCQQYNTYPYTF GGGTKLEIKRGGGGSGGGGSGGGGSDIVMSQSPSSLAVSVGEKVTMSCK SSQSLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGS GTDFTLTISSVKAEDLAVYYCQQYYSYPRTFGGGTKLEIKR.

(349) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(350) TABLE-US-00154 (SEQIDNO:200) DIVLTQSHKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIF SASYRNSGVPDRFTGSGSGTDFTLTITNVQSEDLLEYFCQQYNTYPYTF GGGTKLEIKRGGGGSGGGGSGGGGSDIVLTQSTSSLAVSVGEKVTMSCK SSQSLLFGSNQKNYLAWYQQKLGQSPKLLIFWASTRESGVPDRFTGSGS GTDFTLTISSVKAEDLAVYYCQQYYSYPFTFGSGTKLEIKR.

(351) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(352) TABLE-US-00155 (SEQIDNO:201) DIVLTQSHKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIF SASYRNSGVPDRFTGSGSGTDFTLTITNVQSEDLLEYFCQQYNTYPYTF GGGTKLEIKRGGGGSGGGGSGGGGSDIVLTQTNLTLSITIGQPASISCK SSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSG TDFTLKISRVGAEDLGIYYCWQGTHFPHTFGGGTKLEIKR.

(353) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(354) TABLE-US-00156 (SEQIDNO:202) DIVLTQSHKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIF SASYRNSGVPDRFTGSGSGTDFTLTITNVQSEDLLEYFCQQYNTYPYTF GGGTKLEIKRGGGGSGGGGSGGGGSDIVLTQSPAIMSASPGEKVTMTCR ASSSVSSSYLHWYQQKSGASPKLWIYSTSNLASGVPARFSGSGSGTSYS LTISSVEAEDAATYYCQQYSGYPLTFGAGTKLELKR.

(355) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(356) TABLE-US-00157 (SEQIDNO:203) DIVMTQSPASLAVSLGQRATISCRASETIDNYGISFMNWFQQKPGQPPK LLIYGASNQGSGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQNKEF PWTFGGGTKLEIKRGGGGSGGGGSGGGGSEVKLEESGGGLVKPGGSLKL SCAASGFTFSSYAMSWVRQTPEKRLEWVASISSGGSTYYPDSVKGRFTI SRDNARNTLYLQMSSLRSEDTAMYYCARGRDGYSLYFDYWGQGTTLTVS S.

(357) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(358) TABLE-US-00158 (SEQIDNO:204) DIVMTQSPASLAVSLGQRATISCRASETIDNYGISFMNWFQQKPGQPPK LLIYGASNQGSGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQNKEF PWTFGGGTKLEIKRGGGGSGGGGSGGGGSQVKLQESGGGLVKPGGSLKL SCAASGFTFSSYAMSWVRQTPEKRLEWVAGISSGGSFTYYPDTVKGRFT ISRDNARNTLYLQMSSLRSEDTAMYSCAREGVYSDYRAWFAYWGQGTLV T.

(359) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(360) TABLE-US-00159 (SEQIDNO:205) DIVMTQSPASLAVSLGQRATISCRASETIDNYGISFMNWFQQKPGQPPKL LIYGASNQGSGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQNKEFPW TFGGGTKLEIKRGGGSGGGGSGGGGSEVKLEQSGPSLVQPSQSLSITCTV SGFSLTNFGVHWVRQSPGKGLEWLGLIWRGGSTDYNAAFMSRLSITKDNS KSQVFFKMNSLQADDTAIYYCAKMGITYYFDYWGQGTTLTVSS.

(361) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(362) TABLE-US-00160 (SEQIDNO:206) DIVMTQSPASLAVSLGQRATISCRASETIDNYGISFMNWFQQKPGQPPK LLIYGASNQGSGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQNKEF PWTFGGGTKLEIKRGGGGSGGGGSGGGGSQVKLQQSGDDLVKPGASVKL SCKASGYTFTSYWINWIKQRPGQGLEWIGHIAPGTGSTYYSEMFKDKAT LTVDTPSSSAYIQLSSLSSEDSAVYFCAREGGRYYTLDCWGQGTSVTVS S.

(363) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(364) TABLE-US-00161 (SEQIDNO:207) DIVMTQSPASLAVSLGQRATISCRASETIDNYGISFMNWFQQKPGQPPK LLIYGASNQGSGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQNKEF PWTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLEESGPGLVKPSQTVSL TCTVTGISITTGNYRWSWIRQFPGNKLEWIGYIYYSGTITYNPSLTSRT TITRDTSKNQFFLEMNSLTAEDTATYYCARWLNNFDVWGTGTTVTVS.

(365) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(366) TABLE-US-00162 (SEQIDNO:208) DIVMTQSPASLAVSLGQRATISCRASETIDNYGISFMNWFQQKPGQPPK LLIYGASNQGSGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQNKEF PWTFGGGTKLEIKRGGGGSGGGGSGGGGSDVVMTQTPLTLSVTTGQPAS ISCKSSQSLLNSDGKTFLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTG SGSGTDFTLKICRVEAEDLGVYYCWQGTHFPYTFGGGTKLEIKR.

(367) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(368) TABLE-US-00163 (SEQIDNO:209) DIVMTQSPASLAVSLGQRATISCRASETIDNYGISFMNWFQQKPGQPPK LLIYGASNQGSGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQNKEF PWTFGGGTKLEIKRGGGGSGGGGSGGGGSDIVMSQSPSSLAVSVGEKVT MSCKSSQSLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFT GSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPRTFGGGTKLEIKR.

(369) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(370) TABLE-US-00164 (SEQIDNO:210) DIVMTQSPASLAVSLGQRATISCRASETIDNYGISFMNWFQQKPGQPPK LLIYGASNQGSGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQNKEF PWTFGGGTKLEIKRGGGGSGGGGSGGGGSDIVLTQSTSSLAVSVGEKVT MSCKSSQSLLFGSNQKNYLAWYQQKLGQSPKLLIFWASTRESGVPDRFT GSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPFTFGSGTKLEIKR.

(371) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(372) TABLE-US-00165 (SEQIDNO:211) DIVMTQSPASLAVSLGQRATISCRASETIDNYGISFMNWFQQKPGQPPK LLIYGASNQGSGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQNKEF PWTFGGGTKLEIKRGGGGSGGGGSGGGGSDIVLTQTNLTLSITIGQPAS ISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTG SGSGTDFTLKISRVGAEDLGIYYCWQGTHFPHTFGGGTKLEIKR.

(373) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(374) TABLE-US-00166 (SEQIDNO:212) DIVMTQSPASLAVSLGQRATISCRASETIDNYGISFMNWFQQKPGQPPK LLIYGASNQGSGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQNKEF PWTFGGGTKLEIKRGGGGSGGGGSGGGGSDIVLTQSPAIMSASPGEKVT MTCRASSSVSSSYLHWYQQKSGASPKLWIYSTSNLASGVPARFSGSGSG TSYSLTISSVEAEDAATYYCQQYSGYPLTFGAGTKLELKR.

(375) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(376) TABLE-US-00167 (SEQIDNO:213) DIVMTQSHKFMSTSVGGRVSVTCKASQNVDTNVAWYQQKPGQSPKALIY SASYRYSGVPDRFTGSGSGTDFTLTITNVQSEDLAEYFCQQYNSYPLTF GAGTKLELKRGGGGSGGGGSGGGGSEVKLEESGGGLVKPGGSLKLSCAA SGFTFSSYAMSWVRQTPEKRLEWVASISSGGSTYYPDSVKGRFTISRDN ARNTLYLQMSSLRSEDTAMYYCARGRDGYSLYFDYWGQGTTLTVSS.

(377) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(378) TABLE-US-00168 (SEQIDNO:214) DIVMTQSHKFMSTSVGGRVSVTCKASQNVDTNVAWYQQKPGQSPKALIY SASYRYSGVPDRFTGSGSGTDFTLTITNVQSEDLAEYFCQQYNSYPLTF GAGTKLELKRGGGGSGGGGGGGGSQVKLQESGGGLVKPGGSLKLSCAAS GFTFSSYAMSWVRQTPEKRLEWVAGISSGGSFTYYPDTVKGRFTISRDN ARNTLYLQMSSLRSEDTAMYSCAREGVYSDYRAWFAYWGQGTLVT.

(379) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(380) TABLE-US-00169 (SEQIDNO:215) DIVMTQSHKFMSTSVGGRVSVTCKASQNVDTNVAWYQQKPGQSPKALI YSASYRYSGVPDRFTGSGSGTDFTLTITNVQSEDLAEYFCQQYNSYPL TFGAGTKLELKRGGGGSGGGGSGGGGSEVKLEQSGPSLVQPSQSLSIT CTVSGFSLTNFGVHWVRQSPGKGLEWLGLIWRGGSTDYNAAFMSRLSI TKDNSKSQVFFKMNSLQADDTAIYYCAKMGITYYFDYWGQGTTLTVSS.

(381) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(382) TABLE-US-00170 (SEQIDNO:216) DIVMTQSHKFMSTSVGGRVSVTCKASQNVDTNVAWYQQKPGQSPKALI YSASYRYSGVPDRFTGSGSGTDFTLTITNVQSEDLAEYFCQQYNSYPL TFGAGTKLELKRGGGGSGGGGSGGGGSQVKLQQSGDDLVKPGASVKLS CKASGYTFTSYWINWIKQRPGQGLEWIGHIAPGTGSTYYSEMFKDKAT LTVDTPSSSAYIQLSSLSSEDSAVYFCAREGGRYYTLDCWGQGTSVTV SS.

(383) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(384) TABLE-US-00171 (SEQIDNO:217) DIVMTQSHKFMSTSVGGRVSVTCKASQNVDTNVAWYQQKPGQSPKALI YSASYRYSGVPDRFTGSGSGTDFTLTITNVQSEDLAEYFCQQYNSYPL TFGAGTKLELKRGGGGSGGGGSGGGGSQVQLEESGPGLVKPSQTVSLT CTVTGISITTGNYRWSWIRQFPGNKLEWIGYIYYSGTITYNPSLTSRT TITRDTSKNQFFLEMNSLTAEDTATYYCARWLNNFDVWGTGTTVTVS.

(385) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(386) TABLE-US-00172 (SEQIDNO:218) DIVMTQSHKFMSTSVGGRVSVTCKASQNVDTNVAWYQQKPGQSPKALI YSASYRYSGVPDRFTGSGSGTDFTLTITNVQSEDLAEYFCQQYNSYPL TFGAGTKLELKRGGGGSGGGGSGGGGSDVVMTQTPLTLSVTTGQPASI SCKSSQSLLNSDGKTFLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTG SGSGTDFTLKICRVEAEDLGVYYCWQGTHFPYTFGGGTKLEIKR.

(387) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(388) TABLE-US-00173 (SEQIDNO:219) DIVMTQSHKFMSTSVGGRVSVTCKASQNVDTNVAWYQQKPGQSPKALIYS ASYRYSGVPDRFTGSGSGTDFTLTITNVQSEDLAEYFCQQYNSYPLTFGA GTKLELKRGGGGSGGGGSGGGGSDIVMSQSPSSLAVSVGEKVTMSCKSSQ SLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDF TLTISSVKAEDLAVYYCQQYYSYPRTFGGGTKLEIKR

(389) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(390) TABLE-US-00174 (SEQIDNO:220) DIVMTQSHKFMSTSVGGRVSVTCKASQNVDTNVAWYQQKPGQSPKALIYS ASYRYSGVPDRFTGSGSGTDFTLTITNVQSEDLAEYFCQQYNSYPLTFGA GTKLELKRGGGGSGGGGSGGGGSDIVLTQSTSSLAVSVGEKVTMSCKSSQ SLLFGSNQKNYLAWYQQKLGQSPKLLIFWASTRESGVPDRFTGSGSGTDF TLTISSVKAEDLAVYYCQQYYSYPFTFGSGTKLEIKR

(391) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(392) TABLE-US-00175 (SEQIDNO:221) DIVMTQSHKFMSTSVGGRVSVTCKASQNVDTNVAWYQQKPGQSPKALIYS ASYRYSGVPDRFTGSGSGTDFTLTITNVQSEDLAEYFCQQYNSYPLTFGA GTKLELKRGGGGSGGGGSGGGGSDIVLTQTNLTLSITIGQPASISCKSSQ SLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFT LKISRVGAEDLGIYYCWQGTHFPHTFGGGTKLEIKR

(393) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(394) TABLE-US-00176 (SEQIDNO:222) DIVMTQSHKFMSTSVGGRVSVTCKASQNVDTNVAWYQQKPGQSPKALIYS ASYRYSGVPDRFTGSGSGTDFTLTITNVQSEDLAEYFCQQYNSYPLTFGA GTKLELKRGGGGSGGGGSGGGGSDIVLTQSPAIMSASPGEKVTMTCRASS SVSSSYLHWYQQKSGASPKLWIYSTSNLASGVPARFSGSGSGTSYSLTIS SVEAEDAATYYCQQYSGYPLTFGAGTKLELKR

(395) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(396) TABLE-US-00177 (SEQIDNO:223) DIVLTQTHKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYW ASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYSSYPLTFGG GTKLEIKGGGGSGGGGSGGGGSEVKLEESGGGLVKPGGSLKLSCAASGFT FSSYAMSWVRQTPEKRLEWVASISSGGSTYYPDSVKGRFTISRDNARNTL YLQMSSLRSEDTAMYYCARGRDGYSLYFDYWGQGTTLTVSS.

(397) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(398) TABLE-US-00178 (SEQIDNO:224) DIVLTQTHKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYW ASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYSSYPLTFGG GTKLEIKGGGGSGGGGSGGGGSQVKLQESGGGLVKPGGSLKLSCAASGFT FSSYAMSWVRQTPEKRLEWVAGISSGGSFTYYPDTVKGRFTISRDNARNT LYLQMSSLRSEDTAMYSCAREGVYSDYRAWFAYWGQGTLVT.

(399) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(400) TABLE-US-00179 (SEQIDNO:225) DIVLTQTHKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYW ASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYSSYPLTFGG GTKLEIKGGGGSGGGGSGGGGSEVKLEQSGPSLVQPSQSLSITCTVSGFS LTNFGVHWVRQSPGKGLEWLGLIWRGGSTDYNAAFMSRLSITKDNSKSQV FFKMNSLQADDTAIYYCAKMGITYYFDYWGQGTTLTVSS.

(401) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(402) TABLE-US-00180 (SEQIDNO:226) DIVLTQTHKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYW ASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYSSYPLTFGG GTKLEIKGGGGSGGGGSGGGGSQVKLQQSGDDLVKPGASVKLSCKASGYT FTSYWINWIKQRPGQGLEWIGHIAPGTGSTYYSEMFKDKATLTVDTPSSS AYIQLSSLSSEDSAVYFCAREGGRYYTLDCWGQGTSVTVSS.

(403) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(404) TABLE-US-00181 (SEQIDNO:227) DIVLTQTHKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYW ASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYSSYPLTFGG GTKLEIKGGGGSGGGGSGGGGSQVQLEESGPGLVKPSQTVSLTCTVTGIS ITTGNYRWSWIRQFPGNKLEWIGYIYYSGTITYNPSLTSRTTITRDTSKN QFFLEMNSLTAEDTATYYCARWLNNFDVWGTGTTVTVS.

(405) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(406) TABLE-US-00182 (SEQIDNO:228) DIVLTQTHKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYW ASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYSSYPLTFGG GTKLEIKGGGGSGGGGSGGGGSDWVMTQTPLTLSVTTGQPASISCKSSQS LLNSDGKTFLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTL KICRVEAEDLGVYYCWQGTHEPYTFGGGTKLEIKR.

(407) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(408) TABLE-US-00183 (SEQIDNO:229) DIVLTQTHKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYW ASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYSSYPLTFGG GTKLEIKGGGGSGGGGSGGGGSDIVMSQSPSSLAVSVGEKVTMSCKSSQS LLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFT LTISSVKAEDLAVYYCQQYYSYPRTFGGGTKLEIKR.

(409) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(410) TABLE-US-00184 (SEQIDNO:230) DIVLTQTHKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYW ASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYSSYPLTFGG GTKLEIKGGGGSGGGGSGGGGSDIVLTQSTSSLAVSVGEKVTMSCKSSQS LLFGSNQKNYLAWYQQKLGQSPKLLIFWASTRESGVPDRFTGSGSGTDFT LTISSVKAEDLAVYYCQQYYSYPFTFGSGTKLEIKR.

(411) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(412) TABLE-US-00185 (SEQIDNO:231) DIVLTQTHKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYW ASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYSSYPLTFGG GTKLEIKGGGGSGGGGGGGGSDIVLTQTNLTLSITIGQPASISCKSSQSL LDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLK ISRVGAEDLGIYYCWQGTHFPHTFGGGTKLEIKR.

(413) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(414) TABLE-US-00186 (SEQIDNO:232) DIVLTQTHKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYW ASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYSSYPLTFGG GTKLEIKGGGGSGGGGSGGGGSDIVLTQSPAIMSASPGEKVTMTCRASSS VSSSYLHWYQQKSGASPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISS VEAEDAATYYCQQYSGYPLTFGAGTKLELKR.

(415) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(416) TABLE-US-00187 (SEQIDNO:233) DIVITQSHKFMPTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYS ASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSTPYTFGG GTKLEIKRGGGGSGGGGSGGGGSEVKLEESGGGLVKPGGSLKLSCAASGF TFSSYAMSWVRQTPEKRLEWVASISSGGSTYYPDSVKGRFTISRDNARNT LYLQMSSLRSEDTAMYYCARGRDGYSLYFDYWGQGTTLTVSS.

(417) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(418) TABLE-US-00188 (SEQIDNO:234) DIVITQSHKFMPTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYS ASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSTPYTFGG GTKLEIKRGGGGSGGGGSGGGGSQVKLQESGGGLVKPGGSLKLSCAASGF TFSSYAMSWVRQTPEKRLEWVAGISSGGSFTYYPDTVKGRFTISRDNARN TLYLQMSSLRSEDTAMYSCAREGVYSDYRAWFAYWGQGTLVT.

(419) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(420) TABLE-US-00189 (SEQIDNO:235) DIVITQSHKFMPTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYS ASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSTPYTFGG GTKLEIKRGGGGSGGGGSGGGGSEVKLEQSGPSLVQPSQSLSITCTVSGF SLTNFGVHWVRQSPGKGLEWLGLIWRGGSTDYNAAFMSRLSITKDNSKSQ VFFKMNSLQADDTAIYYCAKMGITYYFDYWGQGTTLTVSS.

(421) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(422) TABLE-US-00190 (SEQIDNO:236) DIVITQSHKFMPTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYS ASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSTPYTFGG GTKLEIKRGGGGSGGGGSGGGGSQVKLQQSGDDLVKPGASVKLSCKASGY TFTSYWINWIKQRPGQGLEWIGHIAPGTGSTYYSEMFKDKATLTVDTPSS SAYIQLSSLSSEDSAVYFCAREGGRYYTLDCWGQGTSVTVSS.

(423) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(424) TABLE-US-00191 (SEQIDNO:237) DIVITQSHKFMPTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYS ASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSTPYTFGG GTKLEIKRGGGGSGGGGSGGGGSQVQLEESGPGLVKPSQTVSLTCTVTGI SITTGNYRWSWIRQFPGNKLEWIGYIYYSGTITYNPSLTSRTTITRDTSK NQFFLEMNSLTAEDTATYYCARWLNNFDVWGTGTTVTVS.

(425) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(426) TABLE-US-00192 (SEQIDNO:238) DIVITQSHKFMPTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYS ASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSTPYTFGG GTKLEIKRGGGGSGGGGSGGGGSDVVMTQTPLTLSVTTGQPASISCKSSQ SLLNSDGKTFLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFT LKICRVEAEDLGVYYCWQGTHFPYTFGGGTKLEIKR.

(427) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(428) TABLE-US-00193 (SEQIDNO:239) DIVITQSHKFMPTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYS ASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSTPYTFGG GTKLEIKRGGGGSGGGGSGGGGSDIVMSQSPSSLAVSVGEKVTMSCKSSQ SLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDF TLTISSVKAEDLAVYYCQQYYSYPRTFGGGTKLEIKR.

(429) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(430) TABLE-US-00194 (SEQIDNO:240) DIVITQSHKFMPTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYS ASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSTPYTFGG GTKLEIKRGGGGSGGGGSGGGGSDIVLTQSTSSLAVSVGEKVTMSCKSSQ SLLFGSNQKNYLAWYQQKLGQSPKLLIFWASTRESGVPDRFTGSGSGTDF TLTISSVKAEDLAVYYCQQYYSYPFTFGSGTKLEIKR.

(431) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(432) TABLE-US-00195 (SEQIDNO:241) DIVITQSHKFMPTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYS ASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSTPYTFGG GTKLEIKRGGGGSGGGGSGGGGSDIVLTQTNLTLSITIGQPASISCKSSQ SLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFT LKISRVGAEDLGIYYCWQGTHFPHTFGGGTKLEIKR.

(433) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(434) TABLE-US-00196 (SEQIDNO:242) DIVITQSHKFMPTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYS ASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSTPYTFGG GTKLEIKRGGGGSGGGGSGGGGSDIVLTQSPAIMSASPGEKVTMTCRASS SVSSSYLHWYQQKSGASPKLWIYSTSNLASGVPARFSGSGSGTSYSLTIS SVEAEDAATYYCQQYSGYPLTFGAGTKLELKR.

(435) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(436) TABLE-US-00197 (SEQIDNO:243) DVVMTQTPLTLSVTTGQPASISCKSSQSLLNSDGKTFLNWLLQRPGQSPK RLIYLVSKLDSGVPDRFTGSGSGTDFTLKICRVEAEDLGVYYCWQGTHFP YTFGGGTKLEIKRGGGGSGGGGSGGGGSEVKLEESGGGLVKPGGSLKLSC AASGFTFSSYAMSWVRQTPEKRLEWVASISSGGSTYYPDSVKGRFTISRD NARNTLYLQMSSLRSEDTAMYYCARGRDGYSLYFDYWGQGTTLTVSS.

(437) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(438) TABLE-US-00198 (SEQIDNO:244) DVVMTQTPLTLSVTTGQPASISCKSSQSLLNSDGKTFLNWLLQRPGQSPK RLIYLVSKLDSGVPDRFTGSGSGTDFTLKICRVEAEDLGVYYCWQGTHFP YTFGGGTKLEIKRGGGGSGGGGSGGGGSQVKLQESGGGLVKPGGSLKLSC AASGFTFSSYAMSWVRQTPEKRLEWVAGISSGGSFTYYPDTVKGRFTISR DNARNTLYLQMSSLRSEDTAMYSCAREGVYSDYRAWFAYWGQGTLVTVS.

(439) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(440) TABLE-US-00199 (SEQIDNO:245) DVVMTQTPLTLSVTTGQPASISCKSSQSLLNSDGKTFLNWLLQRPGQSPK RLIYLVSKLDSGVPDRFTGSGSGTDFTLKICRVEAEDLGVYYCWQGTHFP YTFGGGTKLEIKRGGGGSGGGGSGGGGSEVKLEQSGPSLVQPSQSLSITC TVSGFSLTNFGVHWVRQSPGKGLEWLGLIWRGGSTDYNAAFMSRLSITKD NSKSQVFFKMNSLQADDTAIYYCAKMGITYYFDYWGQGTTLTVSS.

(441) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(442) TABLE-US-00200 (SEQIDNO:246) DVVMTQTPLTLSVTTGQPASISCKSSQSLLNSDGKTFLNWLLQRPGQSPK RLIYLVSKLDSGVPDRFTGSGSGTDFTLKICRVEAEDLGVYYCWQGTHFP YTFGGGTKLEIKRGGGGSGGGGSGGGGSQVKLQQSGDDLVKPGASVKLSC KASGYTFTSYWINWIKQRPGQGLEWIGHIAPGTGSTYYSEMFKDKATLTV DTPSSSAYIQLSSLSSEDSAVYFCAREGGRYYTLDCWGQGTSVTVSS.

(443) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(444) TABLE-US-00201 (SEQIDNO:247) DVVMTQTPLTLSVTTGQPASISCKSSQSLLNSDGKTFLNWLLQRPGQSPK RLIYLVSKLDSGVPDRFTGSGSGTDFTLKICRVEAEDLGVYYCWQGTHFP YTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLEESGPGLVKPSQTVSLTC TVTGISITTGNYRWSWIRQFPGNKLEWIGYIYYSGTITYNPSLTSRTTIT RDTSKNQFFLEMNSLTAEDTATYYCARWLNNFDVWGTGTTVTVS.

(445) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(446) TABLE-US-00202 (SEQIDNO:248) DVVMTQTPLTLSVTTGQPASISCKSSQSLLNSDGKTFLNWLLQRPGQSPK RLIYLVSKLDSGVPDRFTGSGSGTDFTLKICRVEAEDLGVYYCWQGTHFP YTFGGGTKLEIKRGGGGSGGGGSGGGGSEVMLVESGGGLVKPGGSLKLSC AASGFTFSRYAMSWNRQTPEKRLEWVATISPGGGYIYYSDSVKGRFTISR DNARNTLYLQMSSLRSEDTAMYYCAGDYVDYWGQGTTLTVSS.

(447) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(448) TABLE-US-00203 (SEQIDNO:249) DWVMTQTPLTLSVTTGQPASISCKSSQSLLNSDGKTFLNWLLQRPGQSP KRLIYLVSKLDSGVPDRFTGSGSGTDFTLKICRVEAEDLGVYYCWQGTH FPYTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLQESGPGLVKPSQSLS LTCTVTGYSITSDYAWNWIRQFPGNKLEWMGYISYSGSTTYNPSLKGRI SFTRDTSKNQFFLHLKSVTTEDSATYYCARNWVYAMDYWGQGTSVTVSS.

(449) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(450) TABLE-US-00204 (SEQIDNO:250) DWVMTQTPLTLSVTTGQPASISCKSSQSLLNSDGKTFLNWLLQRPGQSP KRLIYLVSKLDSGVPDRFTGSGSGTDFTLKICRVEAEDLGVYYCWQGTH FPYTFGGGTKLEIKRGGGGSGGGGSGGGGSEVKLQQSGPVLVKPGASVK ISCKASGYTFTDYYYMNWVKQSHGKSLEWIGYIYPNNSGTSYNQKFRGK ATLTVDKSSSTAYMEVRSLTSEDSAVYYCARYYDGFNAGFAYWGQGTLV TVSA.

(451) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(452) TABLE-US-00205 (SEQIDNO:251) DWVMTQTPLTLSVTTGQPASISCKSSQSLLNSDGKTFLNWLLQRPGQSP KRLIYLVSKLDSGVPDRFTGSGSGTDFTLKICRVEAEDLGVYYCWQGTH FPYTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLEESGPGLVAPSQSLS ITCTVSGFSLSRYSVHWVRQPPGKGLEWLGMIWVNGNTDYNSALKSRLN INKDNSKSQVFLKMNSLQTDDTAMYYCATYYGNYDSFTYWGQGTLVTVS A.

(453) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(454) TABLE-US-00206 (SEQIDNO:252) DWMTQTPLTLSVTTGQPASISCKSSQSLLNSDGKTFLNWLLQRPGQSPK RLIYLVSKLDSGVPDRFTGSGSGTDFTLKICRVEAEDLGVYYCWQGTHF PYTFGGGTKLEIKRGGGGSGGGGSGGGGSEVQLQESGAELARPGASVKM SCKASGYTFTSYWMHWVKQRPGQGLEWIGAIYPGNSDTSYNQKFKGKAK LTAVTSASTAYMELSSLTNEDSAVYYCTTSLAYWGQGTLVTVSA.

(455) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(456) TABLE-US-00207 (SEQIDNO:253) DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQS PKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYY SYPRTFGGGTKLEIKRGGGGSGGGGSGGGGSEVKLEESGGGLVKPGGSL KLSCAASGFTFSSYAMSWVRQTPEKRLEWVASISSGGSTYYPDSVKGRF TISRDNARNTLYLQMSSLRSEDTAMYYCARGRDGYSLYFDYWGQGTTLT VSS.

(457) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(458) TABLE-US-00208 (SEQIDNO:254) DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQS PKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYY SYPRTFGGGTKLEIKRGGGGGGGGSGGGGSQVKLQESGGGLVKPGGSLK LSCAASGFTFSSYAMSWRQTPEKRLEWVAGISSGGSFTYYPDTVKGRFT ISRDNARNTLYLQMSSLRSEDTAMYSCAREGVYSDYRAWFAYWGQGTLV T.

(459) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(460) TABLE-US-00209 (SEQIDNO:255) DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQS PKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYY SYPRTFGGGTKLEIKRGGGGSGGGGSGGGGSEVKLEQSGPSLVQPSQSL SITCTVSGFSLTNFGVHWVRQSPGKGLEWLGLIWRGGSTDYNAAFMSRL SITKDNSKSQVFFKMNSLQADDTAIYYCAKMGITYYFDYWGQGTTLTVS S.

(461) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(462) TABLE-US-00210 (SEQIDNO:256) DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQS PKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYY SYPRTFGGGTKLEIKRGGGGSGGGGSGGGGSQVKLQQSGDDLVKPGASV KLSCKASGYTFTSYWINWIKQRPGQGLEWIGHIAPGTGSTYYSEMFKDK ATLTVDTPSSSAYIQLSSLSSEDSAVYFCAREGGRYYTLDCWGQGTSVT VSS.

(463) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(464) TABLE-US-00211 (SEQIDNO:257) DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQS PKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYY SYPRTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLEESGPGLVKPSQTV SLTCTVTGISITTGNYRWSWIRQFPGNKLEWIGYIYYSGTITYNPSLTS RTTITRDTSKNQFFLEMNSLTAEDTATYYCARWLNNFDVWGTGTTVTVS.

(465) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(466) TABLE-US-00212 (SEQIDNO:258) DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQS PKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYY SYPRTFGGGTKLEIKRGGGGSGGGGSGGGGSEVMLVESGGGLVKPGGSL KLSCAASGFTFSRYAMSWNRQTPEKRLEWVATISPGGGYIYYSDSVKGR FTISRDNARNTLYLQMSSLRSEDTAMYYCAGDYVDYWGQGTTLTVSS.

(467) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(468) TABLE-US-00213 (SEQIDNO:259) DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQS PKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYY SYPRTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLQESGPGLVKPSQSL SLTCTVTGYSITSDYAWNWIRQFPGNKLEWMGYISYSGSTTYNPSLKGR ISFTRDTSKNQFFLHLKSVTTEDSATYYCARNWVYAMDYWGQGTSVTVS S.

(469) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(470) TABLE-US-00214 (SEQIDNO:260) DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQS PKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYY SYPRTFGGGTKLEIKRGGGGSGGGGSGGGGSEVKLQQSGPVLVKPGASV KISCKASGYTFTDYYYMNWKQSHGKSLEWIGYIYPNNSGTSYNQKFRGK ATLTVDKSSSTAYMEVRSLTSEDSAVYYCARYYDGFNAGFAYWGQGTLV TVSA.

(471) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(472) TABLE-US-00215 (SEQIDNO:261) DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQS PKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYY SYPRTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLEESGPGLVAPSQSL SITCTVSGFSLSRYSVHWVRQPPGKGLEWLGMIWVNGNTDYNSALKSRL NINKDNSKSQVFLKMNSLQTDDTAMYYCATYYGNYDSFTYWGQGTLVTV SA.

(473) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(474) TABLE-US-00216 (SEQIDNO:262) DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQS PKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYY SYPRTFGGGTKLEIKRGGGGSGGGGSGGGGSEVQLQESGAELARPGASV KMSCKASGYTFTSYWMHWKQRPGQGLEWIGAIYPGNSDTSYNQKFKGKA KLTAVTSASTAYMELSSLTNEDSAVYYCTTSLAYWGQGTLVTVSA.

(475) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(476) TABLE-US-00217 (SEQIDNO:263) DIVLTQSTSSLAVSVGEKVTMSCKSSQSLLFGSNQKNYLAWYQQKLGQS PKLLIFWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYY SYPFTFGSGTKLEIKRGGGGSGGGGSGGGGSEVKLEESGGGLVKPGGSL KLSCAASGFTFSSYAMSWVRQTPEKRLEWVASISSGGSTYYPDSVKGRF TISRDNARNTLYLQMSSLRSEDTAMYYCARGRDGYSLYFDYWGQGTTLT VSS.

(477) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(478) TABLE-US-00218 (SEQIDNO:264) DIVLTQSTSSLAVSVGEKVTMSCKSSQSLLFGSNQKNYLAWYQQKLGQSP KLLIFWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSY PFTFGSGTKLEIKRGGGGSGGGGSGGGGSQVKLQESGGGLVKPGGSLKLS CAASGFTFSSYAMSWVRQTPEKRLEWVAGISSGGSFTYYPDTVKGRFTIS RDNARNTLYLQMSSLRSEDTAMYSCAREGVYSDYRAWFAYWGQGTLVTVS.

(479) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(480) TABLE-US-00219 (SEQIDNO:265) DIVLTQSTSSLAVSVGEKVTMSCKSSQSLLFGSNQKNYLAWYQQKLGQSP KLLIFWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSY PFTFGSGTKLEIKRGGGGSGGGGSGGGGSEVKLEQSGPSLVQPSQSLSIT CTVSGFSLTNFGVHWVRQSPGKGLEWLGLIWRGGSTDYNAAFMSRLSITK DNSKSQVFFKMNSLQADDTAIYYCAKMGITYYFDYWGQGTTLTVSS.

(481) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(482) TABLE-US-00220 (SEQIDNO:266) DIVLTQSTSSLAVSVGEKVTMSCKSSQSLLFGSNQKNYLAWYQQKLGQSP KLLIFWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSY PFTFGSGTKLEIKRGGGGSGGGGSGGGGSQVKLQQSGDDLVKPGASVKLS CKASGYTFTSYWINWIKQRPGQGLEWIGHIAPGTGSTYYSEMFKDKATLT VDTPSSSAYIQLSSLSSEDSAVYFCAREGGRYYTLDCWGQGTSVTVSS.

(483) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(484) TABLE-US-00221 (SEQIDNO:267) DIVLTQSTSSLAVSVGEKVTMSCKSSQSLLFGSNQKNYLAWYQQKLGQSP KLLIFWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSY PFTFGSGTKLEIKRGGGGSGGGGSGGGGSQVQLEESGPGLVKPSQTVSLT CTVTGISITTGNYRWSWIRQFPGNKLEWIGYIYYSGTITYNPSLTSRTTI TRDTSKNQFFLEMNSLTAEDTATYYCARWLNNFDVWGTGTTVTVS.

(485) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(486) TABLE-US-00222 (SEQIDNO:268) DIVLTQSTSSLAVSVGEKVTMSCKSSQSLLFGSNQKNYLAWYQQKLGQSP KLLIFWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSY PFTFGSGTKLEIKRGGGGSGGGGSGGGGSEVMLVESGGGLVKPGGSLKLS CAASGFTFSRYAMSWNRQTPEKRLEWVATISPGGGYIYYSDSVKGRFTIS RDNARNTLYLQMSSLRSEDTAMYYCAGDYVDYWGQGTTLTVSS.

(487) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(488) TABLE-US-00223 (SEQIDNO:269) DIVLTQSTSSLAVSVGEKVTMSCKSSQSLLFGSNQKNYLAWYQQKLGQSP KLLIFWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSY PFTFGSGTKLEIKRGGGGSGGGGSGGGGSQVQLQESGPGLVKPSQSLSLT CTVTGYSITSDYAWNWIRQFPGNKLEWMGYISYSGSTTYNPSLKGRISFT RDTSKNQFFLHLKSVTTEDSATYYCARNWVYAMDYWGQGTSVTVSS.

(489) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(490) TABLE-US-00224 (SEQIDNO:270) DIVLTQSTSSLAVSVGEKVTMSCKSSQSLLFGSNQKNYLAWYQQKLGQSP KLLIFWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSY PFTFGSGTKLEIKRGGGGSGGGGSGGGGSEVKLQQSGPVLVKPGASVKIS CKASGYTFTDYYYMNWVKQSHGKSLEWIGYIYPNNSGTSYNQKFRGKATL TVDKSSSTAYMEVRSLTSEDSAVYYCARYYDGFNAGFAYWGQGTLVTVSA.

(491) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(492) TABLE-US-00225 (SEQIDNO:271) DIVLTQSTSSLAVSVGEKVTMSCKSSQSLLFGSNQKNYLAWYQQKLGQSP KLLIFWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSY PFTFGSGTKLEIKRGGGGSGGGGSGGGGSQVQLEESGPGLVAPSQSLSIT CTVSGFSLSRYSVHWVRQPPGKGLEWLGMIWVNGNTDYNSALKSRLNINK DNSKSQVFLKMNSLQTDDTAMYYCATYYGNYDSFTYWGQGTLVTVSA.

(493) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(494) TABLE-US-00226 (SEQIDNO:272) DIVLTQSTSSLAVSVGEKVTMSCKSSQSLLFGSNQKNYLAWYQQKLGQSP KLLIFWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSY PFTFGSGTKLEIKRGGGGSGGGGSGGGGSEVQLQESGAELARPGASVKMS CKASGYTFTSYWMHWVKQRPGQGLEWIGAIYPGNSDTSYNQKFKGKAKLT AVTSASTAYMELSSLTNEDSAVYYCTTSLAYWGQGTLVTVSA.

(495) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(496) TABLE-US-00227 (SEQIDNO:273) DIVLTQTNLTLSITIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPK RLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVGAEDLGIYYCWQGTHFP HTFGGGTKLEIKRGGGGSGGGGSGGGGSEVKLEESGGGLVKPGGSLKLSC AASGFTFSSYAMSWVRQTPEKRLEWVASISSGGSTYYPDSVKGRFTISRD NARNTLYLQMSSLRSEDTAMYYCARGRDGYSLYFDYWGQGTTLTVSS.

(497) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(498) TABLE-US-00228 (SEQIDNO:274) DIVLTQTNLTLSITIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPK RLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVGAEDLGIYYCWQGTHFP HTFGGGTKLEIKRGGGGSGGGGSGGGGSQVKLQESGGGLVKPGGSLKLSC AASGFTFSSYAMSWVRQTPEKRLEWVAGISSGGSFTYYPDTVKGRFTISR DNARNTLYLQMSSLRSEDTAMYSCAREGVYSDYRAWFAYWGQGTLVTVS.

(499) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(500) TABLE-US-00229 (SEQIDNO:275) DIVLTQTNLTLSITIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPK RLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVGAEDLGIYYCWQGTHFP HTFGGGTKLEIKRGGGGSGGGGSGGGGSEVKLEQSGPSLVQPSQSLSITC TVSGFSLTNFGVHWVRQSPGKGLEWLGLIWRGGSTDYNAAFMSRLSITKD NSKSQVFFKMNSLQADDTAIYYCAKMGITYYFDYWGQGTTLTVSS.

(501) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(502) TABLE-US-00230 (SEQIDNO:276) DIVLTQTNLTLSITIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPK RLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVGAEDLGIYYCWQGTHFP HTFGGGTKLEIKRGGGGSGGGGSGGGGSQVKLQQSGDDLVKPGASVKLSC KASGYTFTSYWINWIKQRPGQGLEWIGHIAPGTGSTYYSEMFKDKATLTV DTPSSSAYIQLSSLSSEDSAVYFCAREGGRYYTLDCWGQGTSVTVSS.

(503) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(504) TABLE-US-00231 (SEQIDNO:277) DIVLTQTNLTLSITIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPK RLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVGAEDLGIYYCWQGTHFP HTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLEESGPGLVKPSQTVSLTC TVTGISITTGNYRWSWIRQFPGNKLEWIGYIYYSGTITYNPSLTSRTTIT RDTSKNQFFLEMNSLTAEDTATYYCARWLNNFDVWGTGTTVTVS.

(505) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(506) TABLE-US-00232 (SEQIDNO:278) DIVLTQTNLTLSITIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPK RLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVGAEDLGIYYCWQGTHFP HTFGGGTKLEIKRGGGGSGGGGSGGGGSEVMLVESGGGLVKPGGSLKLSC AASGFTFSRYAMSWNRQTPEKRLEWVATISPGGGYIYYSDSVKGRFTISR DNARNTLYLQMSSLRSEDTAMYYCAGDYVDYWGQGTTLTVSS.

(507) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(508) TABLE-US-00233 (SEQIDNO:279) DIVLTQTNLTLSITIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPK RLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVGAEDLGIYYCWQGTHFP HTFGGGTKLEIKRGGGGSGGGGGGGGSQVQLQESGPGLVKPSQSLSLTCT VTGYSITSDYAWNWIRQFPGNKLEWMGYISYSGSTTYNPSLKGRISFTRD TSKNQFFLHLKSVTTEDSATYYCARNWVYAMDYWGQGTSVTVSS.

(509) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(510) TABLE-US-00234 (SEQIDNO:280) DIVLTQTNLTLSITIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPK RLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVGAEDLGIYYCWQGTHFP HTFGGGTKLEIKRGGGGSGGGGSGGGGSEVKLQQSGPVLVKPGASVKISC KASGYTFTDYYYMNWVKQSHGKSLEWIGYIYPNNSGTSYNQKFRGKATLT VDKSSSTAYMEVRSLTSEDSAVYYCARYYDGFNAGFAYWGQGTLVTVSA.

(511) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(512) TABLE-US-00235 (SEQIDNO:281) DIVLTQTNLTLSITIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPK RLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVGAEDLGIYYCWQGTHFP HTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLEESGPGLVAPSQSLSITC TVSGFSLSRYSVHWVRQPPGKGLEWLGMIWVNGNTDYNSALKSRLNINKD NSKSQVFLKMNSLQTDDTAMYYCATYYGNYDSFTYWGQGTLVTVSA.

(513) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(514) TABLE-US-00236 (SEQIDNO:282) DIVLTQTNLTLSITIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPK RLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVGAEDLGIYYCWQGTHFP HTFGGGTKLEIKRGGGGSGGGGSGGGGSEVQLQESGAELARPGASVKMSC KASGYTFTSYWMHWVKQRPGQGLEWIGAIYPGNSDTSYNQKFKGKAKLTA VTSASTAYMELSSLTNEDSAVYYCTTSLAYWGQGTLVTVSA.

(515) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(516) TABLE-US-00237 (SEQIDNO:283) DIVLTQSPAIMSASPGEKVTMTCRASSSVSSSYLHWYQQKSGASPKLWIY STSNLASGVPARFSGSGSGTSYSLTISSVEAEDAATYYCQQYSGYPLTFG AGTKLELKRGGGGSGGGGSGGGGSEVKLEESGGGLVKPGGSLKLSCAASG FTFSSYAMSWVRQTPEKRLEWVASISSGGSTYYPDSVKGRFTISRDNARN TLYLQMSSLRSEDTAMYYCARGRDGYSLYFDYWGQGTTLTVSS.

(517) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(518) TABLE-US-00238 (SEQIDNO:284) DIVLTQSPAIMSASPGEKVTMTCRASSSVSSSYLHWYQQKSGASPKLWIY STSNLASGVPARFSGSGSGTSYSLTISSVEAEDAATYYCQQYSGYPLTFG AGTKLELKRGGGGSGGGGSGGGGSQVKLQESGGGLVKPGGSLKLSCAASG FTFSSYAMSWVRQTPEKRLEWVAGISSGGSFTYYPDTVKGRFTISRDNAR NTLYLQMSSLRSEDTAMYSCAREGVYSDYRAWFAYWGQGTLVTVS.

(519) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(520) TABLE-US-00239 (SEQIDNO:285) DIVLTQSPAIMSASPGEKVTMTCRASSSVSSSYLHWYQQKSGASPKLWIY STSNLASGVPARFSGSGSGTSYSLTISSVEAEDAATYYCQQYSGYPLTFG AGTKLELKRGGGGSGGGGSGGGGSEVKLEQSGPSLVQPSQSLSITCTVSG FSLTNFGVHWVRQSPGKGLEWLGLIWRGGSTDYNAAFMSRLSITKDNSKS QVFFKMNSLQADDTAIYYCAKMGITYYFDYWGQGTTLTVSS.

(521) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(522) TABLE-US-00240 (SEQIDNO:286) DIVLTQSPAIMSASPGEKVTMTCRASSSVSSSYLHWYQQKSGASPKLWIY STSNLASGVPARFSGSGSGTSYSLTISSVEAEDAATYYCQQYSGYPLTFG AGTKLELKRGGGGSGGGGSGGGGSQVKLQQSGDDLVKPGASVKLSCKASG YTFTSYWINWIKQRPGQGLEWIGHIAPGTGSTYYSEMFKDKATLTVDTPS SSAYIQLSSLSSEDSAVYFCAREGGRYYTLDCWGQGTSVTVSS.

(523) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(524) TABLE-US-00241 (SEQIDNO:287) DIVLTQSPAIMSASPGEKVTMTCRASSSVSSSYLHWYQQKSGASPKLWIY STSNLASGVPARFSGSGSGTSYSLTISSVEAEDAATYYCQQYSGYPLTFG AGTKLELKRGGGGSGGGGSGGGGSQVQLEESGPGLVKPSQTVSLTCTVTG ISITTGNYRWSWIRQFPGNKLEWIGYIYYSGTITYNPSLTSRTTITRDTS KNQFFLEMNSLTAEDTATYYCARWLNNFDVWGTGTTVTVS.

(525) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(526) TABLE-US-00242 (SEQIDNO:288) DIVLTQSPAIMSASPGEKVTMTCRASSSVSSSYLHWYQQKSGASPKLWIY STSNLASGVPARFSGSGSGTSYSLTISSVEAEDAATYYCQQYSGYPLTFG AGTKLELKRGGGGSGGGGSGGGGSEVMLVESGGGLVKPGGSLKLSCAASG FTFSRYAMSWNRQTPEKRLEWVATISPGGGYIYYSDSVKGRFTISRDNAR NTLYLQMSSLRSEDTAMYYCAGDYVDYWGQGTTLTVSS.

(527) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(528) TABLE-US-00243 (SEQIDNO:289) DIVLTQSPAIMSASPGEKVTMTCRASSSVSSSYLHWYQQKSGASPKLWIY STSNLASGVPARFSGSGSGTSYSLTISSVEAEDAATYYCQQYSGYPLTFG AGTKLELKRGGGGSGGGGSGGGGSQVQLQESGPGLVKPSQSLSLTCTVTG YSITSDYAWNWIRQFPGNKLEWMGYISYSGSTTYNPSLKGRISFTRDTSK NQFFLHLKSVTTEDSATYYCARNWVYAMDYWGQGTSVTVSS.

(529) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(530) TABLE-US-00244 (SEQIDNO:290) DIVLTQSPAIMSASPGEKVTMTCRASSSVSSSYLHWYQQKSGASPKLWIY STSNLASGVPARFSGSGSGTSYSLTISSVEAEDAATYYCQQYSGYPLTFG AGTKLELKRGGGGSGGGGSGGGGSEVKLQQSGPVLVKPGASVKISCKASG YTFTDYYYMNWVKQSHGKSLEWIGYIYPNNSGTSYNQKFRGKATLTVDKS SSTAYMEVRSLTSEDSAVYYCARYYDGFNAGFAYWGQGTLVTVSA.

(531) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(532) TABLE-US-00245 (SEQIDNO:291) DIVLTQSPAIMSASPGEKVTMTCRASSSVSSSYLHWYQQKSGASPKLWIY STSNLASGVPARFSGSGSGTSYSLTISSVEAEDAATYYCQQYSGYPLTFG AGTKLELKRGGGGSGGGGSGGGGSQVQLEESGPGLVAPSQSLSITCTVSG FSLSRYSVHWVRQPPGKGLEWLGMIWVNGNTDYNSALKSRLNINKDNSKS QVFLKMNSLQTDDTAMYYCATYYGNYDSFTYWGQGTLVTVSA.

(533) In some embodiments, the anti-CD19 scFv comprises an amino acid sequence:

(534) TABLE-US-00246 (SEQIDNO:292) DIVLTQSPAIMSASPGEKVTMTCRASSSVSSSYLHWYQQKSGASPKLWIY STSNLASGVPARFSGSGSGTSYSLTISSVEAEDAATYYCQQYSGYPLTFG AGTKLELKRGGGGSGGGGSGGGGSEVQLQESGAELARPGASVKMSCKASG YTFTSYWMHWVKQRPGQGLEWIGAIYPGNSDTSYNQKFKGKAKLTAVTSA STAYMELSSLTNEDSAVYYCTTSLAYWGQGTLVTVSA.

(535) In some embodiments, the anti-CD19 scFv binds to CD19 and comprises an amino acid sequence that is 95%, 96%, 97%, 98% or 99% identical to any of the specific anti-CD19 scFv amino acid sequences disclosed herein.

(536) In some embodiments, the anti-CD19 scFv comprises an antigen binding domain of clone FMC63, described in Hohmann, A. W. Mol. Immunol. 34(16-17):1157-1165, which is incorporated by reference for the teaching of this antibody.

(537) In some embodiments, the anti-CD19 scFv comprises an antigen binding domain of clone SJ25C1.

(538) In some embodiments, the anti-CD19 scFv comprises the FVS191 or FVS192 scFv describe in Bejcek B E, et al. Cancer Res. 1995 55(11):2346-51, which is incorporated by reference for the teaching of this antibody.

(539) Anti-CD20 scFv

(540) In some embodiments, the anti-CD20 scFv is derived from hybridoma 1C3, 3C5, 8B7, 1A1, 18H11, 1B3, or combinations thereof. In some embodiments, the anti-CD20 scFv can comprise a variable heavy (V.sub.H) domain having CDR1, CDR2 and CDR3 sequences and a variable light (V.sub.L) domain having CDR1, CDR2 and CDR3 sequences.

(541) In some embodiments, the anti-CD20 scFv can comprise a variable heavy (V.sub.H) domain having CDR1, CDR2 and CDR3 sequences and a variable light (V.sub.L) domain having CDR1, CDR2 and CDR3 sequences.

(542) For example, in some embodiments, the CDR1 sequence of the V.sub.H domain comprises the amino acid sequence GYTFTDYE (SEQ ID NO:293), GFDFSRYW (SEQ ID NO:294), GFNIKDTY (SEQ ID NO:295), GYTFTSYG (SEQ ID NO:296), SFAMS (SEQ ID NO:297), or NYGMS (SEQ ID NO:298); CDR2 sequence of the V.sub.H domain comprises the amino acid sequence IDPETGDT (SEQ ID NO:299), INPDSSTI (SEQ ID NO:300), IDPANGNV (SEQ ID NO:301), IYPRSGNT (SEQ ID NO:302), TISSGGAYTFYKDSVKGRFT (SEQ ID NO:303), or SISSGDGRTYYSDNIRGRFT (SEQ ID NO:304); CDR3 sequence of the V.sub.H domain comprises the amino acid sequence TRANSFGY (SEQ ID NO:305), ARPGYYYAMDY (SEQ ID NO:306), DLSHYTMDY (SEQ ID NO:307), or ARSRV (SEQ ID NO:308), HSGYDGYYLYAMDY (SEQ ID NO:309), or RGDAMDY (SEQ ID NO:310); CDR1 sequence of the V.sub.L comprises the amino acid sequence TGAVTTSNY (SEQ ID NO:311), KSVSTSGYSY (SEQ ID NO:312), SSVSY (SEQ ID NO:313), RASQDISNYLN (SEQ ID NO:314), or SASSSVSYMH (SEQ ID NO:315); CDR2 sequence of the V.sub.L domain comprises the amino acid sequence GTN (SEQ ID to NO:316), LVS (SEQ ID NO:317), LTS (SEQ ID NO:318), YTSRLHS (SEQ ID NO:319), or EISKLAS (SEQ ID NO:320); and CDR3 sequence of the V.sub.L domain comprises the amino acid sequence ALWYNNHLV (SEQ ID NO:321), QHIRELT (SEQ ID NO:322), QQWSSNPFT (SEQ ID NO:323), QQGNTLPPT (SEQ ID NO:324), or QQWNYPLIT (SEQ ID NO:325).

(543) Therefore, in some embodiments, the anti-CD20 scFv V.sub.H domain comprises the amino acid sequence: EVQLQESGAELVKPGASVKLSCTASGFNIKDTYMHWVKQRPEQGLEWIGRIDPAN GNVEYDPKFQGKATLTADTSSNTAYLQLSSLTSEDTAVYYCDLSHYTMDYWGQGT SVTVSS (SEQ ID NO:326, 8B7).

(544) Therefore, in some embodiments, the anti-CD20 scFv V.sub.H domain is encoded by the nucleic acid sequence:

(545) TABLE-US-00247 (SEQIDNO:337,8B7) GAGGTACAGCTGCAGGAGTCTGGGGCAGAACTTGTGAAGCCAGGGGCCTC TGTCAAGTTGTCCTGCACAGCTTCTGGCTTCAACATTAAAGACACCTATA TGCACTGGGTGAAACAGAGGCCTGAACAGGGCCTGGAGTGGATTGGAAGG ATTGATCCTGCGAATGGTAATGTTGAATATGACCCGAAGTTCCAGGGCAA GGCCACTCTAACAGCAGACACATCCTCCAATACAGCCTACCTGCAACTCA GCAGCCTGACATCTGAGGACACTGCCGTCTATTACTGTGACCTATCCCAC TATACTATGGACTACTGGGGTCAGGGAACCTCAGTCACCGTCTCCTCA.

(546) Therefore, in some embodiments, the anti-CD20 scFv V.sub.H domain comprises the amino acid sequence:

(547) TABLE-US-00248 (SEQIDNO:327,1A1) QVQLQQSGAELVRPGASVTLSCKASGYTFTDYEMHWVKQTPVHGLEWIGA IDPETGDTAYNQKFKGKATLTADKSSSTAYMELSSLTSEDSAVYYCTRAN SFGYWGQGTTLTVSS.

(548) Therefore, in some embodiments, the anti-CD20 scFv V.sub.H domain is encoded

(549) TABLE-US-00249 (SEQIDNO:338,1A1) CAGGTTCAACTGCAGCAGTCTGGAGCTGAGCTGGTGAGGCCTGGGGCTTC AGTGACGCTGTCCTGCAAGGCTTCGGGCTACACATTTACTGACTATGAAA TGCACTGGGTGAAGCAGACACCTGTGCATGGCCTGGAATGGATTGGAGCT ATTGATCCTGAAACTGGTGATACTGCCTACAATCAGAAGTTCAAGGGCAA GGCCACACTGACTGCAGACAAATCCTCCAGCACAGCCTACATGGAGCTCA GCAGCCTGACATCTGAGGACTCTGCCGTCTATTACTGTACAAGAGCTAAC TCTTTTGGCTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCA.

(550) Therefore, in some embodiments, the anti-CD20 scFv V.sub.H domain comprises the amino acid sequence:

(551) TABLE-US-00250 (SEQIDNO:328,18H11) VQLQQSGAELARPGASVKLSCKASGYTFTSYGISWVKQRTGQGLEWIGEI YPRSGNTYYNEKFKGKATLTADKSSSTAYMELRSLTSEDSAVYFCARSRV WGTGTTVTVSS.

(552) Therefore, in some embodiments, the anti-CD20 scFv V.sub.H domain is encoded by the nucleic acid sequence:

(553) TABLE-US-00251 (SEQIDNO:339,18H11) GTTCAGCTGCAGCAGTCTGGAGCTGAGCTGGCGAGGCCTGGGGCTTCAGT GAAGCTGTCCTGCAAGGCTTCTGGCTACACCTTCACAAGCTATGGTATAA GCTGGGTGAAGCAGAGAACTGGACAGGGCCTTGAGTGGATTGGAGAGATT TATCCTAGAAGTGGTAATACTTACTACAATGAGAAGTTCAAGGGCAAGGC CACACTGACTGCAGACAAATCCTCCAGCACAGCGTACATGGAGCTCCGCA GCCTGACATCTGAAGACTCTGCGGTCTATTTCTGTGCAAGATCCCGAGTC TGGGGCACAGGGACCACGGTCACCGTCTCCTCA.

(554) Therefore, in some embodiments, the anti-CD20 scFv V.sub.H domain comprises the amino acid sequence:

(555) TABLE-US-00252 (SEQIDNO:329,1B3) DVKLQESGGGLVKPGGSLKLSCAVSGFTFSSFAMSWVRQTPEKRLEWVAT ISSGGAYTFYKDSVKGRFTISRDNAKNTLYLQMSSLRSEDSAMYYCARHS GYDGYYLYAMDYWGQGTSVTVSS.

(556) Therefore, in some embodiments, the anti-CD20 scFv V.sub.H domain is encoded by the nucleic acid sequence:

(557) TABLE-US-00253 (SEQIDNO:340,1B3) GATGTGAAGCTTCAGGAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGGGTC CCTGAAACTCTCCTGTGCAGTCTCTGGATTCACTTTCAGTTCCTTTGCCA TGTCTTGGGTTCGCCAGACTCCGGAGAAGAGGCTGGAGTGGGTCGCAACC ATTAGTAGTGGTGGAGCTTACACCTTCTATAAAGACAGTGTGAAGGGGCG ATTCACCATCTCCAGAGACAATGCCAAGAATACCCTGTACCTGCAAATGA GCAGTCTGAGGTCTGAGGACTCGGCCATGTATTACTGTGCAAGACATAGC GGCTATGATGGTTACTACCTCTATGCTATGGACTACTGGGGTCAAGGAAC CTCAGTCACCGTCTCCTCA.

(558) Therefore, in some embodiments, the anti-CD20 scFv V.sub.H domain comprises the amino acid sequence:

(559) TABLE-US-00254 (SEQIDNO:330,1C3) EVKLVESGGDLVKPGASLKLSCAASGFTFSNYGMSWIRQTSDKRLEWVAS ISSGDGRTYYSDNIRGRFTISSENAKNTLYLQMSSLKSEDTALYYCTRGR GLRGDAMDYWGQGTSVTVSS.

(560) Therefore, in some embodiments, the anti-CD20 scFv V.sub.H domain is encoded by the nucleic acid sequence:

(561) TABLE-US-00255 (SEQIDNO:341,1C3) GAAGTGAAGCTGGTGGAGTCTGGGGGAGACTTAGTGAAGCCTGGAGCGTC TCTGAAACTCTCCTGTGCAGCCTCTGGGTTCACTTTCAGTAACTATGGCA TGTCTTGGATTCGCCAGACTTCAGACAAGAGGCTGGAGTGGGTCGCATCC ATTAGTAGTGGTGATGGTAGAACCTACTATTCAGACAATATAAGGGGCCG ATTCACCATCTCCAGCGAGAATGCCAAGAACACCCTGTACCTGCAAATGA GCAGTCTGAAGTCTGAGGACACGGCCTTGTATTACTGTACAAGAGGCCGG GGATTACGGGGGGATGCTATGGACTACTGGGGTCAAGGAACCTCAGTCAC CGTCTCCTCA.

(562) Therefore, in some embodiments, the anti-CD20 scFv V.sub.H domain comprises the amino acid sequence:

(563) TABLE-US-00256 (SEQIDNO:331,3C5) EVKLLESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGE INPDSSTINYTPSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCARPG YYYAMDYWGQGTSVTVSS.

(564) Therefore, in some embodiments, the anti-CD20 scFv V.sub.H domain is encoded by the nucleic acid sequence:

(565) TABLE-US-00257 (SEQIDNO:342,3C5) GAGGTGAAGCTTCTCGAGTCTGGAGGTGGCCTGGTGCAGCCTGGAGGATC CCTGAAACTCTCCTGTGCAGCCTCAGGATTCGATTTTAGTAGATACTGGA TGAGTTGGGTCCGGCAGGCTCCAGGGAAAGGGCTAGAATGGATTGGAGAA ATTAATCCAGATAGCAGTACGATAAACTATACGCCATCTCTAAAGGATAA ATTCATCATCTCCAGAGACAACGCCAAAAATACGCTGTACCTGCAAATGA GCAAAGTGAGATCTGAGGACACAGCCCTTTATTACTGTGCAAGACCGGGT TACTACTATGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTC CTCA.

(566) In some embodiments, the anti-CD20 scFv V.sub.L domain comprises the amino acid sequence:

(567) TABLE-US-00258 (SEQIDNO:332,8B7&1A1) QAIVTQESALTTSPGETVTLTCRSSTGAVTTSNYATWVQEKPDHLFTGLM GGTNIRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYNNHLVF GGGTKLTV.

(568) Therefore, in some embodiments, the anti-CD20 scFv V.sub.L domain is encoded by the nucleic acid sequence:

(569) TABLE-US-00259 (SEQIDNO:343,8B7&1A1) CAGGCTATTGTGACTCAGGAATCTGCACTCACCACATCACCTGGTGAAAC AGTCACACTCACTTGTCGCTCAAGCACTGGGGCTGTTACAACTAGTAATT ATGCCACCTGGGTCCAAGAAAAACCAGATCATTTATTCACTGGTCTGATG GGTGGCACCAACATCCGAGCTCCAGGTGTTCCTGCCAGATTCTCAGGCTC CCTGATTGGAGACAAGGCTGCCCTCACCATCACAGGGGCACAGACTGAGG ATGAGGCAATATATTTCTGTGCTCTATGGTACAACAACCATTTGGTGTTC GGTGGAGGAACCAAACTGACTGTC.

(570) In some embodiments, the anti-CD20 scFv V.sub.L domain comprises the amino acid sequence:

(571) TABLE-US-00260 (SEQIDNO:333,18H11) QIVLTQSPALMSASPGEKVTMTCSASSSVSYMYWYQQKPRSSPKPWIYLT SNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPFTFGSG TKLEIKR.

(572) Therefore, in some embodiments, the anti-CD20 scFv V.sub.L domain is encoded by the nucleic acid sequence:

(573) TABLE-US-00261 (SEQIDNO:344,18H11) CAAATTGTTCTCACCCAGTCTCCAGCACTCATGTCTGCATCTCCAGGGGA GAAGGTCACCATGACCTGCAGTGCCAGCTCAAGTGTAAGTTACATGTACT GGTACCAGCAGAAGCCAAGATCCTCCCCCAAACCCTGGATTTATCTCACA TCCAACCTGGCTTCTGGAGTCCCTGCTCGCTTCAGTGGCAGTGGGTCTGG GACCTCTTACTCTCTCACAATCAGCAGCATGGAGGCTGAAGATGCTGCCA CTTATTACTGCCAGCAGTGGAGTAGTAACCCATTCACGTTCGGCTCGGGG ACAAAGTTGGAAATAAAACGG.

(574) Therefore, in some embodiments, the anti-CD20 scFv V.sub.L domain comprises the amino acid sequence:

(575) TABLE-US-00262 (SEQIDNO:334,1B3) DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYY TSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPPTFGG GTKLEIK.

(576) Therefore, in some embodiments, the anti-CD20 scFv V.sub.L domain is encoded by the nucleic acid sequence:

(577) TABLE-US-00263 (SEQIDNO:345,1B3) GATATCCAGATGACACAGACTACATCCTCCCTGTCTGCCTCTCTGGGAGA CAGAGTCACCATCAGTTGCAGGGCAAGTCAGGACATTAGCAATTATTTAA ACTGGTATCAGCAGAAACCAGATGGAACTGTTAAACTCCTGATCTACTAC ACATCAAGATTACACTCAGGAGTCCCATCAAGGTTCAGTGGCAGTGGGTC TGGAACAGATTATTCTCTCACCATTAGCAACCTGGAGCAAGAAGATATTG CCACTTACTTTTGCCAACAGGGTAATACGCTTCCTCCGACGTTCGGTGGA GGCACCAAGCTGGAAATCAAA.

(578) Therefore, in some embodiments, the anti-CD20 scFv V.sub.L domain comprises the amino acid sequence:

(579) TABLE-US-00264 (SEQIDNO:335,1C3) EIVLTQSPAITAASLGQKVTITCSASSSVSYMHWYQQKSGTSPKPWIYEI SKLASGVPARFSGSGSGTSYSLTISSMEAEDAAIYYCQQWNYPLITFGGG TKLEI.

(580) Therefore, in some embodiments, the anti-CD20 scFv V.sub.L domain is encoded by the nucleic acid sequence:

(581) TABLE-US-00265 (SEQIDNO:346,1C3) GAAATTGTGCTCACTCAGTCTCCAGCCATCACAGCTGCATCTCTGGGGCA AAAGGTCACCATCACCTGCAGTGCCAGCTCAAGTGTAAGTTACATGCACT GGTACCAGCAGAAGTCAGGCACCTCCCCCAAACCATGGATTTATGAAATA TCCAAACTGGCTTCTGGAGTCCCAGCTCGCTTCAGTGGCAGTGGGTCTGG GACCTCTTACTCTCTCACAATCAGCAGCATGGAGGCTGAAGATGCTGCCA TTTATTACTGCCAGCAGTGGAATTATCCTCTTATCACGTTCGGAGGGGGG ACCAAGCTGGAAATA.

(582) Therefore, in some embodiments, the anti-CD20 scFv V.sub.L domain comprises the amino acid sequence:

(583) TABLE-US-00266 (SEQIDNO:336,3C5) DIVLTQSPASLAVSLGQRATISYRASKSVSTSGYSYMHWNQQKPGQPPRL LIYLVSNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHIRELTR SEGGPSWK.

(584) Therefore, in some embodiments, the anti-CD20 scFv V.sub.L domain is encoded by the nucleic acid sequence:

(585) TABLE-US-00267 (SEQIDNO:347,3C5) GACATTGTGCTGACACAGTCTCCTGCTTCCTTAGCTGTATCTCTGGGGCA GAGGGCCACCATCTCATACAGGGCCAGCAAAAGTGTCAGTACATCTGGCT ATAGTTATATGCACTGGAACCAACAGAAACCAGGACAGCCACCCAGACTC CTCATCTATCTTGTATCCAACCTAGAATCTGGGGTCCCTGCCAGGTTCAG TGGCAGTGGGTCTGGGACAGACTTCACCCTCAACATCCATCCTGTGGAGG AGGAGGATGCTGCAACCTATTACTGTCAGCACATTAGGGAGCTTACACGT TCGGAGGGGGGACCAAGCTGGAAATAA.

(586) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(587) TABLE-US-00268 (SEQIDNO:348) EVQLQESGAELVKPGASVKLSCTASGFNIKDTYMHWVKQRPEQGLEWIGR IDPANGNVEYDPKFQGKATLTADTSSNTAYLQLSSLTSEDTAVYYCDLSH YTMDYWGQGTSVTVSSGGGGSGGGGSGGGGSQAIVTQESALTTSPGETVT LTCRSSTGAVTTSNYATWVQEKPDHLFTGLMGGTNIRAPGVPARFSGSLI GDKAALTITGAQTEDEAIYFCALWYNNHLVFGGGTKLTV.

(588) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(589) TABLE-US-00269 (SEQIDNO:349) EVQLQESGAELVKPGASVKLSCTASGFNIKDTYMHWVKQRPEQGLEWIGR IDPANGNVEYDPKFQGKATLTADTSSNTAYLQLSSLTSEDTAVYYCDLSH YTMDYWGQGTSVTVSSGGGGSGGGGSGGGGSQIVLTQSPALMSASPGEKV TMTCSASSSVSYMYWYQQKPRSSPKPWIYLTSNLASGVPARFSGSGSGTS YSLTISSMEAEDAATYYCQQWSSNPFTFGSGTKLEIKR.

(590) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(591) TABLE-US-00270 (SEQIDNO:350) EVQLQESGAELVKPGASVKLSCTASGFNIKDTYMHWVKQRPEQGLEWIGR IDPANGNVEYDPKFQGKATLTADTSSNTAYLQLSSLTSEDTAVYYCDLSH YTMDYWGQGTSVTVSSGGGGSGGGGSGGGGSDIQMTQTTSSLSASLGDRV TISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGT DYSLTISNLEQEDIATYFCQQGNTLPPTFGGGTKLEIK.

(592) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(593) TABLE-US-00271 (SEQIDNO:351) EVQLQESGAELVKPGASVKLSCTASGFNIKDTYMHWVKQRPEQGLEWIGR IDPANGNVEYDPKFQGKATLTADTSSNTAYLQLSSLTSEDTAVYYCDLSH YTMDYWGQGTSVTVSSGGGGSGGGGSGGGGSEIVLTQSPAITAASLGQKV TITCSASSSVSYMHWYQQKSGTSPKPWIYEISKLASGVPARFSGSGSGTS YSLTISSMEAEDAAIYYCQQWNYPLITFGGGTKLEI.

(594) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(595) TABLE-US-00272 (SEQIDNO:352) EVQLQESGAELVKPGASVKLSCTASGFNIKDTYMHWVKQRPEQGLEWIGR IDPANGNVEYDPKFQGKATLTADTSSNTAYLQLSSLTSEDTAVYYCDLSH YTMDYWGQGTSVTVSSGGGGSGGGGSGGGGSDIVLTQSPASLAVSLGQRA TISYRASKSVSTSGYSYMHWNQQKPGQPPRLLIYLVSNLESGVPARFSGS GSGTDFTLNIHPVEEEDAATYYCQHIRELTRSEGGPSWK.

(596) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(597) TABLE-US-00273 (SEQIDNO:353) QVQLQQSGAELVRPGASVTLSCKASGYTFTDYEMHWVKQTPVHGLEWIGA IDPETGDTAYNQKFKGKATLTADKSSSTAYMELSSLTSEDSAVYYCTRAN SFGYWGQGTTLTVSSGGGGSGGGGSGGGGSQAIVTQESALTTSPGETVTL TCRSSTGAVTTSNYATWVQEKPDHLFTGLMGGTNIRAPGVPARFSGSLIG DKAALTITGAQTEDEAIYFCALWYNNHLVFGGGTKLTV.

(598) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(599) TABLE-US-00274 (SEQIDNO:354) QVQLQQSGAELVRPGASVTLSCKASGYTFTDYEMHWVKQTPVHGLEWIGA IDPETGDTAYNQKFKGKATLTADKSSSTAYMELSSLTSEDSAVYYCTRAN SFGYWGQGTTLTVSSGGGGSGGGGSGGGGSQIVLTQSPALMSASPGEKVT MTCSASSSVSYMYWYQQKPRSSPKPWIYLTSNLASGVPARFSGSGSGTSY SLTISSMEAEDAATYYCQQWSSNPFTFGSGTKLEIKR.

(600) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(601) TABLE-US-00275 (SEQIDNO:355) QVQLQQSGAELVRPGASVTLSCKASGYTFTDYEMHWVKQTPVHGLEWIGA IDPETGDTAYNQKFKGKATLTADKSSSTAYMELSSLTSEDSAVYYCTRAN SFGYWGQGTTLTVSSGGGGSGGGGSGGGGSDIQMTQTTSSLSASLGDRVT ISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTD YSLTISNLEQEDIATYFCQQGNTLPPTFGGGTKLEIK.

(602) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(603) TABLE-US-00276 (SEQIDNO:356) QVQLQQSGAELVRPGASVTLSCKASGYTFTDYEMHWVKQTPVHGLEWIGA IDPETGDTAYNQKFKGKATLTADKSSSTAYMELSSLTSEDSAVYYCTRAN SFGYWGQGTTLTVSSGGGGSGGGGSGGGGSEIVLTQSPAITAASLGQKVT ITCSASSSVSYMHWYQQKSGTSPKPWIYEISKLASGVPARFSGSGSGTSY SLTISSMEAEDAAIYYCQQWNYPLITFGGGTKLEI.

(604) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(605) TABLE-US-00277 (SEQIDNO:357) QVQLQQSGAELVRPGASVTLSCKASGYTFTDYEMHWVKQTPVHGLEWIGA IDPETGDTAYNQKFKGKATLTADKSSSTAYMELSSLTSEDSAVYYCTRAN SFGYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVLTQSPASLAVSLGQRAT ISYRASKSVSTSGYSYMHWNQQKPGQPPRLLIYLVSNLESGVPARFSGSG SGTDFTLNIHPVEEEDAATYYCQHIRELTRSEGGPSWK.

(606) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(607) TABLE-US-00278 (SEQIDNO:358) VQLQQSGAELARPGASVKLSCKASGYTFTSYGISWVKQRTGQGLEWIGE IYPRSGNTYYNEKFKGKATLTADKSSSTAYMELRSLTSEDSAVYFCARS RVWGTGTTVTVSSGGGGSGGGGSGGGGSQAIVTQESALTTSPGETVTLT CRSSTGAVTTSNYATWVQEKPDHLFTGLMGGTNIRAPGVPARFSGSLIG DKAALTITGAQTEDEAIYFCALWYNNHLVFGGGTKLTV.

(608) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(609) TABLE-US-00279 (SEQIDNO:359) VQLQQSGAELARPGASVKLSCKASGYTFTSYGISWVKQRTGQGLEWIGE IYPRSGNTYYNEKFKGKATLTADKSSSTAYMELRSLTSEDSAVYFCARS RVWGTGTTVTVSSGGGGSGGGGSGGGGSQIVLTQSPALMSASPGEKVTM TCSASSSVSYMYWYQQKPRSSPKPWIYLTSNLASGVPARFSGSGSGTSY SLTISSMEAEDAATYYCQQWSSNPFTFGSGTKLEIKR.

(610) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(611) TABLE-US-00280 (SEQIDNO:360) VQLQQSGAELARPGASVKLSCKASGYTFTSYGISWVKQRTGQGLEWIGE IYPRSGNTYYNEKFKGKATLTADKSSSTAYMELRSLTSEDSAVYFCARS RVWGTGTTVTVSSGGGGSGGGGSGGGGSDIQMTQTTSSLSASLGDRVTI SCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTD YSLTISNLEQEDIATYFCQQGNTLPPTFGGGTKLEIK.

(612) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(613) TABLE-US-00281 (SEQIDNO:361) VQLQQSGAELARPGASVKLSCKASGYTFTSYGISWVKQRTGQGLEWIGE IYPRSGNTYYNEKFKGKATLTADKSSSTAYMELRSLTSEDSAVYFCARS RVWGTGTTVTVSSGGGGSGGGGSGGGGSEIVLTQSPAITAASLGQKVTI TCSASSSVSYMHWYQQKSGTSPKPWIYEISKLASGVPARFSGSGSGTSY SLTISSMEAEDAAIYYCQQWNYPLITFGGGTKLEI.

(614) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(615) TABLE-US-00282 (SEQIDNO:362) VQLQQSGAELARPGASVKLSCKASGYTFTSYGISWVKQRTGQGLEWIGE IYPRSGNTYYNEKFKGKATLTADKSSSTAYMELRSLTSEDSAVYFCARS RVWGTGTTVTVSSGGGGSGGGGSGGGGSDIVLTQSPASLAVSLGQRATI SYRASKSVSTSGYSYMHWNQQKPGQPPRLLIYLVSNLESGVPARFSGSG SGTDFTLNIHPVEEEDAATYYCQHIRELTRSEGGPSWK.

(616) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(617) TABLE-US-00283 (SEQIDNO:363) DVKLQESGGGLVKPGGSLKLSCAVSGFTFSSFAMSWVRQTPEKRLEWVA TISSGGAYTFYKDSVKGRFTISRDNAKNTLYLQMSSLRSEDSAMYYCAR HSGYDGYYLYAMDYWGQGTSVTVSSGGGGSGGGGSGGGGSQAIVTQESA LTTSPGETVTLTCRSSTGAVTTSNYATWVQEKPDHLFTGLMGGTNIRAP GVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYNNHLVFGGGTKLT V.

(618) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(619) TABLE-US-00284 (SEQIDNO:364) DVKLQESGGGLVKPGGSLKLSCAVSGFTFSSFAMSWVRQTPEKRLEWVA TISSGGAYTFYKDSVKGRFTISRDNAKNTLYLQMSSLRSEDSAMYYCAR HSGYDGYYLYAMDYWGQGTSVTVSSGGGGSGGGGSGGGGSQIVLTQSPA LMSASPGEKVTMTCSASSSVSYMYWYQQKPRSSPKPWIYLTSNLASGVP ARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPFTFGSGTKLEIKR.

(620) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(621) TABLE-US-00285 (SEQIDNO:365) DVKLQESGGGLVKPGGSLKLSCAVSGFTFSSFAMSWVRQTPEKRLEWVA TISSGGAYTFYKDSVKGRFTISRDNAKNTLYLQMSSLRSEDSAMYYCAR HSGYDGYYLYAMDYWGQGTSVTVSSGGGGSGGGGSGGGGSDIQMTQTTS SLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGV PSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPPTFGGGTKLEIK.

(622) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(623) TABLE-US-00286 (SEQIDNO:366) DVKLQESGGGLVKPGGSLKLSCAVSGFTFSSFAMSWVRQTPEKRLEWVA TISSGGAYTFYKDSVKGRFTISRDNAKNTLYLQMSSLRSEDSAMYYCAR HSGYDGYYLYAMDYWGQGTSVTVSSGGGGSGGGGSGGGGSEIVLTQSPA ITAASLGQKVTITCSASSSVSYMHWYQQKSGTSPKPWIYEISKLASGVP ARFSGSGSGTSYSLTISSMEAEDAAIYYCQQWNYPLITFGGGTKLEI.

(624) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(625) TABLE-US-00287 (SEQIDNO:367) DVKLQESGGGLVKPGGSLKLSCAVSGFTFSSFAMSWVRQTPEKRLEWVA TISSGGAYTFYKDSVKGRFTISRDNAKNTLYLQMSSLRSEDSAMYYCAR HSGYDGYYLYAMDYWGQGTSVTVSSGGGGSGGGGSGGGGSDIVLTQSPA SLAVSLGQRATISYRASKSVSTSGYSYMHWNQQKPGQPPRLLIYLVSNL ESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHIRELTRSEGGPSW K.

(626) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(627) TABLE-US-00288 (SEQIDNO:368) EVKLVESGGDLVKPGASLKLSCAASGFTFSNYGMSWIRQTSDKRLEWVA SISSGDGRTYYSDNIRGRFTISSENAKNTLYLQMSSLKSEDTALYYCTR GRGLRGDAMDYWGQGTSVTVSSGGGGSGGGGGGGGSQAIVTQESALTTS PGETVTLTCRSSTGAVTTSNYATWVQEKPDHLFTGLMGGTNIRAPGVPA RFSGSLIGDKAALTITGAQTEDEAIYFCALWYNNHLVFGGGTKLTV.

(628) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(629) TABLE-US-00289 (SEQIDNO:369) EVKLVESGGDLVKPGASLKLSCAASGFTFSNYGMSWIRQTSDKRLEWVA SISSGDGRTYYSDNIRGRFTISSENAKNTLYLQMSSLKSEDTALYYCTR GRGLRGDAMDYWGQGTSVTVSSGGGGSGGGGSGGGGSQIVLTQSPALMS ASPGEKVTMTCSASSSVSYMYWYQQKPRSSPKPWIYLTSNLASGVPARF SGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPFTFGSGTKLEIKR.

(630) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(631) TABLE-US-00290 (SEQIDNO:370) EVKLVESGGDLVKPGASLKLSCAASGFTFSNYGMSWIRQTSDKRLEWVA SISSGDGRTYYSDNIRGRFTISSENAKNTLYLQMSSLKSEDTALYYCTR GRGLRGDAMDYWGQGTSVTVSSGGGGSGGGGSGGGGSDIQMTQTTSSLS ASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSR FSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPPTFGGGTKLEIK.

(632) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(633) TABLE-US-00291 (SEQIDNO:371) EVKLVESGGDLVKPGASLKLSCAASGFTFSNYGMSWIRQTSDKRLEWVA SISSGDGRTYYSDNIRGRFTISSENAKNTLYLQMSSLKSEDTALYYCTR GRGLRGDAMDYWGQGTSVTVSSGGGGSGGGGSGGGGSEIVLTQSPAITA ASLGQKVTITCSASSSVSYMHWYQQKSGTSPKPWIYEISKLASGVPARF SGSGSGTSYSLTISSMEAEDAAIYYCQQWNYPLITFGGGTKLEI.

(634) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(635) TABLE-US-00292 (SEQIDNO:372) EVKLVESGGDLVKPGASLKLSCAASGFTFSNYGMSWIRQTSDKRLEWVA SISSGDGRTYYSDNIRGRFTISSENAKNTLYLQMSSLKSEDTALYYCTR GRGLRGDAMDYWGQGTSVTVSSGGGGSGGGGSGGGGSDIVLTQSPASLA VSLGQRATISYRASKSVSTSGYSYMHWNQQKPGQPPRLLIYLVSNLESG VPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHIRELTRSEGGPSWK.

(636) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(637) TABLE-US-00293 (SEQIDNO:373) EVKLLESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGE INPDSSTINYTPSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCARPG YYYAMDYWGQGTSVTVSSGGGGSGGGGSGGGGSQAIVTQESALTTSPGET VTLTCRSSTGAVTTSNYATWVQEKPDHLFTGLMGGTNIRAPGVPARFSGS LIGDKAALTITGAQTEDEAIYFCALWYNNHLVFGGGTKLTV.

(638) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(639) TABLE-US-00294 (SEQIDNO:374) EVKLLESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGE INPDSSTINYTPSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCARPG YYYAMDYWGQGTSVTVSSGGGGGGGGSGGGGSQIVLTQSPALMSASPGEK VTMTCSASSSVSYMYWYQQKPRSSPKPWIYLTSNLASGVPARFSGSGSGT SYSLTISSMEAEDAATYYCQQWSSNPFTFGSGTKLEIKR.

(640) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(641) TABLE-US-00295 (SEQIDNO:375) EVKLLESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGE INPDSSTINYTPSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCARPG YYYAMDYWGQGTSVTVSSGGGGSGGGGSGGGGSDIQMTQTTSSLSASLGD RVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGS GTDYSLTISNLEQEDIATYFCQQGNTLPPTFGGGTKLEIK.

(642) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(643) TABLE-US-00296 (SEQIDNO:376) EVKLLESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGE INPDSSTINYTPSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCARPG YYYAMDYWGQGTSVTVSSGGGGSGGGGSGGGGSEIVLTQSPAITAASLGQ KVTITCSASSSVSYMHWYQQKSGTSPKPWIYEISKLASGVPARFSGSGSG TSYSLTISSMEAEDAAIYYCQQWNYPLITFGGGTKLEI.

(644) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(645) TABLE-US-00297 (SEQIDNO:377) EVKLLESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGE INPDSSTINYTPSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCARPG YYYAMDYWGQGTSVTVSSGGGGSGGGGSGGGGSDIVLTQSPASLAVSLGQ RATISYRASKSVSTSGYSYMHWNQQKPGQPPRLLIYLVSNLESGVPARFS GSGSGTDFTLNIHPVEEEDAATYYCQHIRELTRSEGGPSWK.

(646) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(647) TABLE-US-00298 (SEQIDNO:378) QAIVTQESALTTSPGETVTLTCRSSTGAVTTSNYATWVQEKPDHLFTGLM GGTNIRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYNNHLVF GGGTKLTVGGGGSGGGGSGGGGSEVQLQESGAELVKPGASVKLSCTASGF NIKDTYMHWVKQRPEQGLEWIGRIDPANGNVEYDPKFQGKATLTADTSSN TAYLQLSSLTSEDTAVYYCDLSHYTMDYWGQGTSVTVSS.

(648) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(649) TABLE-US-00299 (SEQIDNO:379) QAIVTQESALTTSPGETVTLTCRSSTGAVTTSNYATWVQEKPDHLFTGLM GGTNIRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYNNHLVF GGGTKLTVGGGGSGGGGSGGGGSQVQLQQSGAELVRPGASVTLSCKASGY TFTDYEMHWVKQTPVHGLEWIGAIDPETGDTAYNQKFKGKATLTADKSSS TAYMELSSLTSEDSAVYYCTRANSFGYWGQGTTLTVSS.

(650) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(651) TABLE-US-00300 (SEQIDNO:380) QAIVTQESALTTSPGETVTLTCRSSTGAVTTSNYATWVQEKPDHLFTGLM GGTNIRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYNNHLVF GGGTKLTVGGGGSGGGGSGGGGSVQLQQSGAELARPGASVKLSCKASGYT FTSYGISWVKQRTGQGLEWIGEIYPRSGNTYYNEKFKGKATLTADKSSST AYMELRSLTSEDSAVYFCARSRVWGTGTTVTVSS.

(652) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(653) TABLE-US-00301 (SEQIDNO:381) QAIVTQESALTTSPGETVTLTCRSSTGAVTTSNYATWVQEKPDHLFTGLM GGTNIRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYNNHLVF GGGTKLTVGGGGSGGGGSGGGGSDVKLQESGGGLVKPGGSLKLSCAVSGF TFSSFAMSWVRQTPEKRLEWVATISSGGAYTFYKDSVKGRFTISRDNAKN TLYLQMSSLRSEDSAMYYCARHSGYDGYYLYAMDYWGQGTSVTVSS.

(654) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(655) TABLE-US-00302 (SEQIDNO:382) QAIVTQESALTTSPGETVTLTCRSSTGAVTTSNYATWVQEKPDHLFTGLM GGTNIRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYNNHLVF GGGTKLTVGGGGSGGGGSGGGGSEVKLVESGGDLVKPGASLKLSCAASGF TFSNYGMSWIRQTSDKRLEWVASISSGDGRTYYSDNIRGRFTISSENAKN TLYLQMSSLKSEDTALYYCTRGRGLRGDAMDYWGQGTSVTVSS.

(656) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(657) TABLE-US-00303 (SEQIDNO:383) QAIVTQESALTTSPGETVTLTCRSSTGAVTTSNYATWVQEKPDHLFTGLM GGTNIRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYNNHLVF GGGTKLTVGGGGSGGGGSGGGGSEVKLLESGGGLVQPGGSLKLSCAASGF DFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYTPSLKDKFIISRDNAKN TLYLQMSKVRSEDTALYYCARPGYYYAMDYWGQGTSVTVSS.

(658) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(659) TABLE-US-00304 (SEQIDNO:384) QIVLTQSPALMSASPGEKVTMTCSASSSVSYMYWYQQKPRSSPKPWIYLT SNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPFTFGSG TKLEIKRGGGGSGGGGSGGGGSEVQLQESGAELVKPGASVKLSCTASGFN IKDTYMHWVKQRPEQGLEWIGRIDPANGNVEYDPKFQGKATLTADTSSNT AYLQLSSLTSEDTAVYYCDLSHYTMDYWGQGTSVTVSS.

(660) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(661) TABLE-US-00305 (SEQIDNO:385) QIVLTQSPALMSASPGEKVTMTCSASSSVSYMYWYQQKPRSSPKPWIYLT SNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPFTFGSG TKLEIKRGGGGSGGGGSGGGGSQVQLQQSGAELVRPGASVTLSCKASGYT FTDYEMHWVKQTPVHGLEWIGAIDPETGDTAYNQKFKGKATLTADKSSST AYMELSSLTSEDSAVYYCTRANSFGYWGQGTTLTVSS.

(662) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(663) TABLE-US-00306 (SEQIDNO:386) QIVLTQSPALMSASPGEKVTMTCSASSSVSYMYWYQQKPRSSPKPWIYLT SNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPFTFGSG TKLEIKRGGGGSGGGGSGGGGSVQLQQSGAELARPGASVKLSCKASGYTF TSYGISWVKQRTGQGLEWIGEIYPRSGNTYYNEKFKGKATLTADKSSSTA YMELRSLTSEDSAVYFCARSRVWGTGTTVTVSS.

(664) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(665) TABLE-US-00307 (SEQIDNO:387) QIVLTQSPALMSASPGEKVTMTCSASSSVSYMYWYQQKPRSSPKPWIYLT SNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPFTFGSG TKLEIKRGGGGSGGGGSGGGGSDVKLQESGGGLVKPGGSLKLSCAVSGFT FSSFAMSWVRQTPEKRLEWVATISSGGAYTFYKDSVKGRFTISRDNAKNT LYLQMSSLRSEDSAMYYCARHSGYDGYYLYAMDYWGQGTSVTVSS.

(666) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(667) TABLE-US-00308 (SEQIDNO:388) QIVLTQSPALMSASPGEKVTMTCSASSSVSYMYWYQQKPRSSPKPWIYLT SNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPFTFGSG TKLEIKRGGGGSGGGGSGGGGSEVKLVESGGDLVKPGASLKLSCAASGFT FSNYGMSWIRQTSDKRLEWVASISSGDGRTYYSDNIRGRFTISSENAKNT LYLQMSSLKSEDTALYYCTRGRGLRGDAMDYWGQGTSVTVSS.

(668) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(669) TABLE-US-00309 (SEQIDNO:389) QIVLTQSPALMSASPGEKVTMTCSASSSVSYMYWYQQKPRSSPKPWIYLT SNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPFTFGSG TKLEIKRGGGGSGGGGSGGGGSEVKLLESGGGLVQPGGSLKLSCAASGFD FSRYWMSWVRQAPGKGLEWIGEINPDSSTINYTPSLKDKFIISRDNAKNT LYLQMSKVRSEDTALYYCARPGYYYAMDYWGQGTSVTVSS.

(670) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(671) TABLE-US-00310 (SEQIDNO:390) DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYY TSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPPTFGG GTKLEIKGGGGSGGGGSGGGGSEVQLQESGAELVKPGASVKLSCTASGFN IKDTYMHWVKQRPEQGLEWIGRIDPANGNVEYDPKFQGKATLTADTSSNT AYLQLSSLTSEDTAVYYCDLSHYTMDYWGQGTSVTVSS.

(672) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(673) TABLE-US-00311 (SEQIDNO:391) DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYY TSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPPTFGG GTKLEIKGGGGSGGGGSGGGGSQVQLQQSGAELVRPGASVTLSCKASGYT FTDYEMHWVKQTPVHGLEWIGAIDPETGDTAYNQKFKGKATLTADKSSST AYMELSSLTSEDSAVYYCTRANSFGYWGQGTTLTVSS.

(674) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(675) TABLE-US-00312 (SEQIDNO:392) DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYY TSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPPTFGG GTKLEIKGGGGSGGGGSGGGGSVQLQQSGAELARPGASVKLSCKASGYTF TSYGISWKQRTGQGLEWIGEIYPRSGNTYYNEKFKGKATLTADKSSSTAY MELRSLTSEDSAVYFCARSRVWGTGTTVTVSS.

(676) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(677) TABLE-US-00313 (SEQIDNO:393) DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYY TSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPPTFGG GTKLEIKGGGGSGGGGSGGGGSDVKLQESGGGLVKPGGSLKLSCAVSGFT FSSFAMSWVRQTPEKRLEWVATISSGGAYTFYKDSVKGRFTISRDNAKNT LYLQMSSLRSEDSAMYYCARHSGYDGYYLYAMDYWGQGTSVTVSS.

(678) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(679) TABLE-US-00314 (SEQIDNO:394) DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYY TSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPPTFGG GTKLEIKGGGGSGGGGSGGGGSEVKLVESGGDLVKPGASLKLSCAASGFT FSNYGMSWIRQTSDKRLEWVASISSGDGRTYYSDNIRGRFTISSENAKNT LYLQMSSLKSEDTALYYCTRGRGLRGDAMDYWGQGTSVTVSS.

(680) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(681) TABLE-US-00315 (SEQIDNO:395) DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYY TSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPPTFGG GTKLEIKGGGGSGGGGSGGGGSEVKLLESGGGLVQPGGSLKLSCAASGFD FSRYWMSWVRQAPGKGLEWIGEINPDSSTINYTPSLKDKFIISRDNAKNT LYLQMSKVRSEDTALYYCARPGYYYAMDYWGQGTSVTVSS.

(682) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(683) TABLE-US-00316 (SEQIDNO:396) EIVLTQSPAITAASLGQKVTITCSASSSVSYMHWYQQKSGTSPKPWIYEI SKLASGVPARFSGSGSGTSYSLTISSMEAEDAAIYYCQQWNYPLITFGGG TKLEIGGGGSGGGGSGGGGSEVQLQESGAELVKPGASVKLSCTASGFNIK DTYMHWVKQRPEQGLEWIGRIDPANGNVEYDPKFQGKATLTADTSSNTAY LQLSSLTSEDTAVYYCDLSHYTMDYWGQGTSVTVSS.

(684) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(685) TABLE-US-00317 (SEQIDNO:397) EIVLTQSPAITAASLGQKVTITCSASSSVSYMHWYQQKSGTSPKPWIYEI SKLASGVPARFSGSGSGTSYSLTISSMEAEDAAIYYCQQWNYPLITFGGG TKLEIGGGGSGGGGSGGGGSQVQLQQSGAELVRPGASVTLSCKASGYTFT DYEMHWVKQTPVHGLEWIGAIDPETGDTAYNQKFKGKATLTADKSSSTAY MELSSLTSEDSAVYYCTRANSFGYWGQGTTLTVSS.

(686) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(687) TABLE-US-00318 (SEQIDNO:398) EIVLTQSPAITAASLGQKVTITCSASSSVSYMHWYQQKSGTSPKPWIYEI SKLASGVPARFSGSGSGTSYSLTISSMEAEDAAIYYCQQWNYPLITFGGG TKLEIGGGGSGGGGSGGGGSVQLQQSGAELARPGASVKLSCKASGYTFTS YGISWVKQRTGQGLEWIGEIYPRSGNTYYNEKFKGKATLTADKSSSTAYM ELRSLTSEDSAVYFCARSRVWGTGTTVTVSS.

(688) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(689) TABLE-US-00319 (SEQIDNO:399) EIVLTQSPAITAASLGQKVTITCSASSSVSYMHWYQQKSGTSPKPWIYEI SKLASGVPARFSGSGSGTSYSLTISSMEAEDAAIYYCQQWNYPLITFGGG TKLEIGGGGSGGGGSGGGGSDVKLQESGGGLVKPGGSLKLSCAVSGFTFS SFAMSWVRQTPEKRLEWVATISSGGAYTFYKDSVKGRFTISRDNAKNTLY LQMSSLRSEDSAMYYCARHSGYDGYYLYAMDYWGQGTSVTVSS.

(690) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(691) TABLE-US-00320 (SEQIDNO:400) EIVLTQSPAITAASLGQKVTITCSASSSVSYMHWYQQKSGTSPKPWIYEI SKLASGVPARFSGSGSGTSYSLTISSMEAEDAAIYYCQQWNYPLITFGGG TKLEIGGGGSGGGGSGGGGSEVKLVESGGDLVKPGASLKLSCAASGFTFS NYGMSWIRQTSDKRLEWVASISSGDGRTYYSDNIRGRFTISSENAKNTLY LQMSSLKSEDTALYYCTRGRGLRGDAMDYWGQGTSVTVSS.

(692) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(693) TABLE-US-00321 (SEQIDNO:401) EIVLTQSPAITAASLGQKVTITCSASSSVSYMHWYQQKSGTSPKPWIYEI SKLASGVPARFSGSGSGTSYSLTISSMEAEDAAIYYCQQWNYPLITFGGG TKLEIGGGGGGGGSGGGGSEVKLLESGGGLVQPGGSLKLSCAASGFDFSR YWMSWVRQAPGKGLEWIGEINPDSSTINYTPSLKDKFIISRDNAKNTLYL QMSKVRSEDTALYYCARPGYYYAMDYWGQGTSVTVSS.

(694) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(695) TABLE-US-00322 (SEQIDNO:402) DIVLTQSPASLAVSLGQRATISYRASKSVSTSGYSYMHWNQQKPGQPPRL LIYLVSNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHIRELTR SEGGPSWKGGGGSGGGGSGGGGSEVQLQESGAELVKPGASVKLSCTASGF NIKDTYMHWVKQRPEQGLEWIGRIDPANGNVEYDPKFQGKATLTADTSSN TAYLQLSSLTSEDTAVYYCDLSHYTMDYWGQGTSVTVSS.

(696) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(697) TABLE-US-00323 (SEQIDNO:403) DIVLTQSPASLAVSLGQRATISYRASKSVSTSGYSYMHWNQQKPGQPPRL LIYLVSNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHIRELTR SEGGPSWKGGGGSGGGGSGGGGSQVQLQQSGAELVRPGASVTLSCKASGY TFTDYEMHWVKQTPVHGLEWIGAIDPETGDTAYNQKFKGKATLTADKSSS TAYMELSSLTSEDSAVYYCTRANSFGYWGQGTTLTVSS.

(698) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(699) TABLE-US-00324 (SEQIDNO:404) DIVLTQSPASLAVSLGQRATISYRASKSVSTSGYSYMHWNQQKPGQPPRL LIYLVSNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHIRELTR SEGGPSWKGGGGSGGGGSGGGGSVQLQQSGAELARPGASVKLSCKASGYT FTSYGISWVKQRTGQGLEWIGEIYPRSGNTYYNEKFKGKATLTADKSSST AYMELRSLTSEDSAVYFCARSRVWGTGTTVTVSS.

(700) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(701) TABLE-US-00325 (SEQIDNO:405) DIVLTQSPASLAVSLGQRATISYRASKSVSTSGYSYMHWNQQKPGQPPRL LIYLVSNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHIRELTR SEGGPSWKGGGGSGGGGSGGGGSDVKLQESGGGLVKPGGSLKLSCAVSGF TFSSFAMSWVRQTPEKRLEWVATISSGGAYTFYKDSVKGRFTISRDNAKN TLYLQMSSLRSEDSAMYYCARHSGYDGYYLYAMDYWGQGTSVTVSS.

(702) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(703) TABLE-US-00326 (SEQIDNO:406) DIVLTQSPASLAVSLGQRATISYRASKSVSTSGYSYMHWNQQKPGQPPRL LIYLVSNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHIRELTR SEGGPSWKGGGGSGGGGSGGGGSEVKLVESGGDLVKPGASLKLSCAASGF TFSNYGMSWIRQTSDKRLEWVASISSGDGRTYYSDNIRGRFTISSENAKN TLYLQMSSLKSEDTALYYCTRGRGLRGDAMDYWGQGTSVTVSS.

(704) In some embodiments, the anti-CD20 scFv comprises an amino acid sequence:

(705) TABLE-US-00327 (SEQIDNO:407) DIVLTQSPASLAVSLGQRATISYRASKSVSTSGYSYMHWNQQKPGQPPRL LIYLVSNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHIRELTR SEGGPSWKGGGGSGGGGSGGGGSEVKLLESGGGLVQPGGSLKLSCAASGF DFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYTPSLKDKFIISRDNAKN TLYLQMSKVRSEDTALYYCARPGYYYAMDYWGQGTSVTVSS.

(706) In some embodiments, the anti-CD20 scFv binds to CD20 and comprises an amino acid sequence that is 95%, 96%, 97%, 98% or 99% identical to any of the specific anti-CD20 scFv amino acid sequences disclosed herein.

(707) In some embodiments, the anti-CD20 scFv comprises an antigen binding domain of veltuzumab (hA20 IMMU-106, Immunomedics, Inc.).

(708) In some embodiments, the anti-CD20 scFv comprises an antigen binding domain of rituximab (IDEC-C2B8), described in U.S. Pat. No. 7,682,612, which is incorporated by reference for the teaching of this antibody.

(709) In some embodiments, the anti-CD20 scFv comprises an antigen binding domain of clone Leu16.

(710) In some embodiments, the anti-CD20 scFv comprises an antigen binding domain of tositumomab (Bexxar, GSK).

(711) In some embodiments, the anti-CD20 scFv comprises an antigen binding domain of ocrelizumab (hu2H7, Biogen/Genentech), described in EP2301966, which is incorporated by reference for the teaching of this antibody.

(712) In some embodiments, the anti-CD20 scFv comprises an antigen binding domain of ibritumomab tiuxetan (Zevalin, Spectrum Pharmaceuticals).

(713) In some embodiments, the anti-CD20 scFv comprises an antigen binding domain of ofatumumab (Arzerra, GSK), described in U.S. Pat. No. 7,850,962, which is incorporated by reference for the teaching of this antibody.

(714) In some embodiments, the anti-CD20 scFv comprises an antigen binding domain of obinutuzumab (Gazyva, GA101), described in EP1692182, which is incorporated by reference for the teaching of this antibody.

(715) In some embodiments, the anti-CD20 scFv comprises an antigen binding domain of ocaratuzumab (AME/Eli Lilly, now Mentrik), described in US20030219433, which is incorporated by reference for the teaching of this antibody.

(716) Anti-CD22 scFv

(717) In some embodiments, the anti-CD22 scFv is derived from hybridoma from CD22 plate 1 (CD22 (L) NS1)), CD22 plate 2 (CD22 (L) NS1)), CD22 plate 3 (CD22 (L) NS1)), CD22 plate 4 (CD22 (L) NS1)), CD22 plate 5 (CD22 (L) NS1)), CD22 plate 6 (CD22 (L) NS1)), CD22 plate 7 (CD22 (L) NS1)), CD22 plate 8 (CD22 (L) NS1)), CD22 plate 9 (CD22 (L) SP20)), CD22 plate 10 (CD22 (L) SP20)), CD22 plate 11 (CD22 (L) SP20)), CD22 plate 12 (CD22 (L) SP20)), CD22 plate 13 (CD22 (O) NS1)), CD22 plate 14 (CD22 (O) NS1)), CD22 plate 15 (CD22 (O) NS1)), CD22 plate 16 (CD22 (O) NS1)), CD22 plate 17 (CD22 (O) SP20)), CD22 plate 18 (CD22 (O) SP20)), CD22 plate 19 (CD22 (O) SP20)), or CD22 plate 20 (CD22 (O) SP20)). Each plate has 96 wells consisting of 8 columns (A-H) and 12 rows (1-12), so each well contains 96 hybridomas identified by their plate and well, e.g. CD22 Plate1-A1. In some embodiments, the anti-CD22 scFv can comprise a variable heavy (V.sub.H) domain having CDR1, CDR2 and CDR3 sequences and a variable light (V.sub.L) domain having CDR1, CDR2 and CDR3 sequences.

(718) In some embodiments, the anti-CD22 scFv is derived from hybridoma 2B12, 5H12, 10C1, 10H6, 18A3, 9D4, 11D11, or 20B4.

(719) In some embodiments, the anti-CD22 scFv can comprise a variable heavy (V.sub.H) domain having CDR1, CDR2 and CDR3 sequences and a variable light (V.sub.L) domain having CDR1, CDR2 and CDR3 sequences.

(720) For example, in some embodiments, the CDR1 sequence of the V.sub.H domain comprises the amino acid sequence GYTFTSYW (SEQ ID NO:408), GFTFSSFG (SEQ ID NO:409), GFEFSRYW (SEQ ID NO:410), GFSLTGYG (SEQ ID NO:411), GFTFSNYG (SEQ ID NO:412), GYAFSSSW (SEQ ID NO:413), or SFAMSW (SEQ ID NO:414); CDR2 sequence of the V.sub.H domain comprises the amino acid sequence INPNSGST (SEQ ID NO:415), ISSGSSTL (SEQ ID NO:416), VNPDSSTI (SEQ ID NO:417), IWGDGST (SEQ ID NO:418), IYPGNSDT (SEQ ID NO:419), ISSGGGRI (SEQ ID NO:420), IYPGDGDT (SEQ ID NO:421), or TISSGGAYTFYKDSVKGRFT (SEQ ID NO:422); CDR3 sequence of the V.sub.H domain comprises the amino acid sequence TRPGV (SEQ ID NO:423), GRDSNYGYFDV (SEQ ID NO:424), ARGGYDFDY (SEQ ID NO:425), TRSHYVEGYFDV (SEQ ID NO:426), SQSTHVSYT (SEQ ID NO:27), ANSNYPSSQSSRTYSRRDWFAY (SEQ ID NO:428), or HSGYDGYYLYAMDC (SEQ ID NO:429); CDR1 sequence of the V.sub.L comprises the amino acid sequence QSIVHSNGNTY (SEQ ID NO:430), ENIYGA (SEQ ID NO:431), QSVDYDGDSY (SEQ ID NO:432), SSVSY (SEQ ID NO:433), KSISKY (SEQ ID NO:434), QSLVHSNGNTY (SEQ ID NO:435), SSVSD (SEQ ID NO:436), or RASESVDSYGNSFMH (SEQ ID NO:437); CDR2 sequence of the V.sub.L domain comprises the amino acid sequence KVS (SEQ ID NO:438), GAT (SEQ ID NO:439), AAS (SEQ ID NO:440), RTS (SEQ ID NO:441), SGS (SEQ ID NO:442), KVS (SEQ ID NO:443), DTS (SEQ ID NO:444), or LASNLES (SEQ ID NO:445); and CDR3 sequence of the V.sub.L domain comprises the amino acid sequence FQGSHVPPT (SEQ ID NO:446), QNVLSTPWT (SEQ ID NO:447), QQSNEDPFT (SEQ ID NO:448), QQYHSYPYT (SEQ ID NO:449), QQHNEYPWT (SEQ ID NO:450), SQSTHVSYT (SEQ ID NO:451), QQWSSNPLT (SEQ ID NO:452), or NNEDPWT (SEQ ID NO:453).

(721) Therefore, in some embodiments, the anti-CD22 scFv V.sub.H domain comprises the amino acid sequence:

(722) TABLE-US-00328 (SEQIDNO:454,2B12) QVKLQQSGAELGKPGTSVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGN INPNSGSTNYNEKFKSKATLTVDKSSSTAYMQLSTLTSEDSAVYYCTRPG VWGTGTTVTVSS.

(723) Therefore, in some embodiments, the anti-CD22 scFv V.sub.H domain is encoded

(724) TABLE-US-00329 (SEQIDNO:470,2B12) CAAGTTAAGCTGCAGCAGTCTGGGGCTGAACTGGGCAAGCCTGGGACATC AGTGAAGCTGTCCTGCAAGGCTTCTGGCTACACCTTCACCAGCTATTGGA TGCACTGGGTGAAGCAGAGGCCTGGACAAGGCCTTGAGTGGATTGGAAAT ATTAATCCTAATAGTGGTAGTACTAACTACAATGAGAAGTTCAAGAGCAA GGCCACACTGACTGTAGACAAATCCTCCAGCACAGCCTACATGCAGCTCA GCACCCTGACATCTGAGGACTCTGCGGTCTACTACTGTACAAGACCGGGG GTCTGGGGCACAGGGACCACGGTCACCGTCTCCTCA.

(725) Therefore, in some embodiments, the anti-CD22 scFv V.sub.H domain comprises the amino acid sequence:

(726) TABLE-US-00330 (SEQIDNO:455,5H12) EVKLQQSGGGLVQPGGSRKLSCAASGFTFSSFGMHWVRQAPEKGLEWVAY ISSGSSTLHYADTVKGRFTISRDNPKNTLFLQMKLPSLCYGLLGSRNLSH RLLSQNDTPICL.

(727) Therefore, in some embodiments, the anti-CD22 scFv V.sub.H domain is encoded by the nucleic acid sequence:

(728) TABLE-US-00331 (SEQIDNO:471,5H12) GAGGTGAAGCTGCAGCAGTCTGGGGGAGGCTTAGTGCAGCCTGGAGGGTC CCGGAAACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTAGCTTTGGAA TGCACTGGGTTCGTCAGGCTCCAGAGAAGGGGCTGGAGTGGGTCGCATAC ATTAGTAGTGGCAGTAGTACCCTCCACTATGCAGACACAGTGAAGGGCCG ATTCACCATCTCCAGAGACAATCCCAAGAACACCCTGTTCCTGCAAATGA AACTACCCTCACTATGCTATGGACTACTGGGGTCAAGGAACCTCAGTCAC CGTCTCCTCAGCCAAAACGACACCCCCATCTGCCTA.

(729) Therefore, in some embodiments, the anti-CD22 scFv V.sub.H domain comprises the amino acid sequence:

(730) TABLE-US-00332 (SEQIDNO:456,10C1) VKLLESGGGLVQPGGSLKLSCAASGFEFSRYWMSWVRQVPGKGLEWIGEV NPDSSTINYTTSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCGRDSN YGYFDVWGTGTTVTVSS.

(731) Therefore, in some embodiments, the anti-CD22 scFv V.sub.H domain is encoded by the nucleic acid sequence:

(732) TABLE-US-00333 (SEQIDNO:472,10C1) GTGAAGCTTCTCGAGTCTGGAGGTGGCCTGGTGCAGCCTGGAGGATCCCT GAAACTCTCCTGTGCAGCCTCAGGATTCGAATTTAGTAGATACTGGATGA GTTGGGTCCGGCAGGTTCCAGGGAAAGGGCTAGAATGGATTGGAGAAGTT AATCCAGATAGCAGTACGATAAACTATACGACATCTCTAAAGGATAAATT CATCATCTCCAGAGACAACGCCAAAAATACGCTGTACCTGCAAATGAGCA AAGTGAGATCTGAGGACACAGCCCTTTATTACTGTGGAAGAGATAGTAAT TACGGGTACTTCGATGTCTGGGGCACAGGGACCACGGTCACCGTCTCCTC A.

(733) Therefore, in some embodiments, the anti-CD22 scFv V.sub.H domain comprises the amino acid sequence:

(734) TABLE-US-00334 (SEQIDNO:457,10H6) VQLKESGPGLVAPSQSLSITCTVSGFSLTGYGVNWVRQPPGKGLEWLGMI WGDGSTDYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTARYYCARGGYD FDYWGQGTTLTVSS.

(735) Therefore, in some embodiments, the anti-CD22 scFv V.sub.H domain is encoded by the nucleic acid sequence:

(736) TABLE-US-00335 (SEQIDNO:473,10H6) GTGCAGCTGAAGGAGTCAGGACCTGGCCTGGTGGCGCCCTCACAGAGCCT GTCCATCACATGCACCGTCTCAGGGTTCTCATTAACCGGCTATGGTGTAA ACTGGGTTCGCCAGCCTCCAGGAAAGGGTCTGGAGTGGCTGGGAATGATA TGGGGTGATGGAAGCACAGACTATAATTCAGCTCTCAAATCCAGACTGAG CATCAGCAAGGACAACTCCAAGAGCCAAGTTTTCTTAAAAATGAACAGTC TGCAAACTGATGACACAGCCAGGTACTACTGTGCCAGAGGAGGCTACGAC TTTGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCA.

(737) Therefore, in some embodiments, the anti-CD22 scFv V.sub.H domain comprises the amino acid sequence:

(738) TABLE-US-00336 (SEQIDNO:458,18A3) VQLQQSGAELARPGASVKMSCKASGYTFTSYWMHWVKQRPGQGLEWIGAI YPGNSDTSYNQKFKGKAKLTAVTSASTAYMELSSLTNEDSAVYYCTRSHY VEGYFDVWGTGTTVTVSS.

(739) Therefore, in some embodiments, the anti-CD22 scFv V.sub.H domain is encoded by the nucleic acid sequence:

(740) TABLE-US-00337 (SEQIDNO:474,18A3) GTTCAGCTCCAGCAGTCTGGGGCTGAGCTGGCAAGACCTGGGGCTTCAGT GAAGATGTCCTGCAAGGCTTCTGGCTACACCTTTACCAGCTACTGGATGC ACTGGGTAAAACAGAGGCCTGGACAGGGTCTGGAATGGATTGGCGCTATT TATCCTGGAAATAGTGATACTAGCTACAATCAGAAGTTCAAGGGCAAGGC CAAACTGACTGCAGTCACATCCGCCAGCACTGCCTACATGGAGCTCAGCA GCCTAACAAATGAGGACTCTGCGGTCTATTACTGTACAAGAAGCCACTAC GTAGAGGGATACTTCGATGTCTGGGGCACAGGGACCACGGTCACCGTCTC CTCA.

(741) Therefore, in some embodiments, the anti-CD22 scFv V.sub.H domain comprises the amino acid sequence:

(742) TABLE-US-00338 (SEQIDNO:459,9D4) QVKLQQSGAELVKPGASVKISCKASGYAFSSSWMNWVKQRPGKGLEWIGQ IYPGDGDTKYNGKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCANSN YPSSQSSRTYSRRDWFAYWGQGTLVTVSA.

(743) Therefore, in some embodiments, the anti-CD22 scFv V.sub.H domain is encoded by the nucleic acid sequence:

(744) TABLE-US-00339 (SEQIDNO:475,9D4) CAAGTTAAGCTGCAGCAGTCTGGGGCTGAGCTGGTGAAGCCTGGGGCCTC AGTGAAGATTTCCTGCAAAGCTTCTGGCTACGCATTCAGTAGCTCCTGGA TGAACTGGGTGAAGCAGAGGCCTGGAAAGGGTCTTGAGTGGATTGGACAG ATTTATCCTGGAGATGGTGATACTAAGTACAATGGAAAGTTCAAGGGCAA AGCCACACTGACTGCAGACAAATCCTCCAGCACAGCCTACATGCAACTCA GCAGCCTGACATCTGAGGACTCTGCGGTCTATTTCTGTGCAAATAGTAAC TACCCCAGTAGTCAAAGTAGTCGTACCTATAGTAGAAGGGACTGGTTTGC TTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA.

(745) Therefore, in some embodiments, the anti-CD22 scFv V.sub.H domain comprises the amino acid sequence:

(746) TABLE-US-00340 (SEQIDNO:460,11D11) DVKLQESGGGLVKPGGSLKLSCAVSGFTFSSFAMSWVRQTPEKRLEWVAT ISSGGAYTFYKDSVKGRFTISRDNAKNTLYLQMSSLRSEDSAMYYCARHS GYDGYYLYAMDCWGQGTSVTVSS.

(747) Therefore, in some embodiments, the anti-CD22 scFv V.sub.H domain is encoded by the nucleic acid sequence:

(748) TABLE-US-00341 (SEQIDNO:476,11D11) GATGTGAAGCTTCAGGAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGGGTC CCTGAAACTCTCCTGTGCAGTCTCTGGATTCACTTTCAGTTCCTTTGCCA TGTCTTGGGTTCGCCAGACTCCGGAGAAGAGGCTGGAGTGGGTCGCAACC ATTAGTAGTGGTGGAGCTTACACCTTCTATAAAGACAGTGTGAAGGGGCG ATTCACCATCTCCAGAGACAATGCCAAGAATACCCTGTACCTGCAAATGA GCAGTCTGAGGTCTGAGGACTCGGCCATGTATTACTGTGCAAGACATAGC GGCTATGATGGTTACTACCTCTATGCTATGGACTGCTGGGGTCAAGGAAC CTCAGTCACCGTCTCCTCA.

(749) Therefore, in some embodiments, the anti-CD22 scFv V.sub.H domain comprises the amino acid sequence:

(750) TABLE-US-00342 (SEQIDNO:461,20B4) EVKLQQSGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQTSDKRLEWVAS ISSGGGRIYYPDNVKGRFTISRENAKNTLYLQMNSLKSDDTALYYCAREP PNYYGGTYGDYWGQGTTLTVSS.

(751) Therefore, in some embodiments, the anti-CD22 scFv V.sub.H domain is encoded by the nucleic acid sequence:

(752) TABLE-US-00343 (SEQIDNO:477,20B4) GAGGTCAAGCTGCAGCAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGCGTC TCTGAAACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTAACTATGGCA TGTCTTGGGTTCGCCAGACTTCAGACAAGAGGCTGGAGTGGGTCGCATCC ATTAGTAGTGGTGGTGGTAGGATATACTATCCAGACAATGTAAAGGGCCG ATTCACCATCTCCAGAGAAAATGCCAAGAACACCCTGTACCTGCAAATGA ATAGTCTGAAGTCTGACGACACGGCCTTGTATTACTGTGCAAGAGAGCCC CCTAATTACTATGGTGGTACCTACGGAGACTACTGGGGCCAAGGCACCAC TCTCACAGTCTCCTCA.

(753) In some embodiments, the anti-CD22 scFv V.sub.L domain comprises the amino acid sequence:

(754) TABLE-US-00344 (SEQIDNO:462,2B12) DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPK LLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVP PTFGGGTKLEIKR.

(755) Therefore, in some embodiments, the anti-CD22 scFv V.sub.L domain is encoded by the nucleic acid sequence:

(756) TABLE-US-00345 (SEQIDNO:478,2B12) GATGTTTTGATGACCCAAACTCCACTCTCCCTGCCTGTCAGTCTTGGAGA TCAAGCCTCCATCTCTTGCAGATCTAGTCAGAGCATTGTACATAGTAATG GAAACACCTATTTAGAATGGTACCTGCAGAAACCAGGCCAGTCTCCAAAG CTCCTGATCTACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGACAGGTT CAGTGGCAGTGGATCAGGGACAGATTTCACACTCAAGATCAGCAGAGTGG AGGCTGAGGATCTGGGAGTTTATTACTGCTTTCAAGGTTCACATGTTCCT CCGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAACGG.

(757) In some embodiments, the anti-CD22 scFv V.sub.L domain comprises the amino acid sequence:

(758) TABLE-US-00346 (SEQIDNO:463,5H12) DIQMTQSPASLSASVGETVTITCGASENIYGALNWYQRKQGKSPQLLIYG ATNLADGMSSRFSGSGSGRQYSLKISSLHPDDVATYYCQNVLSTPWTFGG GTKLEIKR.

(759) Therefore, in some embodiments, the anti-CD22 scFv V.sub.L domain is encoded by the nucleic acid sequence:

(760) TABLE-US-00347 (SEQIDNO:479,5H12) GACATCCAGATGACTCAGTCTCCAGCTTCACTGTCTGCATCTGTGGGAGA AACTGTCACCATCACATGTGGAGCAAGTGAGAATATTTACGGTGCTTTAA ATTGGTATCAGCGGAAACAGGGAAAATCTCCTCAGCTCCTGATCTATGGT GCAACCAACTTGGCAGATGGCATGTCATCGAGGTTCAGTGGCAGTGGATC TGGTAGACAGTATTCTCTCAAGATCAGTAGCCTGCATCCTGACGATGTTG CAACGTATTACTGTCAAAATGTGTTAAGTACTCCGTGGACGTTCGGTGGA GGCACCAAGCTGGAAATCAAACGG.

(761) In some embodiments, the anti-CD22 scFv V.sub.L domain comprises the amino acid sequence:

(762) TABLE-US-00348 (SEQIDNO:464,10C1) DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPKL LIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPF TFGSGTKLEIKR.

(763) Therefore, in some embodiments, the anti-CD22 scFv V.sub.L domain is encoded

(764) TABLE-US-00349 (SEQIDNO:480,10C1) GACATTGTGCTGACCCAATCTCCAGCTTCTTTGGCTGTGTCTCTAGGGCA GAGGGCCACCATCTCCTGCAAGGCCAGCCAAAGTGTTGATTATGATGGTG ATAGTTATATGAACTGGTACCAACAGAAACCAGGACAGCCACCCAAACTC CTCATCTATGCTGCATCCAATCTAGAATCTGGGATCCCAGCCAGGTTTAG TGGCAGTGGGTCTGGGACAGACTTCACCCTCAACATCCATCCTGTGGAGG AGGAGGATGCTGCAACCTATTACTGTCAGCAAAGTAATGAGGATCCATTC ACGTTCGGCTCGGGGACAAAGTTGGAAATAAAACGG.

(765) In some embodiments, the anti-CD22 scFv V.sub.L domain comprises the amino acid sequence:

(766) TABLE-US-00350 (SEQIDNO:465,10H6) DIVLTQSPAIMSASPGEKVTISCSASSSVSYMYWYQQKPGSSPKPWIYRT SNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQYHSYPYTFGGG TKLEIKR.

(767) Therefore, in some embodiments, the anti-CD22 scFv V.sub.L domain is encoded by the nucleic acid sequence:

(768) TABLE-US-00351 (SEQIDNO:481,10H6) GATATTGTGCTGACACAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGA GAAGGTCACCATATCCTGCAGTGCCAGCTCAAGTGTAAGTTACATGTACT GGTACCAGCAGAAGCCAGGATCCTCCCCCAAACCCTGGATTTATCGCACA TCCAACCTGGCTTCTGGAGTCCCTGCTCGCTTCAGTGGCAGTGGGTCTGG GACCTCTTACTCTCTCACAATCAGCAGCATGGAGGCTGAAGATGCTGCCA CTTATTACTGCCAGCAGTATCATAGTTACCCGTACACGTTCGGAGGGGGG ACCAAGCTGGAAATAAAACGG.

(769) In some embodiments, the anti-CD22 scFv V.sub.L domain comprises the amino acid sequence:

(770) TABLE-US-00352 (SEQIDNO:466,18A3) DVQITQSPSYLAASPGETITINCRASKSISKYLAWYQEKPGKTNKLLIYS GSTLQSGIPSRFSGSGSGTDFTLTISSLEPEDFAMYYCQQHNEYPWTFGG GTKLEIKR.

(771) Therefore, in some embodiments, the anti-CD22 scFv V.sub.L domain is encoded by the nucleic acid sequence:

(772) TABLE-US-00353 (SEQIDNO:482,18A3) GATGTCCAGATAACCCAGTCTCCATCTTATCTTGCTGCATCTCCTGGAGA AACCATTACTATTAATTGCAGGGCAAGTAAGAGCATTAGCAAATATTTAG CCTGGTATCAAGAGAAACCTGGGAAAACTAATAAGCTTCTTATCTACTCT GGATCCACTTTGCAATCTGGAATTCCATCAAGGTTCAGTGGCAGTGGATC TGGTACAGATTTCACTCTCACCATCAGTAGCCTGGAGCCTGAAGATTTTG CAATGTATTACTGTCAACAGCATAATGAATACCCGTGGACGTTCGGTGGA GGCACCAAGCTGGAAATCAAACGG.

(773) Therefore, in some embodiments, the anti-CD22 scFv V.sub.L domain comprises the amino acid sequence:

(774) TABLE-US-00354 (SEQIDNO:467,9D4) QIVLTQSPVIMSASPGEKVTMTCSASSSVSDMHWYQQKSGTSPKRWIYDT SKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAG TKLELKR.

(775) Therefore, in some embodiments, the anti-CD22 scFv V.sub.L domain is encoded by the nucleic acid sequence:

(776) TABLE-US-00355 (SEQIDNO:483,9D4) CAAATTGTTCTCACCCAGTCTCCAGTAATCATGTCTGCATCTCCAGGGGA GAAGGTCACCATGACCTGCAGTGCCAGCTCAAGTGTAAGTGACATGCACT GGTACCAGCAGAAGTCAGGCACCTCCCCCAAAAGATGGATTTATGACACA TCCAAACTGGCTTCTGGAGTCCCTGCTCGCTTCAGTGGCAGTGGGTCTGG GACCTCTTACTCTCTCACAATCAGCAGCATGGAGGCTGAAGATGCTGCCA CTTATTACTGCCAGCAGTGGAGTAGTAACCCGCTCACGTTCGGTGCTGGG ACCAAGCTGGAGCTGAAACGG.

(777) Therefore, in some embodiments, the anti-CD22 scFv V.sub.L domain comprises the amino acid sequence:

(778) TABLE-US-00356 (SEQIDNO:468,11D11) NIVLTQSPASLAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPKL LIYLASNLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNEDPW TFGGGTKLEIK.

(779) Therefore, in some embodiments, the anti-CD22 scFv V.sub.L domain is encoded by the nucleic acid sequence:

(780) TABLE-US-00357 (SEQIDNO:484,11D11) AACATTGTGCTGACCCAATCTCCAGCTTCTTTGGCTGTGTCTCTAGGGCA GAGGGCCACCATATCCTGCAGAGCCAGTGAAAGTGTTGATAGTTATGGCA ATAGTTTTATGCACTGGTACCAGCAGAAACCAGGACAGCCACCCAAACTC CTCATCTATCTTGCATCCAACCTAGAATCTGGGGTCCCTGCCAGGTTCAG TGGCAGTGGGTCTAGGACAGACTTCACCCTCACCATTGATCCTGTGGAGG CTGATGATGCTGCAACCTATTACTGTCAGCAAAATAATGAGGATCCGTGG ACGTTCGGTGGAGGCACCAAGCTGGAAATCAAA.

(781) Therefore, in some embodiments, the anti-CD22 scFv V.sub.L domain comprises the amino acid sequence:

(782) TABLE-US-00358 (SEQIDNO:469,20B4) DVVMTQSPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPK LLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVS YTFGGGTKLEIKR.

(783) Therefore, in some embodiments, the anti-CD22 scFv V.sub.L domain is encoded by the nucleic acid sequence:

(784) TABLE-US-00359 (SEQIDNO:485,20B4) GATGTTGTGATGACCCAAAGTCCACTCTCCCTGCCTGTCAGTCTAGGAGA TCAAGCCTCCATCTCTTGCAGATCTAGTCAGAGCCTTGTACACAGTAATG GAAACACCTATTTACATTGGTACCTGCAGAAGCCAGGCCAGTCTCCAAAG CTCCTGATCTACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGACAGGTT CAGTGGCAGTGGATCAGGGACAGATTTCACACTCAAGATCAGCAGAGTGG AGGCTGAGGATCTGGGAGTTTATTTCTGCTCTCAAAGTACACATGTTTCG TACACGTTCGGAGGGGGGACCAAACTGGAAATAAAACGG.

(785) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(786) TABLE-US-00360 (SEQIDNO:486) QVKLQQSGAELGKPGTSVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGN INPNSGSTNYNEKFKSKATLTVDKSSSTAYMQLSTLTSEDSAVYYCTRPG VWGTGTTVTVSSGGGGSGGGGSGGGGSDVLMTQTPLSLPVSLGDQASISC RSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSG TDFTLKISRVEAEDLGVYYCFQGSHVPPTFGGGTKLEIKR.

(787) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(788) TABLE-US-00361 (SEQIDNO:487) QVKLQQSGAELGKPGTSVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGN INPNSGSTNYNEKFKSKATLTVDKSSSTAYMQLSTLTSEDSAVYYCTRPG VWGTGTTVTVSSGGGGGGGGSGGGGSDIQMTQSPASLSASVGETVTITCG ASENIYGALNWYQRKQGKSPQLLIYGATNLADGMSSRFSGSGSGRQYSLK ISSLHPDDVATYYCQNVLSTPWTFGGGTKLEIKR.

(789) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(790) TABLE-US-00362 (SEQIDNO:488) QVKLQQSGAELGKPGTSVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGN INPNSGSTNYNEKFKSKATLTVDKSSSTAYMQLSTLTSEDSAVYYCTRPG VWGTGTTVTVSSGGGGSGGGGSGGGGSDIVLTQSPASLAVSLGQRATISC KASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASNLESGIPARFSGSGSGT DFTLNIHPVEEEDAATYYCQQSNEDPFTFGSGTKLEIKR.

(791) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(792) TABLE-US-00363 (SEQIDNO:489) QVKLQQSGAELGKPGTSVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGN INPNSGSTNYNEKFKSKATLTVDKSSSTAYMQLSTLTSEDSAVYYCTRPG VWGTGTTVTVSSGGGGSGGGGSGGGGSDIVLTQSPAIMSASPGEKVTISC SASSSVSYMYWYQQKPGSSPKPWIYRTSNLASGVPARFSGSGSGTSYSLT ISSMEAEDAATYYCQQYHSYPYTFGGGTKLEIKR.

(793) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(794) TABLE-US-00364 (SEQIDNO:490) QVKLQQSGAELGKPGTSVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGN INPNSGSTNYNEKFKSKATLTVDKSSSTAYMQLSTLTSEDSAVYYCTRPG VWGTGTTVTVSSGGGGSGGGGSGGGGSDVQITQSPSYLAASPGETITINC RASKSISKYLAWYQEKPGKTNKLLIYSGSTLQSGIPSRFSGSGSGTDFTL TISSLEPEDFAMYYCQQHNEYPWTFGGGTKLEIKR.

(795) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(796) TABLE-US-00365 (SEQIDNO:491) QVKLQQSGAELGKPGTSVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGN INPNSGSTNYNEKFKSKATLTVDKSSSTAYMQLSTLTSEDSAVYYCTRPG VWGTGTTVTVSSGGGGSGGGGSGGGGSQIVLTQSPVIMSASPGEKVTMTC SASSSVSDMHWYQQKSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLT ISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKR.

(797) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(798) TABLE-US-00366 (SEQIDNO:492) QVKLQQSGAELGKPGTSVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGN INPNSGSTNYNEKFKSKATLTVDKSSSTAYMQLSTLTSEDSAVYYCTRPG VWGTGTTVTVSSGGGGSGGGGSGGGGSNIVLTQSPASLAVSLGQRATISC RASESVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSRT DFTLTIDPVEADDAATYYCQQNNEDPWTFGGGTKLEIK.

(799) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(800) TABLE-US-00367 (SEQIDNO:493) QVKLQQSGAELGKPGTSVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGN INPNSGSTNYNEKFKSKATLTVDKSSSTAYMQLSTLTSEDSAVYYCTRPG VWGTGTTVTVSSGGGGSGGGGSGGGGSDVVMTQSPLSLPVSLGDQASISC RSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSG TDFTLKISRVEAEDLGVYFCSQSTHVSYTFGGGTKLEIKR.

(801) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(802) TABLE-US-00368 (SEQIDNO:494) EVKLQQSGGGLVQPGGSRKLSCAASGFTFSSFGMHWVRQAPEKGLEWVAY ISSGSSTLHYADTVKGRFTISRDNPKNTLFLQMKLPSLCYGLLGSRNLSH RLLSQNDTPICLGGGGSGGGGSGGGGSDVLMTQTPLSLPVSLGDQASISC RSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSG TDFTLKISRVEAEDLGVYYCFQGSHVPPTFGGGTKLEIKR.

(803) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(804) TABLE-US-00369 (SEQIDNO:495) EVKLQQSGGGLVQPGGSRKLSCAASGFTFSSFGMHWVRQAPEKGLEWVAY ISSGSSTLHYADTVKGRFTISRDNPKNTLFLQMKLPSLCYGLLGSRNLSH RLLSQNDTPICLGGGGSGGGGSGGGGSDIQMTQSPASLSASVGETVTITC GASENIYGALNWYQRKQGKSPQLLIYGATNLADGMSSRFSGSGSGRQYSL KISSLHPDDVATYYCQNVLSTPWTFGGGTKLEIKR.

(805) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(806) TABLE-US-00370 (SEQIDNO:496) EVKLQQSGGGLVQPGGSRKLSCAASGFTFSSFGMHWVRQAPEKGLEWVAY ISSGSSTLHYADTVKGRFTISRDNPKNTLFLQMKLPSLCYGLLGSRNLSH RLLSQNDTPICLGGGGSGGGGSGGGGSDIVLTQSPASLAVSLGQRATISC KASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASNLESGIPARFSGSGSGT DFTLNIHPVEEEDAATYYCQQSNEDPFTFGSGTKLEIKR.

(807) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(808) TABLE-US-00371 (SEQIDNO:497) EVKLQQSGGGLVQPGGSRKLSCAASGFTFSSFGMHWVRQAPEKGLEWVAY ISSGSSTLHYADTVKGRFTISRDNPKNTLFLQMKLPSLCYGLLGSRNLSH RLLSQNDTPICLGGGGSGGGGSGGGGSDIVLTQSPAIMSASPGEKVTISC SASSSVSYMYWYQQKPGSSPKPWIYRTSNLASGVPARFSGSGSGTSYSLT ISSMEAEDAATYYCQQYHSYPYTFGGGTKLEIKR.

(809) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(810) TABLE-US-00372 (SEQIDNO:498) EVKLQQSGGGLVQPGGSRKLSCAASGFTFSSFGMHWVRQAPEKGLEWVAY ISSGSSTLHYADTVKGRFTISRDNPKNTLFLQMKLPSLCYGLLGSRNLSH RLLSQNDTPICLGGGGSGGGGSGGGGSDVQITQSPSYLAASPGETITINC RASKSISKYLAWYQEKPGKTNKLLIYSGSTLQSGIPSRFSGSGSGTDFTL TISSLEPEDFAMYYCQQHNEYPWTFGGGTKLEIKR.

(811) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(812) TABLE-US-00373 (SEQIDNO:499) EVKLQQSGGGLVQPGGSRKLSCAASGFTFSSFGMHWVRQAPEKGLEWVAY ISSGSSTLHYADTVKGRFTISRDNPKNTLFLQMKLPSLCYGLLGSRNLSH RLLSQNDTPICLGGGGSGGGGSGGGGSQIVLTQSPVIMSASPGEKVTMTC SASSSVSDMHWYQQKSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLT ISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKR.

(813) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(814) TABLE-US-00374 (SEQIDNO:500) EVKLQQSGGGLVQPGGSRKLSCAASGFTFSSFGMHWVRQAPEKGLEWVAY ISSGSSTLHYADTVKGRFTISRDNPKNTLFLQMKLPSLCYGLLGSRNLSH RLLSQNDTPICLGGGGGGGGSGGGGSNIVLTQSPASLAVSLGQRATISCR ASESVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSRTD FTLTIDPVEADDAATYYCQQNNEDPWTFGGGTKLEIK.

(815) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(816) TABLE-US-00375 (SEQIDNO:501) EVKLQQSGGGLVQPGGSRKLSCAASGFTFSSFGMHWVRQAPEKGLEWVAY ISSGSSTLHYADTVKGRFTISRDNPKNTLFLQMKLPSLCYGLLGSRNLSH RLLSQNDTPICLGGGGSGGGGSGGGGSDVVMTQSPLSLPVSLGDQASISC RSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSG TDFTLKISRVEAEDLGVYFCSQSTHVSYTFGGGTKLEIKR.

(817) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(818) TABLE-US-00376 (SEQIDNO:502) VKLLESGGGLVQPGGSLKLSCAASGFEFSRYWMSWVRQVPGKGLEWIGEV NPDSSTINYTTSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCGRDSN YGYFDVWGTGTTVTVSSGGGGSGGGGSGGGGSDVLMTQTPLSLPVSLGDQ ASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFS GSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPPTFGGGTKLEIKR.

(819) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(820) TABLE-US-00377 (SEQIDNO:503) VKLLESGGGLVQPGGSLKLSCAASGFEFSRYWMSWVRQVPGKGLEWIGEV NPDSSTINYTTSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCGRDSN YGYFDVWGTGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSPASLSASVGET VTITCGASENIYGALNWYQRKQGKSPQLLIYGATNLADGMSSRFSGSGSG RQYSLKISSLHPDDVATYYCQNVLSTPWTFGGGTKLEIKR.

(821) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(822) TABLE-US-00378 (SEQIDNO:504) VKLLESGGGLVQPGGSLKLSCAASGFEFSRYWMSWVRQVPGKGLEWIGEV NPDSSTINYTTSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCGRDSN YGYFDVWGTGTTVTVSSGGGGSGGGGSGGGGSDIVLTQSPASLAVSLGQR ATISCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASNLESGIPARFSG SGSGTDFTLNIHPVEEEDAATYYCQQSNEDPFTFGSGTKLEIKR.

(823) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(824) TABLE-US-00379 (SEQIDNO:505) VKLLESGGGLVQPGGSLKLSCAASGFEFSRYWMSWVRQVPGKGLEWIGEV NPDSSTINYTTSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCGRDSN YGYFDVWGTGTTVTVSSGGGGSGGGGSGGGGSDIVLTQSPAIMSASPGEK VTISCSASSSVSYMYWYQQKPGSSPKPWIYRTSNLASGVPARFSGSGSGT SYSLTISSMEAEDAATYYCQQYHSYPYTFGGGTKLEIKR.

(825) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(826) TABLE-US-00380 (SEQIDNO:506) VKLLESGGGLVQPGGSLKLSCAASGFEFSRYWMSWVRQVPGKGLEWIGEV NPDSSTINYTTSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCGRDSN YGYFDVWGTGTTVTVSSGGGGSGGGGSGGGGSDVQITQSPSYLAASPGET ITINCRASKSISKYLAWYQEKPGKTNKLLIYSGSTLQSGIPSRFSGSGSG TDFTLTISSLEPEDFAMYYCQQHNEYPWTFGGGTKLEIKR.

(827) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(828) TABLE-US-00381 (SEQIDNO:507) VKLLESGGGLVQPGGSLKLSCAASGFEFSRYWMSWVRQVPGKGLEWIGEV NPDSSTINYTTSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCGRDSN YGYFDVWGTGTTVTVSSGGGGSGGGGSGGGGSQIVLTQSPVIMSASPGEK VTMTCSASSSVSDMHWYQQKSGTSPKRWIYDTSKLASGVPARFSGSGSGT SYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKR.

(829) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(830) TABLE-US-00382 (SEQIDNO:508) VKLLESGGGLVQPGGSLKLSCAASGFEFSRYWMSWVRQVPGKGLEWIGEV NPDSSTINYTTSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCGRDSN YGYFDVWGTGTTVTVSSGGGGSGGGGSGGGGSNIVLTQSPASLAVSLGQR ATISCRASESVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPARFSG SGSRTDFTLTIDPVEADDAATYYCQQNNEDPWTFGGGTKLEIK.

(831) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(832) TABLE-US-00383 (SEQIDNO:509) VKLLESGGGLVQPGGSLKLSCAASGFEFSRYWMSWVRQVPGKGLEWIGEV NPDSSTINYTTSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCGRDSN YGYFDVWGTGTTVTVSSGGGGSGGGGSGGGGSDVVMTQSPLSLPVSLGDQ ASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFS GSGSGTDFTLKISRVEAEDLGVYFCSQSTHVSYTFGGGTKLEIKR.

(833) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(834) TABLE-US-00384 (SEQIDNO:510) VQLKESGPGLVAPSQSLSITCTVSGFSLTGYGVNWVRQPPGKGLEWLGMI WGDGSTDYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTARYYCARGGYD FDYWGQGTTLTVSSGGGGSGGGGSGGGGSDVLMTQTPLSLPVSLGDQASI SCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSG SGTDFTLKISRVEAEDLGVYYCFQGSHVPPTFGGGTKLEIKR.

(835) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(836) TABLE-US-00385 (SEQIDNO:511) VQLKESGPGLVAPSQSLSITCTVSGFSLTGYGVNWVRQPPGKGLEWLGMI WGDGSTDYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTARYYCARGGYD FDYWGQGTTLTVSSGGGGGGGGSGGGGSDIQMTQSPASLSASVGETVTIT CGASENIYGALNWYQRKQGKSPQLLIYGATNLADGMSSRFSGSGSGRQYS LKISSLHPDDVATYYCQNVLSTPWTFGGGTKLEIKR.

(837) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(838) TABLE-US-00386 (SEQIDNO:512) VQLKESGPGLVAPSQSLSITCTVSGFSLTGYGVNWVRQPPGKGLEWLGMI WGDGSTDYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTARYYCARGGYD FDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVLTQSPASLAVSLGQRATI SCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASNLESGIPARFSGSGS GTDFTLNIHPVEEEDAATYYCQQSNEDPFTFGSGTKLEIKR.

(839) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(840) TABLE-US-00387 (SEQIDNO:513) VQLKESGPGLVAPSQSLSITCTVSGFSLTGYGVNWVRQPPGKGLEWLGMI WGDGSTDYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTARYYCARGGYD FDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVLTQSPAIMSASPGEKVTI SCSASSSVSYMYWYQQKPGSSPKPWIYRTSNLASGVPARFSGSGSGTSYS LTISSMEAEDAATYYCQQYHSYPYTFGGGTKLEIKR.

(841) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(842) TABLE-US-00388 (SEQIDNO:514) VQLKESGPGLVAPSQSLSITCTVSGFSLTGYGVNWVRQPPGKGLEWLGMI WGDGSTDYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTARYYCARGGYD FDYWGQGTTLTVSSGGGGSGGGGSGGGGSDVQITQSPSYLAASPGETITI NCRASKSISKYLAWYQEKPGKTNKLLIYSGSTLQSGIPSRFSGSGSGTDF TLTISSLEPEDFAMYYCQQHNEYPWTFGGGTKLEIKR.

(843) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(844) TABLE-US-00389 (SEQIDNO:515) VQLKESGPGLVAPSQSLSITCTVSGFSLTGYGVNWVRQPPGKGLEWLGMI WGDGSTDYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTARYYCARGGYD FDYWGQGTTLTVSSGGGGGGGGSGGGGSQIVLTQSPVIMSASPGEKVTMT CSASSSVSDMHWYQQKSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSL TISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKR.

(845) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(846) TABLE-US-00390 (SEQIDNO:516) VQLKESGPGLVAPSQSLSITCTVSGFSLTGYGVNWVRQPPGKGLEWLGMI WGDGSTDYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTARYYCARGGYD FDYWGQGTTLTVSSGGGGSGGGGGGGGSNIVLTQSPASLAVSLGQRATIS CRASESVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSR TDFTLTIDPVEADDAATYYCQQNNEDPWTFGGGTKLEIK.

(847) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(848) TABLE-US-00391 (SEQIDNO:517) VQLKESGPGLVAPSQSLSITCTVSGFSLTGYGVNWVRQPPGKGLEWLGMI WGDGSTDYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTARYYCARGGYD FDYWGQGTTLTVSSGGGGSGGGGSGGGGSDVVMTQSPLSLPVSLGDQASI SCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSG SGTDFTLKISRVEAEDLGVYFCSQSTHVSYTFGGGTKLEIKR.

(849) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(850) TABLE-US-00392 (SEQIDNO:518) VQLQQSGAELARPGASVKMSCKASGYTFTSYWMHWVKQRPGQGLEWIGAI YPGNSDTSYNQKFKGKAKLTAVTSASTAYMELSSLTNEDSAVYYCTRSHY VEGYFDVWGTGTTVTVSSGGGGSGGGGSGGGGSDVLMTQTPLSLPVSLGD QASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPPTFGGGTKLEIKR.

(851) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(852) TABLE-US-00393 (SEQIDNO:519) VQLQQSGAELARPGASVKMSCKASGYTFTSYWMHWVKQRPGQGLEWIGAI YPGNSDTSYNQKFKGKAKLTAVTSASTAYMELSSLTNEDSAVYYCTRSHY VEGYFDVWGTGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSPASLSASVGE TVTITCGASENIYGALNWYQRKQGKSPQLLIYGATNLADGMSSRFSGSGS GRQYSLKISSLHPDDVATYYCQNVLSTPWTFGGGTKLEIKR.

(853) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(854) TABLE-US-00394 (SEQIDNO:520) VQLQQSGAELARPGASVKMSCKASGYTFTSYWMHWVKQRPGQGLEWIGAI YPGNSDTSYNQKFKGKAKLTAVTSASTAYMELSSLTNEDSAVYYCTRSHY VEGYFDVWGTGTTVTVSSGGGGSGGGGSGGGGSDIVLTQSPASLAVSLGQ RATISCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASNLESGIPARFS GSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPFTFGSGTKLEIKR.

(855) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(856) TABLE-US-00395 (SEQIDNO:521) VQLQQSGAELARPGASVKMSCKASGYTFTSYWMHWVKQRPGQGLEWIGAI YPGNSDTSYNQKFKGKAKLTAVTSASTAYMELSSLTNEDSAVYYCTRSHY VEGYFDVWGTGTTVTVSSGGGGSGGGGSGGGGSDIVLTQSPAIMSASPGE KVTISCSASSSVSYMYWYQQKPGSSPKPWIYRTSNLASGVPARFSGSGSG TSYSLTISSMEAEDAATYYCQQYHSYPYTFGGGTKLEIKR.

(857) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(858) TABLE-US-00396 (SEQIDNO:522) VQLQQSGAELARPGASVKMSCKASGYTFTSYWMHWVKQRPGQGLEWIGAI YPGNSDTSYNQKFKGKAKLTAVTSASTAYMELSSLTNEDSAVYYCTRSHY VEGYFDVWGTGTTVTVSSGGGGSGGGGSGGGGSDVQITQSPSYLAASPGE TITINCRASKSISKYLAWYQEKPGKTNKLLIYSGSTLQSGIPSRFSGSGS GTDFTLTISSLEPEDFAMYYCQQHNEYPWTFGGGTKLEIKR.

(859) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(860) TABLE-US-00397 (SEQIDNO:523) VQLQQSGAELARPGASVKMSCKASGYTFTSYWMHWVKQRPGQGLEWIGAI YPGNSDTSYNQKFKGKAKLTAVTSASTAYMELSSLTNEDSAVYYCTRSHY VEGYFDVWGTGTTVTVSSGGGGSGGGGSGGGGSQIVLTQSPVIMSASPGE KVTMTCSASSSVSDMHWYQQKSGTSPKRWIYDTSKLASGVPARFSGSGSG TSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKR.

(861) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(862) TABLE-US-00398 (SEQIDNO:524) VQLQQSGAELARPGASVKMSCKASGYTFTSYWMHWVKQRPGQGLEWIGAI YPGNSDTSYNQKFKGKAKLTAVTSASTAYMELSSLTNEDSAVYYCTRSHY VEGYFDVWGTGTTVTVSSGGGGSGGGGSGGGGSNIVLTQSPASLAVSLGQ RATISCRASESVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPARFS GSGSRTDFTLTIDPVEADDAATYYCQQNNEDPWTFGGGTKLEIK.

(863) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(864) TABLE-US-00399 (SEQIDNO:525) VQLQQSGAELARPGASVKMSCKASGYTFTSYWMHWVKQRPGQGLEWIGAI YPGNSDTSYNQKFKGKAKLTAVTSASTAYMELSSLTNEDSAVYYCTRSHY VEGYFDVWGTGTTVTVSSGGGGSGGGGSGGGGSDVVMTQSPLSLPVSLGD QASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRF SGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVSYTFGGGTKLEIKR.

(865) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(866) TABLE-US-00400 (SEQIDNO:526) QVKLQQSGAELVKPGASVKISCKASGYAFSSSWMNWVKQRPGKGLEWIGQ IYPGDGDTKYNGKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCANSN YPSSQSSRTYSRRDWFAYWGQGTLVTVSAGGGGSGGGGSGGGGSDVLMTQ TPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKV SNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPPTFGGG TKLEIKR.

(867) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(868) TABLE-US-00401 (SEQIDNO:527) QVKLQQSGAELVKPGASVKISCKASGYAFSSSWMNWVKQRPGKGLEWIGQ IYPGDGDTKYNGKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCANSN YPSSQSSRTYSRRDWFAYWGQGTLVTVSAGGGGSGGGGSGGGGSDIQMTQ SPASLSASVGETVTITCGASENIYGALNWYQRKQGKSPQLLIYGATNLAD GMSSRFSGSGSGRQYSLKISSLHPDDVATYYCQNVLSTPWTFGGGTKLEI KR.

(869) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(870) TABLE-US-00402 (SEQIDNO:528) QVKLQQSGAELVKPGASVKISCKASGYAFSSSWMNWVKQRPGKGLEWIGQ IYPGDGDTKYNGKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCANSN YPSSQSSRTYSRRDWFAYWGQGTLVTVSAGGGGSGGGGSGGGGSDIVLTQ SPASLAVSLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAAS NLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPFTFGSGT KLEIKR.

(871) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(872) TABLE-US-00403 (SEQIDNO:529) QVKLQQSGAELVKPGASVKISCKASGYAFSSSWMNWVKQRPGKGLEWIGQ IYPGDGDTKYNGKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCANSN YPSSQSSRTYSRRDWFAYWGQGTLVTVSAGGGGSGGGGSGGGGSDIVLTQ SPAIMSASPGEKVTISCSASSSVSYMYWYQQKPGSSPKPWIYRTSNLASG VPARFSGSGSGTSYSLTISSMEAEDAATYYCQQYHSYPYTFGGGTKLEIK R.

(873) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(874) TABLE-US-00404 (SEQIDNO:530) QVKLQQSGAELVKPGASVKISCKASGYAFSSSWMNWVKQRPGKGLEWIGQ IYPGDGDTKYNGKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCANSN YPSSQSSRTYSRRDWFAYWGQGTLVTVSAGGGGSGGGGSGGGGSDVQITQ SPSYLAASPGETITINCRASKSISKYLAWYQEKPGKTNKLLIYSGSTLQS GIPSRFSGSGSGTDFTLTISSLEPEDFAMYYCQQHNEYPWTFGGGTKLEI KR.

(875) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(876) TABLE-US-00405 (SEQIDNO:531) QVKLQQSGAELVKPGASVKISCKASGYAFSSSWMNWVKQRPGKGLEWIGQ IYPGDGDTKYNGKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCANSN YPSSQSSRTYSRRDWFAYWGQGTLVTVSAGGGGSGGGGSGGGGSQIVLTQ SPVIMSASPGEKVTMTCSASSSVSDMHWYQQKSGTSPKRWIYDTSKLASG VPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELK R.

(877) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(878) TABLE-US-00406 (SEQIDNO:532) QVKLQQSGAELVKPGASVKISCKASGYAFSSSWMNWVKQRPGKGLEWIGQ IYPGDGDTKYNGKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCANSN YPSSQSSRTYSRRDWFAYWGQGTLVTVSAGGGGSGGGGSGGGGSNIVLTQ SPASLAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPKLLIYLAS NLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNEDPWTFGGGT KLEIK.

(879) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(880) TABLE-US-00407 (SEQIDNO:533) QVKLQQSGAELVKPGASVKISCKASGYAFSSSWMNWVKQRPGKGLEWIGQ IYPGDGDTKYNGKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCANSN YPSSQSSRTYSRRDWFAYWGQGTLVTVSAGGGGSGGGGSGGGGSDVVMTQ SPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKV SNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVSYTFGGG TKLEIKR.

(881) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(882) TABLE-US-00408 (SEQIDNO:534) DVKLQESGGGLVKPGGSLKLSCAVSGFTFSSFAMSWVRQTPEKRLEWVAT ISSGGAYTFYKDSVKGRFTISRDNAKNTLYLQMSSLRSEDSAMYYCARHS GYDGYYLYAMDCWGQGTSVTVSSGGGGSGGGGSGGGGSDVLMTQTPLSLP VSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSG VPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPPTFGGGTKLEIK R.

(883) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(884) TABLE-US-00409 (SEQIDNO:535) DVKLQESGGGLVKPGGSLKLSCAVSGFTFSSFAMSWVRQTPEKRLEWVAT ISSGGAYTFYKDSVKGRFTISRDNAKNTLYLQMSSLRSEDSAMYYCARHS GYDGYYLYAMDCWGQGTSVTVSSGGGGSGGGGSGGGGSDIQMTQSPASLS ASVGETVTITCGASENIYGALNWYQRKQGKSPQLLIYGATNLADGMSSRF SGSGSGRQYSLKISSLHPDDVATYYCQNVLSTPWTFGGGTKLEIKR.

(885) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(886) TABLE-US-00410 (SEQIDNO:536) DVKLQESGGGLVKPGGSLKLSCAVSGFTFSSFAMSWVRQTPEKRLEWVAT ISSGGAYTFYKDSVKGRFTISRDNAKNTLYLQMSSLRSEDSAMYYCARHS GYDGYYLYAMDCWGQGTSVTVSSGGGGGGGGSGGGGSDIVLTQSPASLAV SLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASNLESGIP ARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPFTFGSGTKLEIKR.

(887) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(888) TABLE-US-00411 (SEQIDNO:537) DVKLQESGGGLVKPGGSLKLSCAVSGFTFSSFAMSWVRQTPEKRLEWVAT ISSGGAYTFYKDSVKGRFTISRDNAKNTLYLQMSSLRSEDSAMYYCARHS GYDGYYLYAMDCWGQGTSVTVSSGGGGSGGGGSGGGGSDIVLTQSPAIMS ASPGEKVTISCSASSSVSYMYWYQQKPGSSPKPWIYRTSNLASGVPARFS GSGSGTSYSLTISSMEAEDAATYYCQQYHSYPYTFGGGTKLEIKR.

(889) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(890) TABLE-US-00412 (SEQIDNO:538) DVKLQESGGGLVKPGGSLKLSCAVSGFTFSSFAMSWVRQTPEKRLEWVAT ISSGGAYTFYKDSVKGRFTISRDNAKNTLYLQMSSLRSEDSAMYYCARHS GYDGYYLYAMDCWGQGTSVTVSSGGGGSGGGGSGGGGSDVQITQSPSYLA ASPGETITINCRASKSISKYLAWYQEKPGKTNKLLIYSGSTLQSGIPSRF SGSGSGTDFTLTISSLEPEDFAMYYCQQHNEYPWTFGGGTKLEIKR.

(891) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(892) TABLE-US-00413 (SEQIDNO:539) DVKLQESGGGLVKPGGSLKLSCAVSGFTFSSFAMSWVRQTPEKRLEWVA TISSGGAYTFYKDSVKGRFTISRDNAKNTLYLQMSSLRSEDSAMYYCAR HSGYDGYYLYAMDCWGQGTSVTVSSGGGGSGGGGSGGGGSQIVLTQSPV IMSASPGEKVTMTCSASSSVSDMHWYQQKSGTSPKRWIYDTSKLASGVP ARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKR.

(893) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(894) TABLE-US-00414 (SEQIDNO:540) DVKLQESGGGLVKPGGSLKLSCAVSGFTFSSFAMSWVRQTPEKRLEWVA TISSGGAYTFYKDSVKGRFTISRDNAKNTLYLQMSSLRSEDSAMYYCAR HSGYDGYYLYAMDCWGQGTSVTVSSGGGGSGGGGSGGGGSNIVLTQSPA SLAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPKLLIYLASNL ESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNEDPWTFGGGTK LEIK.

(895) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(896) TABLE-US-00415 (SEQIDNO:541) DVKLQESGGGLVKPGGSLKLSCAVSGFTFSSFAMSWVRQTPEKRLEWVA TISSGGAYTFYKDSVKGRFTISRDNAKNTLYLQMSSLRSEDSAMYYCAR HSGYDGYYLYAMDCWGQGTSVTVSSGGGGSGGGGSGGGGSDVVMTQSPL SLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSN RFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVSYTFGGGT KLEIKR.

(897) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(898) TABLE-US-00416 (SEQIDNO:542) EVKLQQSGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQTSDKRLEWVA SISSGGGRIYYPDNVKGRFTISRENAKNTLYLQMNSLKSDDTALYYCAR EPPNYYGGTYGDYWGQGTTLTVSSGGGGSGGGGSGGGGSDVLMTQTPLS LPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNR FSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPPTFGGGTK LEIKR.

(899) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(900) TABLE-US-00417 (SEQIDNO:543) EVKLQQSGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQTSDKRLEWVA SISSGGGRIYYPDNVKGRFTISRENAKNTLYLQMNSLKSDDTALYYCAR EPPNYYGGTYGDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIQMTQSPAS LSASVGETVTITCGASENIYGALNWYQRKQGKSPQLLIYGATNLADGMS SRFSGSGSGRQYSLKISSLHPDDVATYYCQNVLSTPWTFGGGTKLEIKR.

(901) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(902) TABLE-US-00418 (SEQIDNO:544) EVKLQQSGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQTSDKRLEWVA SISSGGGRIYYPDNVKGRFTISRENAKNTLYLQMNSLKSDDTALYYCAR EPPNYYGGTYGDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVLTQSPAS LAVSLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASNLE SGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPFTFGSGTKL EIKR.

(903) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(904) TABLE-US-00419 (SEQIDNO:545) EVKLQQSGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQTSDKRLEWVA SISSGGGRIYYPDNVKGRFTISRENAKNTLYLQMNSLKSDDTALYYCAR EPPNYYGGTYGDYWGQGTTLTVSSGGGGSGGGGSGGGGSDIVLTQSPAI MSASPGEKVTISCSASSSVSYMYWYQQKPGSSPKPWIYRTSNLASGVPA RFSGSGSGTSYSLTISSMEAEDAATYYCQQYHSYPYTFGGGTKLEIKR.

(905) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(906) TABLE-US-00420 (SEQIDNO:546) EVKLQQSGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQTSDKRLEWVA SISSGGGRIYYPDNVKGRFTISRENAKNTLYLQMNSLKSDDTALYYCAR EPPNYYGGTYGDYWGQGTTLTVSSGGGGSGGGGSGGGGSDVQITQSPSY LAASPGETITINCRASKSISKYLAWYQEKPGKTNKLLIYSGSTLQSGIP SRFSGSGSGTDFTLTISSLEPEDFAMYYCQQHNEYPWTFGGGTKLEIKR.

(907) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(908) TABLE-US-00421 (SEQIDNO:547) EVKLQQSGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQTSDKRLEWVA SISSGGGRIYYPDNVKGRFTISRENAKNTLYLQMNSLKSDDTALYYCAR EPPNYYGGTYGDYWGQGTTLTVSSGGGGSGGGGSGGGGSQIVLTQSPVI MSASPGEKVTMTCSASSSVSDMHWYQQKSGTSPKRWIYDTSKLASGVPA RFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKR.

(909) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(910) TABLE-US-00422 (SEQIDNO:548) EVKLQQSGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQTSDKRLEWVA SISSGGGRIYYPDNVKGRFTISRENAKNTLYLQMNSLKSDDTALYYCAR EPPNYYGGTYGDYWGQGTTLTVSSGGGGSGGGGSGGGGSNIVLTQSPAS LAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPKLLIYLASNLE SGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNEDPWTFGGGTKL EIK.

(911) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(912) TABLE-US-00423 (SEQIDNO:549) EVKLQQSGGGLVKPGASLKLSCAASGFTFSNYGMSWVRQTSDKRLEWVA SISSGGGRIYYPDNVKGRFTISRENAKNTLYLQMNSLKSDDTALYYCAR EPPNYYGGTYGDYWGQGTTLTVSSGGGGSGGGGSGGGGSDVVMTQSPLS LPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNR FSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVSYTFGGGTK LEIKR.

(913) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(914) TABLE-US-00424 (SEQIDNO:550) DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSP KLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSH VPPTFGGGTKLEIKRGGGGSGGGGSGGGGSQVKLQQSGAELGKPGTSVK LSCKASGYTFTSYWMHWVKQRPGQGLEWIGNINPNSGSTNYNEKFKSKA TLTVDKSSSTAYMQLSTLTSEDSAVYYCTRPGVWGTGTTVTVSS.

(915) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(916) TABLE-US-00425 (SEQIDNO:551) DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSP KLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSH VPPTFGGGTKLEIKRGGGGSGGGGSGGGGSEVKLQQSGGGLVQPGGSRK LSCAASGFTFSSFGMHWVRQAPEKGLEWAYISSGSSTLHYADTVKGRFT ISRDNPKNTLFLQMKLPSLCYGLLGSRNLSHRLLSQNDTPICL.

(917) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(918) TABLE-US-00426 (SEQIDNO:552) DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSP KLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSH VPPTFGGGTKLEIKRGGGGSGGGGSGGGGSVKLLESGGGLVQPGGSLKL SCAASGFEFSRYWMSWVRQVPGKGLEWIGEVNPDSSTINYTTSLKDKFI ISRDNAKNTLYLQMSKVRSEDTALYYCGRDSNYGYFDVWGTGTTVTVSS.

(919) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(920) TABLE-US-00427 (SEQIDNO:553) DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSP KLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSH VPPTFGGGTKLEIKRGGGGSGGGGSGGGGSVQLKESGPGLVAPSQSLSI TCTVSGFSLTGYGVNWVRQPPGKGLEWLGMIWGDGSTDYNSALKSRLSI SKDNSKSQVFLKMNSLQTDDTARYYCARGGYDFDYWGQGTTLTVSS.

(921) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(922) TABLE-US-00428 (SEQIDNO:554) DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSP KLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSH VPPTFGGGTKLEIKRGGGGSGGGGSGGGGSVQLQQSGAELARPGASVKM SCKASGYTFTSYWMHWVKQRPGQGLEWIGAIYPGNSDTSYNQKFKGKAK LTAVTSASTAYMELSSLTNEDSAVYYCTRSHYVEGYFDVWGTGTTVTVS S.

(923) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(924) TABLE-US-00429 (SEQIDNO:555) DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSP KLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSH VPPTFGGGTKLEIKRGGGGSGGGGSGGGGSQVKLQQSGAELVKPGASVK ISCKASGYAFSSSWMNWVKQRPGKGLEWIGQIYPGDGDTKYNGKFKGKA TLTADKSSSTAYMQLSSLTSEDSAVYFCANSNYPSSQSSRTYSRRDWFA YWGQGTLVTVSA.

(925) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(926) TABLE-US-00430 (SEQIDNO:556) DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSP KLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSH VPPTFGGGTKLEIKRGGGGSGGGGSGGGGSDVKLQESGGGLVKPGGSLK LSCAVSGFTFSSFAMSWVRQTPEKRLEWVATISSGGAYTFYKDSVKGRF TISRDNAKNTLYLQMSSLRSEDSAMYYCARHSGYDGYYLYAMDCWGQGT SVTVSS.

(927) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(928) TABLE-US-00431 (SEQIDNO:557) DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSP KLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSH VPPTFGGGTKLEIKRGGGGSGGGGSGGGGSEVKLQQSGGGLVKPGASLK LSCAASGFTFSNYGMSWVRQTSDKRLEWVASISSGGGRIYYPDNVKGRF TISRENAKNTLYLQMNSLKSDDTALYYCAREPPNYYGGTYGDYWGQGTT LTVSS.

(929) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(930) TABLE-US-00432 (SEQIDNO:558) DIQMTQSPASLSASVGETVTITCGASENIYGALNWYQRKQGKSPQLLIY GATNLADGMSSRFSGSGSGRQYSLKISSLHPDDVATYYCQNVLSTPWTF GGGTKLEIKRGGGGSGGGGSGGGGSQVKLQQSGAELGKPGTSVKLSCKA SGYTFTSYWMHWVKQRPGQGLEWIGNINPNSGSTNYNEKFKSKATLTVD KSSSTAYMQLSTLTSEDSAVYYCTRPGVWGTGTTVTVSS.

(931) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(932) TABLE-US-00433 (SEQIDNO:559) DIQMTQSPASLSASVGETVTITCGASENIYGALNWYQRKQGKSPQLLIY GATNLADGMSSRFSGSGSGRQYSLKISSLHPDDVATYYCQNVLSTPWTF GGGTKLEIKRGGGGSGGGGSGGGGSEVKLQQSGGGLVQPGGSRKLSCAA SGFTFSSFGMHWVRQAPEKGLEWVAYISSGSSTLHYADTVKGRFTISRD NPKNTLFLQMKLPSLCYGLLGSRNLSHRLLSQNDTPICL.

(933) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(934) TABLE-US-00434 (SEQIDNO:560) DIQMTQSPASLSASVGETVTITCGASENIYGALNWYQRKQGKSPQLLIY GATNLADGMSSRFSGSGSGRQYSLKISSLHPDDVATYYCQNVLSTPWTF GGGTKLEIKRGGGGSGGGGSGGGGSVKLLESGGGLVQPGGSLKLSCAAS GFEFSRYWMSWVRQVPGKGLEWIGEVNPDSSTINYTTSLKDKFIISRDN AKNTLYLQMSKVRSEDTALYYCGRDSNYGYFDVWGTGTTVTVSS.

(935) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(936) TABLE-US-00435 (SEQIDNO:561) DIQMTQSPASLSASVGETVTITCGASENIYGALNWYQRKQGKSPQLLIY GATNLADGMSSRFSGSGSGRQYSLKISSLHPDDVATYYCQNVLSTPWTF GGGTKLEIKRGGGGSGGGGSGGGGSVQLKESGPGLVAPSQSLSITCTVS GFSLTGYGVNWVRQPPGKGLEWLGMIWGDGSTDYNSALKSRLSISKDNS KSQVFLKMNSLQTDDTARYYCARGGYDFDYWGQGTTLTVSS.

(937) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(938) TABLE-US-00436 (SEQIDNO:562) DIQMTQSPASLSASVGETVTITCGASENIYGALNWYQRKQGKSPQLLIY GATNLADGMSSRFSGSGSGRQYSLKISSLHPDDVATYYCQNVLSTPWTF GGGTKLEIKRGGGGSGGGGSGGGGSVQLQQSGAELARPGASVKMSCKAS GYTFTSYWMHWVKQRPGQGLEWIGAIYPGNSDTSYNQKFKGKAKLTAVT SASTAYMELSSLTNEDSAVYYCTRSHYVEGYFDVWGTGTTVTVSS.

(939) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(940) TABLE-US-00437 (SEQIDNO:563) DIQMTQSPASLSASVGETVTITCGASENIYGALNWYQRKQGKSPQLLIY GATNLADGMSSRFSGSGSGRQYSLKISSLHPDDVATYYCQNVLSTPWTF GGGTKLEIKRGGGGSGGGGSGGGGSQVKLQQSGAELVKPGASVKISCKA SGYAFSSSWMNWVKQRPGKGLEWIGQIYPGDGDTKYNGKFKGKATLTAD KSSSTAYMQLSSLTSEDSAVYFCANSNYPSSQSSRTYSRRDWFAYWGQG TLVTVSA.

(941) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(942) TABLE-US-00438 (SEQIDNO:564) DIQMTQSPASLSASVGETVTITCGASENIYGALNWYQRKQGKSPQLLIY GATNLADGMSSRFSGSGSGRQYSLKISSLHPDDVATYYCQNVLSTPWTF GGGTKLEIKRGGGGSGGGGSGGGGSDVKLQESGGGLVKPGGSLKLSCAV SGFTFSSFAMSWVRQTPEKRLEWVATISSGGAYTFYKDSVKGRFTISRD NAKNTLYLQMSSLRSEDSAMYYCARHSGYDGYYLYAMDCWGQGTSVTVS S.

(943) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(944) TABLE-US-00439 (SEQIDNO:565) DIQMTQSPASLSASVGETVTITCGASENIYGALNWYQRKQGKSPQLLIY GATNLADGMSSRFSGSGSGRQYSLKISSLHPDDVATYYCQNVLSTPWTF GGGTKLEIKRGGGGSGGGGSGGGGSEVKLQQSGGGLVKPGASLKLSCAA SGFTFSNYGMSWVRQTSDKRLEWVASISSGGGRIYYPDNVKGRFTISRE NAKNTLYLQMNSLKSDDTALYYCAREPPNYYGGTYGDYWGQGTTLTVSS.

(945) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(946) TABLE-US-00440 (SEQIDNO:566) DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPK LLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNED PFTFGSGTKLEIKRGGGGSGGGGSGGGGSQVKLQQSGAELGKPGTSVKL SCKASGYTFTSYWMHWVKQRPGQGLEWIGNINPNSGSTNYNEKFKSKAT LTVDKSSSTAYMQLSTLTSEDSAVYYCTRPGVWGTGTTVTVSS.

(947) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(948) TABLE-US-00441 (SEQIDNO:567) DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPK LLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNED PFTFGSGTKLEIKRGGGGSGGGGSGGGGSEVKLQQSGGGLVQPGGSRKL SCAASGFTFSSFGMHWVRQAPEKGLEWVAYISSGSSTLHYADTVKGRFT ISRDNPKNTLFLQMKLPSLCYGLLGSRNLSHRLLSQNDTPICL.

(949) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(950) TABLE-US-00442 (SEQIDNO:568) DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPK LLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNED PFTFGSGTKLEIKRGGGGSGGGGSGGGGSVKLLESGGGLVQPGGSLKLS CAASGFEFSRYWMSWVRQVPGKGLEWIGEVNPDSSTINYTTSLKDKFII SRDNAKNTLYLQMSKVRSEDTALYYCGRDSNYGYFDVWGTGTTVTVSS.

(951) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(952) TABLE-US-00443 (SEQIDNO:569) DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPK LLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNED PFTFGSGTKLEIKRGGGGSGGGGSGGGGSVQLKESGPGLVAPSQSLSIT CTVSGFSLTGYGVNWVRQPPGKGLEWLGMIWGDGSTDYNSALKSRLSIS KDNSKSQVFLKMNSLQTDDTARYYCARGGYDFDYWGQGTTLTVSS.

(953) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(954) TABLE-US-00444 (SEQIDNO:570) DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPK LLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNED PFTFGSGTKLEIKRGGGGSGGGGSGGGGSVQLQQSGAELARPGASVKMS CKASGYTFTSYWMHWVKQRPGQGLEWIGAIYPGNSDTSYNQKFKGKAKL TAVTSASTAYMELSSLTNEDSAVYYCTRSHYVEGYFDVWGTGTTVTVSS.

(955) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(956) TABLE-US-00445 (SEQIDNO:571) DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPK LLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNED PFTFGSGTKLEIKRGGGGSGGGGGGGGSQVKLQQSGAELVKPGASVKIS CKASGYAFSSSWMNWVKQRPGKGLEWIGQIYPGDGDTKYNGKFKGKATL TADKSSSTAYMQLSSLTSEDSAVYFCANSNYPSSQSSRTYSRRDWFAYW GQGTLVTVSA.

(957) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(958) TABLE-US-00446 (SEQIDNO:572) DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPK LLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNED PFTFGSGTKLEIKRGGGGSGGGGSGGGGSDVKLQESGGGLVKPGGSLKL SCAVSGFTFSSFAMSWVRQTPEKRLEWVATISSGGAYTFYKDSVKGRFT ISRDNAKNTLYLQMSSLRSEDSAMYYCARHSGYDGYYLYAMDCWGQGTS VTVSS.

(959) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(960) TABLE-US-00447 (SEQIDNO:573) DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPK LLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNED PFTFGSGTKLEIKRGGGGSGGGGSGGGGSEVKLQQSGGGLVKPGASLKL SCAASGFTFSNYGMSWVRQTSDKRLEWVASISSGGGRIYYPDNVKGRFT ISRENAKNTLYLQMNSLKSDDTALYYCAREPPNYYGGTYGDYWGQGTTL TVSS.

(961) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(962) TABLE-US-00448 (SEQIDNO:574) DIVLTQSPAIMSASPGEKVTISCSASSSVSYMYWYQQKPGSSPKPWIYR TSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQYHSYPYTFG GGTKLEIKRGGGGSGGGGSGGGGSQVKLQQSGAELGKPGTSVKLSCKAS GYTFTSYWMHWVKQRPGQGLEWIGNINPNSGSTNYNEKFKSKATLTVDK SSSTAYMQLSTLTSEDSAVYYCTRPGVWGTGTTVTVSS.

(963) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(964) TABLE-US-00449 (SEQIDNO:575) DIVLTQSPAIMSASPGEKVTISCSASSSVSYMYWYQQKPGSSPKPWIYR TSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQYHSYPYTFG GGTKLEIKRGGGGSGGGGSGGGGSEVKLQQSGGGLVQPGGSRKLSCAAS GFTFSSFGMHWVRQAPEKGLEWVAYISSGSSTLHYADTVKGRFTISRDN PKNTLFLQMKLPSLCYGLLGSRNLSHRLLSQNDTPICL.

(965) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(966) TABLE-US-00450 (SEQIDNO:576) DIVLTQSPAIMSASPGEKVTISCSASSSVSYMYWYQQKPGSSPKPWIYR TSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQYHSYPYTFG GGTKLEIKRGGGGSGGGGSGGGGSVKLLESGGGLVQPGGSLKLSCAASG FEFSRYWMSWVRQVPGKGLEWIGEVNPDSSTINYTTSLKDKFIISRDNA KNTLYLQMSKVRSEDTALYYCGRDSNYGYFDVWGTGTTVTVSS.

(967) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(968) TABLE-US-00451 (SEQIDNO:577) DIVLTQSPAIMSASPGEKVTISCSASSSVSYMYWYQQKPGSSPKPWIYR TSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQYHSYPYTFG GGTKLEIKRGGGGSGGGGSGGGGSVQLKESGPGLVAPSQSLSITCTVSG FSLTGYGVNWVRQPPGKGLEWLGMIWGDGSTDYNSALKSRLSISKDNSK SQVFLKMNSLQTDDTARYYCARGGYDFDYWGQGTTLTVSS.

(969) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(970) TABLE-US-00452 (SEQIDNO:578) DIVLTQSPAIMSASPGEKVTISCSASSSVSYMYWYQQKPGSSPKPWIYR TSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQYHSYPYTFG GGTKLEIKRGGGGSGGGGSGGGGSVQLQQSGAELARPGASVKMSCKASG YTFTSYWMHWVKQRPGQGLEWIGAIYPGNSDTSYNQKFKGKAKLTAVTS ASTAYMELSSLTNEDSAVYYCTRSHYVEGYFDVWGTGTTVTVSS.

(971) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(972) TABLE-US-00453 (SEQIDNO:579) DIVLTQSPAIMSASPGEKVTISCSASSSVSYMYWYQQKPGSSPKPWIYR TSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQYHSYPYTFG GGTKLEIKRGGGGSGGGGSGGGGSQVKLQQSGAELVKPGASVKISCKAS GYAFSSSWMNWVKQRPGKGLEWIGQIYPGDGDTKYNGKFKGKATLTADK SSSTAYMQLSSLTSEDSAVYFCANSNYPSSQSSRTYSRRDWFAYWGQGT LVTVSA.

(973) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(974) TABLE-US-00454 (SEQIDNO:580) DIVLTQSPAIMSASPGEKVTISCSASSSVSYMYWYQQKPGSSPKPWIYR TSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQYHSYPYTFG GGTKLEIKRGGGGSGGGGSGGGGSDVKLQESGGGLVKPGGSLKLSCAVS GFTFSSFAMSWVRQTPEKRLEWVATISSGGAYTFYKDSVKGRFTISRDN AKNTLYLQMSSLRSEDSAMYYCARHSGYDGYYLYAMDCWGQGTSVTVSS.

(975) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(976) TABLE-US-00455 (SEQIDNO:581) DIVLTQSPAIMSASPGEKVTISCSASSSVSYMYWYQQKPGSSPKPWIYR TSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQYHSYPYTFG GGTKLEIKRGGGGSGGGGSGGGGSEVKLQQSGGGLVKPGASLKLSCAAS GFTFSNYGMSWVRQTSDKRLEWVASISSGGGRIYYPDNVKGRFTISREN AKNTLYLQMNSLKSDDTALYYCAREPPNYYGGTYGDYWGQGTTLTVSS.

(977) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(978) TABLE-US-00456 (SEQIDNO:582) DVQITQSPSYLAASPGETITINCRASKSISKYLAWYQEKPGKTNKLLIY SGSTLQSGIPSRFSGSGSGTDFTLTISSLEPEDFAMYYCQQHNEYPWTF GGGTKLEIKRGGGGSGGGGSGGGGSQVKLQQSGAELGKPGTSVKLSCKA SGYTFTSYWMHWVKQRPGQGLEWIGNINPNSGSTNYNEKFKSKATLTVD KSSSTAYMQLSTLTSEDSAVYYCTRPGVWGTGTTVTVSS.

(979) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(980) TABLE-US-00457 (SEQIDNO:583) DVQITQSPSYLAASPGETITINCRASKSISKYLAWYQEKPGKTNKLLIY SGSTLQSGIPSRFSGSGSGTDFTLTISSLEPEDFAMYYCQQHNEYPWTF GGGTKLEIKRGGGGSGGGGSGGGGSEVKLQQSGGGLVQPGGSRKLSCAA SGFTFSSFGMHWVRQAPEKGLEWVAYISSGSSTLHYADTVKGRFTISRD NPKNTLFLQMKLPSLCYGLLGSRNLSHRLLSQNDTPICL.

(981) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(982) TABLE-US-00458 (SEQIDNO:584) DVQITQSPSYLAASPGETITINCRASKSISKYLAWYQEKPGKTNKLLIY SGSTLQSGIPSRFSGSGSGTDFTLTISSLEPEDFAMYYCQQHNEYPWTF GGGTKLEIKRGGGGSGGGGSGGGGSVKLLESGGGLVQPGGSLKLSCAAS GFEFSRYWMSWVRQVPGKGLEWIGEVNPDSSTINYTTSLKDKFIISRDN AKNTLYLQMSKVRSEDTALYYCGRDSNYGYFDVWGTGTTVTVSS.

(983) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(984) TABLE-US-00459 (SEQIDNO:585) DVQITQSPSYLAASPGETITINCRASKSISKYLAWYQEKPGKTNKLLIY SGSTLQSGIPSRFSGSGSGTDFTLTISSLEPEDFAMYYCQQHNEYPWTF GGGTKLEIKRGGGGSGGGGSGGGGSVQLKESGPGLVAPSQSLSITCTVS GFSLTGYGVNWVRQPPGKGLEWLGMIWGDGSTDYNSALKSRLSISKDNS KSQVFLKMNSLQTDDTARYYCARGGYDFDYWGQGTTLTVSS.

(985) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(986) TABLE-US-00460 (SEQIDNO:586) DVQITQSPSYLAASPGETITINCRASKSISKYLAWYQEKPGKTNKLLIY SGSTLQSGIPSRFSGSGSGTDFTLTISSLEPEDFAMYYCQQHNEYPWTF GGGTKLEIKRGGGGSGGGGSGGGGSVQLQQSGAELARPGASVKMSCKAS GYTFTSYWMHWVKQRPGQGLEWIGAIYPGNSDTSYNQKFKGKAKLTAVT SASTAYMELSSLTNEDSAVYYCTRSHYVEGYFDVWGTGTTVTVSS.

(987) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(988) TABLE-US-00461 (SEQIDNO:587) DVQITQSPSYLAASPGETITINCRASKSISKYLAWYQEKPGKTNKLLIY SGSTLQSGIPSRFSGSGSGTDFTLTISSLEPEDFAMYYCQQHNEYPWTF GGGTKLEIKRGGGGSGGGGSGGGGSQVKLQQSGAELVKPGASVKISCKA SGYAFSSSWMNWVKQRPGKGLEWIGQIYPGDGDTKYNGKFKGKATLTAD KSSSTAYMQLSSLTSEDSAVYFCANSNYPSSQSSRTYSRRDWFAYWGQG TLVTVSA.

(989) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(990) TABLE-US-00462 (SEQIDNO:588) DVQITQSPSYLAASPGETITINCRASKSISKYLAWYQEKPGKTNKLLIY SGSTLQSGIPSRFSGSGSGTDFTLTISSLEPEDFAMYYCQQHNEYPWTF GGGTKLEIKRGGGGSGGGGSGGGGSDVKLQESGGGLVKPGGSLKLSCAV SGFTFSSFAMSWVRQTPEKRLEWVATISSGGAYTFYKDSVKGRFTISRD NAKNTLYLQMSSLRSEDSAMYYCARHSGYDGYYLYAMDCWGQGTSVTVS S.

(991) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(992) TABLE-US-00463 (SEQIDNO:589) DVQITQSPSYLAASPGETITINCRASKSISKYLAWYQEKPGKTNKLLIY SGSTLQSGIPSRFSGSGSGTDFTLTISSLEPEDFAMYYCQQHNEYPWTF GGGTKLEIKRGGGGSGGGGSGGGGSEVKLQQSGGGLVKPGASLKLSCAA SGFTFSNYGMSWVRQTSDKRLEWVASISSGGGRIYYPDNVKGRFTISRE NAKNTLYLQMNSLKSDDTALYYCAREPPNYYGGTYGDYWGQGTTLTVSS.

(993) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(994) TABLE-US-00464 (SEQIDNO:590) QIVLTQSPVIMSASPGEKVTMTCSASSSVSDMHWYQQKSGTSPKRWIYD TSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFG AGTKLELKRGGGGSGGGGSGGGGSQVKLQQSGAELGKPGTSVKLSCKAS GYTFTSYWMHWVKQRPGQGLEWIGNINPNSGSTNYNEKFKSKATLTVDK SSSTAYMQLSTLTSEDSAVYYCTRPGVWGTGTTVTVSS.

(995) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(996) TABLE-US-00465 (SEQIDNO:591) QIVLTQSPVIMSASPGEKVTMTCSASSSVSDMHWYQQKSGTSPKRWIYD TSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFG AGTKLELKRGGGGSGGGGGGGGSEVKLQQSGGGLVQPGGSRKLSCAASG FTFSSFGMHWVRQAPEKGLEWVAYISSGSSTLHYADTVKGRFTISRDNP KNTLFLQMKLPSLCYGLLGSRNLSHRLLSQNDTPICL.

(997) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(998) TABLE-US-00466 (SEQIDNO:592) QIVLTQSPVIMSASPGEKVTMTCSASSSVSDMHWYQQKSGTSPKRWIYD TSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFG AGTKLELKRGGGGSGGGGSGGGGSVKLLESGGGLVQPGGSLKLSCAASG FEFSRYWMSWVRQVPGKGLEWIGEVNPDSSTINYTTSLKDKFIISRDNA KNTLYLQMSKVRSEDTALYYCGRDSNYGYFDVWGTGTTVTVSS.

(999) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(1000) TABLE-US-00467 (SEQIDNO:593) QIVLTQSPVIMSASPGEKVTMTCSASSSVSDMHWYQQKSGTSPKRWIYD TSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFG AGTKLELKRGGGGSGGGGSGGGGSVQLKESGPGLVAPSQSLSITCTVSG FSLTGYGVNWVRQPPGKGLEWLGMIWGDGSTDYNSALKSRLSISKDNSK SQVFLKMNSLQTDDTARYYCARGGYDFDYWGQGTTLTVSS.

(1001) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(1002) TABLE-US-00468 (SEQIDNO:594) QIVLTQSPVIMSASPGEKVTMTCSASSSVSDMHWYQQKSGTSPKRWIYD TSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFG AGTKLELKRGGGGSGGGGSGGGGSVQLQQSGAELARPGASVKMSCKASG YTFTSYWMHWVKQRPGQGLEWIGAIYPGNSDTSYNQKFKGKAKLTAVTS ASTAYMELSSLTNEDSAVYYCTRSHYVEGYFDVWGTGTTVTVSS.

(1003) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(1004) TABLE-US-00469 (SEQIDNO:595) QIVLTQSPVIMSASPGEKVTMTCSASSSVSDMHWYQQKSGTSPKRWIYD TSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFG AGTKLELKRGGGGSGGGGSGGGGSQVKLQQSGAELVKPGASVKISCKAS GYAFSSSWMNWVKQRPGKGLEWIGQIYPGDGDTKYNGKFKGKATLTADK SSSTAYMQLSSLTSEDSAVYFCANSNYPSSQSSRTYSRRDWFAYWGQGT LVTVSA.

(1005) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(1006) TABLE-US-00470 (SEQIDNO:596) QIVLTQSPVIMSASPGEKVTMTCSASSSVSDMHWYQQKSGTSPKRWIYD TSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFG AGTKLELKRGGGGSGGGGSGGGGSDVKLQESGGGLVKPGGSLKLSCAVS GFTFSSFAMSWVRQTPEKRLEWVATISSGGAYTFYKDSVKGRFTISRDN AKNTLYLQMSSLRSEDSAMYYCARHSGYDGYYLYAMDCWGQGTSVTVSS.

(1007) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(1008) TABLE-US-00471 (SEQIDNO:597) QIVLTQSPVIMSASPGEKVTMTCSASSSVSDMHWYQQKSGTSPKRWIYD TSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFG AGTKLELKRGGGGSGGGGSGGGGSEVKLQQSGGGLVKPGASLKLSCAAS GFTFSNYGMSWVRQTSDKRLEWVASISSGGGRIYYPDNVKGRFTISREN AKNTLYLQMNSLKSDDTALYYCAREPPNYYGGTYGDYWGQGTTLTVSS.

(1009) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(1010) TABLE-US-00472 (SEQIDNO:598) NIVLTQSPASLAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPK LLIYLASNLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNED PWTFGGGTKLEIKGGGGSGGGGSGGGGSQVKLQQSGAELGKPGTSVKLS CKASGYTFTSYWMHWVKQRPGQGLEWIGNINPNSGSTNYNEKFKSKATL TVDKSSSTAYMQLSTLTSEDSAVYYCTRPGVWGTGTTVTVSS.

(1011) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(1012) TABLE-US-00473 (SEQIDNO:599) NIVLTQSPASLAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPK LLIYLASNLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNED PWTFGGGTKLEIKGGGGSGGGGSGGGGSEVKLQQSGGGLVQPGGSRKLS CAASGFTFSSFGMHWVRQAPEKGLEWVAYISSGSSTLHYADTVKGRFTI SRDNPKNTLFLQMKLPSLCYGLLGSRNLSHRLLSQNDTPICL.

(1013) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(1014) TABLE-US-00474 (SEQIDNO:600) NIVLTQSPASLAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPK LLIYLASNLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNED PWTFGGGTKLEIKGGGGSGGGGSGGGGSVKLLESGGGLVQPGGSLKLSC AASGFEFSRYWMSWVRQVPGKGLEWIGEVNPDSSTINYTTSLKDKFIIS RDNAKNTLYLQMSKVRSEDTALYYCGRDSNYGYFDVWGTGTTVTVSS.

(1015) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(1016) TABLE-US-00475 (SEQIDNO:601) NIVLTQSPASLAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPK LLIYLASNLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNED PWTFGGGTKLEIKGGGGSGGGGSGGGGSVQLKESGPGLVAPSQSLSITC TVSGFSLTGYGVNWVRQPPGKGLEWLGMIWGDGSTDYNSALKSRLSISK DNSKSQVFLKMNSLQTDDTARYYCARGGYDFDYWGQGTTLTVSS.

(1017) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(1018) TABLE-US-00476 (SEQIDNO:602) NIVLTQSPASLAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPK LLIYLASNLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNED PWTFGGGTKLEIKGGGGSGGGGSGGGGSVQLQQSGAELARPGASVKMSC KASGYTFTSYWMHWVKQRPGQGLEWIGAIYPGNSDTSYNQKFKGKAKLT AVTSASTAYMELSSLTNEDSAVYYCTRSHYVEGYFDVWGTGTTVTVSS.

(1019) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(1020) TABLE-US-00477 (SEQIDNO:603) NIVLTQSPASLAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPK LLIYLASNLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNED PWTFGGGTKLEIKGGGGSGGGGSGGGGSQVKLQQSGAELVKPGASVKIS CKASGYAFSSSWMNWVKQRPGKGLEWIGQIYPGDGDTKYNGKFKGKATL TADKSSSTAYMQLSSLTSEDSAVYFCANSNYPSSQSSRTYSRRDWFAYW GQGTLVTVSA.

(1021) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(1022) TABLE-US-00478 (SEQIDNO:604) NIVLTQSPASLAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPK LLIYLASNLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNED PWTFGGGTKLEIKGGGGSGGGGSGGGGSDVKLQESGGGLVKPGGSLKLS CAVSGFTFSSFAMSWVRQTPEKRLEWVATISSGGAYTFYKDSVKGRFTI SRDNAKNTLYLQMSSLRSEDSAMYYCARHSGYDGYYLYAMDCWGQGTSV TVSS.

(1023) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(1024) TABLE-US-00479 (SEQIDNO:605) NIVLTQSPASLAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPK LLIYLASNLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNED PWTFGGGTKLEIKGGGGSGGGGSGGGGSEVKLQQSGGGLVKPGASLKLS CAASGFTFSNYGMSWVRQTSDKRLEWVASISSGGGRIYYPDNVKGRFTI SRENAKNTLYLQMNSLKSDDTALYYCAREPPNYYGGTYGDYWGQGTTLT VSS.

(1025) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(1026) TABLE-US-00480 (SEQIDNO:606) DWVMTQSPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSP KLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTH VSYTFGGGTKLEIKRGGGGSGGGGSGGGGSQVKLQQSGAELGKPGTSVK LSCKASGYTFTSYWMHWVKQRPGQGLEWIGNINPNSGSTNYNEKFKSKA TLTVDKSSSTAYMQLSTLTSEDSAVYYCTRPGVWGTGTTVTVSS.

(1027) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(1028) TABLE-US-00481 (SEQIDNO:607) DWMTQSPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPK LLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHV SYTFGGGTKLEIKRGGGGSGGGGSGGGGSEVKLQQSGGGLVQPGGSRKL SCAASGFTFSSFGMHWVRQAPEKGLEWVAYISSGSSTLHYADTVKGRFT ISRDNPKNTLFLQMKLPSLCYGLLGSRNLSHRLLSQNDTPICL.

(1029) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(1030) TABLE-US-00482 (SEQIDNO:608) DWMTQSPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPK LLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHV SYTFGGGTKLEIKRGGGGGGGGSGGGGSVKLLESGGGLVQPGGSLKLSC AASGFEFSRYWMSWVRQVPGKGLEWIGEVNPDSSTINYTTSLKDKFIIS RDNAKNTLYLQMSKVRSEDTALYYCGRDSNYGYFDVWGTGTTVTVSS.

(1031) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(1032) TABLE-US-00483 (SEQIDNO:609) DWVMTQSPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSP KLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTH VSYTFGGGTKLEIKRGGGGSGGGGSGGGGSVQLKESGPGLVAPSQSLSI TCTVSGFSLTGYGVNWVRQPPGKGLEWLGMIWGDGSTDYNSALKSRLSI SKDNSKSQVFLKMNSLQTDDTARYYCARGGYDFDYWGQGTTLTVSS.

(1033) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(1034) TABLE-US-00484 (SEQIDNO:610) DWMTQSPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPK LLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHV SYTFGGGTKLEIKRGGGGSGGGGSGGGGSVQLQQSGAELARPGASVKMS CKASGYTFTSYWMHWVKQRPGQGLEWIGAIYPGNSDTSYNQKFKGKAKL TAVTSASTAYMELSSLTNEDSAVYYCTRSHYVEGYFDVWGTGTTVTVSS.

(1035) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(1036) TABLE-US-00485 (SEQIDNO:611) DWVMTQSPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSP KLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTH VSYTFGGGTKLEIKRGGGGSGGGGSGGGGSQVKLQQSGAELVKPGASVK ISCKASGYAFSSSWMNWVKQRPGKGLEWIGQIYPGDGDTKYNGKFKGKA TLTADKSSSTAYMQLSSLTSEDSAVYFCANSNYPSSQSSRTYSRRDWFA YWGQGTLVTVSA.

(1037) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(1038) TABLE-US-00486 (SEQIDNO:612) DWVMTQSPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSP KLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTH VSYTFGGGTKLEIKRGGGGSGGGGSGGGGSDVKLQESGGGLVKPGGSLK LSCAVSGFTFSSFAMSWVRQTPEKRLEWVATISSGGAYTFYKDSVKGRF TISRDNAKNTLYLQMSSLRSEDSAMYYCARHSGYDGYYLYAMDCWGQGT SVTVSS.

(1039) In some embodiments, the anti-CD22 scFv comprises an amino acid sequence:

(1040) TABLE-US-00487 (SEQIDNO:613) DVVMTQSPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSP KLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTH VSYTFGGGTKLEIKRGGGGSGGGGSGGGGSEVKLQQSGGGLVKPGASLK LSCAASGFTFSNYGMSWVRQTSDKRLEWVASISSGGGRIYYPDNVKGRF TISRENAKNTLYLQMNSLKSDDTALYYCAREPPNYYGGTYGDYWGQGTT LTVSS.

(1041) In some embodiments, the anti-CD22 scFv binds to CD22 and comprises an amino acid sequence that is 95%, 96%, 97%, 98% or 99% identical to any of the specific anti-CD22 scFv amino acid sequences disclosed herein.

(1042) In some embodiments, the anti-CD22 scFv comprises an antigen binding domain of Inotuzumab (CMC-544, Besponsa, Pfizer), described in CN106661123A, which is incorporated by reference for the teaching of this antibody.

(1043) In some embodiments, the anti-CD22 scFv comprises an antigen binding domain of clone Epratuzumab (LymoCide, Immunomedics, Inc.), described in U.S. Pat. No. 9,139,649, which is incorporated by reference for the teaching of this antibody.

(1044) In some embodiments, the anti-CD22 scFv comprises an antigen binding domain of clone HB22.7, described in EP1999148B1, which is incorporated by reference for the teaching of this antibody.

(1045) In some embodiments, the anti-CD22 scFv comprises an antigen binding domain of Bectumomab (LymphoScan).

(1046) In some embodiments, the anti-CD22 scFv comprises an antigen binding domain of clone RFB4 (BL22). In some embodiments, the anti-CD22 scFv comprises an antigen binding domain of clone HA22, described in WO2003027135A2, which is incorporated by reference for the teaching of this antibody.

(1047) In some embodiments, the anti-CD22 scFv comprises an antigen binding domain of clone m972, described in WO2009124109A1, which is incorporated by reference for the teaching of this antibody.

(1048) In some embodiments, the anti-CD22 scFv comprises an antigen binding domain of clone m971, described in WO2009124109A1, which is incorporated by reference for the teaching of this antibody.

(1049) Nucleic Acids and Vectors

(1050) Also disclosed are polynucleotides and polynucleotide vectors encoding the disclosed CD19-, CD20-, and CD22-specific CARs that allow expression of the CD19-, CD20-, and CD22-specific CARs in the disclosed immune effector cells.

(1051) Nucleic acid sequences encoding the disclosed CARs, and regions thereof, can be obtained using recombinant methods known in the art, such as, for example by screening libraries from cells expressing the gene, by deriving the gene from a vector known to include the same, or by isolating directly from cells and tissues containing the same, using standard techniques. Alternatively, the gene of interest can be produced synthetically, rather than cloned.

(1052) Expression of nucleic acids encoding CARs is typically achieved by operably linking a nucleic acid encoding the CAR polypeptide to a promoter, and incorporating the construct into an expression vector. Typical cloning vectors contain transcription and translation terminators, initiation sequences, and promoters useful for regulation of the expression of the desired nucleic acid sequence.

(1053) The disclosed nucleic acid can be cloned into a number of types of vectors. For example, the nucleic acid can be cloned into a vector including, but not limited to a plasmid, a phagemid, a phage derivative, an animal virus, and a cosmid. Vectors of particular interest include expression vectors, replication vectors, probe generation vectors, and sequencing vectors.

(1054) Further, the expression vector may be provided to a cell in the form of a viral vector. Viral vector technology is well known in the art and is described, for example, in Sambrook et al. (2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York), and in other virology and molecular biology manuals. Viruses, which are useful as vectors include, but are not limited to, retroviruses, adenoviruses, adeno-associated viruses, herpes viruses, and lentiviruses. In general, a suitable vector contains an origin of replication functional in at least one organism, a promoter sequence, convenient restriction endonuclease sites, and one or more selectable markers. In some embodiments, the polynucleotide vectors are lentiviral or retroviral vectors.

(1055) A number of viral based systems have been developed for gene transfer into mammalian cells. For example, retroviruses provide a convenient platform for gene delivery systems. A selected gene can be inserted into a vector and packaged in retroviral particles using techniques known in the art. The recombinant virus can then be isolated and delivered to cells of the subject either in vivo or ex vivo.

(1056) One example of a suitable promoter is the immediate early cytomegalovirus (CMV) promoter sequence. This promoter sequence is a strong constitutive promoter sequence capable of driving high levels of expression of any polynucleotide sequence operatively linked thereto. Another example of a suitable promoter is Elongation Growth Factor-1? (EF-1?). However, other constitutive promoter sequences may also be used, including, but not limited to the simian virus 40 (SV40) early promoter, MND (myeloproliferative sarcoma virus) promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, an avian leukemia virus promoter, an Epstein-Barr virus immediate early promoter, a Rous sarcoma virus promoter, as well as human gene promoters such as, but not limited to, the actin promoter, the myosin promoter, the hemoglobin promoter, and the creatine kinase promoter. The promoter can alternatively be an inducible promoter. Examples of inducible promoters include, but are not limited to a metallothionine promoter, a glucocorticoid promoter, a progesterone promoter, and a tetracycline promoter.

(1057) Additional promoter elements, e.g., enhancers, regulate the frequency of transcriptional initiation. Typically, these are located in the region 30-110 bp upstream of the start site, although a number of promoters have recently been shown to contain functional elements downstream of the start site as well. The spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another.

(1058) In order to assess the expression of a CAR polypeptide or portions thereof, the expression vector to be introduced into a cell can also contain either a selectable marker gene or a reporter gene or both to facilitate identification and selection of expressing cells from the population of cells sought to be transfected or infected through viral vectors. In other aspects, the selectable marker may be carried on a separate piece of DNA and used in a co-transfection procedure. Both selectable markers and reporter genes may be flanked with appropriate regulatory sequences to enable expression in the host cells. Useful selectable markers include, for example, antibiotic-resistance genes.

(1059) Reporter genes are used for identifying potentially transfected cells and for evaluating the functionality of regulatory sequences. In general, a reporter gene is a gene that is not present in or expressed by the recipient organism or tissue and that encodes a polypeptide whose expression is manifested by some easily detectable property, e.g., enzymatic activity. Expression of the reporter gene is assayed at a suitable time after the DNA has been introduced into the recipient cells. Suitable reporter genes may include genes encoding luciferase, beta-galactosidase, chloramphenicol acetyl transferase, secreted alkaline phosphatase, or the green fluorescent protein gene. Suitable expression systems are well known and may be prepared using known techniques or obtained commercially. In general, the construct with the minimal 5 flanking region showing the highest level of expression of reporter gene is identified as the promoter. Such promoter regions may be linked to a reporter gene and used to evaluate agents for the ability to modulate promoter-driven transcription.

(1060) Methods of introducing and expressing genes into a cell are known in the art. In the context of an expression vector, the vector can be readily introduced into a host cell, e.g., mammalian, bacterial, yeast, or insect cell by any method in the art. For example, the expression vector can be transferred into a host cell by physical, chemical, or biological means.

(1061) Physical methods for introducing a polynucleotide into a host cell include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, and the like. Methods for producing cells comprising vectors and/or exogenous nucleic acids are well-known in the art. See, for example, Sambrook et al. (2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York).

(1062) Biological methods for introducing a polynucleotide of interest into a host cell include the use of DNA and RNA vectors. Viral vectors, and especially retroviral vectors, have become the most widely used method for inserting genes into mammalian, e.g., human cells.

(1063) Chemical means for introducing a polynucleotide into a host cell include colloidal dispersion systems, such as macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. An exemplary colloidal system for use as a delivery vehicle in vitro and in vivo is a liposome (e.g., an artificial membrane vesicle).

(1064) In the case where a non-viral delivery system is utilized, an exemplary delivery vehicle is a liposome. In another aspect, the nucleic acid may be associated with a lipid. The nucleic acid associated with a lipid may be encapsulated in the aqueous interior of a liposome, interspersed within the lipid bilayer of a liposome, attached to a liposome via a linking molecule that is associated with both the liposome and the oligonucleotide, entrapped in a liposome, complexed with a liposome, dispersed in a solution containing a lipid, mixed with a lipid, combined with a lipid, contained as a suspension in a lipid, contained or complexed with a micelle, or otherwise associated with a lipid. Lipid, lipid/DNA or lipid/expression vector associated compositions are not limited to any particular structure in solution. For example, they may be present in a bilayer structure, as micelles, or with a collapsed structure. They may also simply be interspersed in a solution, possibly forming aggregates that are not uniform in size or shape. Lipids are fatty substances which may be naturally occurring or synthetic lipids. For example, lipids include the fatty droplets that naturally occur in the cytoplasm as well as the class of compounds which contain long-chain aliphatic hydrocarbons and their derivatives, such as fatty acids, alcohols, amines, amino alcohols, and aldehydes. Lipids suitable for use can be obtained from commercial sources. For example, dimyristyl phosphatidylcholine (DMPC) can be obtained from Sigma, St. Louis, Mo.; dicetyl phosphate (DCP) can be obtained from K & K Laboratories (Plainview, N.Y.); cholesterol (Choi) can be obtained from Calbiochem-Behring; dimyristyl phosphatidylglycerol (DMPG) and other lipids may be obtained from Avanti Polar Lipids, Inc, (Birmingham, Ala.).

(1065) Immune Effector Cells

(1066) Also disclosed are immune effector cells that are engineered to express the disclosed CARs (also referred to herein as CAR-T cells). These cells are preferably obtained from the subject to be treated (i.e. are autologous). However, in some embodiments, immune effector cell lines or donor effector cells (allogeneic) are used. Immune effector cells can be obtained from a number of sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors. Immune effector cells can be obtained from blood collected from a subject using any number of techniques known to the skilled artisan, such as Ficoll? separation. For example, cells from the circulating blood of an individual may be obtained by apheresis. In some embodiments, immune effector cells are isolated from peripheral blood lymphocytes by lysing the red blood cells and depleting the monocytes, for example, by centrifugation through a PERCOLL? gradient or by counterflow centrifugal elutriation. A specific subpopulation of immune effector cells can be further isolated by positive or negative selection techniques. For example, immune effector cells can be isolated using a combination of antibodies directed to surface markers unique to the positively selected cells, e.g., by incubation with antibody-conjugated beads for a time period sufficient for positive selection of the desired immune effector cells. Alternatively, enrichment of immune effector cells population can be accomplished by negative selection using a combination of antibodies directed to surface markers unique to the negatively selected cells. In some embodiments, the immune effector cells comprise any leukocyte involved in defending the body against infectious disease and foreign materials. For example, the immune effector cells can comprise lymphocytes, monocytes, macrophages, dentritic cells, mast cells, neutrophils, basophils, eosinophils, or any combinations thereof. For example, the immune effector cells can comprise T lymphocytes, preferably cytotoxic T lymphocytes (CTLs).

(1067) T cells or T lymphocytes can be distinguished from other lymphocytes, such as B cells and natural killer cells (NK cells), by the presence of a T-cell receptor (TCR) on the cell surface. They are called T cells because they mature in the thymus (although some also mature in the tonsils). There are several subsets of T cells, each with a distinct function.

(1068) T helper cells (T H cells) assist other white blood cells in immunologic processes, including maturation of B cells into plasma cells and memory B cells, and activation of cytotoxic T cells and macrophages. These cells are also known as CD4+ T cells because they express the CD4 glycoprotein on their surface. Helper T cells become activated when they are presented with peptide antigens by MHC class II molecules, which are expressed on the surface of antigen-presenting cells (APCs). Once activated, they divide rapidly and secrete small proteins called cytokines that regulate or assist in the active immune response. These cells can differentiate into one of several subtypes, including T.sub.H1, T.sub.H2, T.sub.H3, T.sub.H17, T.sub.H9, or T.sub.FH, which secrete different cytokines to facilitate a different type of immune response.

(1069) Cytotoxic T cells (T.sub.C cells, or CTLs) destroy virally infected cells and tumor cells, and are also implicated in transplant rejection. These cells are also known as CD8.sup.+ T cells since they express the CD8 glycoprotein at their surface. These cells recognize their targets by binding to antigen associated with MHC class I molecules, which are present on the surface of all nucleated cells. Through IL-10, adenosine and other molecules secreted by regulatory T cells, the CD8+ cells can be inactivated to an anergic state, which prevents autoimmune diseases.

(1070) Memory T cells are a subset of antigen-specific T cells that persist long-term after an infection has resolved. They quickly expand to large numbers of effector T cells upon re-exposure to their cognate antigen, thus providing the immune system with memory against past infections. Memory cells may be either CD4.sup.+ or CD8.sup.+. Memory T cells typically express the cell surface protein CD45RO.

(1071) Regulatory T cells (T.sub.reg cells), formerly known as suppressor T cells, are crucial for the maintenance of immunological tolerance. Their major role is to shut down T cell-mediated immunity toward the end of an immune reaction and to suppress auto-reactive T cells that escaped the process of negative selection in the thymus. Two major classes of CD4.sup.+ T.sub.reg cells have been describednaturally occurring T.sub.reg cells and adaptive T.sub.reg cells.

(1072) Natural killer T (NKT) cells (not to be confused with natural killer (NK) cells) bridge the adaptive immune system with the innate immune system. Unlike conventional T cells that recognize peptide antigens presented by major histocompatibility complex (MHC) molecules, NKT cells recognize glycolipid antigen presented by a molecule called CD1d.

(1073) In some embodiments, the T cells comprise a mixture of CD4+ cells. In other embodiments, the T cells are enriched for one or more subsets based on cell surface expression. For example, in some cases, the T comprise are cytotoxic CD8.sup.+ T lymphocytes. In some embodiments, the T cells comprise ?? T cells, which possess a distinct T-cell receptor (TCR) having one ? chain and one ? chain instead of a and ? chains.

(1074) Natural-killer (NK) cells are CD56.sup.+CD3.sup.? large granular lymphocytes that can kill virally infected and transformed cells, and constitute a critical cellular subset of the innate immune system (Godfrey J, et al. Leuk Lymphoma 2012 53:1666-1676). Unlike cytotoxic CD8.sup.+ T lymphocytes, NK cells launch cytotoxicity against tumor cells without the requirement for prior sensitization, and can also eradicate MHC-I-negative cells (Narni-Mancinelli E, et al. Int Immunol 2011 23:427-431). NK cells are safer effector cells, as they may avoid the potentially lethal complications of cytokine storms (Morgan R A, et al. Mol Ther 2010 18:843-851), tumor lysis syndrome (Porter D L, et al. N Engl J Med 2011 365:725-733), and on-target, off-tumor effects. Although NK cells have a well-known role as killers of cancer cells, and NK cell impairment has been extensively documented as crucial for progression of MM (Godfrey J, et al. Leuk Lymphoma 2012 53:1666-1676; Fauriat C, et al. Leukemia 2006 20:732-733), the means by which one might enhance NK cell-mediated anti-MM activity has been largely unexplored prior to the disclosed CARs.

(1075) Epstein-Barr virus (EBV)-induced lymphoproliferative diseases (EBV-LPDs) and other EBV-associated cancers are a significant cause of morbidity and mortality for recipients of allogeneic hematopoietic cell transplantation (HCT) or solid organ transplants (SOT), particularly in those who have received certain T-cell reactive Abs to prevent or treat GVHD. Prophylaxis and treatment by the adoptive transfer of autologous or allogeneic EBV-specific cytotoxic T cells and the subsequent long-term restoration of immunity against EBV-associated lymphoproliferation have provided positive outcomes in the management of these uniformly fatal complications of allogeneic tissue transfer. Therefore, in some embodiments, the disclosed immune effector cells that comprise one or more of the CAR polypeptides of the present invention are allogeneic or autologous EBV-specific cytotoxic T lymphocytes (CTLs). For example, generation of EBV-specific cytotoxic T cells may involve isolating PBMCs from of an EBV-seropositive autologous or allogenic donor and enriching them for T cells by depletion of monocytes and NK cells. EBV-specific cytotoxic T cells may also be produced by contacting donor PBMCs or purified donor T cells with a stimulator cell that expresses one or more EBV antigen(s) and presents the EBV antigen(s) to unstimulated T cells, thereby causing stimulation and expansion of EBV-specific CTLs. EBV antigens include, for example, latent membrane protein (LMP) and EBV nuclear antigen (EBNA) proteins, such as LMP-1, LMP-2A, and LMP-2B and EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C and EBNA-LP. Cytotoxic T cells that comprise T cell receptor(s) which recognize one or more EBV-specific antigens are deemed to have been sensitized to those EBV antigen(s) and are therefore termed EBV-sensitized cytotoxic T cells herein. Known methods for generating allogeneic or autologous EBV-specific cytotoxic T cell populations that may comprise one or more of the CAR polypeptides of the present invention are described, for example, in Barker et al., Blood 2010 116(23):5045-49; Doubrovina, et al., Blood 2012 119(11):2644-56; Koehne, et al. Blood 2002 99(5):1730-40; and Smith et al. Cancer Res 2012 72(5):1116-25, which are incorporated by reference for these teachings.

(1076) Therapeutic Methods

(1077) Immune effector cells expressing the disclosed CARs can elicit an anti-tumor immune response against CD19-, CD20-, and/or CD22-expressing cancer cells. The anti-tumor immune response elicited by the disclosed CAR-modified immune effector cells may be an active or a passive immune response. In addition, the CAR-mediated immune response may be part of an adoptive immunotherapy approach in which CAR-modified immune effector cells induce an immune response specific to CD19, CD20, and/or CD22.

(1078) Adoptive transfer of immune effector cells expressing chimeric antigen receptors is a promising anti-cancer therapeutic. Following the collection of a patient's immune effector cells, the cells may be genetically engineered to express the disclosed CD19-, CD20-, and/or CD22-specific CARs, then infused back into the patient. Moreover, immune effector cells obtained from a donor other than the patient (i.e., allogeneic to the patient) may be genetically engineered to express the disclosed CD19-, CD20-, and/or CD22-specific CARs, then the CAR-containing cells infused into the patient. In one specific embodiment, the immune effector cells are allogeneic EBV-specific cytotoxic T cells.

(1079) The disclosed CAR-modified immune effector cells may be administered either alone, or as a pharmaceutical composition in combination with diluents and/or with other components such as IL-2, IL-15, or other cytokines or cell populations. Briefly, pharmaceutical compositions may comprise a target cell population as described herein, in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients. Such compositions may comprise buffers such as neutral buffered saline, phosphate buffered saline and the like; carbohydrates such as glucose, mannose, sucrose or dextrans, mannitol; proteins; polypeptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives. Compositions for use in the disclosed methods are in some embodiments formulated for intravenous administration. Pharmaceutical compositions may be administered in any manner appropriate treat MM. The quantity and frequency of administration will be determined by such factors as the condition of the patient, and the severity of the patient's disease, although appropriate dosages may be determined by clinical trials.

(1080) When an immunologically effective amount, an anti-tumor effective amount, an tumor-inhibiting effective amount, or therapeutic amount is indicated, the precise amount of the compositions of the present invention to be administered can be determined by a physician with consideration of individual differences in age, weight, tumor size, extent of infection or metastasis, and condition of the patient (subject). It can generally be stated that a pharmaceutical composition comprising the T cells described herein may be administered at a dosage of 10.sup.4 to 10.sup.9 cells/kg body weight, such as 10.sup.5 to 10.sup.6 cells/kg body weight, including all integer values within those ranges. T cell compositions may also be administered multiple times at these dosages. The cells can be administered by using infusion techniques that are commonly known in immunotherapy (see, e.g., Rosenberg et al., New Eng. J. of Med. 319:1676, 1988). The optimal dosage and treatment regime for a particular patient can readily be determined by one skilled in the art of medicine by monitoring the patient for signs of disease and adjusting the treatment accordingly.

(1081) In certain embodiments, it may be desired to administer activated T cells to a subject and then subsequently re-draw blood (or have an apheresis performed), activate T cells therefrom according to the disclosed methods, and reinfuse the patient with these activated and expanded T cells. This process can be carried out multiple times every few weeks. In certain embodiments, T cells can be activated from blood draws of from 10 cc to 400 cc. In certain embodiments, T cells are activated from blood draws of 20 cc, 30 cc, 40 cc, 50 cc, 60 cc, 70 cc, 80 cc, 90 cc, or 100 cc. Using this multiple blood draw/multiple reinfusion protocol may serve to select out certain populations of T cells.

(1082) The administration of the disclosed compositions may be carried out in any convenient manner, including by injection, transfusion, or implantation. The compositions described herein may be administered to a patient subcutaneously, intradermally, intratumorally, intranodally, intramedullary, intramuscularly, by intravenous (i.v.) injection, or intraperitoneally. In some embodiments, the disclosed compositions are administered to a patient by intradermal or subcutaneous injection. In some embodiments, the disclosed compositions are administered by i.v. injection. The compositions may also be injected directly into a tumor, lymph node, or site of infection.

(1083) In certain embodiments, the disclosed CAR-modified immune effector cells are administered to a patient in conjunction with (e.g., before, simultaneously or following) any number of relevant treatment modalities, including but not limited to thalidomide, dexamethasone, bortezomib, and lenalidomide. In further embodiments, the CAR-modified immune effector cells may be used in combination with chemotherapy, radiation, immunosuppressive agents, such as cyclosporin, azathioprine, methotrexate, mycophenolate, and FK506, antibodies, or other immunoablative agents such as CAM PATH, anti-CD3 antibodies or other antibody therapies, cytoxin, fludaribine, cyclosporin, FK506, rapamycin, mycophenolic acid, steroids, FR901228, cytokines, and irradiation. In some embodiments, the CAR-modified immune effector cells are administered to a patient in conjunction with (e.g., before, simultaneously or following) bone marrow transplantation, T cell ablative therapy using either chemotherapy agents such as, fludarabine, external-beam radiation therapy (XRT), cyclophosphamide, or antibodies such as OKT3 or CAMPATH. In another embodiment, the cell compositions of the present invention are administered following B-cell ablative therapy such as agents that react with CD20, e.g., Rituxan. For example, in some embodiments, subjects may undergo standard treatment with high dose chemotherapy followed by peripheral blood stem cell transplantation. In certain embodiments, following the transplant, subjects receive an infusion of the expanded immune cells of the present invention. In an additional embodiment, expanded cells are administered before or following surgery.

(1084) The cancer of the disclosed methods can be any CD19-, CD20-, and/or CD22-expressing cell in a subject undergoing unregulated growth, invasion, or metastasis. Cancers that express CD19, CD20, or CD22 include prostate cancer, ovarian cancer, adenocarcinoma of the lung, breast cancer, endometrial cancer, gastric cancer, colon cancer, and pancreatic cancer. CD19, CD20, or CD22 has also been found on Jurkat cells. In some aspects, the cancer is a gallbladder cancer, exocrine adenocarcinoma, or apocrine adenocarcinomas.

(1085) In some aspects, the cancer can be any neoplasm or tumor for which radiotherapy is currently used. Alternatively, the cancer can be a neoplasm or tumor that is not sufficiently sensitive to radiotherapy using standard methods. Thus, the cancer can be a sarcoma, lymphoma, leukemia, carcinoma, blastoma, or germ cell tumor. A representative but non-limiting list of cancers that the disclosed compositions can be used to treat include lymphoma, B cell lymphoma, T cell lymphoma, mycosis fungoides, Hodgkin's Disease, myeloid leukemia, bladder cancer, brain cancer, nervous system cancer, head and neck cancer, squamous cell carcinoma of head and neck, kidney cancer, lung cancers such as small cell lung cancer and non-small cell lung cancer, neuroblastoma/glioblastoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, liver cancer, melanoma, squamous cell carcinomas of the mouth, throat, larynx, and lung, endometrial cancer, cervical cancer, cervical carcinoma, breast cancer, epithelial cancer, renal cancer, genitourinary cancer, pulmonary cancer, esophageal carcinoma, head and neck carcinoma, large bowel cancer, hematopoietic cancers; testicular cancer; colon and rectal cancers, prostatic cancer, and pancreatic cancer.

(1086) The disclosed CARs can be used in combination with any compound, moiety or group which has a cytotoxic or cytostatic effect. Drug moieties include chemotherapeutic agents, which may function as microtubulin inhibitors, mitosis inhibitors, topoisomerase inhibitors, or DNA intercalators, and particularly those which are used for cancer therapy.

(1087) The disclosed CARs can be used in combination with a checkpoint inhibitor. The two known inhibitory checkpoint pathways involve signaling through the cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed-death 1 (PD-1) receptors. These proteins are members of the CD28-B7 family of cosignaling molecules that play important roles throughout all stages of T cell function. The PD-1 receptor (also known as CD279) is expressed on the surface of activated T cells. Its ligands, PD-L1 (67-H1; CD274) and PD-L2 (B7-DC; CD273), are expressed on the surface of APCs such as dendritic cells or macrophages. PD-L1 is the predominant ligand, while PD-L2 has a much more restricted expression pattern. When the ligands bind to PD-1, an inhibitory signal is transmitted into the T cell, which reduces cytokine production and suppresses T-cell proliferation. Checkpoint inhibitors include, but are not limited to antibodies that block PD-1 (Nivolumab (BMS-936558 or MDX1106), CT-011, MK-3475), PD-L1 (MDX-1105 (BMS-936559), MPDL3280A, MS60010718C), PD-L2 (rHIgM1267), CTLA-4 (Ipilimumab (MDX-010), Tremelimumab (CP-675,206)), IDO, B7-H3 (MGA271), B7-H4, TIM3, LAG-3 (BMS-986016). Techniques for combining CARs with checkpoint inhibitors in immune effector cells and use thereof for the treatment of various disorders are described, for example, in WO 2017/040945, which is incorporated by reference herein.

(1088) Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics are described in U.S. Pat. No. 8,008,449, which is incorporated by reference for these antibodies. Anti-PD-L1 antibodies and uses therefor are described in U.S. Pat. No. 8,552,154, which is incorporated by reference for these antibodies. Anticancer agent comprising anti-PD-1 antibody or anti-PD-L1 antibody are described in U.S. Pat. No. 8,617,546, which is incorporated by reference for these antibodies.

(1089) In some embodiments, the PDL1 inhibitor comprises an antibody that specifically binds PDL1, such as BMS-936559 (Bristol-Myers Squibb) or MPDL3280A (Roche). In some embodiments, the PD1 inhibitor comprises an antibody that specifically binds PD1, such as lambrolizumab (Merck), nivolumab (Bristol-Myers Squibb), or MED14736 (AstraZeneca). Human monoclonal antibodies to PD-1 and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics are described in U.S. Pat. No. 8,008,449, which is incorporated by reference for these antibodies. Anti-PD-L1 antibodies and uses therefor are described in U.S. Pat. No. 8,552,154, which is incorporated by reference for these antibodies. Anticancer agent comprising anti-PD-1 antibody or anti-PD-L1 antibody are described in U.S. Pat. No. 8,617,546, which is incorporated by reference for these antibodies.

(1090) The disclosed CARs can be used in combination with other cancer immunotherapies. There are two distinct types of immunotherapy: passive immunotherapy uses components of the immune system to direct targeted cytotoxic activity against cancer cells, without necessarily initiating an immune response in the patient, while active immunotherapy actively triggers an endogenous immune response. Passive strategies include the use of the monoclonal antibodies (mAbs) produced by B cells in response to a specific antigen. The development of hybridoma technology in the 1970s and the identification of tumor-specific antigens permitted the pharmaceutical development of mAbs that could specifically target tumor cells for destruction by the immune system. Thus far, mAbs have been the biggest success story for immunotherapy; the top three best-selling anticancer drugs in 2012 were mAbs. Among them is rituximab (Rituxan, Genentech), which binds to the CD20 protein that is highly expressed on the surface of B cell malignancies such as non-Hodgkin's lymphoma (NHL). Rituximab is approved by the FDA for the treatment of NHL and chronic lymphocytic leukemia (CLL) in combination with chemotherapy. Another important mAb is trastuzumab (Herceptin; Genentech), which revolutionized the treatment of HER2 (human epidermal growth factor receptor 2)-positive breast cancer by targeting the expression of HER2.

(1091) Generating optimal killer CD8 T cell responses also requires T cell receptor activation plus co-stimulation, which can be provided through ligation of tumor necrosis factor receptor family members, including OX40 (CD134) and 4-1BB (CD137). OX40 is of particular interest as treatment with an activating (agonist) anti-OX40 mAb augments T cell differentiation and cytolytic function leading to enhanced anti-tumor immunity against a variety of tumors.

(1092) In some embodiments, such an additional therapeutic agent may be selected from an antimetabolite, such as methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, fludarabine, 5-fluorouracil, decarbazine, hydroxyurea, asparaginase, gemcitabine or cladribine.

(1093) In some embodiments, such an additional therapeutic agent may be selected from an alkylating agent, such as mechlorethamine, thioepa, chlorambucil, melphalan, carmustine (BSNU), lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, dacarbazine (DTIC), procarbazine, mitomycin C, cisplatin and other platinum derivatives, such as carboplatin.

(1094) In some embodiments, such an additional therapeutic agent may be selected from an anti-mitotic agent, such as taxanes, for instance docetaxel, and paclitaxel, and vinca alkaloids, for instance vindesine, vincristine, vinblastine, and vinorelbine.

(1095) In some embodiments, such an additional therapeutic agent may be selected from a topoisomerase inhibitor, such as topotecan or irinotecan, or a cytostatic drug, such as etoposide and teniposide.

(1096) In some embodiments, such an additional therapeutic agent may be selected from a growth factor inhibitor, such as an inhibitor of ErbBI (EGFR) (such as an EGFR antibody, e.g. zalutumumab, cetuximab, panitumumab or nimotuzumab or other EGFR inhibitors, such as gefitinib or erlotinib), another inhibitor of ErbB2 (HER2/neu) (such as a HER2 antibody, e.g. trastuzumab, trastuzumab-DM I or pertuzumab) or an inhibitor of both EGFR and HER2, such as lapatinib).

(1097) In some embodiments, such an additional therapeutic agent may be selected from a tyrosine kinase inhibitor, such as imatinib (Glivec, Gleevec STI571) or lapatinib.

(1098) Therefore, in some embodiments, a disclosed antibody is used in combination with ofatumumab, zanolimumab, daratumumab, ranibizumab, nimotuzumab, panitumumab, hu806, daclizumab (Zenapax), basiliximab (Simulect), infliximab (Remicade), adalimumab (Humira), natalizumab (Tysabri), omalizumab (Xolair), efalizumab (Raptiva), and/or rituximab.

(1099) In some embodiments, a therapeutic agent for use in combination with a CARs for treating the disorders as described above may be an anti-cancer cytokine, chemokine, or combination thereof. Examples of suitable cytokines and growth factors include IFNy, IL-2, IL-4, IL-6, IL-7, IL-10, IL-12, IL-13, IL-15, IL-18, IL-23, IL-24, IL-27, IL-28a, IL-28b, IL-29, KGF, IFNa (e.g., INFa2b), IFN, GM-CSF, CD40L, Flt3 ligand, stem cell factor, ancestim, and TNFa. Suitable chemokines may include Glu-Leu-Arg (ELR)-negative chemokines such as IP-10, MCP-3, MIG, and SDF-Ia from the human CXC and C-C chemokine families. Suitable cytokines include cytokine derivatives, cytokine variants, cytokine fragments, and cytokine fusion proteins.

(1100) In some embodiments, a therapeutic agent for use in combination with a CARs for treating the disorders as described above may be a cell cycle control/apoptosis regulator (or regulating agent). A cell cycle control/apoptosis regulator may include molecules that target and modulate cell cycle control/apoptosis regulators such as (i) cdc-25 (such as NSC 663284), (ii) cyclin-dependent kinases that overstimulate the cell cycle (such as flavopiridol (L868275, HMR1275), 7-hydroxystaurosporine (UCN-01, KW-2401), and roscovitine (R-roscovitine, CYC202)), and (iii) telomerase modulators (such as BIBR1532, SOT-095, GRN163 and compositions described in for instance U.S. Pat. Nos. 6,440,735 and 6,713,055). Non-limiting examples of molecules that interfere with apoptotic pathways include TNF-related apoptosis-inducing ligand (TRAIL)/apoptosis-2 ligand (Apo-2L), antibodies that activate TRAIL receptors, IFNs, and anti-sense Bcl-2.

(1101) In some embodiments, a therapeutic agent for use in combination with a CARs for treating the disorders as described above may be a hormonal regulating agent, such as agents useful for anti-androgen and anti-estrogen therapy. Examples of such hormonal regulating agents are tamoxifen, idoxifene, fulvestrant, droloxifene, toremifene, raloxifene, diethylstilbestrol, ethinyl estradiol/estinyl, an antiandrogene (such as flutaminde/eulexin), a progestin (such as such as hydroxyprogesterone caproate, medroxy-progesterone/provera, megestrol acepate/megace), an adrenocorticosteroid (such as hydrocortisone, prednisone), luteinizing hormone-releasing hormone (and analogs thereof and other LHRH agonists such as buserelin and goserelin), an aromatase inhibitor (such as anastrazole/arimidex, aminoglutethimide/cytraden, exemestane) or a hormone inhibitor (such as octreotide/sandostatin).

(1102) In some embodiments, a therapeutic agent for use in combination with an CARs for treating the disorders as described above may be an anti-cancer nucleic acid or an anti-cancer inhibitory RNA molecule.

(1103) Combined administration, as described above, may be simultaneous, separate, or sequential. For simultaneous administration the agents may be administered as one composition or as separate compositions, as appropriate.

(1104) In some embodiments, the disclosed CARs is administered in combination with radiotherapy. Radiotherapy may comprise radiation or associated administration of radiopharmaceuticals to a patient is provided. The source of radiation may be either external or internal to the patient being treated (radiation treatment may, for example, be in the form of external beam radiation therapy (EBRT) or brachytherapy (BT)). Radioactive elements that may be used in practicing such methods include, e.g., radium, cesium-137, iridium-192, americium-241, gold-198, cobalt-57, copper-67, technetium-99, iodide-123, iodide-131, and indium-111.

(1105) In some embodiments, the disclosed CARs is administered in combination with surgery.

(1106) CAR-T cells may be designed in several ways that enhance tumor cytotoxicity and specificity, evade tumor immunosuppression, avoid host rejection, and prolong their therapeutic half-life. TRUCK (T-cells Redirected for Universal Cytokine Killing) T cells for example, possess a CAR but are also engineered to release cytokines such as IL-12 that promote tumor killing. Because these cells are designed to release a molecular payload upon activation of the CAR once localized to the tumor environment, these CAR-T cells are sometimes also referred to as armored CARs. Several cytokines as cancer therapies are being investigated both pre-clinically and clinically, and may also prove useful when similarly incorporated into a TRUCK form of CAR-T therapy. Among these include IL-2, IL-3. IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-13, IL-15, IL-18, M-CSF, GM-CSF, IFN-?, IFN-?, TNF-?, TRAIL, FLT3 ligand, Lymphotactin, and TGF-? (Dranoff 2004). Self-driving or homing CAR-T cells are engineered to express a chemokine receptor in addition to their CAR. As certain chemokines can be upregulated in tumors, incorporation of a chemokine receptor aids in tumor trafficking to and infiltration by the adoptive T-cell, thereby enhancing both specificity and functionality of the CAR-T (Moon 2011). Universal CAR-T cells also possess a CAR, but are engineered such that they do not express endogenous TCR (T-cell receptor) or MHC (major histocompatibility complex) proteins. Removal of these two proteins from the signaling repertoire of the adoptive T-cell therapy prevents graft-versus-host-disease and rejection, respectively. Armored CAR-T cells are additionally so named for their ability to evade tumor immunosuppression and tumor-induced CAR-T hypofunction. These particular CAR-Ts possess a CAR, and may be engineered to not express checkpoint inhibitors. Alternatively, these CAR-Ts can be co-administered with a monoclonal antibody (mAb) that blocks checkpoint signaling. Administration of an anti-PDL1 antibody significantly restored the killing ability of CAR TILs (tumor infiltrating lymphocytes). While PD1-PDL1 and CTLA-4-CD80/CD86 signaling pathways have been investigated, it is possible to target other immune checkpoint signaling molecules in the design of an armored CAR-T including LAG-3, Tim-3, IDO-1, 2B4, and KIR. Other intracellular inhibitors of TILs include phosphatases (SHP1), ubiquitin-ligases (i.e., cbl-b), and kinases (i.e., diacylglycerol kinase). Armored CAR-Ts may also be engineered to express proteins or receptors that protect them against or make them resistant to the effects of tumor-secreted cytokines. For example, CTLs (cytotoxic T lymphocytes) transduced with the double negative form of the TGF-6 receptor are resistant to the immunosuppression by lymphoma secreted TGF-6. These transduced cells showed notably increased antitumor activity in vivo when compared to their control counterparts.

(1107) Tandem and dual CAR-T cells are unique in that they possess two distinct antigen binding domains. A tandem CAR contains two sequential antigen binding domains facing the extracellular environment connected to the intracellular costimulatory and stimulatory domains. A dual CAR is engineered such that one extracellular antigen binding domain is connected to the intracellular costimulatory domain and a second, distinct extracellular antigen binding domain is connected to the intracellular stimulatory domain. Because the stimulatory and costimulatory domains are split between two separate antigen binding domains, dual CARs are also referred to as split CARs. In both tandem and dual CAR designs, binding of both antigen binding domains is necessary to allow signaling of the CAR circuit in the T-cell. Because these two CAR designs have binding affinities for different, distinct antigens, they are also referred to as bi-specific CARs.

(1108) One primary concern with CAR-T cells as a form of living therapeutic is their manipulability in vivo and their potential immune-stimulating side effects. To better control CAR-T therapy and prevent against unwanted side effects, a variety of features have been engineered including off-switches, safety mechanisms, and conditional control mechanisms. Both self-destruct and marked/tagged CAR-T cells for example, are engineered to have an off-switch that promotes clearance of the CAR-expressing T-cell. A self-destruct CAR-T contains a CAR, but is also engineered to express a pro-apoptotic suicide gene or elimination gene inducible upon administration of an exogenous molecule. A variety of suicide genes may be employed for this purpose, including HSV-TK (herpes simplex virus thymidine kinase), Fas, iCasp9 (inducible caspase 9), CD20, MYC TAG, and truncated EGFR (endothelial growth factor receptor). HSK for example, will convert the prodrug ganciclovir (GCV) into GCV-triphosphate that incorporates itself into replicating DNA, ultimately leading to cell death. iCasp9 is a chimeric protein containing components of FK506-binding protein that binds the small molecule AP1903, leading to caspase 9 dimerization and apoptosis. A marked/tagged CAR-T cell however, is one that possesses a CAR but also is engineered to express a selection marker. Administration of a mAb against this selection marker will promote clearance of the CAR-T cell. Truncated EGFR is one such targetable antigen by the anti-EGFR mAb, and administration of cetuximab works to promotes elimination of the CAR-T cell. CARs created to have these features are also referred to as sCARs for switchable CARs, and RCARs for regulatable CARs. A safety CAR, also known as an inhibitory CAR (iCAR), is engineered to express two antigen binding domains. One of these extracellular domains is directed against a tumor related antigen and bound to an intracellular costimulatory and stimulatory domain. The second extracellular antigen binding domain however is specific for normal tissue and bound to an intracellular checkpoint domain such as CTLA4, PD1, or CD45. Incorporation of multiple intracellular inhibitory domains to the iCAR is also possible. Some inhibitory molecules that may provide these inhibitory domains include B7-H1, B7-1, CD160, PIH, 2B4, CEACAM (CEACAM-1. CEACAM-3, and/or CEACAM-5), LAG-3, TIGIT, BTLA, LAIR1, and TGF?-R. In the presence of normal tissue, stimulation of this second antigen binding domain will work to inhibit the CAR. It should be noted that due to this dual antigen specificity, iCARs are also a form of bi-specific CAR-T cells. The safety CAR-T engineering enhances specificity of the CAR-T cell for tumor tissue, and is advantageous in situations where certain normal tissues may express very low levels of a tumor associated antigen that would lead to off target effects with a standard CAR (Morgan 2010). A conditional CAR-T cell expresses an extracellular antigen binding domain connected to an intracellular costimulatory domain and a separate, intracellular costimulator. The costimulatory and stimulatory domain sequences are engineered in such a way that upon administration of an exogenous molecule the resultant proteins will come together intracellularly to complete the CAR circuit. In this way, CAR-T activation can be modulated, and possibly even fine-tuned or personalized to a specific patient. Similar to a dual CAR design, the stimulatory and costimulatory domains are physically separated when inactive in the conditional CAR; for this reason these too are also referred to as a split CAR.

(1109) In some embodiments, two or more of these engineered features may be combined to create an enhanced, multifunctional CAR-T. For example, it is possible to create a CAR-T cell with either dual- or conditional-CAR design that also releases cytokines like a TRUCK. In some embodiments, a dual-conditional CAR-T cell could be made such that it expresses two CARs with two separate antigen binding domains against two distinct cancer antigens, each bound to their respective costimulatory domains. The costimulatory domain would only become functional with the stimulatory domain after the activating molecule is administered. For this CAR-T cell to be effective the cancer must express both cancer antigens and the activating molecule must be administered to the patient; this design thereby incorporating features of both dual and conditional CAR-T cells.

(1110) Typically, CAR-T cells are created using ?-? T cells, however ?-? T cells may also be used. In some embodiments, the described CAR constructs, domains, and engineered features used to generate CAR-T cells could similarly be employed in the generation of other types of CAR-expressing immune cells including NK (natural killer) cells, B cells, mast cells, myeloid-derived phagocytes, and NKT cells. Alternatively, a CAR-expressing cell may be created to have properties of both T-cell and NK cells. In an additional embodiment, the transduced with CARs may be autologous or allogeneic.

(1111) Several different methods for CAR expression may be used including retroviral transduction (including ?-retroviral), lentiviral transduction, transposon/transposases (Sleeping Beauty and PiggyBac systems), and messenger RNA transfer-mediated gene expression. Gene editing (gene insertion or gene deletion/disruption) has become of increasing importance with respect to the possibility for engineering CAR-T cells as well. CRISPR-Cas9, ZFN (zinc finger nuclease), and TALEN (transcription activator like effector nuclease) systems are three potential methods through which CAR-T cells may be generated.

(1112) Definitions

(1113) The term amino acid sequence refers to a list of abbreviations, letters, characters or words representing amino acid residues. The amino acid abbreviations used herein are conventional one letter codes for the amino acids and are expressed as follows: A, alanine; B, asparagine or aspartic acid; C, cysteine; D aspartic acid; E, glutamate, glutamic acid; F, phenylalanine; G, glycine; H histidine; I isoleucine; K, lysine; L, leucine; M, methionine; N, asparagine; P, proline; Q, glutamine; R, arginine; S, serine; T, threonine; V, valine; W, tryptophan; Y, tyrosine; Z, glutamine or glutamic acid.

(1114) The term antibody refers to an immunoglobulin, derivatives thereof which maintain specific binding ability, and proteins having a binding domain which is homologous or largely homologous to an immunoglobulin binding domain. These proteins may be derived from natural sources, or partly or wholly synthetically produced. An antibody may be monoclonal or polyclonal. The antibody may be a member of any immunoglobulin class from any species, including any of the human classes: IgG, IgM, IgA, IgD, and IgE. In exemplary embodiments, antibodies used with the methods and compositions described herein are derivatives of the IgG class.

(1115) In addition to intact immunoglobulin molecules, also included in the term antibodies are fragments or polymers of those immunoglobulin molecules, and human or humanized versions of immunoglobulin molecules that selectively bind the target antigen.

(1116) The term antibody fragment refers to any derivative of an antibody which is less than full-length. In exemplary embodiments, the antibody fragment retains at least a significant portion of the full-length antibody's specific binding ability. Examples of antibody fragments include, but are not limited to, Fab, Fab, F(ab)2, scFv, Fv, dsFv diabody, Fc, and Fd fragments. The antibody fragment may be produced by any means. For instance, the antibody fragment may be enzymatically or chemically produced by fragmentation of an intact antibody, it may be recombinantly produced from a gene encoding the partial antibody sequence, or it may be wholly or partially synthetically produced. The antibody fragment may optionally be a single chain antibody fragment. Alternatively, the fragment may comprise multiple chains which are linked together, for instance, by disulfide linkages. The fragment may also optionally be a multimolecular complex. A functional antibody fragment will typically comprise at least about 50 amino acids and more typically will comprise at least about 200 amino acids.

(1117) The term antigen binding site refers to a region of an antibody that specifically binds an epitope on an antigen.

(1118) The term aptamer refers to oligonucleic acid or peptide molecules that bind to a specific target molecule. These molecules are generally selected from a random sequence pool. The selected aptamers are capable of adapting unique tertiary structures and recognizing target molecules with high affinity and specificity. A nucleic acid aptamer is a DNA or RNA oligonucleic acid that binds to a target molecule via its conformation, and thereby inhibits or suppresses functions of such molecule. A nucleic acid aptamer may be constituted by DNA, RNA, or a combination thereof. A peptide aptamer is a combinatorial protein molecule with a variable peptide sequence inserted within a constant scaffold protein. Identification of peptide aptamers is typically performed under stringent yeast dihybrid conditions, which enhances the probability for the selected peptide aptamers to be stably expressed and correctly folded in an intracellular context.

(1119) The term carrier means a compound, composition, substance, or structure that, when in combination with a compound or composition, aids or facilitates preparation, storage, administration, delivery, effectiveness, selectivity, or any other feature of the compound or composition for its intended use or purpose. For example, a carrier can be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject.

(1120) The term chimeric molecule refers to a single molecule created by joining two or more molecules that exist separately in their native state. The single, chimeric molecule has the desired functionality of all of its constituent molecules. One type of chimeric molecules is a fusion protein.

(1121) The term engineered antibody refers to a recombinant molecule that comprises at least an antibody fragment comprising an antigen binding site derived from the variable domain of the heavy chain and/or light chain of an antibody and may optionally comprise the entire or part of the variable and/or constant domains of an antibody from any of the Ig classes (for example IgA, IgD, IgE, IgG, IgM and IgY).

(1122) The term epitope refers to the region of an antigen to which an antibody binds preferentially and specifically. A monoclonal antibody binds preferentially to a single specific epitope of a molecule that can be molecularly defined. In the present invention, multiple epitopes can be recognized by a multispecific antibody.

(1123) The term fusion protein refers to a polypeptide formed by the joining of two or more polypeptides through a peptide bond formed between the amino terminus of one polypeptide and the carboxyl terminus of another polypeptide. The fusion protein can be formed by the chemical coupling of the constituent polypeptides or it can be expressed as a single polypeptide from nucleic acid sequence encoding the single contiguous fusion protein. A single chain fusion protein is a fusion protein having a single contiguous polypeptide backbone. Fusion proteins can be prepared using conventional techniques in molecular biology to join the two genes in frame into a single nucleic acid, and then expressing the nucleic acid in an appropriate host cell under conditions in which the fusion protein is produced.

(1124) The term Fab fragment refers to a fragment of an antibody comprising an antigen-binding site generated by cleavage of the antibody with the enzyme papain, which cuts at the hinge region N-terminally to the inter-H-chain disulfide bond and generates two Fab fragments from one antibody molecule.

(1125) The term F(ab)2 fragment refers to a fragment of an antibody containing two antigen-binding sites, generated by cleavage of the antibody molecule with the enzyme pepsin which cuts at the hinge region C-terminally to the inter-H-chain disulfide bond.

(1126) The term Fc fragment refers to the fragment of an antibody comprising the constant domain of its heavy chain.

(1127) The term Fv fragment refers to the fragment of an antibody comprising the variable domains of its heavy chain and light chain.

(1128) Gene construct refers to a nucleic acid, such as a vector, plasmid, viral genome or the like which includes a coding sequence for a polypeptide or which is otherwise transcribable to a biologically active RNA (e.g., antisense, decoy, ribozyme, etc.), may be transfected into cells, e.g. in certain embodiments mammalian cells, and may cause expression of the coding sequence in cells transfected with the construct. The gene construct may include one or more regulatory elements operably linked to the coding sequence, as well as intronic sequences, polyadenylation sites, origins of replication, marker genes, etc.

(1129) The term identity refers to sequence identity between two nucleic acid molecules or polypeptides. Identity can be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same base, then the molecules are identical at that position. A degree of similarity or identity between nucleic acid or amino acid sequences is a function of the number of identical or matching nucleotides at positions shared by the nucleic acid sequences. Various alignment algorithms and/or programs may be used to calculate the identity between two sequences, including FASTA, or BLAST which are available as a part of the GCG sequence analysis package (University of Wisconsin, Madison, Wis.), and can be used with, e.g., default setting. For example, polypeptides having at least 70%, 85%, 90%, 95%, 98% or 99% identity to specific polypeptides described herein and preferably exhibiting substantially the same functions, as well as polynucleotide encoding such polypeptides, are contemplated. Unless otherwise indicated a similarity score will be based on use of BLOSUM62. When BLASTP is used, the percent similarity is based on the BLASTP positives score and the percent sequence identity is based on the BLASTP identities score. BLASTP Identities shows the number and fraction of total residues in the high scoring sequence pairs which are identical; and BLASTP Positives shows the number and fraction of residues for which the alignment scores have positive values and which are similar to each other. Amino acid sequences having these degrees of identity or similarity or any intermediate degree of identity of similarity to the amino acid sequences disclosed herein are contemplated and encompassed by this disclosure. The polynucleotide sequences of similar polypeptides are deduced using the genetic code and may be obtained by conventional means, in particular by reverse translating its amino acid sequence using the genetic code.

(1130) The term linker is art-recognized and refers to a molecule or group of molecules connecting two compounds, such as two polypeptides. The linker may be comprised of a single linking molecule or may comprise a linking molecule and a spacer molecule, intended to separate the linking molecule and a compound by a specific distance.

(1131) The term multivalent antibody refers to an antibody or engineered antibody comprising more than one antigen recognition site. For example, a bivalent antibody has two antigen recognition sites, whereas a tetravalent antibody has four antigen recognition sites. The terms monospecific, bispecific, trispecific, tetraspecific, etc. refer to the number of different antigen recognition site specificities (as opposed to the number of antigen recognition sites) present in a multivalent antibody. For example, a monospecific antibody's antigen recognition sites all bind the same epitope. A bispecific antibody has at least one antigen recognition site that binds a first epitope and at least one antigen recognition site that binds a second epitope that is different from the first epitope. A multivalent monospecific antibody has multiple antigen recognition sites that all bind the same epitope. A multivalent bispecific antibody has multiple antigen recognition sites, some number of which bind a first epitope and some number of which bind a second epitope that is different from the first epitope.

(1132) The term nucleic acid refers to a natural or synthetic molecule comprising a single nucleotide or two or more nucleotides linked by a phosphate group at the 3 position of one nucleotide to the 5 end of another nucleotide. The nucleic acid is not limited by length, and thus the nucleic acid can include deoxyribonucleic acid (DNA) or ribonucleic acid (RNA).

(1133) The term operably linked to refers to the functional relationship of a nucleic acid with another nucleic acid sequence. Promoters, enhancers, transcriptional and translational stop sites, and other signal sequences are examples of nucleic acid sequences operably linked to other sequences. For example, operable linkage of DNA to a transcriptional control element refers to the physical and functional relationship between the DNA and promoter such that the transcription of such DNA is initiated from the promoter by an RNA polymerase that specifically recognizes, binds to and transcribes the DNA.

(1134) The terms peptide, protein, and polypeptide are used interchangeably to refer to a natural or synthetic molecule comprising two or more amino acids linked by the carboxyl group of one amino acid to the alpha amino group of another.

(1135) The term pharmaceutically acceptable refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit/risk ratio.

(1136) The terms polypeptide fragment or fragment, when used in reference to a particular polypeptide, refers to a polypeptide in which amino acid residues are deleted as compared to the reference polypeptide itself, but where the remaining amino acid sequence is usually identical to that of the reference polypeptide. Such deletions may occur at the amino-terminus or carboxy-terminus of the reference polypeptide, or alternatively both. Fragments typically are at least about 5, 6, 8 or 10 amino acids long, at least about 14 amino acids long, at least about 20, 30, 40 or 50 amino acids long, at least about 75 amino acids long, or at least about 100, 150, 200, 300, 500 or more amino acids long. A fragment can retain one or more of the biological activities of the reference polypeptide. In various embodiments, a fragment may comprise an enzymatic activity and/or an interaction site of the reference polypeptide. In another embodiment, a fragment may have immunogenic properties.

(1137) The term protein domain refers to a portion of a protein, portions of a protein, or an entire protein showing structural integrity; this determination may be based on amino acid composition of a portion of a protein, portions of a protein, or the entire protein.

(1138) The term single chain variable fragment or scFv refers to an Fv fragment in which the heavy chain domain and the light chain domain are linked. One or more scFv fragments may be linked to other antibody fragments (such as the constant domain of a heavy chain or a light chain) to form antibody constructs having one or more antigen recognition sites.

(1139) A spacer as used herein refers to a peptide that joins the proteins comprising a fusion protein. Generally a spacer has no specific biological activity other than to join the proteins or to preserve some minimum distance or other spatial relationship between them. However, the constituent amino acids of a spacer may be selected to influence some property of the molecule such as the folding, net charge, or hydrophobicity of the molecule.

(1140) The term specifically binds, as used herein, when referring to a polypeptide (including antibodies) or receptor, refers to a binding reaction which is determinative of the presence of the protein or polypeptide or receptor in a heterogeneous population of proteins and other biologics. Thus, under designated conditions (e.g. immunoassay conditions in the case of an antibody), a specified ligand or antibody specifically binds to its particular target (e.g. an antibody specifically binds to an endothelial antigen) when it does not bind in a significant amount to other proteins present in the sample or to other proteins to which the ligand or antibody may come in contact in an organism. Generally, a first molecule that specifically binds a second molecule has an affinity constant (Ka) greater than about 10.sup.5 M.sup.?1 (e.g., 10.sup.6 M.sup.?1, 10.sup.7 M.sup.?1, 10.sup.8 M.sup.?1, 10.sup.9 M.sup.?1, 10.sup.10 M.sup.?1, 10.sup.11 M.sup.?1, and 10.sup.12 M.sup.?1 or more) with that second molecule.

(1141) The term specifically deliver as used herein refers to the preferential association of a molecule with a cell or tissue bearing a particular target molecule or marker and not to cells or tissues lacking that target molecule. It is, of course, recognized that a certain degree of non-specific interaction may occur between a molecule and a non-target cell or tissue. Nevertheless, specific delivery, may be distinguished as mediated through specific recognition of the target molecule. Typically specific delivery results in a much stronger association between the delivered molecule and cells bearing the target molecule than between the delivered molecule and cells lacking the target molecule.

(1142) The term subject refers to any individual who is the target of administration or treatment. The subject can be a vertebrate, for example, a mammal. Thus, the subject can be a human or veterinary patient. The term patient refers to a subject under the treatment of a clinician, e.g., physician.

(1143) The term therapeutically effective refers to the amount of the composition used is of sufficient quantity to ameliorate one or more causes or symptoms of a disease or disorder. Such amelioration only requires a reduction or alteration, not necessarily elimination.

(1144) The terms transformation and transfection mean the introduction of a nucleic acid, e.g., an expression vector, into a recipient cell including introduction of a nucleic acid to the chromosomal DNA of said cell.

(1145) The term treatment refers to the medical management of a patient with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder. This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder. In addition, this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder.

(1146) The term variant refers to an amino acid or peptide sequence having conservative amino acid substitutions, non-conservative amino acid substitutions (i.e. a degenerate variant), substitutions within the wobble position of each codon (i.e. DNA and RNA) encoding an amino acid, amino acids added to the C-terminus of a peptide, or a peptide having 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% sequence identity to a reference sequence.

(1147) The term vector refers to a nucleic acid sequence capable of transporting into a cell another nucleic acid to which the vector sequence has been linked. The term expression vector includes any vector, (e.g., a plasmid, cosmid or phage chromosome) containing a gene construct in a form suitable for expression by a cell (e.g., linked to a transcriptional control element).

(1148) A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.

EXAMPLES

Example 1

(1149) FIG. 1. Human CD19 CARs and human CD22 CARs induce NF-?B in NF-?B293 reporter cells. NF-?B293 reporter cells stably express a transgene, in which NF-?B responsive transcriptional elements are placed upstream of a minimal CMV-GFP-luciferase cassette. So, luciferase activity reflects activity of NF-?B signaling pathway. CAR constructs were packaged into recombinant retrovirus, which was used to transduce NF-?B293 reporter cells. Forty-eight hours later, cell lysates were prepared from transduced reporter cells and untransduced controls. NF-?B activation was evaluated using luciferase assay (FIGS. 1A and 1B).

(1150) CAR expression in human CAR-T cells. On day 0, human T cells were isolated from healthy donor PBMCs and activated with human CD3/CD28 dynabeads. T cells were spin transduced retrovirally with CARs on day 1 and day 2. On day 3, fresh medium with IL2 were added. On day 4, CAR-T cells were harvested, de-beaded and evaluated by flow cytometry (FIG. 2). All CD19, CD20 or CD22 CARs tested were tagged with GFP. GFP % reflects CAR expression. Hybridoma cell IDs were indicated.

(1151) Human CAR T cells were produced and co-cultured with target cells at E:T ratio of 10:1. Target cell killing was monitored on an xCELLigence RTCA system (FIG. 3). Normalized cell index reflects cell growth.

(1152) Human CAR T cells were produced and co-cultured with target cells at E:T ratio of 10:1. Twenty-four hours later, supernatant was collected and subjected to ELISA analysis for CD19 (FIG. 4), CD20 (FIG. 5), and CD22 (FIG. 6) using an Ella machine

(1153) Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in the art to which the disclosed invention belongs. Publications cited herein and the materials for which they are cited are specifically incorporated by reference.

(1154) Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.